Aarsvold, JN, 474, 112P(ab)
Abdel-Dayem, HM, 56P(ab), 172P(ab), 233P(ab), 261P(ab)
Abdel-Nabi, H, 213P(ab), 246P(ab), 262P(ab)
Abe, M, 2124
Abe, Y, 780
Abi-Dargham, A, 31P(ab), 108P(ab), 109P(ab), 211P(ab)
Abitbol, C, 249P(ab)
Aboud, A, 117P(ab), 137P(ab)
Abrahamowicz, M, 589
Abrams, MJ, 1964, 104P(ab), 172P(ab), 173P(ab), 174P(ab)
Abrams, PG, 908
Aburano, T, 28P(ab), 139P(ab), 223P(ab)
Acevedo, ME, 32P(ab)
Ackermann, B, 148P(ab)
Ackermann, R, 25P(ab), 110P(ab)
Adachi, I, 221P(ab)
Adam, MJ, 237P(ab), 242P(ab)
Adams, S, 205P(ab)
Addison, SJ, 1031
Adelstein, SJ, 1175, 123P(ab), 221P(ab), 241P(ab)
Adiseshan, P, 90P(ab)
Adler, RS, 524(le)
Adolf, J, 112P(ab)
Aerts, R, 222P(ab)
Affleck, D, 218P(ab)
Afriyie, M, 1235
Afriyle, M, 166P(ab)
Agarwal, P, 64P(ab), 65P(ab), 95P(ab), 151P(ab)
Agnew, JE, 1859
Agostini, D, 24P(ab)
Agress, H, 1326
Ahluwalia, R, 62P(ab), 71P(ab), 196P(ab), 249P(ab)
Ahmad, M, 1309, 53P(ab), 54P(ab), 94P(ab)
Ahn, S, 163P(ab)
Ahonen, A, 2068, 3P(ab)
Aillet, G, 1267
Aisen, AM, 1190
Akabani, G, 1367, 1382
Akansel, G, 961
Akkermans, LMA, 582, 170P(ab)
Aksut, S, 85P(ab), 95P(ab)
Aktolun, C, 2276(le)
Akutsu, H, 222P(ab)
Alagona, P, 155P(ab)
Alavi, A, 208, 506, 697, 1009, 1109, 1119, 1214, 1447, 1612, 1681, 1851, 1866, 1910, 2049, 2191, 12P(ab), 16P(ab), 17P(ab), 32P(ab), 43P(ab), 48P(ab), 73P(ab), 76P(ab), 92P(ab), 116P(ab), 121P(ab), 124P(ab), 158P(ab), 162P(ab), 163P(ab), 169P(ab), 181P(ab), 195P(ab), 207P(ab), 210P(ab), 228P(ab), 229P(ab), 230P(ab)
Albani, C, 196P(ab)
Albro, JE, 1905
Alderson, PO, 122P(ab)
Al-Doohan, S, 195P(ab)
Alexoff, D, 131P(ab)
Ali, A, 151P(ab)
Ali, KSM, 66P(ab), 67P(ab), 104P(ab)
Allababidi, S, 245P(ab)
Alle, K, 140P(ab)
Allen, BC, 1239
Allen, DM, 255P(ab)
Allen, EW, 190P(ab), 257P(ab)
Allen, G, 37P(ab)
Allen, IE, 234
Allen, P, 144P(ab)
Allen, SB, 161P(ab)
Allenberg, JR, 139P(ab)
Al-Mohannadi, S, 172P(ab)
Alonso, C, 146P(ab)
Alpert, N, 879
Alpert, NM, 6, 24P(ab), 47P(ab), 51P(ab), 57P(ab), 71P(ab), 73P(ab), 88P(ab), 196P(ab), 203P(ab), 260P(ab)
Alt, A, 41P(ab)
Altehoefer, C, 23P(ab), 148P(ab)
Al-Tikriti, M, 48P(ab), 102P(ab), 108P(ab), 201P(ab), 243P(ab)
Altin, RS, 261P(ab)
Altland, E, 54P(ab)
Altmann, A, 220P(ab)
Amara, SG, 1140
Amarenco, G, 205P(ab)
Amarenco, P, 205P(ab)
Amato, R, 212P(ab)
Ambrecht, JJ, 2038
Ambrose, KR, 946
Ambrosio, A, 115P(ab)
Amendola, MA, 263P(ab)
Amir, D, 104
Amsterdam, JD, 48P(ab)
Amyotte, G, 213P(ab)
Anderson, A-L, 1246
Anderson, CJ, 18P(ab), 28P(ab), 81P(ab), 134P(ab), 216P(ab)
Anderson, CM, 62P(ab), 71P(ab), 157P(ab), 249P(ab)
Anderson, JA, 9P(ab)
Anderson, JR, 200P(ab)
Anderson, T, 250P(ab)
Andreasen, NC, 68P(ab)
Andrey, TW, 268
Andrich, MP, 1854
Anema, PC, 179P(ab), 227P(ab)
Angelberger, P, 1397
Angelides, S, 153P(ab)
Angels, RR, 5P(ab)
Angrist, B, 609, 67P(ab), 102P(ab)
Ansari, AN, 1990
Ansari, MS, 132P(ab), 158P(ab), 202P(ab)
Antar, MA, 400, 1834(le)
Antich, PP, 9P(ab), 124P(ab)
Antico, VF, 1172
Antonuk, LE, 100P(ab)
Anzai, Y, 224P(ab)
Appelbaum, F, 1031
Applebaum, JW, 2111
Applebaum, FR, 1839
Arai, M, 86P(ab), 198P(ab)
Arai, T, 1886
Arano, Y, 29P(ab), 59P(ab)
Aras, T, 84P(ab), 172P(ab)
Arata, L, 40P(ab)
Araujo, LI, 181P(ab)
Aravind, S, 124P(ab)
Archambault, YG, 59P(ab)
Archer, CM, 222
Ardalan, B, 214P(ab)
Areeda, J, 1494, 64P(ab), 148P(ab), 189P(ab)
Arena, AI, 117P(ab)
Arias, JM, 1905
Aretz, HT, 1282
Argenyi, EE, 167P(ab), 185P(ab)
Arimizu, N, 211P(ab)
Ariyoshi, K, 932
Arka, A, 41P(ab)
Armour, K, 217P(ab)
Armstrong, WF, 107P(ab)
Arndt, J-W, 1052
Arochick, J, 230P(ab)
Aronen, H, 206P(ab), 208P(ab)
Aronovitz, M, 65P(ab)
Aronson, F, 210P(ab), 233P(ab)
Artze, M, 137P(ab), 263P(ab)
Asada, Y, 159P(ab)
Asakawa, Y, 161P(ab)
Ascah, KJ, 74P(ab)
Ashburn, WL, 122P(ab)
Ashida, K, 291
Ashok, G, 37P(ab), 77P(ab), 139P(ab)
Ashraf, R, 5P(ab)
Askienazy, S, 1243
Assassa, G, 1990, 261P(ab)
Assassa, GS, 1990
Assies, J, 41P(ab)
Atkins, FB, 227P(ab)
Atkins, H, 43P(ab), 222P(ab)
Atkins, HL, 899, 1382
Atkinson, JB, 826
Atlas, SW, 1447
Atuk, NO, 162P(ab)
Aubin-Brunet, V, 5P(ab)
Aung, MT, 74P(ab)
Austin, MC, 666
Avril, N, 41P(ab)
Awh, ES, 57P(ab)
Axeloff, D, 609
Azuma, M, 111P(ab), 170P(ab)
Azure, MT, 133P(ab), 134P(ab)

Babaian, RJ, 115P(ab)
Babchyck, B, 177P(ab)
Babich, JW, 1282, 1529, 1964, 1975, 2130, 2176, 2253, 15P(ab), 51P(ab), 69P(ab), 73P(ab), 88P(ab), 104P(ab), 172P(ab), 173P(ab), 232P(ab), 240P(ab)
Bach, D, 97P(ab), 107P(ab)
Bacharach, SL, 311, 27P(ab), 60P(ab), 61P(ab), 124P(ab), 177P(ab), 178P(ab)
Bachmayr, S, 122P(ab)
Bacin, FJ, 1260
Bading, JR, 182P(ab)
Baer, L, 47P(ab)
Bag, R, 172P(ab)
Bagni, B, 110P(ab)
Bagni, I, 110P(ab)
Bahnasy, S, 168P(ab)
Baidoo, KE, 18P(ab), 135P(ab)
Bailey, DL, 1367, 1752, 184P(ab)
Baird, J, 78P(ab)
Bairey, CN, 34P(ab)
Baker, JA, 39
Baker, M, 1031
Baker, RW, 78P(ab)
Bakke, A, 352(le)
Bakker, WH, 2025, 165P(ab)
Balasubramanian, N, 61
Baldini, MT, 219P(ab)
Baldwin, B, 1595, 162P(ab)
Baldwin, RM, 31P(ab), 48P(ab), 90P(ab), 102P(ab), 108P(ab), 109P(ab), 157P(ab), 201P(ab), 211P(ab), 243P(ab)
Ballinger, JR, 242, 268, 1274, 242P(ab)
Ballon, D, 1152
Balu, D, 1818
Bamrah, VS, 94P(ab)
Banaszczyk, MG, 39P(ab)
Banerjee, A, 260P(ab)
Bangerter, M, 217P(ab)
Banish, M, 176P(ab)
Banks, W, 8P(ab), 218P(ab)
Baranowska-Kortylewicz, J, 1175, 123P(ab), 221P(ab), 241P(ab), 247P(ab)
Barbarics, E, 242P(ab)
Barber, GG, 74P(ab)
Barbet, J, 1267, 1662
Barbour, MM, 152P(ab)
Barbour, SI, 131P(ab)
Barclay, AB, 179P(ab)
Barclay, PD, 123P(ab), 221P(ab), 241P(ab)
Barefield, KP, 1766
Barentsz, J, 163P(ab)
Bares, R, 98P(ab), 158P(ab), 164P(ab), 183P(ab), 217P(ab)
Barker, WC, 61P(ab), 124P(ab), 178P(ab)
Barlaud, M, 194P(ab)
Barnes, DC, 1377
Barnes, PD, 1045
Barnett, CA, 151P(ab)
Barnhart, CS, 75P(ab), 149P(ab)
Baro, ME, 220P(ab)
Baron, JC, 241P(ab)
Baron, JI, 75P(ab), 85P(ab)
Barré, L, 241P(ab)
Barrett, HH, 474, 27P(ab)
Barrett, JA, 173P(ab)
Barrett, T, 16P(ab), 229P(ab), 230P(ab)
Barrio, J, 183P(ab), 202P(ab), 238P(ab), 239P(ab)
Barrio, JR, 679
Barritault, L, 387
Barron, BJ, 256P(ab), 260P(ab)
Barrow, S, 1975, 172P(ab)
Barrow, SA, 1975, 2176
Bars, DL, 22P(ab), 103P(ab)
Barsamian, S, 190P(ab)
Bar-Shalom, R, 2101
Bartenstein, P, 3P(ab), 45P(ab), 57P(ab)
Bartlett, E, 40P(ab)
Bartlett, M, 178P(ab)
Baruchin, MA, 193
Barzilai, D, 141P(ab)
Baselga, J, 213P(ab)
Basheim, H, 117P(ab)
Bassa, P, 77P(ab)
Bassevitz, R, 152P(ab)
Basten, A, 153P(ab)
Bastidas, DA, 66P(ab), 104P(ab)
Basu, AK, 168P(ab)
Bataille, G, 576, 10P(ab)
Bateman, TM, 75P(ab), 149P(ab)
Bates, E, 107P(ab)
Batjer, H, 1239
Battles, A, 229P(ab)
Baudhuin, T, 15P(ab), 44P(ab), 86P(ab), 121P(ab)
Baudouy, M, 1472, 45P(ab)
Bauer, A, 15P(ab)
Bauer, H, 21P(ab)
Baulieu, J-L, 1217(le), 194P(ab)
Baum, RP, 100P(ab), 126P(ab), 205P(ab)
Bauman, JM, 1995
Baumann, ML, 134P(ab), 216P(ab)
Baumgarten, D, 467
Baumgartner, G, 1039
Baumgold, J, 2169
Bautovich, GJ, 153P(ab)
Bavaria, G, 140P(ab)
Bax, JJ, 147P(ab), 154P(ab)
Baxter, KG, 262P(ab)
Baxter, L, 70P(ab), 183P(ab)
Baxter, LR, 1198
Bayhan, H, 889

Bayouth, JE, 33P(ab), 127P(ab), 134P(ab), 161P(ab), 180P(ab), 192P(ab), 218P(ab)
Beam, CA, 23P(ab)
Beanlands, R, 336, 968
Beanlands, RSB, 83, 35P(ab), 50P(ab), 107P(ab)
Beattie, B, 1152
Beatty, BG, 1294
Beatty, JD, 1294
Beaumier, PL, 908, 2111
Beauregard, GC, 297
Beazley, RM, 2095
Beck, H, 172P(ab)
Beck, RN, 112P(ab)
Becker, JA, 2044, 27P(ab), 179P(ab), 203P(ab), 208P(ab), 212P(ab), 259P(ab)
Becker, LC, 86P(ab)
Becker, W, 92, 37P(ab), 172P(ab)
Beckers, C, 129P(ab)
Beckurts, KTE, 112P(ab)
Beger, HG, 223P(ab), 225P(ab)
Begley, MG, 173
Behta, B, 114P(ab)
Beilin, I, 23P(ab)
Bekdik, CF, 84P(ab)
Belenger, J, 46P(ab)
Belezzuoli, EV, 122P(ab)
Bell, RL, 158P(ab)
Bellande, E, 18P(ab), 134P(ab)
Bellanger, C, 243P(ab)
Beller, GA, 96P(ab)
Belles, B, 249P(ab), 260P(ab), 263P(ab)
Bellina, CR, 2032
Bello, S, 131P(ab)
Belloy, M, 226P(ab)
Beltrami, CA, 166P(ab)
Ben-Arush, MW, 2101
Bencomo, J, 88P(ab)
Bender, D, 68P(ab)
Bendriem, B, 981, 1739, 1899, 36P(ab), 109P(ab), 186P(ab)
Benedetto, P, 33P(ab), 214P(ab)
Benjamin, C, 96P(ab), 121P(ab)
Benjamin, R, 33P(ab), 55P(ab)
Ben-Shahar, M, 2101
Bentourkia, M, 136P(ab)
Benzi, R, 46P(ab)
Berdichevsky, D, 51P(ab), 71P(ab), 88P(ab)
Bererhi, L, 128P(ab)
Beretta, L, 93P(ab)
Berg, BO, 1922
Berger, HJ, 234
Berger, KL, 322, 56P(ab)
Bergin, M, 1082
Bergman, J, 1, 1711, 2068, 3P(ab), 21P(ab), 69P(ab), 224P(ab)
Bergmann, SR, 717, 36P(ab), 79P(ab), 86P(ab), 87P(ab), 154P(ab)
Berk, J, 1152
Berk, MR, 1218(le)
Berkovic, SF, 666
Berlin, JA, 1681
Berman, D, 1485
Berman, DS, 1349, 1494, 1845, 34P(ab), 64P(ab), 130P(ab), 148P(ab), 189P(ab), 257P(ab), 259P(ab)
Berman, HL, 122P(ab)
Berman, KF, 67P(ab), 228P(ab)
Berman, RB, 123P(ab)
Berná, L, 1503, 13P(ab), 145P(ab), 146P(ab)
Bernard, HF, 165P(ab)
Bernardo, J, 1441
Bernardo, M, 77P(ab)
Bernstein, MJ, 131P(ab)
Berridge, MS, 239P(ab)
Berry, JJ, 39
Bertollo, D, 40P(ab)
Besnard, J-C, 235P(ab)
Besozzi, M, 155P(ab), 261P(ab)
Besse, T, 129P(ab)
Better, N, 151P(ab)
Bettinardi, V, 137
Bettman, L, 141P(ab)
Beuter, B, 225P(ab)
Bevilacqua, G, 1175
Bex, M, 576
Bhadkamkar, V, 33P(ab), 53P(ab), 88P(ab), 115P(ab), 223P(ab)
Bhargava, DK, 168P(ab)
Bhargava, R, 138P(ab)
Bhat, G, 153P(ab)
Bianchi, R, 2032
Bianco, JA, 866(le)
Biasio, Y, 1485
Bida, GT, 239P(ab)
Biedermann, M, 148P(ab), 158P(ab)
Biedler, JL, 114P(ab)
Bier, D, 58P(ab)
Biersack, HJ, 1632, 793, 946, 77P(ab), 187P(ab), 204P(ab), 243P(ab)
Bigelow, LB, 228P(ab)
Biggs, T, 370
Bigio, EH, 115P(ab)
Bihl, H, 97P(ab)
Billings, J, 132P(ab), 235P(ab)
Biniakiewicz, D, 120P(ab), 248P(ab)
Binns, R, 62P(ab)
Bischoff, H, 21P(ab)
Biskupiak, JE, 411, 918, 79P(ab)
Bisson, G, 49P(ab)
Bizais, Y, 1204
Bjorn, MJ, 908, 2111
Black, HR, 1416
Black, PM, 241P(ab)
Black, PML, 1045
Blahd, WH, 12P(ab), 88P(ab), 257P(ab)
Blair, J, 172P(ab)
Blake, GM, 141P(ab), 142P(ab)
Blanc, CH, 84P(ab)
Blanc-Feraud, L, 194P(ab)
Blanchard, RA, 2095
Blando, L, 233P(ab)
Blasberg, R, 1152, 37P(ab), 56P(ab)
Blaufox, MD, 250P(ab)
Blevins, L, 133P(ab)
Blickman, H, 171
Bloch, S, 92
Block, TA, 112P(ab)
Blok, D, 1052
Bloom, SR, 41P(ab)
Blumenstock, FA, 229P(ab)
Blumenthal, RD, 1028(le), 215P(ab)
Blumhardt, R, 2160, 247P(ab)
Bochert, R, 8P(ab)
Bockisch, A, 1632, 1134, 161P(ab)
Boecker, H, 32P(ab)
Boecking, A, 222P(ab)
Boer, GJ, 207P(ab), 225P(ab)
Boering, G, 55P(ab)
Boerman, O, 105P(ab), 247P(ab)
Bogdanov, AA Jr., 39P(ab)
Bøgesø, KP, 234P(ab)
Bok, B, 226P(ab)
Bol, A, 15P(ab), 44P(ab), 86P(ab), 121P(ab)
Bolser, B, 11P(ab)
Boman, B, 6P(ab), 55P(ab)
Bomanji, J, 119P(ab)
Bomanji, JB, 845
Bonafous, JF, 1260
Bonar, DC, 200P(ab)
Bonasera, TA, 49P(ab), 56P(ab), 69P(ab), 160P(ab)
Boni, G, 2032
Boniface, G, 213P(ab)
Boniface, GR, 100P(ab), 153P(ab)
Bonnerot, V, 1410
Bonnin, F, 226P(ab)
Bonow, RO, 311
Bonte, FJ, 1239, 115P(ab)
Booker, FS, 222
Borchert, R, 218P(ab)
Bordewyk, RP, 32P(ab)
Borehert, RD, 469
Borer, JS, 1321, 34P(ab), 66P(ab)
Borm, G, 247P(ab)
Bormans, G, 4P(ab), 110P(ab), 141P(ab)
Borrel, E, 57
Borsato, N, 161P(ab)
Bossuyt, A, 152P(ab), 211P(ab)
Botelho, MFR, 1441
Bothun, E, 148P(ab)
Bottlaender, M, 102P(ab), 211P(ab)
Botvinick, EH, 303, 46P(ab), 64P(ab), 65P(ab), 95P(ab), 151P(ab)
Boubaker, A, 84P(ab)
Boudreau, RJ, 29P(ab)
Bougas, C, 199, 879, 1616(le), 2277(le)
Bouillon, R, 576, 110P(ab)
Boulahdour, H, 2105
Boulin, R, 234
Bourachot, ML, 14P(ab)
Bourgoignie, J, 249P(ab)
Bourguet, P, 1204
Bourguignon, M, 14P(ab), 211P(ab)
Bourlart-Daneski, V, 194P(ab)
Bousser, MG, 205P(ab)
Bowen, WD, 2169, 235P(ab)
Bowsher, JE, 19P(ab), 20P(ab)
Boxen, I, 242, 268, 242P(ab)
Boyd, SJ, 1619
Boyer, A, 127P(ab), 192P(ab)
Boyers, AS, 29P(ab)
Braams, JW, 55P(ab)
Brachman, MB, 18
Bradberry, CW, 48P(ab)
Brady, LW, 99, 1574
Brady, TJ, 39P(ab), 208P(ab)
Braegelmann, F, 34P(ab), 66P(ab)
Brandt, J, 5P(ab)
Brandt, KD, 381
Braun, U, 355
Braunstein, EM, 381
Braunstein, P, 1246
Brawer, MK, 218P(ab)
Braziel, R, 352(le)
Brechbiel, MW, 241P(ab)
Breeman, WAP, 2025, 165P(ab)
Breiter, HCR, 47P(ab)
Breithardt, G, 3P(ab), 45P(ab)
Breitz, HB, 908, 2111
Bremner, D, 102P(ab)
Bremner, JD, 205P(ab)
Brenner, H, 82P(ab)
Brenner, RJ, 18
Brenot, F, 229P(ab)
Brewster, LJ, 1595, 162P(ab)
Briançon, C, 1565
Briandet, P, 1204
Brichtswein, K, 77P(ab)
Briele, B, 77P(ab), 204P(ab)
Britton, KE, 845, 82P(ab), 119P(ab)
Brodie, JD, 18P(ab), 40P(ab), 63P(ab), 67P(ab)
Brock, W, 163P(ab)
Broich, K, 77P(ab), 204P(ab)
Brooks, DJ, 57P(ab)
Brown, BP, 11P(ab)
Brown, C, 168P(ab)
Brown, CV, 12P(ab), 257P(ab)
Brown, JW, 1169
Brown, KA, 1467, 2061, 54P(ab), 85P(ab), 147P(ab)
Brown, M, 37P(ab)
Brown, ML, 2236, 2241, 2247, 231P(ab)
Brown, RS, 75
Brown, SJ, 1574, 173P(ab)
Brown, T, 243P(ab)
Brown, WD, 157P(ab)
Brownell, A-L, 25P(ab), 73P(ab), 202P(ab)
Brownell, G, 73P(ab), 202P(ab)
Brucer, M, 354(le), 1219(le)
Bruck, B, 78P(ab)
Bruder, B, 257P(ab)
Bruland, OS, 216P(ab)
Bruni, WL, 97P(ab)
Brunken, RC, 35P(ab)
Bruns, C, 80P(ab)
Brunt, E, 234
Brustesco, C, 124P(ab), 211P(ab)
Bruyns, J, 99P(ab)
Buchbinder, S, 113P(ab)
Buchfelder, M, 37P(ab)
Büchler, M, 223P(ab), 225P(ab)
Buchpiguel, CA, 142P(ab)
Buchsbaum, DJ, 29P(ab), 100P(ab)
Buck, A, 196P(ab)
Buckley, KR, 481
Buckman, BO, 79P(ab)
Buczala, S, 66P(ab)
Budd, P, 231P(ab)
Budd, SE, 1995
Budinger, TF, 184P(ab)
Buell, U, 23P(ab), 98P(ab), 148P(ab), 158P(ab), 164P(ab), 183P(ab), 217P(ab), 222P(ab)
Bugaj, J, 232P(ab)
Buist, MR, 82P(ab)
Bullard, G, 17P(ab)
Bulteau, C, 1717
Bump, K, 1811
Bundesen, PG, 100P(ab), 153P(ab)
Bunko, H, 1478
Buonocore, E, 6P(ab), 109P(ab), 261P(ab)
Buraggi, GL, 219P(ab)
Burchert, W, 1770
Burger, CW, 82P(ab)
Burger, P, 37P(ab)
Burke, G, 112P(ab)
Burke, GJ, 196P(ab)
Burney, RJ, 56P(ab)
Burns, RJ, 1692, 1834(le), 54P(ab), 149P(ab)
Burr, G, 102P(ab), 103P(ab)
Burrows, P, 21P(ab)
Burt, M, 11P(ab)
Burton, ML, 236P(ab)
Burwinkel, P, 153P(ab)
Buscombe, JR, 1621, 138P(ab)
Bush, NE, 1839
Busnardo, B, 1626
Bussiere, F, 1260, 1472, 5P(ab), 45P(ab), 194P(ab)
Butchko, GM, 53P(ab)
Butler, CS, 20P(ab)
Buttram, S, 66P(ab), 104P(ab)
Buxton, DB, 2038, 4P(ab), 50P(ab), 183P(ab)
Byars, LG, 1367
Byrd, S, 62P(ab)
Byrne, H, 26P(ab)
Byulund, DB, 238P(ab)

Cabahug, C, 899
Cadière, GB, 99P(ab)
Cadorette, J, 101P(ab), 136P(ab)
Caillat-Vigneron, N, 128P(ab)
Cairns, HS, 1163
Calam, J, 41P(ab)
Caldwell, JH, 918, 79P(ab)
Callahan, AP, 946, 54P(ab), 236P(ab), 243P(ab)
Callahan, RJ, 1282, 1309,

1529, 39P(ab), 69P(ab), 83P(ab), 171P(ab), 172P(ab)
Callahan, RL, 15P(ab)
Caluser, CI, 145P(ab)
Camera, L, 58P(ab), 241P(ab)
Camici, P, 867(le)
Camsonne, R, 241P(ab)
Caner, B, 162P(ab), 230P(ab)
Canning, LR, 222
Cannon, RA, 2120
Cao, ZJ, 192P(ab)
Capelli, S, 205P(ab)
Capello, WN, 381
Caplin, D, 57P(ab)
Carabasi, M, 105P(ab)
Caracò, C, 82P(ab), 115P(ab)
Caraher, JM, 440, 123P(ab)
Cardella, CJ, 149P(ab)
Cardella, JF, 121P(ab)
Cardenal, C, 1452
Cardillo, A, 231P(ab)
Cardiot, G, 98P(ab)
Caretta, RF, 64P(ab)
Carey, JE, 25P(ab), 123P(ab), 158P(ab)
Caride, VJ, 1390(le)
Carlson, KE, 18P(ab)
Carmant, L, 226P(ab)
Carmichael, N, 83P(ab), 106P(ab), 114P(ab), 213P(ab), 214P(ab)
Carnochan, P, 243P(ab)
Caroline, D, 169P(ab)
Caron, M, 96P(ab)
Caron, PC, 105P(ab)
Carr, KF, 261P(ab)
Carrasquillo, JA, 58P(ab), 124P(ab), 233P(ab), 241P(ab)
Carriero, MV, 213P(ab)
Carrio, I, 171, 1503, 13P(ab), 145P(ab), 146P(ab)
Carson, RE, 311, 27P(ab), 155P(ab)
Casaer, P, 210P(ab)
Casara, D, 1626, 161P(ab)
Casciari, J, 215P(ab)
Casciari, JJ, 21P(ab)
Casey, KL, 56P(ab)
Casey, M, 7P(ab), 55P(ab)
Cassidy, EH, 239P(ab)
Castaigne, A, 1899, 14P(ab), 36P(ab)
Castellani, MR, 219P(ab)
Castelli, L, 82P(ab), 115P(ab), 153P(ab)
Castellino, R, 56P(ab)
Castilla, EP, 589
Castronovo, FP Jr., 157P(ab), 869(br)
Catafau, AM, 77P(ab)
Cava, GL, 117P(ab)
Cavagnaro, F, 117P(ab), 137P(ab), 249P(ab)
Cavaillolès, F, 229P(ab)
Cavallini, AR, 110P(ab)
Cave, V, 75P(ab)
Cazzuola, F, 2032
Cecil, MP, 1826(le)
Cei, A, 1175
Censi, C, 67P(ab)
Ceriani, R, 1067
Ceriani, RL, 53P(ab)
Cerqueira, MD, 1441, 74P(ab)
Cérulus, G, 10P(ab)
Chaar, M, 22P(ab)
Chabriat, H, 205P(ab)
Chadduck, W, 52P(ab)
Chaiken, L, 224P(ab)
Chaitman, BR, 85P(ab), 120P(ab)
Chaiwatanrat, T, 845
Chakraborty, P, 13P(ab), 45P(ab), 123P(ab), 236P(ab)
Chaly, T, 180P(ab), 209P(ab)
Champlin, R, 33P(ab), 161P(ab), 218P(ab)
Chan, A, 165P(ab)
Chan, B, 109P(ab), 132P(ab), 133P(ab), 197P(ab)
Chan, E-Y, 146P(ab)
Chan, J, 172P(ab)
Chan, JG, 666
Chan, KH, 27P(ab)
Chan, Y-W, 18P(ab)
Chandramouli, B, 6P(ab), 7P(ab), 21P(ab), 47P(ab), 73P(ab), 169P(ab)
Chaney, RC, 9P(ab)
Chang, LS, 138P(ab)
Chang, SL, 138P(ab)
Chang, W, 9P(ab), 195P(ab)
Chao, S, 34P(ab)
Chapman, CR, 1839
Chapman, JD, 405, 885
Charalambous, A, 8P(ab)
Charalel, J, 76P(ab)
Charbonnier, P, 194P(ab)
Charkes, DN, 10P(ab)
Charkes, ND, 576, 11P(ab), 169P(ab)
Charlotte, F, 2105
Charney, DS, 31P(ab), 48P(ab), 102P(ab), 108P(ab), 109P(ab), 205P(ab), 211P(ab), 243P(ab)
Chartrand, R, 145P(ab)
Chatal, J-F, 180, 1267, 1662
Chatterton, BE, 125P(ab)
Chau, P, 465
Chaudhuri, TR, 238P(ab)
Chayes, Z, 76P(ab), 77P(ab)
Chen, BC, 203P(ab), 251P(ab)
Chen, C, 1854, 40P(ab), 109P(ab), 132P(ab), 197P(ab), 198P(ab)
Chen, C-T, 112P(ab), 186P(ab)
Chen, DCP, 261P(ab)
Chen, G, 94P(ab)
Chen, IW, 127P(ab)
Chen, J-C, 474
Chen, K, 4P(ab), 40P(ab), 50P(ab)
Chen, LF, 589
Chen, M, 149P(ab)
Chen, MN, 245P(ab)
Chen, MT, 138P(ab)
Chen, WL, 238P(ab)
Chen, Y, 88P(ab), 188P(ab)
Chen, YK, 145P(ab)
Cheng, KT, 106P(ab), 179P(ab), 245P(ab)
Cheng, TP, 238P(ab)
Cherqui, D, 2105
Cherry, SR, 143, 671
Chetanneau, A, 1662
Cheung, N-K, 106P(ab), 114P(ab)
Chevalier, A, 387
Chevres, A, 1574, 163P(ab), 173P(ab)
Chia, LG, 167P(ab)
Chianelli, M, 246P(ab)
Chiao, P, 9P(ab), 148P(ab)
Chiariello, M, 1688, 147P(ab)
Chien, D, 190P(ab)
Chierichetti, F, 161P(ab)
Chimowitz, MI, 207P(ab)
Chin, B, 143P(ab)
Chin, LM, 1811
Chin, MC, 46P(ab)
Chinn, G, 175P(ab), 185P(ab)
Chinol, M, 1536, 166P(ab), 233P(ab)
Chiou, PF, 176P(ab)
Chiron, C, 1717
Chiu, KW, 222
Chiu, ML, 140P(ab)
Chiu, S, 1595, 162P(ab)
Chlouverakis, G, 34P(ab)
Cho, KS, 138P(ab)
Choi, CW, 212P(ab)
Choi, H, 88P(ab)
Choi, J, 258P(ab)
Choi, NC, 1571, 73P(ab)
Choi, SS, 83P(ab)
Choi, Y, 488, 2009, 2038, 1832(le), 4P(ab), 40P(ab), 50P(ab), 137P(ab), 183P(ab), 224P(ab)
Chossat, FM, 1260
Christian, BT, 1058, 184P(ab), 248P(ab)
Christian, PE, 1905, 30P(ab), 62P(ab), 71P(ab), 91P(ab), 157P(ab), 176P(ab), 187P(ab), 196P(ab)
Christin, A, 1367
Chu, LS, 143P(ab)
Chu, TH, 281, 29P(ab), 36P(ab), 44P(ab), 179P(ab)
Chu, YK, 145P(ab)
Chua, T, 1349, 1485, 189P(ab)
Chugo, A, 192P(ab)
Chumpradit, S, 89P(ab), 132P(ab), 235P(ab)
Chung, D-G, 204P(ab)
Chung, DH, 83P(ab)
Chung, HK, 212P(ab)
Chung, J-K, 1651, 212P(ab)
Chung, T-S, 1987
Cicoria, A, 143P(ab)
Cieslak, RD, 1190
Cini, R, 39P(ab)
Cinotti, L, 22P(ab), 103P(ab)
Civelek, AC, 143P(ab)
Clack, R, 80P(ab)
Claessens, RAMJ, 1621, 35N(12), 62P(ab), 105P(ab), 112P(ab), 247P(ab)
Clanton, JA, 469
Clark, J, 185P(ab)
Clark, R, 176P(ab)
Clarke, G, 138P(ab)
Clarke, GA, 1778
Clarke, MF, 6P(ab)
Clarke, SEM, 144P(ab)
Clarke, SW, 1859
Clavo, A, 2279(le)
Clavo, AC, 414, 773, 73P(ab), 93P(ab)
Clerc, J, 387, 1565
Cliff, RO, 2160
Clinthorne, NH, 9P(ab), 90P(ab), 91P(ab), 100P(ab), 113P(ab), 190P(ab)
Clorius, JH, 48, 1075, 139P(ab)
Cloutier, DJ, 75P(ab), 85P(ab), 152P(ab)
Coade, GE, 122P(ab)
Cochoff, S, 150P(ab)
Cochran, AJ, 54P(ab)
Coderre, JA, 222P(ab)
Cody, RL, 224P(ab)
Coenen, HH, 107P(ab)
Cogneau, M, 15P(ab), 86P(ab), 121P(ab)
Cohen, AM, 1656, 83P(ab), 214P(ab)
Cohen, B, 257P(ab)
Cohen, BM, 1101
Cohen, D, 263P(ab)
Cohen, GE, 169P(ab)
Cohen, L, 1877
Cohen, M, 1859
Colao, A, 42P(ab), 219P(ab)
Cole, CW, 74P(ab)
Coleman, E, 16P(ab), 17P(ab)
Coleman, RE, 39, 567, 869(br), 1109, 1119, 1577, 1587, 1998, 2269, 7P(ab), 10P(ab), 17P(ab), 19P(ab), 20P(ab), 21P(ab), 23P(ab), 26P(ab), 30P(ab), 37P(ab), 79P(ab), 80P(ab), 81P(ab), 101P(ab), 144P(ab), 190P(ab), 191P(ab), 195P(ab)
Collecchi, P, 1175
Collier, BD, 961, 2236, 2241, 2247, 44P(ab), 56P(ab), 213P(ab)
Collins, C, 1031, 1839
Collins, DL, 70P(ab)
Collins, PJ, 125P(ab)
Collorec, R, 1204
Colnaghi, MI, 213P(ab)
Colombo, F, 360
Colombo, L, 226P(ab)
Colombo, P, 114P(ab)
Comans, EFI, 649, 15P(ab)
Comar, D, 1460
Comazzi, V, 18P(ab), 134P(ab)
Comtois, R, 1927
Connett, JM, 28P(ab), 81P(ab), 134P(ab), 216P(ab)
Conrad, B, 32P(ab)
Conte, PJ, 54P(ab), 61P(ab)
Conti, PS, 182P(ab)
Conway, J, 1029(le)
Conway, JJ, 226P(ab)
Cook, C, 241P(ab)
Cook, JS, 239P(ab)
Cook, SA, 400, 1834(le)
Cooke, CD, 1494, 96P(ab)
Cooke, I, 232P(ab)
Cooper, JA, 1341, 51P(ab), 142P(ab), 150P(ab), 195P(ab)
Cooper, M, 798, 112P(ab), 239P(ab), 243P(ab)
Coppens, A, 121P(ab)
Coppola, R, 235P(ab)
Corbelli, C, 1166
Corbett, JR, 84P(ab), 90P(ab)
Cordes, M, 31P(ab), 164P(ab)
Corley, JH, 196P(ab)
Corlija, M, 248P(ab)
Cornelius, E, 255P(ab), 262P(ab)
Cornish, KG, 238P(ab)
Correia, JA, 51P(ab), 69P(ab), 73P(ab), 88P(ab)
Corrigan, P, 251P(ab)
Corstens, FHM, 1316, 1621, 62P(ab), 105P(ab), 112P(ab), 163P(ab), 247P(ab)
Cossermelli, W, 142P(ab)
Costa, WL, 258P(ab)
Costi, P, 121P(ab)
Cotton, LA, 148P(ab)
Counsell, RE, 787
Couto, JC, 53P(ab)
Cowan, DSM, 242
Coyle, J, 12P(ab), 88P(ab)
Coyle, K, 88P(ab)
Cradduck, TD, 179P(ab), 256P(ab)
Crain, BJ, 23P(ab)
Crane, J, 223P(ab)
Crawford, SM, 93P(ab)
Creasy, JL, 37P(ab)
Crebs, CK, 62P(ab)
Cromie, WJ, 51P(ab)
Cronmiller, JR, 1829(le)
Croop, JM, 140P(ab)
Crozatier, B, 1899
Crouzel, C, 981, 45P(ab), 109P(ab), 205P(ab)
Culbert, P, 237P(ab)
Cullom, SJ, 96P(ab)
Culver, C, 349
Culver, CM, 1210, 158P(ab)
Cumming, P, 31P(ab)
Cummings, D, 156P(ab), 205P(ab)
Cunningham, J, 53P(ab)
Cuocolo, A, 173, 1602, 1688, 147P(ab), 153P(ab)
Curtet, C, 1267
Curtin, CR, 109P(ab)
Curtis, M, 717
Cutler, PD, 136P(ab), 176P(ab)
Cyr, JE, 18P(ab), 146P(ab)
Czernin, J, 488, 1832(le), 35P(ab), 165P(ab)

Dadparvar, S, 1574, 163P(ab), 173P(ab)
Dae, MW, 303, 46P(ab), 64P(ab), 65P(ab), 95P(ab)
Daghighian, F, 1595, 37P(ab), 114P(ab), 127P(ab), 162P(ab), 213P(ab), 214P(ab)
Dagousset, F, 387
Dahl, J, 148P(ab)

Dahlberg, ST, 927, 14P(ab), 46P(ab), 130P(ab)
Dahlbom, M, 143, 488, 2009, 1832(le), 101P(ab), 137P(ab), 184P(ab)
D'Alessandro, HA, 258P(ab)
D'Alessandro, MP, 258P(ab)
Dalla Pozza, L, 1082
Dalrymple, GV, 896, 111P(ab)
Daly, JJ, 255P(ab)
Daly, PA, 149P(ab)
Dam, K, 168P(ab)
Damjanov, I, 260
Damsker, J, 163P(ab)
Daniel, G, 1267
Dannals, RF, 120, 25P(ab), 31P(ab), 86P(ab), 103P(ab), 109P(ab), 132P(ab), 133P(ab), 197P(ab), 199P(ab), 228P(ab), 234P(ab)
Danos, P, 77P(ab)
Dansereau, RN, 229P(ab)
Darcourt, G, 5P(ab)
Darcourt, J, 1472, 5P(ab), 45P(ab), 194P(ab)
Das, MK, 239P(ab), 243P(ab)
Das Gupta, P, 30
DaSilva, JN, 25P(ab)
Datz, FL, 128, 455, 1905, 1389(le), 2135, 30P(ab), 62P(ab), 71P(ab), 91P(ab), 157P(ab), 176P(ab), 196P(ab), 220P(ab), 249P(ab)
Daube-Witherspoon, ME, 60P(ab), 177P(ab)
Dauphin, F, 241P(ab), 243P(ab)
Dauriac, C, 182
Davidson, J, 30
Davies, RF, 74P(ab)
Davison, A, 242P(ab)
Day, P, 151P(ab)
Daya, SA, 614
Dayanikli, F, 35P(ab), 35P(ab), 148P(ab), 155P(ab)
Dayankikli, BF, 958
Dean, R, 66P(ab)
Dean, RT, 17P(ab), 66P(ab), 104P(ab)
de Andrés, L, 1503
De Biasi, F, 126P(ab)
de Bruin, K, 225P(ab)
Debruyne, D, 241P(ab)
De Carli, F, 91P(ab)
Declerck, P, 227P(ab)
deCosta, BR, 235P(ab)
Dedrick, RL, 1552
Deeb, M, 43P(ab)
de Fatima Pacheco, M, 1441
Defrise, M, 1367
DeFulvio, J, 260
De Geeter, F, 1217(le), 152P(ab)
Degomme, P, 1217(le)
DeGrado, TR, 1287, 45P(ab), 101P(ab), 107P(ab)
De Groof, M, 154P(ab)
DeHaven-Hudkins, DL, 243P(ab)
Dehdashti, F, 49P(ab), 56P(ab)
DeJager, R, 214P(ab)
DeJesus, OT, 8P(ab), 69P(ab)
de Jong, M, 2025, 165P(ab)
deJong, RBJ, 164P(ab)
de Kerviler, E, 98P(ab)
de Kleijn, EMHA, 62P(ab)
de Klerk, JMH, 223P(ab)
De Kock, M, 44P(ab)
Delaage, M, 1267, 1662
Delaloye, AB, 84P(ab)
Delaloye, B, 84P(ab)
DeLaPaz, R, 56P(ab)
De La Pena, RC, 22P(ab)
Delbeke, D, 826, 2185, 86P(ab)
de Leon, MJ, 2019
Delforge, J, 981, 45P(ab), 102P(ab), 109P(ab)
Dell'Acqua, A, 93P(ab)
Della Vittoria, G, 44P(ab)
Delpassand, E, 88P(ab), 119P(ab)
del Rosario, RB, 1147, 135P(ab)
Del Sole, A, 5P(ab)
Del Vecchio, A, 94P(ab)
Del Vecchio, P, 1927
Del Vecchio, S, 213P(ab)
Demacker, PNM, 1316
Demmelbauer, K, 212P(ab)
Dempke, W, 164P(ab)
DeNardo, GL, 1020, 1067, 53P(ab), 93P(ab), 128P(ab), 189P(ab)
DeNardo, SJ, 1020, 1067, 53P(ab), 93P(ab), 128P(ab), 189P(ab)
Denays, R, 1223, 226P(ab)
Dence, CS, 56P(ab), 79P(ab)
Dendale, P, 152P(ab)
den Hollander, W, 82P(ab)
Denton, TA, 150P(ab)
de Paulis, T, 132P(ab), 202P(ab), 158P(ab)
De Pauw, M, 15P(ab), 86P(ab)
DePuey, EG, 1871, 2006, 1829(le), 24P(ab), 64P(ab), 131P(ab), 150P(ab)
DePuey, FG, 1871
Dequeker, J, 141P(ab)
Derbekyan, V, 853, 1992
Derenzo, SE, 101P(ab), 184P(ab)
DeRogatis, A, 24P(ab)
de Rolan, FS, 92P(ab)
De Roo, M, 576, 4P(ab), 10P(ab), 110P(ab), 141P(ab), 210P(ab), 222P(ab), 227P(ab)
Derwanz, R, 1632
De Sadeleer, C, 152P(ab)
De Saedeleer, C, 117P(ab)
Desai, FR, 180P(ab)
Desai, SP, 955, 1748
De Santi, MS, 115P(ab)
Desgrez, A, 229P(ab)
DeSombre, ER, 272
Deutsch, E, 1132, 38P(ab)
Deutsch, EA, 228, 120P(ab), 156P(ab), 248P(ab)
Deutsch, G, 64P(ab)
Deutsch, K, 38P(ab)
Deutsch, KF, 135P(ab)
Deutsh, G, 92P(ab)
Devanand, DP, 1090
DeVito, R, 29P(ab)
Devlin, S, 172P(ab)
Devous, MD, 1239, 23P(ab), 68P(ab), 91P(ab)
Devous, MD Sr., 754
de Vries, DJ, 72P(ab)
Dewald, CL, 50P(ab)
Dewan, N, 20P(ab)
Dewanjee, MK, 172P(ab), 174P(ab), 214P(ab), 221P(ab), 224P(ab)
Dewey, SL, 246, 609, 619, 67P(ab), 78P(ab), 200P(ab)
DeWit, H, 798
Dey, H, 84P(ab), 201P(ab), 205P(ab)
Dey, HM, 1416
Dhawan, A, 40P(ab)
Dhawan, V, 180P(ab), 209P(ab)
Dhumeaux, D, 2105
Diamond, GA, 150P(ab)
Diaz, A, 263P(ab)
Diaz, M, 212P(ab)
DiBella, E, 29P(ab)
DiCarli, M, 184P(ab)
Di Donna, A, 126P(ab)
DiFabrizo, L, 172P(ab)
Diggles, L, 187, 140P(ab), 144P(ab), 231P(ab)
DiGiorgio, ML, 261P(ab)
Dilsizian, V, 178P(ab)
Dilts, C, 151P(ab)
Di Luca, L, 1175
Dimitrakopoulou, A, 12, 1075, 218P(ab), 220P(ab)
Dimopoulos, M, 33P(ab), 161P(ab)
Ding, Y-S, 246, 619, 69P(ab), 78P(ab)
Dione, DP, 97P(ab)
DiPaula, AF Jr., 86P(ab)
DiResta, G, 56P(ab)
DiRocco, R, 15P(ab), 92P(ab)
Di Rocco, RJ, 641
Di Sacco, S, 1175
Di Stefano, R, 1175
Divgi, CR, 422, 1656, 53P(ab), 83P(ab), 94P(ab), 105P(ab), 114P(ab), 127P(ab), 213P(ab), 214P(ab)
Do, T, 1294
Dobbeleir, A, 186P(ab)
Dobko, T, 184P(ab)
Dobrinsky, C, 1871
Docter, R, 2025
Doerr, RJ, 1818
Dogan, AS, 1607, 226P(ab)
Dokumaci, B, 889
Dole, MG, 51P(ab), 220P(ab)
Doll, J, 12, 21P(ab), 218P(ab)
Donaldson, G, 1839
Donath, A, 1367
Dond, M, 129P(ab)
Dondi, M, 1166
Donnerstag, B, 126P(ab)
Dorflinger, E, 131P(ab)
Dorfman, D, 77P(ab)
Dorian, SM, 199P(ab)
Dormans, TPJ, 1316
Dörr, U, 97P(ab)
Dottorini, ME, 226P(ab)
Dougan, H, 235P(ab)
Douglas, MA, 311
Doussal, J-ML, 1662
Douville, C, 62P(ab)
Dragotakes, SC, 199, 172P(ab), 1616(le), 1975, 2176, 2277(le)
Draho, JM, 394, 35P(ab)
Drane, WE, 658
Drüeke, T, 128P(ab)
D'Souza, MF, 190P(ab)
Duatti, A, 18P(ab), 134P(ab)
Dubey, A, 90P(ab)
Dubovsky, EV, 249P(ab)
Duchak, JM, 94P(ab)
Duckett, JW, 117P(ab)
duCret, RP, 29P(ab)
Dudczak, R, 1397
Dufour, JM, 58P(ab)
Duncan, J, 205P(ab)
Duncan, JR, 1728, 59P(ab)
Duncan, JS, 57P(ab), 187P(ab)
Duncker, D, 1503, 13P(ab)
Dunigan, K, 218P(ab)
Dunn, TJ, 135P(ab)
Dunn, WL, 141P(ab), 142P(ab)
Dupont, M, 1642
Duranceau, A, 140P(ab)
Durham, JS, 908
Duryea, RA, 197P(ab), 202P(ab)
Dutoit, M, 84P(ab)
Dutschka, K, 58P(ab)
Duval, D, 243P(ab)
Duvernoy, C, 155P(ab)
Dworkin, HJ, 349, 1028(le), 1210, 158P(ab)

Eades, CG, 182P(ab)
Eagle, K, 149P(ab)
Eary, JF, 1031, 1839
Eber, O, 2278(le), 2280(le), 122P(ab)
Eberl, S, 1752
Ebert, A, 107P(ab)
Ebert, D, 47P(ab)
Eckard, DA, 1239
Eckelman, WC, 641
Edelbroek, MAL, 582
Edgeworth, J, 90P(ab)
Edlin, J, 188P(ab)
Edwards, B, 222
Eenige van, MJ, 649
Efange, SMN, 8P(ab), 90P(ab)
Effert, H, 217P(ab)
Effird, J, 206P(ab)
Eggli, DF, 121P(ab)
Ehlers, M, 31P(ab)
Ehrhardt, GJ, 38P(ab), 231P(ab)
Eidelberg, D, 180P(ab), 209P(ab)
Eisen, HJ, 2049
Eisenberg, B, 169P(ab)
Eisenhut, M, 217P(ab)
Eisert, D, 206P(ab)
Eisner, RL, 281, 978, 29P(ab), 36P(ab), 44P(ab), 96P(ab), 146P(ab), 179P(ab)
Ejiri, K, 159P(ab)
Elder, RC, 38P(ab), 120P(ab), 248P(ab)
Eldredge, WJ, 261P(ab)
Elfner, R, 87P(ab)
Elgazzar, AH, 52P(ab), 227P(ab), 255P(ab), 261P(ab)
Ell, PJ, 169, 1621, 138P(ab), 153P(ab)
Elliott, D, 196P(ab), 203P(ab)
Elliott, DG, 53P(ab)
Ellison, D, 82P(ab)
Elmaleh, DR, 1309, 1529, 25P(ab), 73P(ab), 202P(ab), 232P(ab), 236P(ab)
Elser, H, 217P(ab)
Elsinga, PH, 49P(ab), 183P(ab)
Emmrich, F, 92
Emmrich, JG, 99
Emrich, D, 153P(ab)
Enas, J, 7P(ab)
Endert, E, 225P(ab)
Endo, K, 815, 1745, 2085, 14P(ab), 42P(ab), 119P(ab), 215P(ab)
Engel, J, Jr., 1892
Enright, DJ, 142P(ab)
Ensing, GJ, 2280(le)
Enta, A, 1944
Epelbaum, R, 2101
Epperly, M, 231P(ab)
Epstein, AL, 114P(ab)
Ercan, MT, 84P(ab)
Erickson, KL, 93P(ab)
Eriksson, L, 101P(ab)
Erkonen, W, 256P(ab)
Erlandsson, K, 9P(ab)
Erlichman, C, 242P(ab)
Erwin, WD, 35P(ab), 128P(ab), 151P(ab), 175P(ab)
Eshima, D, 129P(ab), 244P(ab), 246P(ab), 250P(ab)
Esposito, G, 12P(ab), 67P(ab)
Esser, PD, 48P(ab), 60P(ab), 125P(ab)
Essiambre, R, 96P(ab)
Esterbrooks, DJ, 50P(ab)
Esteves, MI, 171P(ab)
Estorch, M, 1503, 13P(ab), 146P(ab)
Estrada, WN, 1214
Ethier, J, 58P(ab)
Eubanks, RS Jr., 345
Eubig, C, 196P(ab), 255P(ab)
Evans, AC, 57P(ab), 70P(ab)
Evans, D, 111P(ab)
Evans, ML, 21P(ab)
Evans, NH, 1818
Even-Sapir, E, 458, 1377
Evora, PH, 8P(ab)
Eysman, L, 230P(ab)
Ezuddin, S, 117P(ab), 137P(ab), 174P(ab), 221P(ab)
Ezzedine, B, 8P(ab), 218P(ab)

Faber, TL, 96P(ab)
Fabry, G, 227P(ab)
Faglia, G, 114P(ab)
Fagret, D, 57, 1392(le)

Fahey, FH, 182P(ab)
Falchook, F, 112P(ab)
Falen, SW, 48P(ab)
Fallone, PS, 1656, 83P(ab), 214P(ab)
Fan, SH, 26P(ab)
Fang, QW, 233P(ab)
Fantanas, C, 190P(ab)
Fanti, S, 1166, 129P(ab)
Fantinato, L, 97P(ab), 135P(ab)
Fanwick, PE, 228
Faraggi, M, 98P(ab)
Farahi, JB, 12P(ab), 257P(ab)
Farde, L, 7P(ab), 89P(ab), 102P(ab)
Farlow, DC, 1172
Faro, H-P, 219P(ab)
Farrell, EL, 1818
Fass, J, 98P(ab), 158P(ab)
Favero, A, 1626
Fawwaz, RA, 48P(ab), 99P(ab)
Fazinni, E, 131P(ab)
Fazio, F, 137, 360, 1460, 5P(ab), 93P(ab), 94P(ab), 114P(ab), 154P(ab)
Febo, R, 106P(ab)
Federici, M, 216P(ab)
Fedio, V, 22N(4)
Feinendegen, LE, 355, 2222, 32P(ab), 107P(ab)
Feistel, H, 47P(ab), 207P(ab)
Felix, R, 31P(ab), 164P(ab)
Feng, D, 185P(ab)
Fenyvs, EJ, 9P(ab)
Ferdeghini, EM, 1175, 2032
Ferency, S, 1031
Ferlin, G, 161P(ab)
Fernandez, G, 1485
Fernandez-Ulloa, M, 171P(ab), 261P(ab)
Fernando, JL, 9P(ab)
Ferone, D, 42P(ab), 219P(ab)
Ferrari, E, 1472, 45P(ab)
Fessler, JA, 25P(ab), 70P(ab), 91P(ab), 190P(ab)
Fetterman, RC, 97P(ab)
Ficaro, EP, 30P(ab), 148P(ab)
Ficken, VJ, 257P(ab)
Fields, L, 245P(ab)
Fig, LM, 11P(ab)
Figulla, HR, 153P(ab)
Filo, RS, 381
Fine, EJ, 250P(ab)
Fink, LM, 896
Finlayson, A, 179P(ab)
Finn, C, 818
Finn, R, 1152
Finn, RD, 37P(ab), 53P(ab), 83P(ab), 105P(ab), 114P(ab), 214P(ab), 239P(ab)
Finstad, CL, 216P(ab)
Firouzbahkt, ML, 69P(ab)
Fischman, AJ, 6, 879, 1282, 1303, 1309, 1529, 1571, 1964, 1975, 2130, 2176, 2253, 15P(ab), 24P(ab), 25P(ab), 39P(ab), 47P(ab), 51P(ab), 73P(ab), 83P(ab), 88P(ab), 104P(ab), 172P(ab), 173P(ab), 206P(ab), 208P(ab), 232P(ab), 236P(ab), 240P(ab), 260P(ab)
Fish, DR, 57P(ab)
Fisher, DR, 908, 106P(ab)
Fisher, KJ, 232P(ab)
Fisher, RS, 11P(ab), 169P(ab)
Fisher, SJ, 75, 787, 104P(ab), 245P(ab)
Fishman, S, 353(le)
Fitchett, DH, 589
Flameng, W, 4P(ab)
Flanagan, R, 58P(ab), 119P(ab)
Fleishman, MJ, 122P(ab)
Flesher, J, 199P(ab)
Flicker, S, 261P(ab)
Flivik, G, 1646
Flores, AR, 1695
Floyd, C, 39
Floyd, CE Jr., 19P(ab), 20P(ab)
Fogarasi, M, 109, 1618(le), 59P(ab), 234P(ab), 240P(ab)
Fogarty, K, 32P(ab)
Foged, C, 7P(ab), 89P(ab)
Fogelman, I, 2236, 2241, 2247, 110P(ab), 141P(ab), 142P(ab), 144P(ab)
Foisy, MF, 394, 130P(ab)
Folio, T, 197P(ab), 198P(ab)
Folks, R, 1494, 87P(ab), 251P(ab)
Fonti, R, 213P(ab)
Foote, C, 65P(ab)
Forman, D, 215P(ab)
Fornazzari, L, 1274
Forrester, DM, 1990
Forsaith, A, 349
Forster, AM, 222
Forstrom, LA, 61P(ab)
Fossella, F, 134P(ab), 223P(ab)
Foster, CE, 18
Foster, NL, 4P(ab), 116P(ab)
Foulon, C, 89P(ab)
Fourie, PJ, 1828(le)
Fourniere, BL, 135P(ab)
Fourré, C, 1565
Fowler, JS, 246, 609, 619, 67P(ab), 69P(ab), 78P(ab), 102P(ab), 103P(ab), 131P(ab), 200P(ab), 237P(ab)
Fox, JG, 171P(ab)
Fox, PT, 39P(ab)
Fragu, P, 1565
Franceschi, D, 899, 43P(ab), 222P(ab)
Franceschi, M, 222P(ab)
Francis, IR, 1420, 127P(ab)
Franck, G, 1460
Frank, A, 2278(le), 7P(ab), 20P(ab), 21P(ab), 55P(ab)
Franken, PR, 152P(ab)
Franks, W, 204P(ab)
Fraunhofer, S, 63P(ab)
Freedman, N, 27P(ab)
Freeman, NMT, 311
Freemer, M, 257P(ab)
Frenkel, A, 141P(ab)
Frey, EC, 72P(ab), 188P(ab), 192P(ab)
Frey, KA, 322, 22P(ab), 25P(ab), 56P(ab), 108P(ab), 116P(ab), 123P(ab), 207P(ab)
Frick, GS, 210P(ab)
Frick, M, 21P(ab), 251P(ab)
Frickhofen, N, 217P(ab)
Friden, A, 33P(ab)
Friedman, AH, 23P(ab)
Friedman, J, 1485, 64P(ab), 130P(ab), 148P(ab)
Friedman, M, 150P(ab)
Friedman, P, 193
Fries, H, 225P(ab)
Frim, DM, 202P(ab)
Frist, WH, 826
Fritzberg, A, 246P(ab)
Fritzberg, AR, 2111
Froelich, J, 2198, 16P(ab), 17P(ab)
Froelich, JW, 1109, 1119
Froideville, JL, 99P(ab)
Froment, JC, 22P(ab), 103P(ab)
Front, D, 1330, 1826(le), 2101
Front, GMKD, 141P(ab)
Frost, A, 165P(ab)
Frost, JJ, 5P(ab), 31P(ab), 103P(ab), 199P(ab), 228(ab)
Frouin, V, 186P(ab)
Frueh, B, 110P(ab)
Fuchs, J, 161P(ab)
Fuji, R, 1543
Fujibayashi, Y, 147P(ab)
Fujii, R, 431, 26P(ab), 198P(ab), 225P(ab)
Fujii, T, 167P(ab)
Fujimori, K, 216P(ab)
Fujimoto, J, 2030
Fujita, H, 57P(ab), 198P(ab), 199P(ab)
Fujita, M, 199P(ab), 201P(ab), 202P(ab)
Fujita, T, 194P(ab)
Fujiwara, T, 780
Fukuchi, K, 199P(ab), 201P(ab)
Fukuchi, M, 126P(ab)
Fukuda, H, 780, 200P(ab)
Fukui, H, 1103, 170P(ab)
Fukumura, T, 288
Fukunaga, M, 208P(ab)
Fukuyama, H, 839
Fulton, RR, 1752
Furlong, RB, 172P(ab)
Furmanski, P, 1067
Furudate, M, 216P(ab)
Furusawa, T, 202P(ab)
Fusamoto, H, 1103, 170P(ab)
Fuseau, C, 1739, 45P(ab), 102P(ab)
Fusselman, MJ, 56P(ab)
Futami, S, 2091
Fyfe, A, 149P(ab)

Gabor, FV, 128, 1389(le)
Gachon, P, 255
Gadhoke, A, 65P(ab)
Gage, HD, 182P(ab)
Gagne, GM, 992, 81P(ab), 97P(ab), 135P(ab)
Galati, G, 12P(ab)
Galati, JS, 111P(ab)
Galema, TW, 147P(ab), 154P(ab)
Galetta, SL, 1009, 1447
Gallagher, JG, 75P(ab)
Gallagher, R, 193
Gallik, DM, 3P(ab)
Gallinger, S, 99P(ab)
Galloway, S, 208
Galonska, P, 164P(ab)
Galvan, G, 122P(ab)
Galvin, J, 256P(ab), 258P(ab)
Galy, G, 103P(ab)
Gambaro, M, 91P(ab)
Gandler, WR, 60P(ab)
Gangopadhyay, A, 246P(ab), 247P(ab)
Ganju-Frishan, A, 224P(ab)
Gansow, OA, 241P(ab)
Ganti, V, 24P(ab), 64P(ab)
Ganz, W, 117P(ab), 137P(ab), 174P(ab), 263P(ab)
Ganz, WI, 33P(ab), 261P(ab)
Gao, Y, 31P(ab), 243P(ab)
Garada, BM, 723, 2044, 27P(ab), 47P(ab), 179P(ab), 203P(ab), 208P(ab), 212P(ab), 259P(ab)
Garber, CE, 75P(ab), 85P(ab), 152P(ab)
Garcia, E, 64P(ab), 148P(ab), 251P(ab)
Garcia, EV, 978, 1494, 96P(ab)
Garcia-Larrea, L, 22P(ab), 103P(ab)
Garg, PK, 79P(ab), 99P(ab), 191P(ab), 216P(ab)
Garg, S, 79P(ab), 99P(ab), 216P(ab)
Garin-Chesa, P, 83P(ab)
Garlich, J, 33P(ab), 244P(ab)
Garmestani, K, 241P(ab)
Garner, S, 89P(ab), 132P(ab), 135P(ab)
Garreau, B, 1717, 78P(ab)
Garreau, L, 235P(ab)
Garrido, JM, 1520
Garty, II, 61
Gascon, P, 53P(ab)
Gaskin, K, 214
Gasparini, M, 219P(ab)
Gatley, SJ, 246, 272, 619, 2208, 49P(ab), 69P(ab), 78P(ab), 131P(ab), 156P(ab)
Gautherot, E, 1662
Gbur, CS, 153P(ab)
Gearhart, JP, 762
Geatti, O, 166P(ab)
Gehl, HB, 183P(ab)
Geissbuhler, A, 1367
Gelfand, MJ, 614, 52P(ab), 205P(ab), 227P(ab), 255P(ab), 261P(ab)
Gelormini, RG, 1169
Geltman, EM, 36P(ab)
Gemmell, HG, 30
Genna, S, 91P(ab)
Georgi, P, 217P(ab)
Georgiou, M, 112P(ab), 117P(ab), 175P(ab), 249P(ab)
Germá, JR, 146P(ab)
Germano, A, 82P(ab)
Germano, G, 1349, 1485, 1494, 64P(ab), 189P(ab)
Gerretsen, M, 1953
Gerson, MC, 1520, 120P(ab), 152P(ab), 153P(ab), 156P(ab), 248P(ab)
Gervais, A, 49P(ab)
Geusens, P, 110P(ab), 14*P(ab)
Gewirtz, H, 862, 24P(ab)
Geworski, L, 58P(ab)
Ghafouripour, AK, 174P(ab), 221P(ab), 224P(ab)
Ghali, SK, 138P(ab)
Ghandour, C, 182
Ghaneemah, A, 131P(ab)
Giacometti, A, 1766
Giap, HB, 127P(ab), 191P(ab), 192P(ab)
Giardino, EC, 173P(ab)
Gibbons, RJ, 146P(ab), 148P(ab)
Giganti, M, 18P(ab)
Gilardi, MC, 137
Gilbey, S, 41P(ab)
Gildersleeve, DL, 123P(ab)
Gildersleeve, K, 13P(ab)
Gill, HK, 222
Gilland, DR, 26P(ab), 30P(ab), 190P(ab)
Gillardi, MC, 5P(ab)
Gilliand, DR, 1577
Gillispie, SB, 60P(ab), 258P(ab)
Gilmore, M, 14P(ab), 46P(ab)
Gilmore, MP, 927
Gilsbach, J, 222P(ab)
Gilson, M, 24P(ab)
Ginos, J, 1152, 37P(ab)
Gionfriddo, M, 244P(ab)
Giordani, BJ, 4P(ab)
Giorgianni, JA, 109P(ab)
Gips, S, 141P(ab)
Girelli, ME, 1626
Gisclon, L, 109P(ab)
Gjedde, A, 31P(ab), 51P(ab), 57P(ab), 181P(ab), 198P(ab), 199P(ab), 200P(ab), 201P(ab)
Gladding, R, 48P(ab)
Gladshteyn, M, 250P(ab)
Glaser, B, 164P(ab)
Glass, EC, 88P(ab)
Gleischman, SH, 18
Glenn, S, 53P(ab), 174P(ab)
Glenn, SD, 1067
Glick, S, 194P(ab)
Glover, DK, 630, 96P(ab)
Glowniak, JV, 1140, 1392(le)
Go, RT, 400, 1834(le), 190P(ab)
Goins, B, 2160, 135P(ab), 247P(ab)
Golan, H, 1218(le)
Golberg, L, 213P(ab)
Golberg, LE, 885
Gold, DV, 214P(ab)
Goldberg, IE, 208P(ab)
Goldberg, MA, 260P(ab)
Goldberg, TE, 228P(ab)
Goldenberg, DM, 61, 1028(le), 1617(le), 53P(ab), 54P(ab), 61P(ab), 94P(ab), 160P(ab), 172P(ab),

214P(ab), 215P(ab), 217P(ab)
Golding, R, 1706
Goldman, M, 109P(ab), 261P(ab)
Goldschmidt, H, 220P(ab)
Goldsmith, SJ, 40N(12), 465, 1235, 1536, 56P(ab), 61P(ab), 66P(ab), 83P(ab), 94P(ab), 104P(ab), 143P(ab), 145P(ab)
Goldstein, DS, 123P(ab), 221P(ab)
Goldstein, J, 210P(ab)
Goldstein, JA, 154P(ab)
Golsch, G, 52P(ab)
Golsch, GJ, 255P(ab)
Gomez, AA, 589
Goncalves, LM, 1441
Goncalves, RJ, 256P(ab)
Gong, W, 68P(ab), 91P(ab)
Gonzales, PM, 165P(ab)
Goodgold, HM, 120P(ab)
Goodman, MM, 159P(ab), 235P(ab)
Goodwin, P, 250P(ab)
Gooneratne, N, 150P(ab)
Gopal, SS, 189P(ab)
Gordon, E, 223P(ab)
Gordon, EE, 1031, 1839
Gordon, I, 118P(ab)
Gordon, L, 255P(ab)
Gorenberg, M, 2101
Gorey, J, 235P(ab)
Goris, ML, 1029(le), 1617(le)
Gosfield, E III, 2191
Gosfield, TE, 12P(ab), 162P(ab)
Goshen, E, 82P(ab)
Goto, M, 1103
Gotoh, E, 161P(ab)
Gottschalk, A, 353(le), 1109, 1119, 16P(ab), 17P(ab)
Gould, HR, 6P(ab)
Goumnerova, LC, 1045
Gracia, S, 32P(ab)
Grady, A, 157P(ab)
Graef, KJ, 164P(ab)
Grafton, ST, 679, 1198, 182P(ab)
Graham, D, 30, 129P(ab), 244P(ab)
Graham, MC, 422, 1595, 53P(ab), 94P(ab), 105P(ab), 127P(ab), 162P(ab)
Graham, MM, 1361, 21P(ab), 137P(ab), 257P(ab), 258P(ab)
Graham, W, 1964, 1975, 2176, 172P(ab), 173P(ab)
Gramatzki, M, 172P(ab)
Grambow, D, 36P(ab), 155P(ab)
Grana, C, 93P(ab)
Grandis, DJ, 1695
Granowska, M, 82P(ab)
Grant, A, 1621
Grassi, F, 5P(ab)
Gravelle, DR, 138P(ab)
Gray, B, 204P(ab)
Gray, C, 142P(ab)
Gray, L, 567
Gray, LG, 1447
Green, MA, 228, 1127, 79P(ab), 123P(ab)
Green, MV, 60P(ab), 70P(ab), 177P(ab), 178P(ab)
Greenberg, HE, 1905
Greenough, R, 6P(ab), 43P(ab)
Greenwald, RA, 233P(ab)
Greer, KL, 1577, 1998, 26P(ab), 30P(ab), 80P(ab), 81P(ab)
Gregory, C, 150P(ab)
Grevitt, M, 144P(ab)
Grey, L, 7P(ab)
Griffeth, LK, 1198, 56P(ab), 81P(ab)
Griffin, TW, 1656
Griffioen, G, 1052
Griffiths, GL, 1617(le), 54P(ab)
Grimm, W, 161P(ab)
Grimmel, S, 217P(ab)
Grimon, G, 229P(ab)
Gritters, LS, 1420
Groch, MW, 35P(ab), 128P(ab), 151P(ab), 175P(ab)
Grode, M, 37P(ab)
Groeneveld, ABJ, 230P(ab)
Grogin, HR, 151P(ab)
Groom, GN, 4P(ab), 108P(ab), 116P(ab)
Groontoonk, S, 1367
Grootoonk, S, 26P(ab)
Gropler, RJ, 36P(ab), 86P(ab), 87P(ab), 106P(ab)
Groshar, D, 885
Gross, M, 11P(ab), 87P(ab), 104P(ab)
Gross, MD, 787
Grossman, HB, 6P(ab), 223P(ab)
Grossman, M, 1009
Grover-McKay, M, 834
Gruaz-Guyon, A, 1267, 1662
Gruber, M, 206P(ab)
Gruenwald, SM, 1172
Grummon, GD, 135P(ab)
Grünwald, F, 793, 77P(ab), 187P(ab), 204P(ab)
Guenther, R, 183P(ab)
Guermazi, F, 117P(ab)
Guerra, G, 249P(ab)
Guerra, UP, 126P(ab), 166P(ab)
Guhlke, S, 80P(ab)
Guidry, GW, 3P(ab)
Guignier, A, 1472, 45P(ab)
Guillaume, M, 211P(ab)
Guilloteau, D, 235P(ab)
Gulenchyn, KY, 74P(ab)
Gullberg, GT, 19P(ab), 30P(ab), 71P(ab), 80P(ab), 81P(ab), 91P(ab), 176P(ab), 187P(ab), 191P(ab), 196P(ab)
Guludec, DL, 98P(ab)
Günalp, B, 889
Gunsenheimer, B, 219P(ab)
Guo, LW, 28P(ab)
Guo, YZ, 135P(ab)
Gupta, N, 2278(le), 6P(ab), 7P(ab), 20P(ab), 21P(ab), 47P(ab), 50P(ab), 55P(ab), 73P(ab)
Gupta, SM, 169P(ab)
Gur, R, 210P(ab)
Gur, RC, 228P(ab)
Gur, RE, 2201, 198P(ab), 228P(ab)
Guthrie, A, 260P(ab)
Gvozdanovic, DV, 30

Haapanen, A, 2068, 3P(ab)
Haaparanta, M, 1711, 2064, 2068, 3P(ab), 21P(ab), 107P(ab)
Habbab, N, 172P(ab)
Haber, E, 2144
Haberkorn, U, 12, 1075, 218P(ab), 220P(ab)
Habi, HA, 1818
Hacker, H, 205P(ab)
Hagen, CA, 220P(ab)
Hahn, K, 161P(ab)
Hahn, SD, 134
Haim, N, 2101
Haire, WD, 896
Haken, RKT, 105P(ab)
Halama, JR, 256P(ab)
Halkar, R, 251P(ab)
Hall, A, 118P(ab)
Hall, H, 7P(ab)
Hall, ML, 138P(ab)
Halldin, C, 7P(ab), 89P(ab), 102P(ab)
Hallgring, E, 723
Halpern, S, 1565
Ham, HR, 1223, 1642, 99P(ab), 166P(ab), 226P(ab)
Hamamoto, K, 19P(ab), 98P(ab), 167P(ab), 222P(ab)
Hamberg, LM, 73P(ab)
Hambuechen, U, 98P(ab), 217P(ab), 222P(ab)
Hamet, P, 58P(ab)
Hamill, JJ, 10P(ab), 192P(ab)
Hammer, HF, 168P(ab)
Hammond, P, 41P(ab)
Handa, N, 63P(ab), 171P(ab), 209P(ab)
Handlin, LR, 149P(ab)
Handt, S, 164P(ab), 217P(ab)
Hanna, M, 221P(ab), 224P(ab)
Hanrath, P, 23P(ab)
Hansen, H, 89P(ab)
Hansen, HJ, 61, 1617(le), 53P(ab), 54P(ab), 61P(ab), 94P(ab), 214P(ab), 217P(ab)
Hansen, HW, 4P(ab), 50P(ab), 154P(ab)
Hansen, L, 39P(ab)
Hanson, J, 22P(ab)
Hanson, MW, 39, 198, 567, 1577, 1998, 7P(ab), 23P(ab), 37P(ab)
Hanson, RH, 232P(ab)
Hara, M, 116P(ab), 177P(ab), 247P(ab)
Hara, T, 1886
Harada, K, 247P(ab)
Harapanhalli, RS, 133P(ab)
Hardoff, R, 66P(ab), 141P(ab)
Harkness, BA, 182P(ab), 259P(ab)
Harkonen, R, 2068, 3P(ab), 107P(ab)
Harr, DP, 11P(ab)
Harrell, C, 178P(ab)
Harrell, CR, 125P(ab)
Harris, CC, 1587
Harris, EW, 1326
Harris, GC, 184P(ab), 2009
Harris, J, 232P(ab)
Harris, TS, 68P(ab)
Harrison, C, 218P(ab)
Harrison, KA, 896, 111P(ab)
Harrison, LA, 262P(ab)
Harrison, R, 60P(ab), 136P(ab)
Hartman, JJ, 717
Hartman, N, 242P(ab)
Hartmann, A, 32P(ab), 204P(ab)
Hartnett, S, 1031
Harwood, SJ, 213P(ab)
Hasapes, JP, 154P(ab)
Hasçelik, Z, 84P(ab)
Hasegawa, W, 176P(ab)
Hasfeld, M, 45P(ab)
Hashikawa, K, 63P(ab), 171P(ab), 207P(ab), 209P(ab)
Hashimoto, S, 2216
Haskard, D, 62P(ab)
Hasselquist, BE, 29P(ab)
Hatabu, H, 121P(ab)
Hatazawa, J, 780, 92P(ab), 200P(ab)
Hattner, RS, 1922, 865(le), 1616(le), 64P(ab), 65P(ab)
Haubold-Reuter, BG, 809
Hauenstein, K, 375
Haugh, CJ, 65P(ab)
Haumont, D, 1223
Hauser, MF, 12P(ab)
Hawkins, H, 257P(ab)
Hawkins, PN, 118P(ab)
Hawkins, RA, 488, 1198, 2009, 2038, 1832(le), 40P(ab), 50P(ab), 137P(ab), 183P(ab), 184P(ab), 224P(ab)
Hawman, EG, 10P(ab), 191P(ab), 192P(ab)
Hawman, PC, 191P(ab)
Hawthorne, MF, 1294
Hay, RV, 104P(ab)
Hayashida, K, 1931, 14P(ab), 24P(ab), 107P(ab), 120P(ab)
Haynie, TP, 1087, 33P(ab), 42P(ab), 55P(ab), 68P(ab), 88P(ab), 115P(ab), 119P(ab), 204P(ab), 206P(ab), 223P(ab)
Haynor, DR, 60P(ab)
Hays, MT, 12P(ab)
Haze, K, 14P(ab)
He, XS, 235P(ab)
He, Z-X, 1472, 45P(ab)
Heath, IJ, 201P(ab)
Hebert, CB, 630
Hebert, TJ, 186P(ab), 189P(ab)
Hegge, J, 210P(ab)
Heiba, SI, 74P(ab)
Heide, G, 222P(ab)
Heidecke, CD, 112P(ab)
Heidorn, DB, 105P(ab)
Heim, M, 1075
Heimpel, H, 217P(ab)
Heimsath, SJ, 112P(ab)
Heisiger, E, 63P(ab)
Heiss, WD, 1460, 101P(ab)
Heller, GV, 134, 75P(ab), 85P(ab), 152P(ab)
Heller, LI, 14P(ab), 130P(ab)
Hellman, RS, 44P(ab), 56P(ab), 94P(ab)
Hellstrom, I, 93P(ab)
Hellstrom, KE, 93P(ab)
Hellwig, BJ, 992
Hellwig, D, 98P(ab)
Helmer, B, 38P(ab)
Helus, F, 12, 1075, 21P(ab), 218P(ab)
Heminger, LA, 127P(ab)
Hendel, RC, 131P(ab), 149P(ab)
Hendry, JH, 133P(ab)
Hengstler, JG, 161P(ab)
Henkin, RE, 1037
Hennemann, G, 41P(ab)
Henrich, MM, 87P(ab), 107P(ab), 217P(ab), 225P(ab)
Henry, TR, 1892, 22P(ab)
Henry-Lebras, F, 194P(ab)
Henze, E, 17N(2)
Heo, J, 75P(ab), 85P(ab), 95P(ab)
Héon, M, 136P(ab)
Herbst, CP, 330, 963
Herd, R, 141P(ab), 142P(ab)
Herholz, K, 1460
Herman, C, 116P(ab)
Herman, SD, 75P(ab), 85P(ab), 152P(ab)
Hermus, AR, 163P(ab)
Hero, AO, 190P(ab)
Herold, TJ, 148P(ab)
Herranz, R, 1452
Herrera, J, 116P(ab)
Herrero, P, 36P(ab), 86P(ab), 87P(ab)
Herrlin, K, 1646
Herrmannsdoerfer, AJ, 229P(ab)
Herrold, EM, 34P(ab), 66P(ab)
Herscheid, JDM, 649, 1953
Herscovitch, P, 155P(ab)
Hertel, A, 126P(ab), 205P(ab)
Herzog, H, 355, 2222, 32P(ab), 107P(ab)
Herzog, SA, 462
Heshmati, HM, 387
Heslip, PG, 2053
Hester, J, 119P(ab)
Hetherington, HP, 92P(ab)
Hewitt, K, 242P(ab)
Heya, T, 215P(ab)
Heyman, S, 117P(ab)
Heyndrickx, G, 15P(ab), 86P(ab)
Hibbelin, JF, 747
Hichwa, RD, 181P(ab), 185P(ab)
Hickey, J, 208
Hicks, K, 68P(ab), 102P(ab)
Hierholzer, J, 31P(ab), 164P(ab)

Higashi, K, 414, 773, 2279(le)
Higashi, N, 198P(ab), 225P(ab)
Higginbotham, C, 232P(ab), 248P(ab)
Higginbotham-Ford, EA, 61
Higley, B, 30, 222
Hijioka, T, 1103
Hill, MC, 165P(ab)
Hill, TC, 193P(ab)
Hilson, AJW, 1163, 138P(ab)
Hilton, S, 1656, 94P(ab), 214P(ab)
Hines, M, 260P(ab)
Hinge, D, 30
Hinnefeld, JD, 42P(ab)
Hirano, T, 2085, 42P(ab)
Hiroe, M, 66P(ab)
Hironaka, F, 142P(ab)
Hirose, Y, 1931
Hisada, K, 1478, 2089, 28P(ab), 92P(ab), 139P(ab), 197P(ab), 223P(ab)
Hittinger, L, 1899
Hitzemann, R, 609, 67P(ab), 102P(ab), 103P(ab)
Hitzemann, RJ, 18P(ab)
Hnatowich, DJ, 109, 1618(le), 59P(ab), 234P(ab), 240P(ab)
Ho, B, 26P(ab)
Hochberg, FH, 206P(ab), 208P(ab)
Hodgson, HJ, 43P(ab)
Hoekstra, HJ, 219P(ab), 225P(ab)
Hoekstra, OS, 1706
Hoffer, PB, 1416, 31P(ab), 48P(ab), 102P(ab), 108P(ab), 109P(ab), 161P(ab), 211P(ab), 243P(ab), 258P(ab)
Hoffman, BJ, 1140
Hoffman, EJ, 671, 1198, 136P(ab), 137P(ab), 180P(ab)
Hoffman, JM, 39, 567, 1587, 4P(ab), 7P(ab), 21P(ab), 23P(ab), 37P(ab), 101P(ab)
Hoffman, TJ, 248P(ab)
Hoffschir, D, 18P(ab), 134P(ab)
Hofmeister, C, 257P(ab)
Hogan, K, 58P(ab)
Hoh, CK, 488, 1198, 2009, 2038, 1832(le), 50P(ab), 137P(ab), 183P(ab), 184P(ab), 224P(ab)
Hohenberger, P, 218P(ab)
Hoit, BD, 1520
Hojo, H, 198P(ab)
Holburn, G, 86P(ab), 132P(ab), 158P(ab)
Holdeman, KP, 896, 111P(ab)
Holden, JE, 481, 8P(ab)
Holland, G, 121P(ab)
Holm, C, 122P(ab)
Holman, BL, 167, 2044, 27N(9), 723, 27P(ab), 47P(ab), 179P(ab), 203P(ab), 208P(ab), 212P(ab), 242P(ab), 259P(ab)
Holman, JM, 249P(ab)
Holmes, RA, 232P(ab), 248P(ab)
Holmgren, G, 118P(ab)
Holoye, P, 223P(ab)
Holschbach, M, 68P(ab)
Holzgrabe, U, 243P(ab)
Holzman, PS, 196P(ab), 203P(ab)
Hombach, V, 87P(ab)
Honda, N, 1984
Hong, CD, 130P(ab), 138P(ab)
Honos, GN, 589
Hoogland, D, 122P(ab)
Hoogma, RPLM, 873
Hör, G, 126P(ab), 205P(ab)
Hori, M, 34P(ab)
Horii, H, 26P(ab)
Hornig-Rohan, M, 48P(ab)
Horowitz, GR, 115P(ab)
Horowitz, M, 582
Horowitz, SF, 193, 36P(ab)
Horton, S, 257P(ab)
Hosain, F, 162P(ab)
Hoshi, H, 2091
Hoskins, W, 216P(ab)
Hoskinson, M, 885
Hosono, M, 815, 1745, 29P(ab), 119P(ab), 215P(ab)
Hosono, MN, 215P(ab)
Hosten, N, 164P(ab)
Hotze, A, 77P(ab), 204P(ab)
Hou, Y, 221P(ab)
Hovi, I, 1428
Howell, RW, 637, 1801, 105P(ab), 133P(ab), 134P(ab)
Howman-Giles, R, 214, 1828(le), 52P(ab)
Howman-Giles, RB, 1435
Hoyes, KP, 133P(ab)
Hsieh, KS, 228P(ab)
Hsieh, YL, 71P(ab), 191P(ab)
Hsu, C-Y, 71, 1918, 167P(ab)
Hsu, HS, 138P(ab)
Hua, L, 9P(ab), 190P(ab)
Huang, CI, 143P(ab)
Huang, G, 9P(ab), 195P(ab)
Huang, S-C, 488, 679, 1006, 2038, 1832(le), 4P(ab), 35P(ab), 40P(ab), 50P(ab), 70P(ab), 175P(ab), 183P(ab), 185P(ab), 202P(ab)
Huang, W, 100P(ab)
Huberty, JP, 39P(ab)
Hubner, KF, 6P(ab), 185P(ab), 209P(ab), 261P(ab)
Hudkins, RL, 236P(ab)
Hudson, C, 82P(ab)
Hughes, A, 272
Hughes, JMB, 43P(ab)
Hui, TE, 106P(ab)
Huijgens, PC, 1706
Huitink, JM, 147P(ab), 154P(ab)
Humen, DP, 2053
Humes, HD, 87P(ab)
Humm, JL, 1811
Hundeshagen, H, 1770
Hung, JC, 523(le), 148P(ab)
Hunter, GJ, 1571, 51P(ab), 73P(ab), 88P(ab)
Hunter, K, 155P(ab), 209P(ab)
Hupp, T, 48, 139P(ab)
Hurtig, R, 68P(ab)
Hurwitz, GA, 138P(ab)
Husni, M, 138P(ab)
Hutchins, GD, 83, 336, 440, 1287, 50P(ab)
Hutchinson, RJ, 51P(ab), 220P(ab)
Hutton, BF, 1752
Huynh, TV, 144P(ab)
Huysmans, DA, 163P(ab)
Hwang, D, 8P(ab), 218P(ab)
Hwang, IR, 130P(ab)
Hwang, YC, 8P(ab)
Hyun, M, 1845

Ichihara, T, 2216, 180P(ab), 193P(ab)
Ichise, M, 1274, 204P(ab)
Ichiya, Y, 288
Ido, T, 431, 780, 103P(ab), 240P(ab), 244P(ab)
Ienuso, R, 117P(ab)
Iervasi, G, 2032
Ignaszewski, AP, 2053
Iida, H, 498, 1333, 24P(ab), 200P(ab)
Iida, Y, 932, 234P(ab)
Iiji, O, 291
Iio, M, 1886
Iizuka, T, 14P(ab)
Ikeda, M, 207P(ab)
Iliff, NT, 143P(ab)
Imahori, Y, 431, 1543, 26P(ab), 198P(ab), 225P(ab)
Imai, T, 229P(ab)
Imaizumi, M, 291
Imakita, S, 1931
Imam, S, 33P(ab)
Imbriaco, M, 1602, 1688, 147P(ab), 153P(ab)
Ind, T, 82P(ab)
Ingels, M, 211P(ab)
Innis, RB, 31P(ab), 48P(ab), 90P(ab), 102P(ab), 108P(ab), 109P(ab), 201P(ab), 205P(ab), 211P(ab), 243P(ab)
Inokuma, T, 6P(ab)
Inoue, T, 2085, 14P(ab), 19P(ab), 29P(ab), 42P(ab), 167P(ab)
Inoue, Y, 1980, 71P(ab), 113P(ab), 182P(ab)
Intenzo, C, 255P(ab)
Intrator, J, 77P(ab)
Inugami, A, 92P(ab)
Iodice, A, 82P(ab)
Iosilevsky, G, 141P(ab)
Isacson, O, 202P(ab)
Isak, E, 889
Isaka, Y, 291, 171P(ab)
Isenmann, R, 225P(ab)
Isern, R, 47P(ab)
Ishibashi, K, 111P(ab), 170P(ab)
Ishida, Y, 1931, 14P(ab), 24P(ab), 34P(ab), 55P(ab), 107P(ab), 120P(ab)
Ishigaki, T, 2124
Ishii, R, 208P(ab)
Ishii, S-I, 1936, 1944
Ishii, Y, 120P(ab)
Ishikawa, M, 839
Ishiwata, K, 780, 1936, 240P(ab)
Ishizu, K, 194P(ab)
Isiklar, I, 204P(ab)
Isitman, A, 44P(ab), 56P(ab)
Iskandrian, AS, 743, 75P(ab), 85P(ab), 95P(ab)
Israel, O, 1330, 1826(le), 2101, 141P(ab)
Itagaki, Y, 63P(ab)
Ito, A, 170P(ab)
Ito, H, 200P(ab)
Itoh, H, 498
Itoh, K, 812
Itoh, T, 815
Itoi, Y, 291
Ivanovic, M, 899, 9P(ab), 60P(ab), 222P(ab)
Iwasaki, Y, 839, 1672
Iyer, K, 256P(ab)
Izembart, M, 387
Izon, D, 53P(ab)

Jackson, H, 133P(ab)
Jackson, J, 41P(ab)
Jackson, LR, 171P(ab)
Jackson, NC, 157P(ab)
Jacobs, A, 211P(ab)
Jacobs, M, 8P(ab), 218P(ab)
Jacobs, W, 137P(ab), 263P(ab)
Jacobson, A, 164P(ab)
Jacobson, AF, 462, 16P(ab), 33P(ab), 74P(ab), 218P(ab)
Jadali, F, 169P(ab)
Jaffar, J, 63P(ab)
Jaffe, CC, 257P(ab)
Jahan, S, 234P(ab)
Jain, D, 1254, 1877
Jain, RK, 73P(ab)
Jaïs, J-P, 387
Jakse, G, 217P(ab)
Jamar, F, 129P(ab)
James, P, 156P(ab)
Jamitzky, T, 163
Jang, S, 1577, 80P(ab)
Janik, M, 228
Janisch, S, 1039
Janssen, AGM, 2076, 207P(ab), 209P(ab), 225P(ab)
Japanwalla, N, 249P(ab)
Jarritt, PH, 1778
Jarry, M, 121P(ab)
Jaszczak, RJ, 1577, 1587, 1998, 10P(ab), 20P(ab), 26P(ab), 30P(ab), 72P(ab), 80P(ab), 81P(ab), 190P(ab), 191P(ab), 195P(ab)
Jatlow, A, 12P(ab), 162P(ab), 163P(ab)
Jay, M, 126P(ab)
Jayanthi, VR, 51P(ab)
Jeghers, O, 1642
Jehan, A, 163P(ab)
Jenike, MA, 47P(ab)
Jeong, JM, 58P(ab), 215P(ab), 233P(ab)
Jester, D, 174P(ab)
Jeusset, J, 1565
Ji, K, 255P(ab)
Jiang, Y, 141P(ab)
Jimenez, H, 38P(ab)
Jinnouchi, S, 2091
Jobert, A, 109P(ab)
Joensuu, H, 1, 1711, 21P(ab)
John, CS, 2169, 248P(ab)
John, E, 260, 246P(ab)
Johnson, BF, 239P(ab)
Johnson, DK, 1656
Johnson, G III, 630
Johnson, J, 75P(ab)
Johnson, KA, 723, 2044, 27P(ab), 179P(ab), 203P(ab), 208P(ab), 212P(ab), 259P(ab)
Johnson, L, 153P(ab)
Johnson, TK, 113P(ab)
Johnson, VE, 20P(ab)
Johnston, DR, 185P(ab)
Jones, AG, 242P(ab)
Jones, AL, 214P(ab)
Jones, BE, 370
Jones, BJ, 2135
Jones, M, 251P(ab)
Jones, P, 100P(ab)
Jones, SR, 128
Jones, T, 1333, 26P(ab)
Jonides, J, 57P(ab)
Jonk, RTM, 170P(ab)
Joraschky, P, 47P(ab)
Jordan, KG, 2188
Joseph, RC, 263P(ab)
Joshi, V, 237P(ab)
Jouanne, E, 140P(ab), 210P(ab)
Juillard, G, 224P(ab)
Julian, D, 194P(ab)
Junaid, T, 233P(ab)
Junck, L, 116P(ab)
Jung, Y-W, 123P(ab), 135P(ab)
Juni, J, 16P(ab), 17P(ab)
Juni, JE, 747, 1109, 1119, 1789, 158P(ab)
Jurisson, S, 641
Jurisson, SS, 231P(ab)
Juweid, M, 506, 1303, 1866, 76P(ab)
Jyawook, S, 1975, 83P(ab), 171P(ab)

Kabalka, GW, 235P(ab)
Kadrmas, DJ, 181P(ab)
Kahn, D, 185P(ab)
Kahn, S, 259P(ab)
Kaick, G, 12
Kaiser, HJ, 183P(ab)
Kalaigian, H, 1595, 56P(ab), 94P(ab), 114P(ab), 127P(ab), 162P(ab)
Kalinyak, KA, 614
Kalkowski, PJ, 311
Källman, K-M, 69P(ab)
Kallmes, DF, 7P(ab)
Kalloo, AN, 168P(ab)
Kalus, ME Jr, 860
Kamada, T, 1103, 34P(ab), 63P(ab), 170P(ab), 171P(ab), 207P(ab), 209P(ab)
Kambara, H, 147P(ab)
Kameoka, Y, 161P(ab)
Kaminaga, T, 1931, 55P(ab)
Kaminski, MS, 127P(ab)
Kaminsky, DA, 868(le)

Kanaya, K, 174P(ab)
Kanaya, S, 174P(ab)
Kang, S-B, 1651
Kanmaz, B, 961
Kanno, I, 498, 92P(ab), 200P(ab)
Kano, M, 95P(ab)
Kanselaar, P, 175P(ab)
Kao, C-H, 71, 1918, 167P(ab), 208P(ab), 228P(ab), 245P(ab)
Kao, T, 176P(ab), 185P(ab)
Kapadvanjwala, M, 174P(ab), 221P(ab), 224P(ab)
Kapilivsky, A, 171P(ab)
Kaplan, J, 229P(ab)
Kaplan, JM, 169P(ab)
Kaplan, MS, 60P(ab)
Kaplan, WD, 74P(ab)
Kappeler, C, 58P(ab)
Kappes, R, 210P(ab)
Kapucu, O, 2076, 207P(ab), 209P(ab)
Karak, PK, 168P(ab)
Karczewski, D, 97P(ab), 135P(ab)
Kari, B, 9P(ab)
Karlsberg, RP, 65P(ab)
Karlsson, P, 7P(ab), 89P(ab)
Karp, JS, 2201, 124P(ab), 137P(ab), 181P(ab), 190P(ab), 195P(ab), 228P(ab)
Karvelis, K, 97P(ab)
Kasagi, K, 107P(ab)
Kasahara, A, 1103, 170P(ab)
Kaschka, WP, 47P(ab)
Kashiwagi, T, 1103, 111P(ab), 170P(ab)
Kasi, LP, 33P(ab), 53P(ab), 119P(ab), 134P(ab), 161P(ab), 180P(ab), 212P(ab), 218P(ab), 223P(ab)
Kasiss, AI, 1175
Kasliwal, R, 197P(ab), 202P(ab)
Kasper, S, 77P(ab)
Kassis, AI, 123P(ab), 221P(ab), 241P(ab), 246P(ab), 247P(ab)
Kastin, SJ, 76P(ab)
Kataoka, M, 932
Katsurgi, M, 2182
Katti, KV, 38P(ab)
Katz, RD, 259P(ab)
Katzenellenbogen, JA, 18P(ab), 49P(ab), 56P(ab), 79P(ab), 160P(ab)
Kauffmann, P, 1260
Kaufman, H, 76P(ab)
Kaul, B, 155P(ab)
Kaul, S, 728
Kavanagh, PB, 1349
Kavanah, MT, 2095
Kawabori, I, 1995
Kawai, Y, 288
Kawakami, K, 161P(ab)
Kawamoto, M, 107P(ab), 120P(ab), 147P(ab)
Kawanaka, M, 126P(ab)
Kawano, S, 1103
Keast, RK, 48P(ab), 174P(ab)
Keelan, E, 62P(ab)
Kegel, J, 95P(ab)
Keiler, A, 10P(ab)
Keilp, J, 77P(ab)
Keinhans, E, 23P(ab)
Keiser, HR, 173
Kelley, AP, 261P(ab)
Kelly, JD, 222
Kemp, B, 251P(ab), 252P(ab)
Kempf, J, 172P(ab)
Kempner, KM, 70P(ab)
Kenemans, P, 82P(ab)
Kennedy, DN, 208P(ab)
Keppler, BK, 220P(ab)
Kerdraon, J, 205P(ab)
Kerremans, R, 222P(ab)
Kertzman, C, 70P(ab)
Keske, U, 164P(ab)
Kessler, ML, 127P(ab)
Kessler, RM, 826, 37P(ab), 38P(ab), 132P(ab), 158P(ab), 202P(ab), 206P(ab)
Ketring, AR, 38P(ab), 231P(ab)
Kevin, KMT, 1866
Keyes, JW Jr., 182P(ab)
Khalkhali, I, 140P(ab), 231P(ab)
Khan, A, 163P(ab), 165P(ab), 173P(ab)
Khan, AS, 1574
Khan, S, 249P(ab)
Khanna, S, 184P(ab)
Khare, AB, 8P(ab), 90P(ab)
Khaw, BA, 1303, 1507, 2144
Khawli, LA, 114P(ab)
Khazaeli, MB, 29P(ab), 53P(ab)
Khonsary, SA, 12P(ab), 257P(ab)
Kiat, H, 1349, 1485, 1494, 64P(ab), 130P(ab), 148P(ab), 189P(ab), 259P(ab)
Kijewski, MF, 2044, 203P(ab), 208P(ab)
Kilbourn, MR, 25P(ab), 123P(ab), 236P(ab)
Killion, D, 88P(ab)
Killius, DR, 69P(ab)
Kilty, JE, 1140
Kim, AS, 4P(ab), 165P(ab)
Kim, CK, 506, 1214, 1851, 1866, 12P(ab), 17P(ab), 43P(ab), 73P(ab), 76P(ab), 92P(ab), 162P(ab), 163P(ab), 207P(ab)
Kim, D-I, 1987
Kim, E, 43P(ab)
Kim, EE, 26P(ab), 33P(ab), 42P(ab), 55P(ab), 68P(ab), 119P(ab), 204P(ab), 206P(ab), 212P(ab), 223P(ab)
Kim, HJ, 124P(ab), 190P(ab), 195P(ab), 198P(ab)
Kim, M, 255P(ab)
Kim, MH, 76P(ab)
Kim, SB, 130P(ab), 138P(ab)
Kim, SE, 199P(ab)
Kim, SY, 169P(ab)
Kim, YT, 83P(ab)
Kim, YY, 83P(ab)
Kimura, RL, 1990
Kinan, D, 65P(ab)
Kindseth, JM, 142P(ab)
King, JL, 400, 1834(le)
King, MA, 72P(ab), 195P(ab)
King, PT, 619
King, S, 217P(ab)
Kinne, RW, 92
Kinney, JB, Jr., 1995
Kinter, CM, 103P(ab)
Kinuya, S, 2169, 28P(ab), 58P(ab), 139P(ab), 241P(ab)
Kipper, SL, 111P(ab)
Kirch, DL, 113P(ab)
Kirchner, PT, 1607, 68P(ab), 188P(ab)
Kirsch, G, 946
Kirsch, J, 99P(ab)
Kirsh, JC, 1274
Kishida, T, 111P(ab), 170P(ab)
Kitakata, Y, 211P(ab)
Kitapci, M, 961
Kitapci, MT, 523(le), 44P(ab)
Kitchen, R, 8P(ab)
Klatte, EC, 381
Klein, HA, 1228
Klein, J, 34P(ab)
Klein, MJ, 1536
Klein, S, 140P(ab)
Klein, WP, 474
Kleinhaus, U, 2101
Klemm, E, 77P(ab)
Klenner, T, 220P(ab)
Kletter, K, 1397
Klever, P, 98P(ab), 183P(ab)
Kline, BD, 190P(ab)
Klipper, R, 2160, 135P(ab), 247P(ab)
Kloppenborg, P, 163P(ab)
Knapp, DW, 123P(ab)
Knapp, FF Jr, 946
Knapp, FF Jr., 15P(ab), 54P(ab), 197P(ab), 236P(ab), 243P(ab)
Knapp, FFR Jr, 649
Knaw, B-A, 2264
Kneeland, B, 2191
Knesaurek, K, 125P(ab), 189P(ab)
Knight, LC, 11P(ab), 17P(ab), 66P(ab), 169P(ab)
Knobloch, E, 112P(ab)
Knopp, MV, 21P(ab)
Knopp, R, 187P(ab)
Knust, EJ, 58P(ab)
Knuuti, J, 224P(ab)
Knuuti, MJ, 2064, 2068, 3P(ab), 107P(ab)
Kobayashi, H, 815, 1745, 119P(ab), 174P(ab), 215P(ab)
Kobayashi, K, 301
Koch, A, 222P(ab)
Kodama, K, 211P(ab)
Koenders, E, 105P(ab), 247P(ab)
Koenders, EB, 1316
Koeppe, RA, 322, 1190, 4P(ab), 13P(ab), 22P(ab), 25P(ab), 51P(ab), 56P(ab), 57P(ab), 70P(ab), 108P(ab), 207P(ab), 220P(ab), 224P(ab)
Koeppel, JA, 181P(ab), 185P(ab)
Koga, I, 288
Koga, S, 159P(ab)
Koh, C-S, 1651, 212P(ab)
Koh, W-J, 21P(ab)
Kohlmyer, S, 136P(ab)
Köhn, H, 122P(ab)
Koivisto, VA, 2064
Kojima, A, 1184, 177P(ab), 247P(ab)
Kolbourn, MR, 8P(ab)
Kolodny, GM, 2101
Kolsky, KL, 237P(ab)
Költringer, P, 2278(le), 2280(le)
Komaroff, A, 47P(ab)
Kondo, T, 159P(ab)
Kondoh, Y, 98P(ab)
Koneru, S, 1859
König, B, 122P(ab)
Konishi, J, 815, 839, 1672, 1745, 2124, 6P(ab), 29P(ab), 107P(ab), 119P(ab), 120P(ab), 147P(ab), 194P(ab), 201P(ab), 215P(ab)
Konstam, MA, 65P(ab)
Kooba, A, 37P(ab), 139P(ab)
Kooij, PPM, 873, 2025, 175P(ab)
Koops, HS, 219P(ab), 225P(ab)
Kooy, PPM, 41P(ab)
Kopecky, KK, 381
Kops, ER, 355
Koral, KF, 524(le), 113P(ab), 127P(ab)
Korkmaz, M, 33P(ab), 42P(ab), 55P(ab), 68P(ab), 119P(ab), 204P(ab), 206P(ab), 212P(ab)
Kornrumpf, D, 223P(ab), 225P(ab)
Korupolu, G, 250P(ab)
Korupolu, GR, 1835(le)
Kostakoglu, L, 114P(ab), 216P(ab)
Kotek, TJ, 260P(ab)
Kotler, JA, 61
Kotoo, Y, 95P(ab)
Kotoura, Y, 1745
Koulibaly, PM, 194P(ab)
Kouris, K, 1778
Koutcher, J, 1152
Koutelou, MG, 75P(ab)
Kowalsky, WP, 172P(ab)
Kozuka, T, 1103, 34P(ab), 170P(ab), 199P(ab), 201P(ab)
Kramer, EL, 1067, 53P(ab), 63P(ab), 128P(ab)
Krane, MJ, 65P(ab)
Kranert, WT, 205P(ab)
Krappel, C, 77P(ab)
Krasnow, AZ, 44P(ab), 56P(ab)
Krause, BJ, 205P(ab)
Krause, T, 375
Krausz, Y, 164P(ab)
Krejs, GJ, 168P(ab)
Krenning, EP, 873, 2025, 41P(ab), 118P(ab), 139P(ab), 165P(ab), 175P(ab)
Kreuzer, H, 153P(ab)
Krevsky, B, 11P(ab), 169P(ab)
Kris, M, 213P(ab)
Krishna, L, 1574, 173P(ab)
Krishnan, R, 95P(ab)
Krivokapich, J, 2038, 183P(ab)
Kroger, LA, 1067, 93P(ab), 128P(ab)
Krogsgaard-Larsen, P, 22P(ab), 103P(ab)
Krohn, KA, 411, 918, 79P(ab), 237P(ab)
Kronauge, JF, 140P(ab), 242P(ab)
Kronmal, S, 243P(ab)
Kroode, K, 110P(ab)
Kroon, D, 1964, 2130, 104P(ab), 173P(ab)
Kropp, J, 946
Kruschke, C, 41P(ab)
Krystal, JH, 205P(ab)
Kubo, A, 2216
Kubota, K, 419, 1936, 103P(ab), 240P(ab), 244P(ab)
Kubota, R, 419, 1936, 103P(ab), 240P(ab), 244P(ab)
Kuczynski, B, 641, 15P(ab), 16P(ab), 92P(ab)
Kudelka, AP, 88P(ab)
Kudoh, T, 815
Kuhar, CJ, 18
Kuhar, MJ, 197P(ab)
Kuhl, D, 251P(ab), 252P(ab)
Kuhl, DE, 322, 4P(ab), 22P(ab), 25P(ab), 51P(ab), 56P(ab), 108P(ab), 116P(ab), 123P(ab), 158P(ab), 207P(ab)
Kuhle, W, 35P(ab)
Kuhle, WG, 488
Kuijper, AFM, 737
Kuiper, MA, 207P(ab)
Kuji, E, 92P(ab)
Kuji, I, 197P(ab)
Kukis, DL, 93P(ab)
Kuklenyik, Z, 39P(ab)
Kulkarni, PV, 9P(ab), 124P(ab)
Kumar, PN, 259P(ab)
Kung, HF, 208, 1910, 89P(ab), 132P(ab), 135P(ab), 158P(ab), 190P(ab), 195P(ab), 196P(ab), 198P(ab), 235P(ab)
Kung, MP, 89P(ab), 132P(ab), 135P(ab), 235P(ab)
Kuni, CC, 29P(ab)
Kunkel, SL, 104P(ab)
Kuroki, T, 301
Kusakabe, K, 174P(ab)
Kuschinksy, V, 793
Kuschinsky, W, 204P(ab)
Kusuoka, H, 34P(ab), 199P(ab)
Kuwabara, H, 31P(ab), 57P(ab), 181P(ab), 198P(ab), 199P(ab), 200P(ab), 201P(ab)
Kuwabara, Y, 288

Kuwert, T, 355, 32P(ab)
Kwan, AJ, 1045
Kwekkeboom, DJ, 873, 139P(ab)

Labar, D, 15P(ab), 86P(ab), 121P(ab)
Labarre, PG, 1260
LaBresh, KA, 152P(ab)
Lacan, G, 202P(ab)
Lafontaine, E, 140P(ab)
Lage, AL, 123P(ab)
Lahiri, A, 30
Lai, J, 2152
Lai, KH, 76P(ab)
Lainé, J, 18P(ab), 134P(ab)
Lalonde, D, 58P(ab)
Lalush, DS, 27P(ab)
Lamb, GE, 130P(ab)
Lambert, CA, 231P(ab)
Lambert, CR, 243P(ab)
Lambert, R, 946, 58P(ab), 96P(ab), 118P(ab), 121P(ab), 140P(ab), 226P(ab)
Lamberts, SWJ, 873, 41P(ab), 118P(ab), 139P(ab)
Lambrecht, RM, 100P(ab), 153P(ab)
Lamers, CBHW, 1052
Lamki, L, 119P(ab), 256P(ab), 260P(ab)
Lammens, J, 227P(ab)
Lammertsma, AA, 26P(ab)
Lamoureux, G, 49P(ab)
Lamy, T, 182
Landais, P, 103P(ab)
Landmeier, BJ, 239P(ab)
Landolt, U, 809
Landoni, C, 137, 154P(ab)
Landy, BR, 106P(ab)
Lang, EV, 345
Lang, JH, 345
Lange, HW, 32P(ab)
Langen, KJ, 355, 32P(ab)
Langhammer, HR, 41P(ab)
Langhans, J, 223P(ab), 225P(ab)
Langley, GR, 1377
Langmore, S, 11P(ab)
Langsteger, W, 2278(le), 2280(le)
Lanphier, EH, 143P(ab)
Lantto, T, 1428
Lapenta, L, 12P(ab)
Larar, JN, 1045
Larsen, S, 174P(ab)
Larson, SM, 422, 1595, 1656, 37P(ab), 53P(ab), 56P(ab), 83P(ab), 94P(ab), 105P(ab), 106P(ab), 114P(ab), 127P(ab), 145P(ab), 162P(ab), 213P(ab), 214P(ab), 216P(ab)
Larsson, S, 89P(ab)
Laruelle, M, 31P(ab), 48P(ab), 108P(ab), 211P(ab), 243P(ab)
Lastoria, S, 12P(ab), 42P(ab), 82P(ab), 115P(ab), 213P(ab), 219P(ab)
Latham, IA, 222
Latino, F, 250P(ab)
Laubenbacher, C, 968, 41P(ab), 112P(ab), 155P(ab)
Lauer, I, 1403
Launspach, J, 167P(ab)
Laurent, RTS, 4P(ab)
Lavenne, F, 22P(ab)
Lawerence, S, 38P(ab)
Lawrence, SK, 2185
Lawson, D, 176P(ab)
Lazar, JM, 1695
Le, N, 215P(ab), 233P(ab)
Leahy, RM, 182P(ab)
Leapman, SB, 381
Lear, JL, 150P(ab), 197P(ab), 202P(ab)
Leb, G, 168P(ab)
LeBouthillier, G, 140P(ab)
Lebtahi, R, 1243, 98P(ab)
Lécayon, M, 18P(ab), 134P(ab)
Leclerc, J, 119P(ab)
Le Cloirec, J, 1204
Lecomte, R, 101P(ab), 136P(ab)
Le Doussal, J-M, 1267, 1662
Lee, AY, 122P(ab)
Lee, BH, 167P(ab)
Lee, BY, 122P(ab)
Lee, DS, 212P(ab)
Lee, EK, 23P(ab)
Lee, FT, 100P(ab), 153P(ab)
Lee, H, 67P(ab)
Lee, HB, 250P(ab)
Lee, HC, 251P(ab)
Lee, HK, 116P(ab)
Lee, H-P, 1651
Lee, J, 42P(ab)
Lee, J-D, 1987, 167P(ab)
Lee, JT, 167P(ab), 215P(ab), 233P(ab)
Lee, K-S, 184P(ab), 224P(ab), 235P(ab)
Lee, KU, 130P(ab)
Lee, M-C, 1651, 212P(ab)
Lee, ME, 169P(ab)
Lee, MH, 76P(ab), 83P(ab), 130P(ab), 138P(ab)
Lee, MJ, 260P(ab)
Lee, RF, 169P(ab)
Lee, RJ, 151P(ab)
Lee, SK, 76P(ab)
Lee, T-Y, 252P(ab)
Lee, VW, 2095
Lee, W, 256P(ab)
Lee, YI, 83P(ab)
Leeds, N, 55P(ab)
Lees, AM, 66P(ab)
Lees, RS, 66P(ab)
Léger, AF, 387
Léger, G, 31P(ab)
Le Guludec, D, 981
Lehikoinen, P, 1711, 21P(ab)
Lehner, CE, 143P(ab)
Lehur, P-A, 1662
Leibling, M, 144P(ab)
Leichner, PK, 938
Leisure, GP, 1000
Leitha, T, 1397
Lelord, G, 78P(ab)
Lemieux, RJ, 297
Lena, I, 235P(ab)
Lenihan, DJ, 120P(ab)
Lensing, AWA, 1834(le)
Lentle, BC, 1612
Leon, AR, 281
Leon, JA, 99P(ab)
Leonard, D, 125P(ab)
Leonidas, JC, 251P(ab)
LePage, M, 209P(ab)
Leppo, JA, 927, 1510, 1722, 14P(ab), 46P(ab), 130P(ab), 149P(ab)
Le Prise, PY, 182
Lerch, H, 3P(ab)
Lerch, R, 46P(ab)
Lerner, E, 1416
Leroy, RF, 754, 23P(ab)
Leroy-willig, A, 205P(ab)
Le Scao, Y, 1217(le)
Leskinen-Kallio, S, 1, 1711, 21P(ab)
Leslie, WD, 165P(ab)
Lesser, I, 210P(ab)
Lette, J, 1389(le), 151P(ab)
Leung, SO, 217P(ab)
Léveillé, J, 96P(ab), 118P(ab), 121P(ab), 140P(ab)
Lever, JR, 103P(ab)
Lever, SZ, 18P(ab), 135P(ab)
Levine, B, 88P(ab)
Levine, G, 53P(ab), 54P(ab), 61P(ab), 94P(ab)
Levine, R, 22P(ab)
Levy, AV, 2019, 40P(ab), 237P(ab)
Levy, D, 196P(ab), 203P(ab)
Lew, K, 214P(ab)
Lew, R, 239P(ab)
Lewandrowski, K, 210P(ab)
Lewellen, BL, 1361
Lewellen, TK, 60P(ab), 136P(ab), 137P(ab), 258P(ab)
Lewis, C, 1766
Lewis, DH, 62P(ab)
Lewis, JP, 93P(ab)
Lewitt, RM, 137P(ab)
Leyvraz, PF, 84P(ab)
Li, J, 10P(ab), 26P(ab), 30P(ab), 80P(ab), 81P(ab), 188P(ab)
Li, M, 28P(ab)
Li, PY, 213P(ab)
Li, QS, 173P(ab)
Li, X, 185P(ab)
Li, Y, 206P(ab), 249P(ab)
Liang, Q, 38P(ab)
Liao, S-Q, 71, 1918
Licence, S, 62P(ab)
Licho, R, 194P(ab)
Lichtenstein, G, 697
Lichtenstein, GL, 849
Lichtenstein, GR, 2276(le)
Lidgren, L, 1646
Liebermann, J, 67P(ab), 102P(ab)
Liebes, L, 1067
Liedtke, AJ, 16P(ab)
Lill, DW, 78P(ab)
Lillimoe, K, 76P(ab)
Lim, CB, 190P(ab)
Limoges, R, 58P(ab)
Lin, K, 70P(ab), 183P(ab)
Lin, TF, 143P(ab)
Lin, W-Y, 71, 1918, 167P(ab), 245P(ab)
Lind, P, 122P(ab)
Lindenmeir, M, 63P(ab)
Linder, KE, 18P(ab)
Lindgren, L, 448
Lindheim, SR, 165P(ab)
Lindholm, P, 1, 1711, 21P(ab), 224P(ab)
Line, BR, 178P(ab), 229P(ab), 262P(ab)
Linehan, WM, 173
Ling, V, 242P(ab)
Lingen, A, 1706
Linggood, RM, 206P(ab)
Link, JM, 237P(ab)
Linke, MJ, 61P(ab)
Linsley, P, 58P(ab)
Lipp, RW, 168P(ab)
Lippitz, B, 222P(ab)
Lips, P, 110P(ab)
Lipszyc, H, 66P(ab), 67P(ab), 104P(ab)
Lisbona, R, 853, 1992
Lister-James, J, 17P(ab), 66P(ab), 104P(ab), 156P(ab)
L'Italian, G, 149P(ab)
Little, JM, 1172
Littman, B, 51P(ab), 88P(ab)
Livingston, RB, 1839
Lisbona, R, 1992
Liu, P, 1692
Liu, RS, 76P(ab), 138P(ab), 143P(ab), 145P(ab), 185P(ab), 238P(ab)
Liu, Y, 9P(ab)
Livio, JJ, 84P(ab)
Livni, E, 240P(ab)
Ljungberg, M, 72P(ab), 80P(ab), 178P(ab)
Ljunggren, K, 113P(ab)
Ljungren, K, 222P(ab)
Llacer, J, 1198, 184P(ab)
Llewellyn, G, 1377
Lloyd, KO, 216P(ab)
Lloyd-Still, JD, 226P(ab)
Lobmeier, G, 212P(ab)
Lobo, RA, 165P(ab)
Loc'h, C, 1717, 1739, 102P(ab), 124P(ab), 211P(ab)
Loessner, A, 210P(ab)
Löffler, S, 161P(ab)
Logan, J, 246, 609, 619, 67P(ab), 78P(ab), 102P(ab), 131P(ab), 200P(ab)
Lohner, W, 37P(ab)
Loizides, A, 24P(ab), 64P(ab), 131P(ab)
Lomeña, FJ, 77P(ab)
Lomuscio, G, 226P(ab)
Loncaric, S, 195P(ab)
London, ED, 40P(ab), 199P(ab)
Longford, CPD, 7P(ab)
Longobardi, S, 42P(ab), 219P(ab)
Lopez, C, 233P(ab)
Lopez, D, 221P(ab)
Lopez-Pousa, A, 1503
Lopez-Pousa, J, 13P(ab)
Lorenz, CH, 826
Lorenz, R, 205P(ab)
Lorenz, W, 21P(ab)
Loring, NA, 51P(ab), 73P(ab), 88P(ab)
Lossau, I, 222P(ab)
Lotter, MG, 330, 963
Louie, JS, 144P(ab)
Lowe, JL, 754
Lowe, VJ, 1998, 7P(ab), 17P(ab), 21P(ab), 37P(ab)
Lu, JG, 26P(ab)
Lu, P, 66P(ab)
Lubin, E, 152P(ab)
Lubushitzky, R, 141P(ab)
Lucas, JR, 64P(ab), 65P(ab), 95P(ab), 151P(ab)
Lucignani, G, 137, 360, 5P(ab), 93P(ab), 154P(ab)
Luck, JV Jr., 144P(ab)
Ludbrook, PA, 717
Luecders, C, 2222
Lufkin, R, 224P(ab)
Lukes, J, 120P(ab)
Luketic, V, 153P(ab)
Luliano, L, 67P(ab)
Lull, RJ, 1827(le)
Lusins, JO, 143P(ab)
Luthra, SK, 57P(ab)
Luurtsema, G, 183P(ab)
Lyle, LR, 104P(ab)
Lynch, PJ, 257P(ab)
Lynch, RE, 2135
Lyons, KP, 65P(ab)
Lyster, DM, 235P(ab)

Ma, D, 231P(ab)
Macapinlac, H, 11P(ab), 37P(ab), 56P(ab), 94P(ab), 127P(ab), 145P(ab)
MacDonald, J, 232P(ab)
Macdonald, WBG, 1082
MacDonell, RC, 2185
Macey, D, 33P(ab), 53P(ab), 127P(ab), 134P(ab), 161P(ab), 180P(ab), 191P(ab), 192P(ab), 218P(ab)
MacFall, JR, 1587
MacGregor, R, 609
MacGregor, RR, 67P(ab), 102P(ab), 131P(ab), 200P(ab)
Mach, RH, 8P(ab)
Machac, J, 67P(ab), 77P(ab)
Machida, K, 1984
MacIntyre, WJ, 400, 1834(le), 190P(ab)
Maciunas, R, 37P(ab), 206P(ab)
MacKenzie, ET, 241P(ab), 243P(ab)
Mackey, DWJ, 232P(ab)
Macklis, RM, 1811
MacLean, G, 213P(ab)
Maclean, JP, 165P(ab)
Macleod, MA, 1616(le)
Maddahi, J, 1494, 2009, 137P(ab), 148P(ab), 184P(ab), 224P(ab)
Madden, T, 88P(ab)
Maddock, SW, 1020
Madsen, JR, 1045
Madsen, MT, 68P(ab), 167P(ab), 188P(ab), 193P(ab)
Maeda, M, 159P(ab)
Maegdenbergh, VVD, 10P(ab)
Maes, A, 4P(ab)
Maffioli, LS, 219P(ab)

Magata, Y, 932, 1672, 2124, 6P(ab), 107P(ab), 147P(ab), 234P(ab)
Magnani, P, 94P(ab), 114P(ab)
Magoun, S, 131
Maguire, GQ Jr., 128P(ab)
Maguire, WM, 83P(ab), 166P(ab)
Mahmarian, JJ, 3P(ab), 54P(ab), 75P(ab), 95P(ab)
Mahmood, A, 242P(ab)
Mahmood, MM, 142P(ab)
Mahraj, RPM, 121P(ab)
Mailliard, J, 6P(ab), 20P(ab), 21P(ab)
Mainolfi, C, 115P(ab)
Maislin, G, 117P(ab)
Majd, M, 52P(ab)
Majmundar, JLH, 1246
Makhoul, E, 166P(ab)
Makino, M, 174P(ab)
Makler, PT Jr., 115P(ab)
Malfetano, J, 262P(ab)
Malison, R, 48P(ab), 102P(ab)
Mallavarapu, C, 85P(ab)
Mallet, J, 150P(ab)
Mallett, R, 2111
Mallin, W, 117P(ab), 137P(ab), 174P(ab), 224P(ab), 261P(ab)
Malmud, LS, 576, 10P(ab)
Mandelbaum, A, 48, 139P(ab)
Mandelkern, MA, 12P(ab), 257P(ab)
Mandelmont, JC, 1260
Manglos, SH, 992, 81P(ab), 193P(ab)
Mangner, TJ, 83, 8P(ab), 25P(ab), 224P(ab)
Mangoni Di S. Stefano, ML, 1602
Mannan, RH, 405, 885
Manning, RG, 132P(ab), 202P(ab)
Manning, RM, 158P(ab)
Mannting, F, 601
Mannting, MGM, 601
Manolis, A, 65P(ab)
Mansfield, RK, 126P(ab)
Mantil, JC, 8P(ab), 218P(ab)
Manttera, J, 1254
Maple, L, 232P(ab)
Marcel, R, 14P(ab)
Marcus, C, 144P(ab)
Mardirossian, G, 109, 1618(le)
Mardon, K, 1739, 124P(ab)
Marek, K, 31P(ab)
Marek, MJ, 231P(ab), 246P(ab)
Marenco, S, 91P(ab)
Margaron, P, 49P(ab)
Margouleff, D, 177P(ab), 209P(ab)
Margulis, G, 1218(le)
Mariacaridad, T, 179P(ab)
Mariani, G, 1175, 2032
Mariani, M, 82P(ab)
Marini, RP, 171P(ab)
Markey, J, 205P(ab)
Markham, J, 87P(ab)
Marks, GF, 54P(ab)
Markt, B, 122P(ab)
Markusse, HM, 118P(ab)
Marmion, ME, 135P(ab)
Marmor, A, 1877
Marois, LJ, 74P(ab)
Marquardt, G, 205P(ab)
Marrett, S, 199P(ab)
Marrie, TJ, 458
Marriott, C, 101P(ab)
Marshall, BJ, 821
Marshall, RC, 35P(ab)
Martich, V, 52P(ab), 227P(ab)
Martin, CC, 39P(ab), 50P(ab)
Martin, D, 161P(ab)
Martin, DJ, 193P(ab)
Martin, EL, 51P(ab)
Martin, GV, 918, 79P(ab)
Martin, M, 1662
Martin, RH, 458
Martin, SE, 281, 96P(ab), 146P(ab)
Martin, WG, 112P(ab)
Martinez, F, 43P(ab)
Martino, J, 63P(ab)
Marumo, F, 66P(ab)
Maruyama, Y, 98P(ab)
Marzilli, LG, 39P(ab)
Marzola, MC, 110P(ab)
Masarotto, G, 1626
Mascheroni, L, 219P(ab)
Mason, GR, 231P(ab)
Mason, NS, 132P(ab), 158P(ab)
Mason, RP, 124P(ab)
Massuger, L, 247P(ab)
Masters, PR, 255P(ab)
Masterson, ME, 106P(ab)
Masterson, TT, 244P(ab)
Masuda, K, 288
Masumoto, M, 159P(ab)
Materassi, M, 117P(ab)
Matheja, P, 45P(ab)
Mather, SJ, 82P(ab), 246P(ab)
Mathews, D, 1239
Mathias, CJ, 228, 1127, 79P(ab), 123P(ab)
Mathis, C, 7P(ab)
Matoba, N, 1672
Matsmoto, K, 198P(ab)
Matsubara, T, 95P(ab)
Matsuda, GR, 2144
Matsuda, H, 92P(ab), 197P(ab)
Matsumoto, K, 1543, 26P(ab), 225P(ab)
Matsumoto, M, 63P(ab), 171P(ab), 207P(ab), 209P(ab)
Matsuno, Y, 95P(ab)
Matsuo, I, 95P(ab)
Matsuura, H, 2227
Mattar, AG, 138P(ab)
Mattay, VS, 228P(ab)
Matthay, KK, 1922
Matteucci, F, 2032
Matthews, KL, 112P(ab)
Matthysse, S, 196P(ab), 203P(ab)
Maublant, JC, 255, 1949
Mauclaire, LP, 1260
Mauguière, F, 22P(ab), 103P(ab)
Maul, FD, 205P(ab)
Maurea, S, 173, 1688, 12P(ab), 147P(ab)
Maurer, AH, 1447, 11P(ab), 17P(ab), 66P(ab), 169P(ab)
Mausner, LF, 93P(ab), 237P(ab)
Maxon, HR, 42P(ab), 127P(ab), 152P(ab), 156P(ab), 248P(ab), 261P(ab)
Maxon, HR III, 525(le)
Mayberg, HS, 5P(ab)
Mayeur, S, 10P(ab)
Mayeur, SM, 576
Mayeux, R, 1090
Maynard, CD, 157
Maze, A, 1204
Maziére, B, 1717, 1739, 102P(ab), 124P(ab), 211P(ab)
Mazière, M, 102P(ab), 211P(ab)
Mazoyer, B, 1899, 36P(ab)
Mazza, S, 205P(ab)
Mazziotta, JC, 679, 1198, 1892
Mazzucchelli, L, 226P(ab)
McAfee, JG, 2169, 48P(ab), 174P(ab), 248P(ab)
McAneny, DB, 2095
McCallister, SH, 747
McCandless, BK, 1341, 142P(ab), 150P(ab), 195P(ab)
McCarter, J, 242P(ab)
McCarthy, TJ, 69P(ab), 89P(ab)
McCarthy, WH, 1435
McCartney, JE, 234
McCartney, WH, 30P(ab)
McClellan, JR, 75P(ab), 85P(ab)
McConnell, JR, 203P(ab)
McCormick, LX, 2053
McCormick, VA, 769, 158P(ab)
McCune, WJ, 207P(ab)
McDermott, K, 1656, 214P(ab)
McDermott, M, 257P(ab)
McDevitt, MR, 260
McDonald, IA, 240P(ab)
McDonald, TW, 6P(ab)
McDougall, IR, 12P(ab)
McDowell, DM, 48P(ab)
McEwan, A, 213P(ab)
McEwan, AJ, 405, 2053
McEwan, AJB, 885
McEwan, J, 255P(ab)
McGarity, W, 165P(ab)
McGill-Clare, D, 172P(ab)
McGonigle, P, 132P(ab)
McGuire, AH, 56P(ab)
McKay, WJ, 666
McKusick, K, 16P(ab), 17P(ab), 44P(ab)
McKusick, KA, 879, 1109, 1119
McLoud, TC, 1571
McMahon, M, 1254, 44P(ab)
McMillan, K, 33P(ab), 244P(ab)
McNamara, D, 297
McNeil, B, 41N(12)
McNeil, L, 179P(ab)
McPartlin, M, 222
McPhail, NV, 74P(ab)
McPhee, MS, 405
McPherson, DW, 946, 197P(ab), 236P(ab), 243P(ab)
McQuarrie, S, 213P(ab)
McSherry, BA, 130P(ab)
Meadors, JN, 261P(ab)
Meares, CF, 28P(ab), 81P(ab), 93P(ab), 94P(ab)
Mease, RC, 237P(ab)
Mechanick, JI, 465
Meder, J-F, 1243
Meerdink, DJ, 927
Meghdadi, S, 1397
Mehta, BM, 106P(ab), 114P(ab)
Mehta, SL, 54P(ab), 149P(ab)
Mehta, VD, 124P(ab)
Meidell, RS, 84P(ab)
Meignan, M, 2105
Meihofer, M, 1574
Meikle, SR, 143, 671, 1752, 184P(ab)
Meinken, GE, 237P(ab)
Meister, E, 2278(le), 2280(le)
Melder, RJ, 73P(ab)
Melega, W, 70P(ab), 183P(ab)
Melega, WP, 679
Melian, E, 94P(ab)
Melin, JA, 15P(ab), 86P(ab), 121P(ab)
Melin, JE, 44P(ab)
Melis, K, 52P(ab)
Mello, NK, 723
Melman, A, 250P(ab)
Mélon, P, 155P(ab)
Meltzer, CC, 5P(ab)
Memsic, LD, 18
Mena, I, 187, 5P(ab), 45P(ab), 140P(ab), 210P(ab)
Menard, JF, 205P(ab)
Menard, S, 213P(ab)
Mendelsohn, J, 213P(ab)
Mendelson, J, 723
Meng, X-J, 25P(ab), 232P(ab), 236P(ab)
Menser, MA, 1082
Mensh, BD, 122P(ab)
Menzel, C, 77P(ab), 204P(ab)
Mercer, JR, 405, 885
Merckx, E, 210P(ab), 222P(ab)
Merelet, P, 1739
Merhige, ME, 23P(ab)
Merino, MJ, 24
Merlet, P, 981, 1899, 14P(ab), 36P(ab), 45P(ab), 124P(ab)
Merola, B, 42P(ab), 219P(ab)
Merriwether, WG, 100P(ab)
Merry, M, 169P(ab)
Messa, C, 5P(ab)
Messian, O, 226P(ab)
Messinger, DE, 134, 152P(ab)
Messmer, BJ, 23P(ab)
Metlev, V, 232P(ab)
Mettler, FA, 260P(ab)
Metz, CE, 1198, 81P(ab)
Metz, J, 798
Metz, KR, 241P(ab)
Meyer, CR, 1190
Meyer, E, 51P(ab), 57P(ab), 181P(ab), 198P(ab), 199P(ab)
Meyer, G-J, 1770
Meyer, MA, 209P(ab), 235P(ab)
Meyer, WA, 238P(ab)
Meyerrose, G, 5P(ab), 168P(ab)
Meylaerts, SAG, 41P(ab)
Micaily, B, 1574
Michel, C, 15P(ab), 44P(ab), 86P(ab), 101P(ab), 121P(ab)
Michelot, J, 1949
Michelot, JM, 1260
Michelson, RH, 8P(ab), 90P(ab)
Michigishi, T, 139P(ab), 223P(ab)
Mickala, P, 241P(ab), 243P(ab)
Miedema, AR, 41P(ab)
Migneco, O, 5P(ab)
Mignon, M, 98P(ab)
Mikasa, K, 229P(ab)
Miklos, JA, 769
Miller, DD, 1823, 85P(ab), 120P(ab)
Miller, J, 112P(ab)
Miller, K, 1218(le)
Miller, L, 15N(11), 17N(12), 19N(12), 23N(10), 32N(11), 209P(ab)
Miller, MI, 20P(ab)
Miller, RF, 1621
Miller, SH, 48P(ab)
Miller, SW, 1396(br)
Miller, TR, 1793, 20P(ab), 106P(ab), 192P(ab)
Mills, BJ, 131
Mills, GO, 171P(ab)
Milne, N, 65P(ab)
Mimura, H, 208P(ab)
Min, YI, 76P(ab)
Minami, C, 144P(ab)
Minear, GS, 48P(ab)
Minn, H, 1, 1711, 21P(ab), 224P(ab)
Minnick, DK, 158P(ab)
Minoshima, S, 322, 22P(ab), 25P(ab), 56P(ab), 57P(ab), 70P(ab), 108P(ab), 116P(ab), 202P(ab), 207P(ab), 211P(ab)
Mintun, MA, 322, 57P(ab), 224P(ab)
Mintzer, RA, 112P(ab)
Miraldi, F, 523(le), 1000, 239P(ab)
Mirick, GR, 93P(ab)
Misaki, T, 107P(ab)
Mitchell, DS, 51P(ab), 220P(ab)
Mitchell, K, 177P(ab)
Mittermayer, C, 164P(ab), 217P(ab)
Miura, S, 1333, 200P(ab)
Miyagawa, M, 222P(ab)
Miyake, T, 107P(ab)
Miyake, Y, 24P(ab)
Miyaoka, RS, 60P(ab)
Miyasaka, M, 66P(ab)

Miyashita, K, 202P(ab)
Miyatake, K, 107P(ab)
Miyauchi, T, 28P(ab), 139P(ab), 223P(ab)
Miyazaki, C, 812
Miyazawa, H, 780, 1886
Miyazawa, Y, 301
Mizrachi, H, 1067
Mnaymneh, W, 33P(ab)
Moak, SA, 233P(ab)
Moase, A, 214
Mochizuki, H, 42P(ab)
Mochizuki, S, 161P(ab)
Mochizuki, T, 98P(ab)
Modell, JG, 211P(ab)
Moeller, JR, 1090
Moffat, F, 214P(ab)
Mohammadpour, H, 2152
Mohan, MK, 165P(ab)
Mohan, R, 1595, 162P(ab)
Mohr, K, 243P(ab)
Mohs, R, 116P(ab)
Mohsin, J, 12P(ab), 162P(ab), 163P(ab)
Moingeon, LI, 242P(ab)
Moins, N, 255
Moisan, A, 182
Mok, DY, 178P(ab)
Mokotoff, M, 231P(ab)
Molea, N, 2032, 83P(ab)
Molenaar, WM, 219P(ab)
Möllenstädt, S, 219P(ab)
Möller, H-J, 77P(ab)
Momose, J, 174P(ab)
Momose, T, 1984, 71P(ab), 113P(ab), 182P(ab)
Monetti, N, 1166, 129P(ab)
Monforte, R, 1452
Mongioj, V, 219P(ab)
Monti, L, 154P(ab)
Moon, DH, 76P(ab), 83P(ab), 130P(ab), 138P(ab)
Moore, BA, 474
Moore, H, 69P(ab)
Moore, RB, 405
Moore, RH, 199, 1616(le), 2277(le)
Moore, SC, 188P(ab)
Moore, W, 151P(ab), 175P(ab), 186P(ab), 189P(ab)
Moots, P, 206P(ab)
Morais, J, 145P(ab)
Morand, P, 1472, 45P(ab)
Morawsky, L, 131P(ab)
Moreau, MFC, 1260
Moresco, RM, 360, 102P(ab), 154P(ab)
Morgan, HT, 30P(ab), 71P(ab), 80P(ab), 191P(ab)
Morgan, LL, 84P(ab)
Morguet, AJ, 153P(ab)
Mori, T, 107P(ab)
Mori, Y, 122P(ab)
Morice, P, 182
Moriel, M, 34P(ab), 148P(ab)
Morikawa, A, 42P(ab)
Morin, P-P, 1217(le)
Morisco, C, 1688, 147P(ab), 153P(ab)
Morise, A, 150P(ab)
Morita, K, 208P(ab)
Moriwaki, H, 63P(ab), 171P(ab), 207P(ab), 209P(ab)
Moriya, E, 161P(ab)
Morozumi, T, 34P(ab)
Morrell, NW, 370
Morris, G, 82P(ab)
Morris, ID, 133P(ab)
Morris, JS, 238P(ab)
Morris, K, 19N(7), 22N(4), 28N(10)
Morris, ST, 115P(ab)
Morrison, JC, 1169
Morrison, KS, 481
Morrison, WB, 123P(ab)
Morrissey, GJ, 151
Morrow, TJ, 56P(ab)
Mortelmans, L, 4P(ab), 110P(ab), 141P(ab), 222P(ab), 227P(ab)
Mortenson, T, 223P(ab)
Mortimer, JE, 56P(ab)
Morton, K, 251P(ab)
Morton, KA, 128, 195, 455, 1905, 2135, 1389(le), 62P(ab), 71P(ab), 157P(ab), 176P(ab), 196P(ab), 220P(ab), 249P(ab)
Mosbach, PE, 131P(ab)
Mosca, F, 1175
Mosca, L, 155P(ab)
Moscatelli, G, 44P(ab)
Moser, E, 375
Moses, WW, 101P(ab)
Moskowitz, GW, 166P(ab)
Mostbeck, A, 122P(ab)
Moster, M, 1447
Motomura, N, 2216, 180P(ab), 193P(ab)
Mountz, JD, 58P(ab)
Mountz, JM, 58P(ab), 64P(ab), 78P(ab), 92P(ab), 206P(ab), 211P(ab)
Mourad, M, 129P(ab)
Moyer, BR, 104P(ab)
Mozley, D, 210P(ab)
Mozley, LH, 228P(ab)
Mozley, PD, 208, 1866, 1910, 12P(ab), 48P(ab), 76P(ab), 92P(ab), 117P(ab), 158P(ab), 162P(ab), 163P(ab), 190P(ab), 195P(ab), 198P(ab), 207P(ab), 228P(ab)
Msaki, P, 136P(ab)
Mueller, B, 158P(ab)
Mueller, PR, 260P(ab)
Mueller-Gartner, HW, 5P(ab)
Mukai, T, 839, 29P(ab), 59P(ab), 194P(ab)
Mukherjee, J, 798, 239P(ab), 243P(ab)
Mukhopadhyay, S, 123P(ab)
Mulholland, GK, 123P(ab)
Mull, M, 222P(ab)
Mullan, BP, 12P(ab), 61P(ab), 166P(ab)
Mullani, NA, 1831(le)
Muller, D, 968
Müller, L, 7P(ab)
Müller, P, 4P(ab)
Müller, SP, 58P(ab)
Müller-Schauenburg, W, 1770
Mulnix, T, 16P(ab)
Muls, V, 1642, 99P(ab), 166P(ab)
Munda, R, 171P(ab)
Munley, MT, 19P(ab)
Munz, DL, 153P(ab)
Murakami, M, 1936, 126P(ab), 200P(ab)
Muraki, A, 1152
Murali, D, 8P(ab)
Muranaka, A, 208P(ab)
Murase, K, 19P(ab), 98P(ab), 167P(ab)
Murphy, KJ, 262P(ab)
Murphy, P, 151P(ab), 175P(ab), 186P(ab), 189P(ab)
Murphy, PH, 34N(3), 50N(6)
Murthy, S, 465, 61P(ab)
Muths, C, 7P(ab)
Muthuswamy, M, 105P(ab)
Muzic, RF Jr, 1000
Muzik, O, 83, 336, 13P(ab), 35P(ab), 36P(ab), 155P(ab)
Muzinic, M, 1235
Myen, R, 26P(ab)

Nabeshima, M, 177P(ab), 247P(ab)
Nagai, K, 208P(ab)
Nagai, T, 63P(ab)
Nagamachi, S, 2091
Nagaraj, N, 127P(ab), 152P(ab), 171P(ab)
Nagata, S, 107P(ab)
Nagata, T, 201P(ab)
Nagata, Y, 2124
Nagel, TL, 106P(ab), 179P(ab)
Nagle, KR, 222
Nagren, K, 1711, 21P(ab)
Naidech, HJ, 261P(ab)
Najafi, A, 237P(ab)
Nakagawa, A, 180P(ab)
Nakagawa, I, 247P(ab)
Nakahashi, H, 431
Nakai, K, 1309
Nakajima, K, 1478
Nakajima, T, 202P(ab), 215P(ab)
Nakajima, Y, 258P(ab)
Nakaki, M, 1282, 1309
Nakamura, M, 103P(ab)
Nakanishi, T, 1980
Nakashima, R, 1184, 177P(ab), 247P(ab)
Nakata, Y, 221P(ab)
Nakatani, N, 98P(ab)
Nakatsuka, I, 932
Nakayama, M, 247P(ab)
Namavari, M, 238P(ab)
Namba, R, 221P(ab)
Nambu, K, 193P(ab)
Nance, RW Jr, 294
Nancy, A, 126P(ab)
Nappi, A, 1602, 1688, 147P(ab), 153P(ab)
Narabayasi, I, 221P(ab)
Narahara, KA, 187
Narendula, S, 256P(ab)
Narita, N, 229P(ab)
Narra, RK, 641, 15P(ab), 146P(ab)
Narra, VR, 637, 133P(ab), 134P(ab)
Naruki, Y, 98P(ab)
Narula, J, 1507, 2264
Nassar, G, 164P(ab)
Nathan, M, 11P(ab), 188P(ab)
Navia, B, 203P(ab), 212P(ab)
Neal, CE, 262P(ab)
Neary, J, 112P(ab)
Nebeling, B, 355
Nedelman, MA, 234
Neild, GH, 1163
Nel, MG, 963
Nellis, SH, 16P(ab)
Nelson, AD, 523(le), 1000
Nelson, C, 110P(ab), 113P(ab)
Neptune, M, 172P(ab)
Neubauer, U, 207P(ab)
Neumann, DR, 400, 1834(le)
Neumann, M, 1397
Neumann, PH, 1341, 150P(ab)
Neumann, RD, 24, 173, 351(le), 2169, 58P(ab), 215P(ab), 233P(ab)
Neumann, WL, 228
Neumeyer, JL, 31P(ab), 243P(ab)
Neumeyer, M, 197P(ab)
Nevo, E, 1877
Newberg, AB, 1681
Newell, DW, 62P(ab)
Newell, J, 149P(ab)
Newkome, GR, 29P(ab)
Newman, MA, 24N(5), 25N(9)
Newman, OC, 104P(ab)
Newman, S, 24P(ab), 64P(ab), 131P(ab)
Newton, MR, 666
Ng, CK, 205P(ab)
Ngai, WM, 99P(ab)
Nguyen, D, 102P(ab)
Nguyen, N, 83, 13P(ab), 45P(ab), 87P(ab)
Nguyen, T, 124P(ab)
Nguyen, TQ, 33P(ab)
Nichols, D, 22N(4)
Nichols, K, 1871, 24P(ab), 64P(ab), 131P(ab), 150P(ab)
Nickerson, J, 218P(ab)
Nickles, RJ, 1058, 8P(ab), 16P(ab), 69P(ab), 157P(ab), 184P(ab), 248P(ab)
Nicol, PD, 2144
Nicolá, JM Ana M Catafau, Ramón Estruc, 1452
Nicolai, E, 1688, 147P(ab), 153P(ab)
Nieweg, O, 219P(ab), 225P(ab)
Nigh, E, 345
Nijran, KS, 370
Nijs, J, 141P(ab)
Nikkels, P, 55P(ab)
Nilsson, R, 448
Nimeth, C, 212P(ab)
Nimmon, CC, 845
Nishida, Y, 95P(ab)
Nishigauchi, K, 1980
Nishiguchi, S, 301
Nishihara, H, 2182
Nishihara, M, 32P(ab)
Nishikawa, J, 71P(ab), 113P(ab), 182P(ab)
Nishimura, K, 222P(ab)
Nishimura, S, 95P(ab)
Nishimura, T, 1013, 1103, 1931, 14P(ab), 24P(ab), 34P(ab), 55P(ab), 63P(ab), 107P(ab), 120P(ab), 159P(ab), 170P(ab), 171P(ab), 199P(ab), 201P(ab), 207P(ab), 209P(ab)
Nishimura, Y, 1103
Nishizawa, S, 839, 147P(ab), 194P(ab), 201P(ab)
Nitzsche, EU, 50P(ab), 88P(ab), 137P(ab)
Nocolai, E, 1602
Noda, EIF, 92P(ab)
Noel, P, 1223, 226P(ab)
Nohara, R, 120P(ab), 147P(ab)
Nomura, S, 815
Nonogi, H, 14P(ab)
Nonomura, A, 139P(ab)
Nordman, E, 21P(ab)
Norrgren, K, 448, 178P(ab)
Northover, JMA, 82P(ab)
Norton, JA, 24, 173
Norton, NS, 203P(ab)
Noujaim, A, 100P(ab), 126P(ab), 213P(ab)
Novales-Diaz, J, 853, 1992
Nowak, PA, 8P(ab)
Nowotnik, DP, 18P(ab)
Noz, ME, 1067, 2019, 63P(ab), 128P(ab)
Nozaki, T, 1944
Nunn, AD, 641, 924, 1058, 15P(ab), 16P(ab), 18P(ab)
Nußbaumer, J, 219P(ab)
Nutila, P, 2064
Nutt, R, 1367
Nuttall, PM, 157P(ab)
Nuutila, P, 2068, 3P(ab), 107P(ab), 224P(ab)
Nuyts, J, 4P(ab), 110P(ab), 141P(ab)

Oakes, TR, 8P(ab), 69P(ab), 157P(ab)
Oates, E, 953
O'Bannon, DD, 240P(ab)
Oberdorfer, F, 12, 1075, 220P(ab)
Obermueller, SD, 3P(ab)
Ochi, H, 301
O'Connell, JW, 65P(ab), 151P(ab)
O'Connell, WJ, 303
O'Connor, MK, 146P(ab), 148P(ab), 166P(ab)
Oda, H, 95P(ab)
Odano, I, 32P(ab), 198P(ab), 202P(ab)
Odhner, D, 256P(ab)
O'Driscoll, GA, 196P(ab), 203P(ab)
Oei, HY, 41P(ab), 118P(ab), 139P(ab), 175P(ab)
Oesch, F, 161P(ab)
Oettgen, HF, 213P(ab)
Offord, SJ, 109P(ab)
Ogawa, K, 2216, 176P(ab), 192P(ab)
O'Grady, LF, 53P(ab), 93P(ab)

Ogris, E, 1039, 122P(ab)
Ohishi, H, 229P(ab)
Ohmomo, Y, 234P(ab)
Ohmori, Y, 431, 1543, 26P(ab), 198P(ab), 225P(ab)
Ohnishi, T, 2091
Ohno, M, 177P(ab)
Ohta, Y, 66P(ab)
Ohtake, T, 71P(ab), 113P(ab), 181P(ab), 182P(ab)
Ohye, C, 2085
Okada, RD, 630
Okada, S, 63P(ab), 211P(ab)
Okazaki, Y, 63P(ab), 171P(ab), 207P(ab), 209P(ab)
O'Keefe, JH, 75P(ab), 149P(ab)
Oku, N, 63P(ab), 171P(ab), 207P(ab), 209P(ab)
Oku, S, 71P(ab), 113P(ab), 182P(ab)
Okubo, M, 32P(ab)
Okuda, K, 120P(ab)
Okunieff, PG, 206P(ab)
Old, LJ, 83P(ab)
Oldhoff, J, 219P(ab), 225P(ab)
O'Leary, DS, 68P(ab)
Olken, NM, 787
Ollier, M, 1949
Olsen, J, 11P(ab)
Oltrogge, J, 126P(ab)
O'Malley, JP, 259P(ab)
Ombetta, J-E, 235P(ab)
Omri, F, 1565
O'Neil, JP, 18P(ab)
O'Neill, M, 257P(ab)
O'Neill, P, 1172
Ono, S, 147P(ab), 208P(ab)
Ono, Y, 24P(ab), 55P(ab)
Onoyama, Y, 215P(ab)
Oohashi, H, 95P(ab)
Opie, L, 867(le)
Oppermann, H, 234
Ordonez, CE, 186P(ab)
Orduña, E, 32P(ab)
Orenstein, SR, 1228
Orie, JE, 1695
Orito, T, 159P(ab)
Oriuchi, N, 2085, 14P(ab), 42P(ab)
O'Rourke, MF, 238P(ab)
Orsolon, PG, 166P(ab)
Osieka, R, 164P(ab)
Ossenkoppele, GJ, 1706
Oster, ZH, 197P(ab)
Ostertag, H, 1075, 21P(ab), 220P(ab)
Ostrem, JL, 228P(ab)
Otsuka, M, 288
Otsuka, N, 208P(ab)
Otsuka, S, 98P(ab)
Otto, AC, 963
O'Tuama, LA, 1045
Ouellet, RG, 59P(ab)
Owens, E, 215P(ab)
Owunwanne, A, 233P(ab), 234P(ab)
Oya, N, 2124
Oya, S, 135P(ab)
Oyen, WJG, 1621, 62P(ab), 105P(ab)
Ozawa, K, 6P(ab)
Özgüven, M, 889
Ozker, K, 56P(ab)
Öztürk, E, 889

Paans, AMJ, 183P(ab), 219P(ab), 225P(ab), 241P(ab)
Pabst, HW, 41P(ab), 63P(ab), 112P(ab), 219P(ab)
Pace, L, 1602, 1688, 147P(ab)
Pacheco, EM, 143P(ab)
Packard, A, 151P(ab)
Packard, AB, 1045
Packer, R, 52P(ab)
Padhy, AK, 845
Paganelli, G, 92, 94P(ab), 114P(ab)
Page, RL, 216P(ab)
Pahl, JJ, 190P(ab)
Pai, LH, 241P(ab)
Paik, C, 48P(ab), 58P(ab), 215P(ab), 233P(ab), 241P(ab)
Paik, CH, 2169
Paine, S, 21P(ab), 23P(ab)
Pajeau, TS, 49P(ab), 160P(ab)
Pak, K, 247P(ab)
Pakzaban, P, 202P(ab)
Palestro, CJ, 818, 1235, 61P(ab), 83P(ab), 166P(ab), 233P(ab), 251P(ab), 262P(ab)
Palevsky, H, 1851, 43P(ab), 229P(ab), 230P(ab)
Palmas, W, 130P(ab), 150P(ab)
Palmer, AM, 156P(ab), 159P(ab)
Palmer, BM, 203P(ab)
Palmer, EL, 527(br), 661, 1837(br)
Palmer, S, 896
Palombo-Kinne, E, 92
Palowski, J, 195P(ab)
Paltiel, HJ, 614, 255P(ab)
Pan, JW, 92P(ab)
Pan, T-S, 195P(ab)
Pan, X, 112P(ab)
Pancholy, S, 75P(ab), 85P(ab)
Pandurangi, R, 232P(ab)
Pang, IW, 474
Pang, RHL, 234
Panico, FG, 250P(ab)
Pannier, L, 226P(ab)
Papageorgiou, I, 46P(ab)
Papon, JM, 1260
Pappas, AA, 896
Pappas, N, 102P(ab), 103P(ab), 131P(ab)
Pappata, S, 109P(ab)
Paradise, AH, 51P(ab)
Pardo, FS, 206P(ab), 208P(ab)
Parekh, J, 162P(ab), 230P(ab)
Parellada, E, 77P(ab)
Parisi, MT, 1922, 865(le)
Park, CH, 255P(ab)
Park, CY, 1987, 167P(ab)
Park, H-M, 381
Park, JS, 130P(ab), 138P(ab)
Park, S, 138P(ab)
Park, SG, 233P(ab)
Parker, J, 141P(ab), 142P(ab)
Parker, JA, 1355
Parkey, RW, 9P(ab)
Parkman, HP, 169P(ab)
Parliament, MB, 885
Parmett, S, 2101, 64P(ab)
Pasqualini, R, 18P(ab), 134P(ab)
Pastan, I, 241P(ab)
Pastor, E, 142P(ab)
Patch, GG, 1905
Pate, BD, 481
Patel, B, 15P(ab), 146P(ab)
Patel, D, 24P(ab), 64P(ab)
Patel, M, 234P(ab)
Patel, NH, 16P(ab)
Patterson, DJ, 169P(ab)
Patterson, RE, 281, 978, 29P(ab), 36P(ab), 44P(ab), 96P(ab), 146P(ab), 179P(ab)
Pattillo, RA, 56P(ab)
Patton, DD, 474
Patz, EF, 21P(ab)
Paul, R, 1428
Pauli, S, 89P(ab)
Pauw, BKH, 873
Pauwels, EKJ, 737, 1052
Pavel, DG, 188P(ab)
Pawlowski, J, 9P(ab)
Pawlyk, D, 53P(ab), 54P(ab), 94P(ab), 160P(ab)
Paxton, RJ, 1294
Payer, F, 116P(ab)
Payne, JK, 754, 68P(ab), 91P(ab)
Payne, S, 129P(ab)
Pecherstorfer, M, 1039
Peck, DJ, 97P(ab)
Pedroso de Lima, JJ, 1441
Pelizzari, C, 94P(ab)
Pelizzari, CA, 1587
Pellerin, M, 140P(ab)
Peltier, P, 1267
Peng, NJ, 76P(ab)
Penney, BC, 195P(ab)
Penninckx, F, 222P(ab)
Pentlow, K, 94P(ab), 127P(ab), 162P(ab)
Pentlow, KS, 1595
Pepys, MB, 118P(ab)
Perani, D, 1460, 5P(ab)
Perez, EA, 53P(ab)
Perlman, SB, 22P(ab)
Pernegger, C, 10P(ab)
Perrone-Filardi, P, 311
Pescatore, F, 172P(ab)
Pesl, H, 10P(ab), 212P(ab)
Peters, AM, 706, 1390(le), 2276(le), 41P(ab), 43P(ab), 62P(ab), 118P(ab)
Petersdorf, S, 1031, 1839
Peterson, A, 237P(ab)
Peterson, C, 8P(ab), 218P(ab)
Pettigrew, RI, 96P(ab)
Pettinger, WA, 251P(ab)
Peyron, R, 22P(ab), 103P(ab)
Pfieffer, N, 208
Pfister, D, 213P(ab)
Phalen, JJ, 238P(ab), 240P(ab), 251P(ab)
Pham, H, 231P(ab)
Phaneuf, DC, 96P(ab)
Phelps, ME, 488, 679, 1006, 2009, 2038, 1832(le), 4P(ab), 70P(ab), 137P(ab), 183P(ab), 184P(ab), 202P(ab), 224P(ab)
Philips, L, 165P(ab)
Phillips, C, 194P(ab)
Phillips, RL, 40P(ab)
Phillips, WT, 2160, 135P(ab), 247P(ab)
Philpott, GW, 28P(ab), 81P(ab), 134P(ab), 216P(ab)
Piatti, PM, 154P(ab)
Picard, D, 145P(ab)
Picard, M, 145P(ab)
Pickett, RD, 222
Piepenburg, R, 161P(ab)
Piepsz, A, 1223, 117P(ab), 226P(ab)
Pierce, M, 37P(ab)
Pierce, PF, 259P(ab)
Pieri, P, 879
Pieri, PL, 44P(ab)
Piers, DA, 354(le)
Pierson, RN Jr, 895
Pietrzyk, U, 101P(ab)
Piffanelli, A, 18P(ab)
Pike, MC, 1964, 173P(ab)
Pilcher, WC, 44P(ab)
Pinheiro, E, 142P(ab)
Pinsky, CM, 61, 214P(ab)
Pinto, AJ, 1441
Pipes, D, 38P(ab), 232P(ab)
Pirro, J, 15P(ab), 92P(ab)
Pitt, H, 76P(ab)
Pitt, S, 148P(ab)
Pitts, NL, 1169
Piwnica-Worms, D, 140P(ab)
Pizzolitto, S, 166P(ab)
Plagne, RJ, 1260
Plotzke, KP, 787
Podoloff, D, 33P(ab), 42P(ab), 53P(ab), 55P(ab), 88P(ab), 115P(ab), 119P(ab), 204P(ab), 212P(ab), 218P(ab), 223P(ab)
Poewe, W, 31P(ab)
Pohost, GM, 92P(ab)
Poland, S, 257P(ab)
Pollack, S, 2095
Pollard, KR, 60P(ab)
Pommier, R, 11P(ab)
Poncin, D, 226P(ab)
Ponto, LLB, 181P(ab), 185P(ab)
Poppe, G, 141P(ab)
Porenta, G, 35P(ab)
Port, SC, 131P(ab)
Postema, PTE, 41P(ab)
Poston, JW, 714
Potts, JM, 255P(ab)
Poublon, RML, 41P(ab)
Pouillart, F, 14P(ab)
Pounds, TR, 64P(ab), 65P(ab)
Powe, EJ, 151
Powers, ER, 728
Pozza, G, 154P(ab)
Prakash, D, 51P(ab)
Prato, F, 251P(ab), 252P(ab)
Pratt, JP, 150P(ab), 202P(ab)
Pratt, JR, 197P(ab)
Praturi, R, 294
Praturlon, S, 126P(ab)
Preece, AW, 156P(ab), 159P(ab)
Prekeges, JL, 169P(ab)
Prellwitz, JA, 238P(ab)
Prescott, MC, 159P(ab)
Pretorius, PH, 330, 963
Prevett, MC, 57P(ab)
Price, DC, 39P(ab)
Price, J, 228(ab)
Price, JC, 27P(ab)
Prigent, FM, 1845
Prince, JR, 190P(ab)
Prior, JO, 9P(ab)
Prohovnik, I, 1090
Pruim, J, 55P(ab), 183P(ab), 219P(ab), 225P(ab)
Pulmano, C, 131
Punja, U, 804
Purdy, PD, 1239
Purnell, GL, 896
Püspöck, J, 212P(ab)
Put, E, 211P(ab)
Putnam, J, 42P(ab)
Pyatt, B, 237P(ab)

Qi, P, 100P(ab)
Qian, J, 20P(ab), 151P(ab)
Quadri, S, 2152
Quadri, SM, 938
Quaife, RA, 84P(ab)
Quaim, SM, 2222
Quigley, EMM, 111P(ab)
Quinlan, D, 116P(ab)
Quinones, N, 12P(ab), 257P(ab)
Quint, LE, 1190
Quint, R, 153P(ab)

Rabinovitch, MA, 589
Rabito, C, 51P(ab), 88P(ab), 250P(ab)
Rabito, CA, 199, 1616(le), 2277(le)
Racadio, J, 257P(ab)
Radford, DM, 56P(ab)
Radtke, RA, 23P(ab)
Rafael, JAS, 1441
Raffel, D, 1739, 124P(ab)
Ragosta, M, 728
Rahmouni, A, 2105
Raijmakers, PGHM, 230P(ab)
Rain, B, 229P(ab)
Raja, S, 209P(ab)
Rajagopalan, R, 135P(ab)
Rajeevan, N, 195P(ab)
Raju, N, 146P(ab)
Rakow, JI, 1326
Ram, S, 100P(ab)
Ramalingam, K, 641, 18P(ab)
Ramanna, L, 18, 37P(ab), 77P(ab), 139P(ab), 168P(ab)
Ramirez, LF, 22P(ab)
Ramos-Gabatin, A, 1169
Ramzi, E, 1246
Rana, S, 24P(ab), 64P(ab)
Randé, JLD, 1899, 36P(ab)
Rao, DV, 637, 1801, 105P(ab), 133P(ab), 134P(ab)
Rao, MG, 997

Rapaport, E, 232P(ab)
Rapp, M, 1949
Rapun, R, 172P(ab)
Rasey, JS, 918, 21P(ab), 79P(ab)
Rath, P, 82P(ab)
Räth, U, 97P(ab)
Ratliff, BA, 908, 2111
Rattner, Z, 211P(ab)
Ratzlaff, N, 65P(ab)
Rauch, SL, 47P(ab), 57P(ab), 71P(ab), 196P(ab), 203P(ab)
Rauh, D, 2130, 104P(ab), 157P(ab), 172P(ab), 174P(ab)
Rauth, AM, 242
Ravert, HT, 120, 25P(ab), 31P(ab), 86P(ab), 103P(ab), 109P(ab), 132P(ab), 133P(ab), 197P(ab), 199P(ab), 228P(ab), 234P(ab)
Raylman, RR, 440, 50P(ab), 93P(ab), 106P(ab), 107P(ab), 113P(ab)
Raynaud, C, 1717, 78P(ab)
Reath, DB, 109P(ab)
Reba, RC, 32N(9), 2169, 233P(ab)
Reese, L, 251P(ab), 252P(ab)
Rege, S, 137P(ab), 224P(ab)
Rehm, PK, 227P(ab)
Reiber, C, 12
Reich, S, 31P(ab)
Reichmann, K, 187P(ab)
Reid, RH, 52P(ab)
Reijs, AEM, 175P(ab)
Reilly, RM, 99P(ab)
Reiman, R, 7P(ab), 144P(ab)
Reinbold, F, 48
Reiners, C, 58P(ab)
Reinhardt, CP, 1510, 1722, 14P(ab), 46P(ab)
Reissman, R, 231P(ab)
Remes, K, 1428
Renn, O, 94P(ab)
Renner, F, 212P(ab)
Rennie, BA, 235P(ab)
Renoux, M, 255
Renshaw, PF, 1101
Renstrom, B, 16P(ab)
Repp, R, 172P(ab)
Reske, SN, 87P(ab), 217P(ab), 223P(ab), 225P(ab)
Resnick, SM, 2201
Rettenbacher, L, 122P(ab)
Rettig, W, 83P(ab)
Reubi, JC, 118P(ab)
Reynolds, JC, 173, 233P(ab)
Rezai, K, 1607, 68P(ab)
Rhodes, BA, 231P(ab), 244P(ab), 246P(ab)
Ribe, JY, 12P(ab), 257P(ab)
Ricaurte, G, 25P(ab), 197P(ab)
Ricaurte, GA, 120
Ricciardi, R, 250P(ab)
Rice, KC, 235P(ab)
Rich, D, 205P(ab)
Richardson, S, 118P(ab)
Richie, JP, 123P(ab), 221P(ab)
Richman, CM, 53P(ab)
Richmond, JCW, 181P(ab), 185P(ab)
Richter, W, 31P(ab)
Rickard-Dickson, KJ, 1294
Rieger, P, 53P(ab)
Rieker, O, 77P(ab)
Rijks, LJM, 225P(ab)
Rijntjes, M, 58P(ab)
Rippon, MB, 53P(ab)
Riva, P, 44P(ab)
Rizzo, G, 137, 5P(ab)
Roamano, J, 66P(ab)
Roberson, PL, 105P(ab)
Robert, P, 5P(ab)
Roberti, RR, 193
Robertson, EF, 262P(ab)
Robertson, JS, 1382
Robeson, W, 177P(ab), 180P(ab), 209P(ab)
Robey, RL, 240P(ab)
Rocco, T, 151P(ab)
Rocque, PA, 28P(ab)
Roden, W, 68P(ab)
Rodriguez, B, 215P(ab)
Rodriguez, G, 91P(ab)
Rodriguez-Sierra, JF, 203P(ab)
Rogan, L, 1818
Rogers, M, 68P(ab)
Rogers, WL, 9P(ab), 30P(ab), 90P(ab), 148P(ab), 190P(ab)
Rogulski, MM, 27P(ab)
Rohe, RC, 156P(ab), 205P(ab)
Roizenblatt, S, 142P(ab)
Rojas-Burke, J, 13N(1), 19N(3), 20N(1), 23N(5), 25N(2), 26N(4), 47N(6)
Romagnuolo, J, 54P(ab), 149P(ab)
Roman, R, 1574
Roman, RA, 163P(ab), 173P(ab)
Romaniello, G, 135P(ab)
Roodenburg, JLN, 55P(ab)
Roos, JC, 82P(ab), 110P(ab)
Ropchan, JR, 12P(ab), 257P(ab)
Rosa, E, 106P(ab), 114P(ab)
Rosadini, G, 91P(ab)
Rosch, F, 2222
Rose, CP, 589
Rose, MR, 159P(ab)
Rosen, BR, 206P(ab), 208P(ab)
Rosen, G, 139P(ab)
Rosenblatt, B, 226P(ab)
Rosenblum, MG, 53P(ab)
Rosenfeld, S, 567
Rosenfeld, SS, 206P(ab)
Rosenthal, D, 205P(ab)
Rosenthal, JT, 88P(ab)
Rosenthal, MS, 1228
Rosenthall, L, 119P(ab)
Rosier, AM, 31P(ab)
Rossi, V, 117P(ab)
Roth, CA, 248P(ab)
Rothley, J, 968, 155P(ab), 158P(ab)
Rothstein, RD, 506
Rottenberg, DA, 200P(ab), 203P(ab)
Rousseau, C, 194P(ab)
Rousseau, J, 49P(ab), 101P(ab)
Rowan, M, 1467
Rowe, CC, 666
Rowe, RK, 474
Rowen, M, 54P(ab), 85P(ab)
Royal, HD, 260P(ab)
Rozanski, A, 1845, 24P(ab), 34P(ab), 64P(ab)
Rozen, S, 69P(ab)
Rubello, D, 1626, 161P(ab)
Rubenfire, M, 36P(ab), 155P(ab)
Rubertone, JA, 99
Rubin, NT, 51P(ab)
Rubin, RA, 697, 849, 2276(le)
Rubin, RH, 1964, 1975, 2130, 2176, 51P(ab), 83P(ab), 88P(ab), 104P(ab), 172P(ab), 173P(ab), 250P(ab)
Rubin, SC, 216P(ab)
Ruckert, ACF, 56P(ab)
Rucknagel, DL, 614
Ruddy, TD, 74P(ab)
Rudolph, AS, 2160, 135P(ab)
Ruijs, J, 163P(ab)
Ruiz, M, 96P(ab)
Rumsey, WL, 15P(ab), 16P(ab), 146P(ab)
Ruotsalainen, U, 1, 1711, 2064, 2068, 3P(ab), 21P(ab), 107P(ab), 224P(ab)
Rupich, RC, 227P(ab)
Rusckowski, M, 109, 1618(le), 59P(ab), 234P(ab), 240P(ab)
Rusinek, H, 2019, 40P(ab)
Russell, CD, 1761, 249P(ab)
Ruth, TJ, 481
Rutishauser, W, 46P(ab)
Ryan, J, 171P(ab)
Ryan, PJ, 110P(ab), 141P(ab), 142P(ab), 144P(ab)
Rydholm, U, 1646
Rylatt, DB, 100P(ab), 153P(ab)
Rysavy, J, 6P(ab), 21P(ab)
Ryu, JS, 76P(ab), 83P(ab), 130P(ab), 138P(ab)

Saal, J-P, 1899
Sabia, PJ, 728
Sabourin, CL, 239P(ab)
Sabry, S, 1739
Sackeim, H, 1090
Sackellares, JC, 22P(ab)
Sacks, SL, 235P(ab)
Sadanega, Y, 1980
Sadato, N, 1672, 147P(ab)
Sadek, S, 233P(ab)
Sadik, A, 172P(ab)
Saelens, E, 1217(le)
Safavy, A, 29P(ab)
Saffer, JR, 61P(ab), 124P(ab), 178P(ab)
Saga, T, 2169, 58P(ab), 215P(ab), 233P(ab)
Sagar, KB, 94P(ab)
Sago, M, 107P(ab)
Saha, GB, 400, 1834(le), 190P(ab)
Sahu, SK, 241P(ab)
Saika, Y, 221P(ab)
Saji, H, 932, 201P(ab), 234P(ab)
Sakahara, H, 815, 1745, 29P(ab), 119P(ab), 215P(ab)
Sakai, K, 32P(ab), 202P(ab)
Sakakura, K, 159P(ab)
Sakamoto, T, 211P(ab)
Sakowski, R, 199P(ab)
Saladini, G, 1626, 161P(ab)
Salako, Q, 53P(ab), 93P(ab)
Salako, QA, 1067
Saleh, MN, 53P(ab)
Salensky, H, 150P(ab)
Salet, A, 170P(ab)
Salk, D, 2111
Salkowski, LR, 151P(ab)
Sallan, SE, 1045
Salmon, E, 1460
Salvadori, PA, 1175
Salvatore, M, 1602, 1688, 12P(ab), 42P(ab), 82P(ab), 115P(ab), 147P(ab), 153P(ab), 213P(ab), 219P(ab)
Samarasekara, S, 124P(ab), 256P(ab)
Samman, B, 134
Samoszuk, MK, 1246
Sampson, WFD, 1616(le)
Samson, Y, 78P(ab), 109P(ab), 205P(ab)
Samtani, S, 165P(ab)
Sanders, J, 135P(ab)
Sandler, ED, 1922
Sandler, MP, 826, 86P(ab)
Sandrock, D, 24
Sanford, I, 65P(ab)
Sanger, JJ, 515, 1835(le), 63P(ab), 128P(ab)
Sansoy, V, 96P(ab)
Santos, CA, 1441
Santos-Ocampo, CD, 75P(ab), 85P(ab), 152P(ab)
Saraste, M, 2068, 3P(ab)
Saravis, C, 247P(ab)
Sasaki, M, 288
Sasaki, T, 1936, 1944
Sasaki, Y, 14P(ab), 71P(ab), 113P(ab), 181P(ab), 182P(ab), 229P(ab)
Sasayama, S, 1672, 120P(ab)
Sass, KA, 231P(ab)
Sassaman, MB, 235P(ab)
Sasso, D, 244P(ab), 245P(ab)
Sastry, J, 231P(ab)
Sastry, KSR, 637
Satlin, A, 2044, 27P(ab), 208P(ab)
Sato, M, 174P(ab)
Sato, T, 780
Satou, T, 211P(ab)
Sattenberg, R, 250P(ab)
Satter, M, 8P(ab), 218P(ab)
Satterly, W, 240P(ab)
Satyamurthy, N, 202P(ab), 238P(ab), 239P(ab)
Sauerberg, P, 7P(ab)
Saunders, M, 156P(ab)
Saunders, R, 235P(ab)
Sawada, S, 968
Sawaki, M, 229P(ab)
Sawaya, R, 206P(ab)
Sax, EJ, 2095
Sayer, J, 115P(ab)
Scalliet, P, 186P(ab)
Scanley, BE, 31P(ab), 243P(ab)
Scasnar, V, 101P(ab)
Schaefer, C, 77P(ab)
Schaeken, B, 186P(ab)
Schäfers, M, 45P(ab)
Schaible, T, 178P(ab)
Scheff, AM, 115P(ab)
Scheffel, U, 120, 18P(ab), 25P(ab), 103P(ab), 197P(ab), 199P(ab), 234P(ab)
Scheibe, PO, 1020
Scheinberg, DA, 422, 53P(ab), 105P(ab)
Scheinman, M, 151P(ab)
Schelbert, HR, 488, 2038, 1832(le), 4P(ab), 35P(ab), 50P(ab), 88P(ab), 154P(ab), 165P(ab), 183P(ab), 184P(ab)
Scheld, H, 45P(ab)
Schelosky, L, 31P(ab)
Scherrer, M, 14P(ab)
Schiebler, M, 121P(ab)
Schiepers, C, 4P(ab), 110P(ab), 141P(ab), 210P(ab), 222P(ab), 227P(ab)
Schiff, RG, 166P(ab), 251P(ab)
Schiffer, JG, 168P(ab)
Schifter, T, 567, 7P(ab)
Schilling, T, 1039
Schippers, DJ, 35P(ab)
Schlag, P, 1075
Schlick, W, 1397
Schlom, J, 53P(ab), 127P(ab), 214P(ab)
Schlyer, D, 609, 619, 67P(ab), 69P(ab), 102P(ab), 131P(ab), 200P(ab), 237P(ab)
Schmarkey, LS, 281, 96P(ab), 146P(ab)
Schmidlin, P, 48
Schmidt, D, 132P(ab), 158P(ab), 202P(ab)
Schmidt, EV, 206P(ab)
Schmidt, KC, 360
Schmidt, MA, 135P(ab)
Schmidt, PF, 100P(ab), 153P(ab)
Schnall, M, 32P(ab)
Schnedl, W, 168P(ab)
Schneider, AJ, 230P(ab)
Schneider, JA, 145P(ab)
Schneider, PM, 175P(ab)
Schneider, R, 64P(ab)
Schneider, RF, 135P(ab)
Schneider-Eicke, J, 112P(ab)
Schnell, P-O, 89P(ab)
Schnobrich, KE, 1656
Schober, O, 3P(ab), 45P(ab)
Schoen, FJ, 65P(ab)
Schofield, TD, 1995
Schooler, NR, 78P(ab)
Schrag, A, 31P(ab)
Schrell, U, 37P(ab)
Schriver, C, 11P(ab)
Schröck, H, 793, 204P(ab)
Schroeder, JM, 222P(ab)

Schuemichen, C, 375
Schüler, P, 207P(ab)
Schüller, M, 68P(ab)
Schulman, DS, 1695
Schulte, L, 126P(ab)
Schumpelick, V, 98P(ab), 158P(ab), 183P(ab)
Schwab, AJ, 589
Schwab, ME, 138P(ab)
Schwaiger, M, 83, 336, 968, 1287, 13P(ab), 30P(ab), 35P(ab), 36P(ab), 45P(ab), 50P(ab), 87P(ab), 107P(ab), 148P(ab), 155P(ab)
Schwartz, RB, 47P(ab)
Schwartz, Z, 104
Schwarz, A, 92
Schwarz, SW, 28P(ab), 81P(ab), 134P(ab), 216P(ab)
Sciagrà, R, 117P(ab)
Sclarovsky, S, 152P(ab)
Scott, AM, 1656, 11P(ab), 37P(ab), 53P(ab), 56P(ab), 83P(ab), 94P(ab), 105P(ab), 106P(ab), 114P(ab), 127P(ab), 145P(ab), 213P(ab), 214P(ab)
Scott, J, 510
Scott, JA, 171, 172, 527(br), 661, 870(br), 1220(br), 1221(br), 1396(br), 1837(br), 1838(br), 2272
Scott, R, 510
Scott, RM, 1045
Scott, W, 20P(ab)
Scuderi, AJ, 455
Seabold, JE, 11P(ab)
Seasholtz, JI, 234
Seed, WA, 370
Segall, GM, 345, 865(le)
Seibyl, J, 31P(ab), 102P(ab), 109P(ab), 161P(ab), 205P(ab), 211P(ab)
Seidel, J, 60P(ab), 70P(ab), 177P(ab)
Seiffert, E, 12
Seiler, CA, 2111
Seipp, C, 205P(ab)
Seki, C, 86P(ab), 199P(ab)
Seki, S, 301
Sekine, H, 161P(ab)
Sela, J, 104
Selikson, MH, 208, 1910, 158P(ab)
Selin, CE, 154P(ab)
Sella, A, 212P(ab)
Semmler, W, 31P(ab)
Semple, WE, 1000
Sen, C, 1235
Senda, M, 1672, 1936, 1944
Senekowitsch, R, 219P(ab)
Senneff, MJ, 717
Seracini, D, 117P(ab)
Serafini, A, 33P(ab), 117P(ab), 172P(ab), 174P(ab), 214P(ab), 221P(ab), 224P(ab), 263P(ab)
Serafini, AN, 61
Serafini, S, 137P(ab)
Serfontein, DE, 330
Serizawa, T, 181P(ab), 182P(ab)
Setaro, JF, 1416
Setlow, RB, 1828(le)
Setoain, J, 77P(ab)
Seymour, A, 118P(ab)
Seymour, JC, 658
Sfakianakis, GN, 33P(ab), 112P(ab), 117P(ab), 137P(ab), 172P(ab), 174P(ab), 175P(ab), 214P(ab), 221P(ab), 224P(ab), 249P(ab), 260P(ab), 261P(ab), 263P(ab)
Sgouros, G, 422, 689, 1020, 1028(le), 1595, 53P(ab), 94P(ab), 105P(ab), 127P(ab), 160P(ab), 162P(ab)
Shah, A, 78P(ab)
Shanahan, M, 17N(10)
Shani, J, 104
Shapiro, B, 865(le), 1638, 11P(ab), 104P(ab), 166P(ab)
Shapiro, CL, 74P(ab)
Sharkey, RM, 61, 1028(le), 53P(ab), 54P(ab), 61P(ab), 94P(ab), 160P(ab), 214P(ab), 215P(ab)
Sharma, HL, 133P(ab), 157P(ab), 159P(ab)
Sharma, S, 256P(ab)
Shattuc, S, 74P(ab)
Shattuck, L, 129P(ab), 244P(ab), 246P(ab), 250P(ab)
Shaw, HM, 1435
Shaw, P, 52P(ab)
Shaya, E, 109P(ab), 197P(ab), 198P(ab)
Shea, C, 246, 609, 131P(ab)
Shealy, DJ, 234
Sheehan, FH, 23P(ab)
Sheldon, K, 242P(ab)
Shelhamer, J, 1854
Shelton, ME, 717
Shen, S, 128P(ab), 189P(ab)
Shen, YY, 145P(ab)
Shepard, J-AO, 1220(br)
Shepherd, JH, 82P(ab)
Sherman, PS, 8P(ab), 123P(ab), 236P(ab)
Shevitz, J, 217P(ab)
Shi, B, 214P(ab)
Shi, O-X, 97P(ab)
Shibazaki, T, 2085
Shibuya, K, 815
Shieh, SH, 176P(ab)
Shields, J, 144P(ab)
Shigeta, M, 42P(ab)
Shih, W-J, 131, 1218(le)
Shihab-Eldeen, A, 233P(ab)
Shimada, S, 201P(ab)
Shimonagata, T, 14P(ab), 24P(ab), 55P(ab), 107P(ab), 120P(ab)
Shimosegawa, E, 92P(ab)
Shin, MJ, 83P(ab)
Shiode, M, 222P(ab)
Shiomi, S, 301
Shirato, M, 1745, 119P(ab), 215P(ab)
Shiue, CY, 203P(ab), 238P(ab), 240P(ab), 251P(ab)
Shiue, GG, 238P(ab), 240P(ab)
Shivalkar, B, 4P(ab)
Shively, JE, 1294
Shoemaker, RL, 27P(ab)
Shoup, T, 25P(ab), 73P(ab), 202P(ab)
Shpitz, B, 99P(ab)
Shreve, P, 87P(ab), 223P(ab)
Shuke, N, 1478, 28P(ab), 92P(ab), 139P(ab), 223P(ab)
Shukla, R, 217P(ab)
Shulkin, B, 865(le)
Shulkin, BL, 13P(ab), 51P(ab), 220P(ab)
Shulman, A, 210P(ab)
Shyu, HL, 143P(ab)
Sibomana, M, 121P(ab)
Siccardi, AG, 94P(ab)
Siddiqui, AR, 381
Sidhu, S, 168P(ab)
Sidibe, S, 229P(ab)
Siegel, BA, 1828(le), 56P(ab), 81P(ab)
Siegel, HJ, 144P(ab)
Siegel, JA, 53P(ab), 54P(ab), 160P(ab)
Siegel, ME, 1990, 144P(ab), 261P(ab)
Siegel, S, 4P(ab)
Sievert, T, 205P(ab)
Siewert, JR, 112P(ab)
Signore, A, 246P(ab)
Signorini, C, 117P(ab)
Sikorska, H, 49P(ab)
Silagan, G, 1494, 64P(ab), 148P(ab)
Silber, H, 130P(ab)
Silberman, A, 139P(ab)
Silberman, AW, 18
Silberstein, EB, 61, 205P(ab), 261P(ab)
Siler, K, 214P(ab)
Silva, DA, 641
Silva, F, 32P(ab)
Silveira, ST, 826
Silver, K, 226P(ab)
Silverman, IE, 1009, 1447
Simkowitz, P, 67P(ab)
Simon, G, 92
Simon, J, 33P(ab), 244P(ab)
Simon, P, 257P(ab)
Simonneau, G, 229P(ab)
Simpson, N, 7P(ab)
Sinaki, M, 142P(ab)
Singer, MJ, 97P(ab)
Singh, A, 142P(ab)
Singh, N, 52P(ab)
Singh, PR, 38P(ab)
Sinusas, AJ, 1254, 97P(ab)
Siraj, Q, 119P(ab)
Sireci, SN, 48P(ab)
Sisson, J, 13P(ab), 110P(ab)
Sitomer, J, 968, 155P(ab)
Sixt, R, 118P(ab)
Sjögren, H-O, 448
Sjögren, K, 9P(ab)
Skinner, RS, 104P(ab)
Skinner, S, 787
Skinner, SF, 169P(ab)
Slama, M, 981
Slanetz, PJ, 1221(br)
Slater, LM, 1246
Slizofski, WJ, 1574, 163P(ab), 173P(ab)
Slomka, PJ, 179P(ab)
Sloof, GW, 649, 15P(ab)
Slosar, J, 9P(ab)
Sloth, M, 1646
Small, M, 119P(ab)
Smalley, SR, 262P(ab)
Smart, RC, 1619
Smart, SC, 44P(ab), 94P(ab)
Smith, AM, 91P(ab), 157P(ab), 159P(ab)
Smith, AP, 91P(ab)
Smith, C, 131P(ab)
Smith, EE, 57P(ab)
Smith, EO, 161P(ab), 211P(ab), 258P(ab)
Smith, FW, 30
Smith, G, 206P(ab)
Smith, GS, 63P(ab), 67P(ab)
Smith, GT, 6P(ab), 109P(ab), 185P(ab), 209P(ab), 261P(ab)
Smith, HS, 142P(ab)
Smith, J, 31P(ab)
Smith, JR, 196P(ab)
Smith, MF, 72P(ab), 187P(ab)
Smith, RJ, 124P(ab), 181P(ab)
Smith, T, 30
Smith, TD, 156P(ab)
Smith, WH, 728, 96P(ab)
Smulian, AG, 61P(ab)
Snow, GB, 1953
Snow, BJ, 481
Snyder, H, 117P(ab)
Snyder, SH, 31P(ab)
Sobel, BE, 717
Sobhani, I, 98P(ab)
Sobnack, R, 82P(ab)
Soffer, EE, 167P(ab)
Sohn, M-H, 2135, 220P(ab)
Sokole-Busemann, E, 2076, 209P(ab)
Sokoloff, L, 360
Solanki, KK, 119P(ab)
Solin, O, 69P(ab)
Solomon, HF, 1964, 1975, 2130, 83P(ab), 104P(ab), 172P(ab), 173P(ab), 174P(ab)
Soltanian-Zadeh, H, 97P(ab)
Som, P, 197P(ab), 243P(ab)
Sone, N, 119P(ab)
Song, JH, 138P(ab)
Songini, C, 94P(ab), 114P(ab)
Sonmezoglu, K, 845
Sood, VK, 48P(ab), 233P(ab)
Soricelli, A, 153P(ab)
Sorsdahl, O, 251P(ab)
Soskolne, WA, 104
Sossi, V, 481
Sostman, D, 16P(ab), 17P(ab)
Sostman, HD, 1109, 1119
Sostre, S, 762, 1701, 5P(ab), 76P(ab), 168P(ab)
Soto, RF, 260P(ab), 261P(ab)
Soucy, JP, 59P(ab)
Souder, E, 1681, 116P(ab), 210P(ab)
Soufer, R, 84P(ab), 205P(ab)
Souteyrand, PA, 1260
South, M, 53P(ab)
Southwick, SM, 205P(ab)
Sovel, M, 214P(ab)
Spaeth, J, 2188
Spanne, P, 160P(ab)
Specht, HD, 352(le)
Speckel, D, 241P(ab)
Spector, J, 34P(ab)
Speelman, JD, 207P(ab)
Spehl, M, 1223
Sperling, M, 207P(ab)
Sperling, MI, 127P(ab)
Spetsieris, P, 180P(ab), 209P(ab)
Spicer, KM, 106P(ab), 179P(ab), 245P(ab)
Spiegel, TA, 169P(ab)
Spiegelhoff, DR, 151P(ab)
Spies, SM, 131P(ab)
Spieth, M, 1835(le)
Spieth, ME, 1990
Spinelli, A, 44P(ab)
Spinks, T, 26P(ab)
Spitz, J, 1403
Spreer, J, 205P(ab)
Sprengelmyer, J, 77P(ab), 168P(ab)
Squifflet, JP, 129P(ab)
Sr., 23P(ab), 68P(ab), 91P(ab)
Srinivasan, A, 135P(ab)
Srivastava, SC, 93P(ab), 237P(ab)
Stabin, M, 1031, 155P(ab), 156P(ab), 158P(ab)
Stabin, MG, 695, 1910
Stadalnik, RA, 2120
Stafford, K, 13P(ab), 45P(ab), 148P(ab), 155P(ab)
Staib, L, 205P(ab)
Stapleton, JM, 40P(ab)
Starksen, N, 65P(ab)
Starling, MR, 747
Stathis, M, 18P(ab)
Staudenherz, A, 36P(ab), 87P(ab)
Stearns, CW, 101P(ab)
Steelhammer, L, 115P(ab)
Steen, L, 118P(ab)
Steenbergen, C, 39
Stefan, H, 207P(ab)
Stefani, I, 154P(ab)
Steigman, J, 233P(ab)
Stein, S, 70P(ab)
Steiner, RM, 261P(ab)
Stephens, AD, 804
Stern, H, 99P(ab)
Stern, Y, 1090
Stevens, JS, 294
Stevens, MM, 1082
Steventon, R, 11P(ab)
Stewart, JA, 589
Stewart, JC, 237P(ab)
Stobbe, DE, 65P(ab)
Stöcklin, G, 2222, 68P(ab), 80P(ab), 107P(ab)
Stocks, G, 184P(ab)
Stoddard, H, 193P(ab)
Stoffel, M, 129P(ab)
Stöhr, M, 220P(ab)
Stoiber, TR, 94P(ab)
Stoltz, ML, 240P(ab)
Stone, CK, 1058, 16P(ab), 184P(ab), 248P(ab)

Storey, AE, 222
Stowasser, G, 10P(ab), 212P(ab)
Strakowski, S, 196P(ab), 203P(ab)
Strand, S-E, 448, 9P(ab), 113P(ab), 160P(ab), 178P(ab), 222P(ab)
Strandh, M, 160P(ab)
Strashun, A, 210P(ab), 233P(ab)
Stratmann, HG, 85P(ab)
Strauss, H, 24P(ab)
Strauss, HW, 17N(6), 879, 1282, 1303, 1309, 1507, 1529, 1616(le), 1825(le), 2130, 2253, 2264, 2274, 15P(ab), 44P(ab), 83P(ab), 104P(ab), 171P(ab), 172P(ab)
Strauss, LG, 12, 1075, 218P(ab), 220P(ab)
Strazhnik, B, 115P(ab)
Striano, G, 137, 360, 154P(ab)
Striepecke, E, 222P(ab)
Strilzke, P, 77P(ab)
Stromswold, K, 57P(ab)
Strother, SC, 200P(ab), 203P(ab)
Stubbs, JB, 821, 1910, 155P(ab), 156P(ab), 158P(ab), 159P(ab)
Studier-Fischer, B, 375
Studnicka, M, 1397
Stuhlmuller, JE, 1607
Subramanian, G, 97P(ab), 135P(ab)
Subramanian, M, 221P(ab), 224P(ab)
Sudati, F, 94P(ab)
Suehiro, M, 120, 25P(ab), 126P(ab), 234P(ab)
Sueyosi, K, 221P(ab)
Suga, K, 1980
Sugarbaker, PH, 804
Sugawara, Y, 19P(ab), 167P(ab)
Sugii, A, 247P(ab)
Sugiyama, A, 95P(ab)
Suh, J-H, 1987
Suhara, T, 89P(ab)
Sumiya, H, 92P(ab)
Sun, B-F, 28P(ab)
Sun, KT, 2038, 4P(ab), 50P(ab), 154P(ab), 183P(ab)
Sun, WY, 184P(ab)
Sunderland, J, 21P(ab), 50P(ab), 55P(ab), 238P(ab)
Sung, C, 1552, 2559(ab)
Supino, PG, 34P(ab)
Suresh, MR, 126P(ab)
Susskind, H, 899, 43P(ab), 222P(ab)
Sutor, R, 968, 36P(ab)
Suwondo, P, 190P(ab)
Suzuki, H, 42P(ab)
Suzuki, T, 14P(ab)
Swahn, C-G, 7P(ab), 89P(ab)
Swanson, D, 231P(ab)
Swarna, US, 3P(ab)
Swayne, LC, 61, 53P(ab), 54P(ab), 61P(ab), 94P(ab)
Swenson, L, 262P(ab)
Swyer, AJ, 83P(ab)
Sy, WM, 17N(5)
Sybirska, E, 102P(ab)
Sychra, JJ, 188P(ab)
Sykes, T, 100P(ab), 213P(ab)
Syravanh, C, 188P(ab)
Syrota, A, 981, 1717, 1739, 1899, 14P(ab), 36P(ab), 45P(ab), 78P(ab), 102P(ab), 109P(ab), 124P(ab), 186P(ab), 205P(ab), 211P(ab)
Szabo, Z, 25P(ab), 86P(ab), 199P(ab)

Taavitsainen, M, 1428
Tada, M, 780, 240P(ab), 244P(ab)
Tadamura, E, 6P(ab), 107P(ab), 147P(ab)
Tagare, H, 187P(ab)
Taillefer, R, 96P(ab), 118P(ab), 121P(ab), 140P(ab)
Taillon, LA, 394, 35P(ab), 130P(ab)
Tajima, K, 234P(ab)
Takagi, T, 815
Takahashi, A, 24P(ab)
Takahashi, H, 2030, 198P(ab)
Takahashi, J, 780
Takahashi, M, 1184, 177P(ab), 247P(ab)
Takahashi, N, 32P(ab), 120P(ab), 202P(ab)
Takai, M, 247P(ab)
Takaki, Y, 1184, 177P(ab)
Takamiya, M, 1931
Takamori, M, 223P(ab)
Takano, M, 98P(ab)
Takashima, T, 139P(ab)
Takata, S, 1478
Takatsu, H, 198P(ab)
Takechi, T, 98P(ab)
Takeda, K, 180P(ab)
Takei, Y, 1103
Takemoto, K, 1485
Takeuchi, A, 159P(ab)
Taki, J, 1478, 139P(ab), 223P(ab)
Takikawa, S, 180P(ab), 209P(ab)
Tall, JG, 227P(ab), 259P(ab)
Tamahashi, N, 103P(ab), 244P(ab)
Tamaki, J, 111P(ab), 170P(ab)
Tamaki, N, 839, 1220(br), 1672, 2124, 6P(ab), 107P(ab), 120P(ab), 147P(ab), 194P(ab)
Tamesis, BR, 85P(ab), 120P(ab)
Tamm, C, 46P(ab)
Tamura, M, 2085
Tamura, Y, 24P(ab)
Tan, JC, 46P(ab)
Tan, P, 1752
Tanabe, H, 207P(ab)
Tanada, S, 19P(ab), 167P(ab), 222P(ab)
Tanahashi, K, 234P(ab)
Tanaka, A, 6P(ab)
Tanaka, F, 201P(ab)
Tang, J, 71P(ab)
Tange, S, 174P(ab)
Tangoren, A, 16P(ab)
Tanihata, S, 95P(ab)
Tansey, W, 68P(ab)
Taoka, Y, 59P(ab)
Tarbell, NJ, 1045
Tartaglia, D, 58P(ab)
Tashiro, T, 2182
Tateno, M, 2085, 14P(ab), 42P(ab)
Tatsu, Y, 221P(ab)
Tatum, JL, 153P(ab)
Taylor, A, 1766, 87P(ab), 251P(ab)
Taylor, A Jr., 467, 39P(ab), 129P(ab), 250P(ab)
Taylor, AM II, 23P(ab)
Taylor, D, 246
Taylor, JW, 109P(ab)
Taylor, M, 144P(ab)
Taylor, S, 7P(ab)
Taylor, SS, 322
Teates, CD, 162P(ab), 230P(ab)
Teerling, T, 649
Telepak, RJ, 2188
Tellier, P, 865(le), 1825(le)
Teoh, SK, 723
Teplick, RS, 250P(ab)
Terās, M, 1711, 2064, 2068, 3P(ab), 21P(ab), 107P(ab), 224P(ab)
Terry, J, 7P(ab), 251P(ab)
Teule, GJJ, 1706, 82P(ab), 110P(ab), 147P(ab), 154P(ab), 230P(ab)
Thakore, K, 87P(ab), 165P(ab)
Thakur, ML, 260, 144P(ab), 246P(ab)
Theiss, A, 87P(ab)
Theriault, C, 1927
Thie, JA, 185P(ab)
Thierauf, P, 37P(ab)
Thijs, LG, 230P(ab)
Thomas, FD, 992, 97P(ab), 135P(ab)
Thomas, JR, 90P(ab)
Thomas, PA, 61P(ab)
Thomas, RG, 260P(ab)
Thomas, SN, 1778
Thomas, SR, 42P(ab), 156P(ab), 205P(ab)
Thompson, B, 256P(ab)
Thompson, JF, 1435
Thompson, NW, 13P(ab)
Thorpe, P, 251P(ab)
Thorson, A, 55P(ab)
Thrall, J, 1109, 1119, 16P(ab), 17P(ab)
Thrall, JH, 260P(ab)
Thrall, R, 244P(ab)
Thron, A, 222P(ab)
Thule, P, 165P(ab)
Thys, O, 1642
Tibben, C, 247P(ab)
Tilbury, R, 33P(ab), 42P(ab), 55P(ab), 68P(ab)
Tillman, KJ, 131P(ab)
Ting, Y, 186P(ab)
Tintner, R, 115P(ab)
Tisselli, A, 44P(ab)
Tittel, K, 1403
Tjuvajev, J, 1152, 37P(ab)
Tobin, M, 259P(ab)
Tochon-Danguy, HJ, 1367
Toeniskoetter, PD, 86P(ab), 87P(ab)
Tohyama, M, 199P(ab), 201P(ab)
Tokuda, T, 107P(ab)
Tolbert, LC, 78P(ab)
Tolkoff-Rubin, N, 250P(ab)
Tomiguchi, S, 1184, 177P(ab), 247P(ab)
Tomiyoshi, K, 2085, 42P(ab)
Tommasino, C, 93P(ab)
Tomomitsu, T, 208P(ab)
Tompkins, RG, 1964, 2130, 2176
Tonami, N, 2089, 28P(ab), 139P(ab), 223P(ab)
Tondeur, M, 1223, 226P(ab)
Tong, CKS, 26P(ab)
Toni, MG, 2032
Toorongian, SA, 1287
Topchik, S, 33P(ab)
Toppet, V, 1223
Torizuka, T, 6P(ab), 107P(ab), 147P(ab)
Tornai, MP, 180P(ab)
Torres, G, 1503, 13P(ab), 145P(ab), 146P(ab)
Torri, G, 93P(ab)
Tou, ZW, 179P(ab), 245P(ab)
Toudou, K, 2182
Touliopoulos, P, 953
Touma, H, 104
Tow, D, 151P(ab), 188P(ab)
Townsend, CE, 1778, 138P(ab)
Townsend, DW, 1367
Toyama, H, 1274
Toyama, T, 55P(ab), 120P(ab)
Tran, HD, 256P(ab), 260P(ab)
Trankle, C, 243P(ab)
Tranquart, F, 194P(ab)
Travin, MI, 75P(ab), 85P(ab)
Trebossen, R, 186P(ab)
Treffert, JD, 175P(ab)
Tremblay, J, 58P(ab)
Trenkler, I, 48P(ab)
Trepashko, DW, 188P(ab)
Treves, S, 151P(ab), 177P(ab)
Treves, ST, 1045
Trimarco, B, 1602, 1688, 147P(ab)
Troup, C, 232P(ab)
Truckenbrodt, R, 219P(ab)
Truex, GT, 148P(ab)
Tsang, BW, 1127, 79P(ab)
Tsay, DG, 76P(ab)
Tse, K, 1866, 2049, 76P(ab), 169P(ab)
Tse, N, 137P(ab)
Tseng, C-Y, 153P(ab)
Tsuchiya, K, 812
Tsuda, T, 19P(ab), 167P(ab)
Tsuhi, A, 1184
Tsui, BMW, 20P(ab), 27P(ab), 30P(ab), 72P(ab), 188P(ab), 192P(ab)
Tsui, W-H, 2019
Tsuji, S, 92P(ab), 197P(ab)
Tsuruo, T, 114P(ab)
Tsutsumi, K, 1984
Tulchinsky, M, 121P(ab)
Tumeh, SS, 173
Tune, LE, 5P(ab)
Tung, CH, 71P(ab)
Turchi, S, 2032
Turek, P, 117P(ab)
Turetsky, B, 2201
Turkington, TG, 1587, 26P(ab), 81P(ab), 101P(ab), 190P(ab), 191P(ab)
Turner, FE, 1140
Turpin, S, 118P(ab)
Turrin, D, 166P(ab)
Turzo, A, 1217(le)
Tutrone, RF, 123P(ab), 221P(ab)
Tuvia, JE, 251P(ab)
Tweedle, MF, 1826(le)

Uccelli, L, 18P(ab)
Uchida, H, 229P(ab)
Uchida, Y, 211P(ab)
Uchisako, H, 1980
Udem, S, 61P(ab)
Udupa, JK, 124P(ab), 256P(ab)
Uebis, R, 23P(ab), 148P(ab)
Ueda, R, 215P(ab)
Ueda, S, 431, 1543, 26P(ab), 198P(ab), 225P(ab)
Ueda, T, 301, 2091
Uehara, T, 14P(ab), 24P(ab), 34P(ab), 63P(ab), 107P(ab), 120P(ab), 171P(ab), 207P(ab), 209P(ab)
Uemura, K, 92P(ab), 200P(ab)
Uezono, T, 59P(ab)
Ugur, O, 106P(ab)
Ungar, DR, 51P(ab), 220P(ab)
Ünlenen, E, 84P(ab)
Ünlü, M, 84P(ab)
Uno, K, 211P(ab)
Ünsal, IS, 84P(ab)
Urbain, D, 1642, 99P(ab), 166P(ab)
Urbain, JL, 11P(ab)
Urbain, JLC, 576
Urbano-Marquez, A, 1452
Ureles, AL, 1829(le)
Uren, R, 214, 1827(le), 52P(ab)
Uren, RF, 1435
Urita, Y, 98P(ab)
Urtasun, RC, 885
Usman, M, 190P(ab)
Ussov, V, 43P(ab)
Uszler, M, 164P(ab)
Utsunomiya, K, 221P(ab)
Uyan, C, 889

v. Schulthess, GK, 809, 196P(ab)
Vaalburg, W, 49P(ab), 55P(ab), 183P(ab), 219P(ab), 225P(ab), 241P(ab)
Vafaee, M, 51P(ab), 181P(ab), 198P(ab)
Vagg, R, 53P(ab), 54P(ab), 61P(ab), 94P(ab)
Vaidyanathan, G, 191P(ab), 218P(ab)
Valance, J, 116P(ab)

Valdivia, S, 455, 1905, 62P(ab), 71P(ab), 157P(ab), 176P(ab), 196P(ab), 249P(ab)
Valette, H, 1739, 1899, 14P(ab), 45P(ab), 124P(ab)
Vallabhajosula, S, 1536, 61P(ab), 66P(ab), 67P(ab), 83P(ab), 104P(ab), 156P(ab)
van Aswegan, A, 963
van Aswegen, A, 330
van Beek, EJR, 1834(le)
VanBrocklin, HF, 79P(ab)
Van Buren, DH, 2185
Vanbutsele, R, 86P(ab)
VanCamp, G, 152P(ab)
Van Cauteren, J, 576
Van Cauteren, JLUJ, 10P(ab)
Vance, ML, 162P(ab)
van de Flierdt, E, 41P(ab)
Van den Abbeele, AD, 1175, 123P(ab), 221P(ab), 241P(ab), 246P(ab), 247P(ab)
Vandenbosch, WA, 41P(ab)
van den Broek, WJM, 112P(ab)
van den Hoff, J, 1770
Van den Maegdenbergh, V, 576
Vanderheyden, JL, 135P(ab)
van der Meer, J, 1621
van der Meer, JWM, 62P(ab)
van der Pluijm, M, 2025
Vanderschot, P, 141P(ab)
van der Sluys Veer, A, 1052
Van der Vusse, GJ, 649
van der Wall, EE, 737
van der Zant, FM, 41P(ab)
Vandevivere, J, 186P(ab)
van Dijk, A, 223P(ab)
van Dongen, A, 227P(ab)
van Dongen, G, 1953
Van Dort, ME, 8P(ab), 236P(ab)
Van Dyck, CH, 48P(ab)
van Eck-Smit, BLF, 737
Vang, M, 256P(ab)
Vanhagen, PM, 118P(ab)
van Heerden, B, 228(ab)
Van Heertum, RL, 61, 48P(ab), 60P(ab), 99P(ab), 125P(ab)
van het Schip, AD, 223P(ab)
VanHorn, JD, 228P(ab), 67P(ab)
van Huffelen, AC, 22P(ab)
van Isselt, JW, 22P(ab), 170P(ab)
van Kaick, G, 48, 1075, 21P(ab), 139P(ab), 218P(ab), 220P(ab)
van Leeuwen, GR, 147P(ab), 154P(ab)
van Lier, JE, 49P(ab), 101P(ab)
van Lingen, A, 110P(ab), 147P(ab), 230P(ab)
van Luijk, WHJ, 354(le)
Van Nerom, C, 129P(ab)
Vannoy, SD, 60P(ab)
van Osdol, WW, 1552
Van Pachterbeke, T, 1223
Vanregemorter, J, 186P(ab)
van Rensburg, AJ, 330
van Rijk, PP, 22P(ab), 170P(ab), 179P(ab), 223P(ab), 227P(ab)
van Roermond, PM, 227P(ab)
van Royen, EA, 2076, 41P(ab), 207P(ab), 209P(ab), 225P(ab)
Vansant, J, 165P(ab)
Van Scoy-Mosher, M, 139P(ab)
Van Sickle, KL, 255P(ab)
Van Steelandt, H, 1217(le)
Van Tosh, A, 193
Van Train, K, 64P(ab), 148P(ab)
Van Train, KF, 1494
Van Trigt, P, 39
van Urk, H, 873
Vanuzzo, D, 126P(ab)
van Waarde, A, 49P(ab), 183P(ab), 241P(ab)
Vanzetto, G, 57
Vaquero, JJ, 178P(ab)
Vardareli, E, 889
Vargas-Cuba, R, 172P(ab), 214P(ab), 224P(ab)
Varma, VM, 2169, 165P(ab)
Varrella, P, 12P(ab), 42P(ab), 82P(ab), 115P(ab), 219P(ab)
Vasiie, R, 47P(ab)
Vazquez, TC, 112P(ab)
Vekemans, MC, 576, 10P(ab)
Veklerov, E, 1198
Veksler, A, 853
Velasquez-Rocha, SJ, 46P(ab)
Ven, M, 112P(ab)
Ventura, B, 193
Venz, S, 164P(ab)
Vera, P, 205P(ab)
Verani, MS, 3P(ab), 54P(ab), 75P(ab), 95P(ab)
Verbanck, S, 1859
Verbruggen, A, 110P(ab), 129P(ab), 210P(ab)
Vergara, E, 12P(ab), 42P(ab), 82P(ab), 115P(ab), 213P(ab), 219P(ab)
Verhoeff, NPLG, 2076, 41P(ab), 207P(ab), 209P(ab)
Verley, G, 194P(ab)
Vermey, A, 55P(ab)
Vermorken, JB, 82P(ab)
Vernon, C, 1031, 1839
Verspaget, HW, 1052
Veyre, AJ, 255, 1260, 1949
Vezina, G, 52P(ab)
Vezzoli, M, 154P(ab)
Viacava, P, 1175
Vignati, A, 226P(ab)
Vigushin, DM, 118P(ab)
Villa, E, 94P(ab)
Villanueva-Meyer, J, 187
Villegas, BJ, 14P(ab), 130P(ab)
Villringer, K, 63P(ab)
Vilner, BJ, 2169
Violi, F, 67P(ab)
Virzi, F, 109, 1618(le), 59P(ab)
Visser, FC, 649, 15P(ab), 147P(ab), 154P(ab)
Visser, G, 1706, 1953, 147P(ab)
Visser, GM, 49P(ab), 225P(ab), 241P(ab)
Visser, TJ, 2025, 165P(ab)
Vleugels, S, 110P(ab), 222P(ab)
Vo, C, 235P(ab)
Vogt-Moykopf, I, 21P(ab)
Voipio-Pulkki, L-M, 2064, 2068, 3P(ab), 107P(ab)
Volkert, WA, 38P(ab), 232P(ab), 248P(ab)
Volkow, ND, 246, 609, 619, 18P(ab), 40P(ab), 43P(ab), 67P(ab), 78P(ab), 102P(ab), 103P(ab), 131P(ab), 200P(ab)
vom Dahl, J, 23P(ab), 155P(ab)
Vonorta, K, 249P(ab)
Voong, C, 163P(ab)
Vorne, M, 1428
Votaw, DB, 158P(ab)
Votaw, JR, 826, 86P(ab), 132P(ab), 158P(ab), 202P(ab)
Vriesendorp, HM, 938, 2152

Wackers, FJT, 1254, 1877, 44P(ab), 84P(ab), 97P(ab), 257P(ab)
Wade, A, 41P(ab)
Wagner, HN Jr, 120, 165, 17N(8), 27N(9)
Wagner, HN Jr., 18P(ab), 25P(ab), 86P(ab), 143P(ab), 197P(ab), 199P(ab), 234P(ab)
Wagner-Manslau, C, 41P(ab), 63P(ab)
Wahl, RL, 75, 414, 773, 787, 958, 1147, 1190, 1420, 2279(le), 6P(ab), 41P(ab), 43P(ab), 73P(ab), 74P(ab), 93P(ab), 104P(ab), 106P(ab), 113P(ab), 127P(ab), 223P(ab), 224P(ab), 245P(ab)
Wahner, HW, 110P(ab), 141P(ab), 142P(ab)
Wakasugi, S, 1282, 1529, 15P(ab)
Wakeman, J, 77P(ab)
Wakisaka, S, 2091
Wakita, K, 431, 1543, 26P(ab), 198P(ab), 225P(ab)
Walker, BS, 1239, 23P(ab)
Walker, KZ, 153P(ab)
Walker, RW, 190P(ab)
Wallace, E, 31P(ab), 161P(ab)
Wallich, R, 220P(ab)
Wallis, J, 34P(ab)
Wallis, JW, 1793, 20P(ab), 106P(ab), 154P(ab), 176P(ab), 192P(ab)
Walovitch, RC, 199P(ab)
Walsh, JF, 36P(ab), 86P(ab), 87P(ab)
Walsh, RA, 1520, 120P(ab), 153P(ab)
Walter, KA, 228(ab)
Walther, MCM, 173
Walzer, PD, 61P(ab)
Wand, G, 132P(ab), 133P(ab), 228P(ab)
Wang, D, 97P(ab)
Wang, F, 1246, 148P(ab)
Wang, G-J, 609, 18P(ab), 67P(ab), 102P(ab), 103P(ab), 131P(ab), 197P(ab), 200P(ab), 243P(ab)
Wang, H, 10P(ab), 80P(ab), 195P(ab)
Wang, JK, 176P(ab), 185P(ab)
Wang, P, 204P(ab)
Wang, PJ, 65P(ab)
Wang, R, 109P(ab)
Wang, S, 31P(ab), 243P(ab)
Wang, S-J, 71, 1918, 167P(ab), 208P(ab), 228P(ab), 245P(ab)
Wang, TST, 99P(ab)
Wang, YL, 228P(ab)
Wanklin, RJ, 235P(ab)
Ward, RJ, 2095
Warnaar, S, 247P(ab)
Warnick, A, 164P(ab)
Warren, FD, 234
Wartski, M, 229P(ab)
Washburn, LC, 42P(ab), 120P(ab), 248P(ab)
Waskin, HA, 567
Wasserleben, V, 75P(ab)
Watanabe, A, 208P(ab)
Watanabe, K, 2091, 222P(ab)
Watanabe, N, 2085, 42P(ab)
Watanabe, S, 95P(ab)
Watanabe, T, 71P(ab), 113P(ab), 182P(ab)
Watanabe, Y, 139P(ab), 223P(ab)
Watkins, GL, 181P(ab), 185P(ab)
Watson, C, 172P(ab)
Watson, DD, 728, 96P(ab)
Watters, GV, 226P(ab)
Waxman, A, 37P(ab), 77P(ab), 139P(ab), 168P(ab)
Waxman, AD, 18
Wazer, DE, 953
Webber, MM, 122P(ab)
Webbon, PM, 222
Weber, C, 165P(ab)
Weber, DA, 899, 9P(ab), 43P(ab), 60P(ab), 222P(ab)
Webner, P, 465
Wegelius, U, 2064, 2068, 3P(ab), 21P(ab), 107P(ab)
Weiden, PL, 908, 2111
Weigand, H, 1403
Weiller, C, 58P(ab)
Weinberger, DR, 67P(ab), 228P(ab), 235P(ab)
Weindl, A, 32P(ab)
Weiner, M, 1326
Weiner, MF, 115P(ab)
Weiner, R, 351(le), 244P(ab), 245P(ab)
Weinheimer, CJ, 86P(ab), 87P(ab)
Weinstein, H, 1510, 1722, 46P(ab)
Weinstein, JN, 1552, 215P(ab), 216P(ab)
Weise, S, 51P(ab), 71P(ab)
Weisman, HF, 234
Weiss, M, 10P(ab), 212P(ab)
Weissleder, R, 39P(ab)
Weissman, A, 43P(ab), 110P(ab)
Weissman, AF, 958
Weissman, DE, 961
Welch, AE, 71P(ab), 187P(ab)
Welch, MJ, 1728, 18P(ab), 28P(ab), 49P(ab), 56P(ab), 59P(ab), 69P(ab), 79P(ab), 81P(ab), 89P(ab), 134P(ab), 160P(ab), 216P(ab)
Wellman, HN, 381
Welsh, P, 218P(ab)
Welt, S, 83P(ab)
Wen, PYC, 241P(ab)
Wendt, R, 175P(ab), 186P(ab)
Weng, Y, 80P(ab)
Wensveen, M, 1367
Wenzel, KW, 164P(ab)
Weprin, R, 8P(ab)
Werner, GS, 153P(ab)
Werns, S, 36P(ab)
West, JH, 658
Wester, HJ, 80P(ab)
Westera, G, 196P(ab)
Wetzel, LW, 262P(ab)
Wheatley, J, 127P(ab)
Wheeler, WJ, 240P(ab)
White, CL III, 115P(ab)
White, G, 52P(ab)
White, J, 241P(ab)
White, MP, 97P(ab)
White, SB, 73P(ab)
White, TA, 474
Whiteman, ML, 261P(ab)
Whiting, JH, 62P(ab), 249P(ab)
Whiting, JH Jr, 128, 1389(le), 2135
Wichter, T, 3P(ab)
Wiebe, LI, 405, 885
Wieland, D, 13P(ab), 45P(ab)
Wieland, DM, 1287, 13P(ab), 25P(ab), 123P(ab), 135P(ab), 220P(ab), 236P(ab)
Wienhard, K, 101P(ab)
Wiens, RD, 85P(ab), 120P(ab)
Wiersinga, WM, 41P(ab)
Wiesnewski, G, 108P(ab)
Wight, JN Jr., 65P(ab)
Wihship, MJ, 172P(ab)
Wijngaarde, R, 41P(ab)
Wijns, W, 15P(ab), 44P(ab), 86P(ab), 121P(ab)
Wilder, S, 246P(ab)
Wilkinson, R, 1282, 1303, 1309, 1529
Wilkinson, RA, 39P(ab), 83P(ab), 171P(ab)
Willemsen, ATM, 183P(ab), 219P(ab), 225P(ab)
Willett, GD, 232P(ab)
Williams, CC, 469
Williams, DJ, 1163
Williams, H, 251P(ab)
Williams, JJ, 101P(ab)

Williams, JR, 938, 2152
Williams, JS, 256P(ab)
Williams, KA, 394, 35P(ab), 130P(ab)
Williams, LE, 1294
Williard, W, 11P(ab)
Wilson, A, 228(ab)
Wilson, DA, 244P(ab)
Wilson, DW, 20P(ab)
Wilson, MA, 143P(ab)
Wilson, ME, 148P(ab)
Wilson, RA, 1518
Wilson, T, 109P(ab)
Winder, DP, 137P(ab)
Windham, JP, 97P(ab)
Winn, HR, 62P(ab)
Winnard, P, 59P(ab)
Winnard, P Jr, 109, 1618(le)
Wioland, M, 1410
Wironen, J, 1722, 46P(ab)
Wise, S, 88P(ab)
Wiseman, GA, 12P(ab)
Wishart, JM, 582
Wisniewski, G, 161P(ab), 211P(ab), 258P(ab)
Withers, S, 242P(ab)
Wittry, MD, 85P(ab), 120P(ab)
Wlodkowski, TJ, 61
Woda, A, 506, 1866, 48P(ab), 76P(ab)
Wojno, T, 467
Wolber, G, 218P(ab)
Wolf, AP, 246, 609, 619, 18P(ab), 67P(ab), 69P(ab), 78P(ab), 102P(ab), 103P(ab), 131P(ab), 237P(ab)
Wolf, F, 92, 37P(ab), 47P(ab), 172P(ab), 207P(ab)
Wolf, J-E, 57
Wolfangel, RG, 38P(ab)
Wolfe, E, 336, 35P(ab)
Wollenweber, SD, 181P(ab)
Wolmer, I, 85P(ab)
Woloszczuk, W, 1039
Wolski, A, 92
Wolters, EC, 207P(ab)
Woltz, M, 1397
Wong, CTC, 899
Wong, CY, 5P(ab), 143P(ab)
Wong, DF, 40P(ab), 109P(ab), 132P(ab), 133P(ab), 197P(ab), 198P(ab)
Wong, F, 26P(ab), 33P(ab), 42P(ab), 55P(ab), 68P(ab), 204P(ab), 206P(ab)
Wong, WH, 33P(ab), 42P(ab), 55P(ab), 68P(ab), 102P(ab), 206P(ab)
Woo, DV, 99
Woo, P, 118P(ab)
Woo, TK, 100P(ab)
Woods, R, 86P(ab)
Woods, S, 102P(ab)
Woolfson, RG, 1163
Worsley, DF, 1612, 1851, 16P(ab), 17P(ab), 121P(ab), 229P(ab), 230P(ab)
Worth, JL, 203P(ab), 212P(ab)
Worthy, M, 44P(ab), 96P(ab), 146P(ab)
Worthy, MA, 281
Wortzman, G, 204P(ab)
Wright, LM, 54P(ab), 149P(ab)
Wu, C, 40P(ab), 112P(ab), 186P(ab)
Wu, JC, 237P(ab)
Wu, LC, 138P(ab), 176P(ab), 185P(ab)
Wu, TL, 138P(ab)
Wullner, U, 202P(ab)
Wynick, D, 41P(ab)
Wynsen, JC, 94P(ab)

Xu, J, 20P(ab)
Xu, X-L, 200P(ab)

Yacoub, T, 233P(ab)
Yadegar, J, 18, 139P(ab)
Yagyu, T, 198P(ab)
Yamada, S, 419, 103P(ab), 240P(ab), 244P(ab)
Yamagami, H, 34P(ab)
Yamaguchi, K, 780
Yamamoto, K, 2182, 6P(ab), 120P(ab)
Yamamuro, T, 1745
Yamanouchi, N, 211P(ab)
Yanagimoto, S, 208P(ab)
Yang, D, 26P(ab), 55P(ab)
Yang, HI, 212P(ab)
Yang, S-O, 83P(ab)
Yang, WS, 130P(ab)
Yang, Z-Y, 239P(ab), 243P(ab)
Yaoita, H, 1303
Yasillo, NJ, 112P(ab)
Yasuda, T, 2227
Yasuhara, Y, 200P(ab), 201P(ab)
Yasunaga, K, 119P(ab)
Yeh, S, 11P(ab), 37P(ab), 56P(ab), 145P(ab)
Yeh, SD, 38N(12)
Yeh, SH, 76P(ab), 138P(ab), 143P(ab), 145P(ab), 167P(ab), 176P(ab), 185P(ab), 208P(ab), 228P(ab), 238P(ab), 245P(ab)
Yelon, WB, 231P(ab)
Yemul, S, 99P(ab)
Yen, SH, 145P(ab)
Yeung, DW, 122P(ab)
Yki-Järvinen, H, 107P(ab)
Yoder, JH, 255P(ab)
Yokoi, T, 498
Yokota, I, 1931
Yokoyama, A, 932, 29P(ab), 59P(ab), 234P(ab)
Yokoyama, I, 181P(ab), 182P(ab)
Yokoyama, K, 28P(ab), 139P(ab), 223P(ab)
Yonekura, Y, 839, 1672, 6P(ab), 107P(ab), 120P(ab), 147P(ab), 194P(ab), 201P(ab)
Yoo, HS, 167P(ab)
Yoo, K, 131P(ab)
Yorkston, J, 100P(ab)
Yoshitake, A, 932
Young, AR, 241P(ab)
Young, H, 243P(ab)
Young, JK, 29P(ab)
Young, TM, 193P(ab)
Younis, LT, 85P(ab)
Yrizzary, J, 249P(ab)
Yu, D-C, 679, 70P(ab), 183P(ab), 185P(ab), 202P(ab)
Yu, JN, 182P(ab)
Yu, MD, 238P(ab)
Yu, SM, 138P(ab)
Yu, X, 182P(ab)
Yuan, A, 93P(ab)
Yuan, J, 38P(ab)
Yuasa, T, 170P(ab)
Yuille, DL, 955, 1748, 151P(ab)
Yung, A, 55P(ab), 204P(ab), 206P(ab)
Yung, BCK, 762, 1701, 76P(ab), 109P(ab), 132P(ab), 133P(ab), 197P(ab)

Zafrani, E-S, 2105
Zafrir, N, 152P(ab)
Zalutsky, MR, 10P(ab), 79P(ab), 99P(ab), 191P(ab), 216P(ab), 218P(ab)
Zamora, PO, 231P(ab), 244P(ab), 246P(ab)
Zang, ZM, 268
Zanzi, I, 177P(ab)
Zanzonico, PB, 66P(ab), 133P(ab)
Zaret, BL, 1254, 1877, 84P(ab), 97P(ab)
Zasadny, K, 41P(ab), 74P(ab), 127P(ab), 224P(ab)
Zasadny, KR, 1420
Zea-Ponce, Y, 31P(ab), 48P(ab), 90P(ab), 102P(ab), 108P(ab), 109P(ab), 211P(ab), 243P(ab)
Zeffiro, T, 70P(ab)
Zemacnik, PC, 232P(ab)
Zeng, GL, 19P(ab), 30P(ab), 71P(ab), 80P(ab), 81P(ab), 196P(ab)
Zenh, GL, 191P(ab)
Zenorini, A, 5P(ab)
Zhang, CG, 250P(ab)
Zhang, HZ, 53P(ab)
Zhang, J, 37P(ab), 56P(ab), 94P(ab), 114P(ab), 127P(ab), 213P(ab), 255P(ab)
Zhang, L, 187P(ab)
Zhang, Y, 9P(ab), 190P(ab)
Zhang, Z, 255, 1949
Zhang, ZM, 242
Zhao, XD, 30P(ab)
Zhou, T, 58P(ab)
Zhu, X, 208
Zhu, YY, 303, 64P(ab), 95P(ab)
Zhuang. ZP, 89P(ab)
Ziady, G, 1695
Ziegler, R, 1039
Ziegler, S, 12
Ziessman, HA, 227P(ab), 259P(ab)
Zilbovicius, M, 78P(ab), 205P(ab)
Zilleruelo, G, 249P(ab)
Zimmerman, RE, 179P(ab), 203P(ab), 212P(ab), 259P(ab)
Zingraff, J, 128P(ab)
Zinn, KR, 28P(ab), 81P(ab), 134P(ab), 216P(ab), 238P(ab)
Zito, F, 5P(ab), 94P(ab)
Zlotikamien, B, 152P(ab)
Zoghbi, S, 31P(ab), 48P(ab), 90P(ab), 102P(ab), 108P(ab), 201P(ab), 211P(ab), 243P(ab)
Zonnenberg, BA, 223P(ab)
Zubal, G, 125P(ab), 161P(ab), 178P(ab), 187P(ab), 205P(ab)
Zubal, IG, 1390(le), 1416
Zubieta, JK, 108P(ab)
Zuckier, LS, 1835(le), 250P(ab)
Zwas, ST, 82P(ab)
Zweit, J, 243P(ab)
Zwinderman, AH, 737

A

ACMUI. *See* Advisory Committee on the Medical Use of Isotopes
ACNP. *See* American College of Nuclear Physicians
Acquired immunodeficiency syndrome (AIDS). *See also* Human immunodeficiency virus (HIV)
  cerebral infections *vs.* lymphoma in, accuracy of PET FDG studies in distinguishing, 142(ab)
  classification of AIDS dementia complex brain perfusion pattern by qualitative and quantitative SPECT, 964(ab)
  lymphoma *vs.* nonmalignant CNS lesions in, FDG-PET in differentiation, 567
  prospective evaluation of sequential ^{201}Tl chloride and ^{67}Ga-citrate scans in, 834(ab)
  SPECT/MR brain image fusion in AIDS dementia complex, 999(ab)
Adenocarcinoma
  human cell line, early response to radiotherapy, assessment of agents for monitoring, 773
  ovarian, xenografts of, intra-tumoral distribution of 2-DG and monoclonal antibodies in, autoradiographic evaluation of, 75
Adenoma
  parathyroid
    comparative study of ^{99m}Tc sestamibi/^{201}Tl with ^{99m}Tc pertechnetate subtraction scintigraphy and ultrasonography in localization of, 804(ab)
    relative ^{201}Tl and ^{99m}Tc MIBI uptake in, 807(ab)
  pituitary
    combined use of ^{111}In PAO and 3-step ISG with anti-CgA monoclonal antibody in diagnosis of, 456(ab)
    imaging using ^{99m}Tc (V)DMSA, 160(ab)
  thyroid, unusual scintigraphic findings, 465
Adenosine, ^{201}Tl SPECT, comparison of results using four- *vs.* six-minute infusion protocol, 737(ab)
Adherence, WBC, quality assurance of labeling with test based on, 345
Adrenal gland
  mild to moderate degree of ^{123}I MIBG uptake must be carefully interpreted for diagnosis of pheochromocytoma, 39(ab)
  paragangliomas, ^{131}I MIBG scintigraphy in preoperative and postoperative evaluation, 173
Adriamycin. *See also* Doxorubicin
  cardiomyopathy, myocardial substrate utilization and left ventricular function in, 52(ab)
Advisory Committee on the Medical Use of Isotopes (ACMUI), 20N(7)
Aging. *See also* Elderly
  comparison of clinical presentation and outcome of pulmonary embolism in younger *vs.* older patients, 1073(ab)
  effect of age of onset on regional cerebral glucose metabolism in Alzheimer's disease, 7(ab)
  effect of amino acid transport from blood to brain in humans using ^{18}F phenylalanine, 951(ab)
AIDS. *See* Acquired immunodeficiency syndrome
Alcohol
  absorption, erythromycin effects on, 582
  effects of detoxification on regional brain glucose metabolism, 409(ab)
  effects on brain, 798
  regional cerebral blood flow SPECT in chronic alcoholism, relation to neuropsychological testing, 1452
Algorithms
  backprojection filtering, for variable focal length collimator, 320(ab)
  diagnostic, uniformity of lung scan interpretation and, 661
  expectation maximization, made practical for clinical use in SPECT by Tanaka's filtered iterative reconstruction method, 68(ab)
  expectation maximization reconstruction, frequency-domain behavior of, 846(ab)
  fast 3-D reconstruction, for PET, 546(ab)
  fast iterative reconstruction, for cone beam SPECT, 317(ab)
  iterative reconstruction
    is the slow way really best?, 913(ab)
    with natural pixel basis, 66(ab)
  noise and spatial resolution properties of ML-EM reconstructed images, 69(ab)
  practical, for assessing flood field uniformity in clinical nuclear medicine, 847(ab)
  three-dimensional Bayesian reconstruction for SPECT, 70(ab)
  weighted least squares-conjugate gradient, for SPECT, 98(ab)
Allograft
  human cardiac transplant, evaluation of vasculopathy by ^{99m}Tc teboroxime washout, 734(ab)
  renal, MRI and SPECT bone scans, 381
Alzheimer's disease
  age of onset of, effect on regional cerebral glucose metabolism, 7(ab)
  probable
    comparability of FDG PET studies in, 7(ab)
    differential diagnosis using NeuroSPECT and neuropsychological tests, 460(ab)
    high resolution ^{99m}Tc HMPAO *vs.* FDG PET in, 10(ab)
  regional cerebral blood flow in, major depression *vs.*, 1090, 1101
  regional glucose metabolic activity in, quantitation of, after correction for effects of atrophy, 8(ab)
  response to visual cognitive stimulation assessed by ^{99m}Tc HMPAO in, 11(ab)
American College of Nuclear Physicians (ACNP), government relations update, 22N(4), 19N(7)
American Society of Nuclear Cardiology (ASNC), formation, 28N(4)
Americium-241, compared with ^{99m}Tc as transmission source for attenuation correction of ^{201}Tl cardiac SPECT, 113(ab)
Amiodarone, and myocardial uptake of ^{123}I MIBG in left ventricular hypertrophy secondary to valvular aortic stenosis, 57
Amyloid
  dialysis-related, metabolic studies of radioiodinated serum amyloid P-component and, 513(ab)
  intra-abdominal massive deposit, ^{99m}Tc(V)DMSA uptake in, 815
Anderson, Carolyn J., Medi-Physics Award, 22N(7)
Angiography
  compared with sensitivity of dual isotope perfusion imaging for detection of specific atherosclerotic lesions, 254(ab)
  coronary
    normal, reversible ^{201}Tl perfusion defects in right bundle branch block and, 1218(le)
    prognostic efficacy in patients with and without prior myocardial infarction, 127(ab)
  pulmonary
    prevalence of thromboembolic disease in patients with intermediate probability lung scans, 55(ab)
    regional distribution of pulmonary emboli, 56(ab)
  serial, recovery of myocardial function following coronary revascularization, 84(ab)
Angiography, radionuclide
  first pass, with new high performance single crystal camera, 741(ab)
  first-pass
    quantitative measure of left ventricular systolic and diastolic performance, 130(ab)
    ^{99m}Tc, left ventricular function, 394
  MIBG evaluation as potential tracer for monitoring doxorubicin cardiomyopathy, 1282
  systolic pressure alteration effect on measurements of left ventricular filling dynamics, 747
Angiosarcoma, scintigraphic "doughnut sign" on skeletal imaging, 297
Animal-remains disposal, cost is reducible, 30N(8)
Animals, small
  high resolution pinhole SPECT for imaging, 27(ab)
  high resolution slit aperture for SPECT imaging, 26(ab)
  pinhole collimation for ultra-high resolution, SPECT studies, 29(ab)
  whole body cylindrical detector for imaging, 25(ab)
Antibodies. *See also* Monoclonal antibodies
  antimyosin, imaging for identification of catheter ablation induced myocardial necrosis, 256(ab)
  antithyroid hormone autoantibodies, antigen responsible for formation of, 506(ab)
  directly and indirectly ^{99m}Tc labeled, 109
  DTPA-conjugated, semi-preparative isoelectrophoresis leads to isolation of antibody isoforms with different immunoreactivities, 1146(ab)
  guided therapy of CEA positive tumors using biotinylated monoclonal antibodies, avidin and 90Y-DOTA-biotin, 373(ab)
  ^{111}In C110 radioimmunoscintigraphy in colorectal carcinoma, 1656
  novel biological method to evaluate chelating agents for labeling of, with metallic radionuclides, 230(ab)

radiolabeled, simple TLC assay to assess percent immunoreactive fraction of, 1079(ab)
^{99m}Tc and ^{186}Re labeled, can blood retention be predicted in vitro by challenge with cysteine?, 1142(ab)
^{99m}Tc antigranulocyte antibody *fragment*, immunoscintigraphy of infection, 240(ab)
^{99m}Tc labeled, 1617(le)
can cysteine-challenge assay predict in vivo stability and biodistribution of?, 231(ab)
Antiferritin antibody, evaluation of ^{111}In- and ^{90}Y-labeled linker-immunoconjugates in nude mice and dogs, 938
Antimyosin
antibody imaging for identification of catheter ablation induced myocardial necrosis, 256(ab)
^{111}In, cardiotoxicity assessment by bolus administration *vs.* continuous infusion of doxorubicin, 43(ab)
^{123}I MIBG *vs.*, 44(ab)
^{99m}Tc-labeled, recombinant single-chain Fv, rapid infarct imaging, 234
Anti-sense oligonucleotides, use to predict chemotherapy resistance of tumors, 23N(5)
Arsenic-77, for therapy, dosimetric basis of, 789(ab)
Artery
cerebral
posterior, infarction, and related visual field defects, SPECT and MRI in, 1009
SPECT HMPAO and balloon test occlusion, predicting tolerance prior to permanent occlusion of, 1243
coronary, transient occlusion, simultaneous assessment of myocardial perfusion and left ventricular function during, 1(ab)
examination of errors introduced by alternative approaches to characterization of arterial input functions, 884(ab)
noninvasive monitor, for quantitative ^{15}O water blood flow studies, 1000
plasma, modeling approach to eliminate need to separate, in ^{15}O inhalation PET, 1333
plasma activity curve for PET measurement of regional cerebral metabolic rate for glucose, 152(ab)
radial, effect of smear-correcting blood activity curves on FDG-PET measurements of cerebral metabolic rate for glucose, 962(ab)
trial arterial occlusion, brain blood flow SPECT in, 1239
Artificial neural network
classifier for MAG3 renogram analysis, 844(ab)
post-reconstruction, for compensation of collimator, attenuation and scatter effects in SPECT, 67(ab)
Ascorbic acid, as radioprotector against ^{131}I, 637
Asia and Oceania Congress in Nuclear Medicine and Biology, scientific highlights, 17N(5)
ASNC. *See* American Society of Nuclear Cardiology
Astatine-211, measuring distributions with SPECT, 911(ab)
Atrophy, quantitation of regional glucose metabolic activity in Alzheimer's disease after correction for effects of, 8(ab)
Attenuation correction
can liquids be used to predict abnormal solid phase gastric emptying?, 33(ab)
of cardiac SPECT, scatter imaging with external source for, 926(ab)
channel ratio method for radionuclide image quantitation, 330
in clinical cardiac SPECT, 111(ab)
comparison of Am-241 and ^{99m}Tc as transmission sources for, in ^{201}Tl cardiac SPECT, 113(ab)
count-limited transmission data in PET, 143
emission based technique for obtaining data for myocardial SPECT studies, 898(ab)
evaluation of new post-reconstruction method for quantitative SPECT, 916(ab)
fast transmission CT for determining attenuation maps using collimated line source, rotatable air-copper-lead attenuators and fan-beam collimation, 1577
importance of attenuation compensation and its implementation in cardiac SPECT imaging, 110(ab)
measurements with position gating and time-of-flight windowing to reject emission events from patient, 543(ab)
noise and spatial resolution properties of ML-EM reconstructed images, 69(ab)
non-uniform
for quantitative thorax SPECT based on lung emission, 908(ab)
technique for filtered backprojection, 920(ab)
non-uniform compensation for ^{99m}Tc cardiac SPECT using acquired transmission data, 112(ab)
PET, noise reduction by maximum likelihood histogram sharpening of attenuation images, 101(ab)
planar, of geometric mean images, 237(ab)
post-reconstruction artificial neural network for, in SPECT, 67(ab)
pulse transmission, with cone-beam SPECT, 927(ab)
scanning line source for simultaneous emission and transmission measurements in SPECT, 1752
Attenuation scans, PET, cardiac, three-dimensional registration of, 311
Autoimmunity, nuclear imaging of tolerance loss in autoimmune mice, 227(ab)
Autoradiography
changes in local cerebral glucose utilization in awake rat during acute and chronic ethanol administration, 793
double tracer, using ^{123}I Iomazenil and ^{99m}Tc HMPAO in experimental brain ischemia, 935(ab)
dual isotope analysis of effects of decreased flow on benzodiazepine receptor tracer uptake in rat brain, 953(ab)
dual tracer, of cerebral acetate metabolism, 936(ab)
evaluation of intra-tumoral distribution of 2-DG and monoclonal antibodies in xenografts of human ovarian adenocarcinoma, 75
Avascular necrosis
early detection of, animal model of, 710(ab)
MRI and SPECT bone scans in renal allograft recipients, 381

B

Bayesian reconstruction, three-dimensional, for SPECT, 70(ab)
"Below regulatory concern" (BRC) exemptions, Congress erects ambiguous wall against, 20N(1)
Benzodiazepine, receptors
binding compared with cerebral perfusion in gerbil brain after transient ischemia, 955(ab)
^{123}I Iomazenil SPECT in presurgical work-up of patients with medically intractable focal epilepsy, 80(ab)
^{123}I Iomazenil study of cerebral distribution in anxiety disorders, 181(ab)
new selective radioligands for examination of, 352(ab)
potential imaging agent for SPECT investigations of, 932
quantification in vivo in human brain, 433(ab)
regional alteration of distribution in refractory temporal lobe epilepsy revealed by group averaging techniques, 81(ab)
regional discordance between distribution and glucose metabolism in ischemic cerebrovascular disease, 977(ab)
Berson-Yalow Award, Michael Jay and Robert K. Mansfield, 30N(7)
BGO block detectors, rotating PET scanner using, 1367
Bile. *See also* Hepatobiliary tract
leak from gallbladder perforation mimicking bowel activity and false-negative result in morphine-augmented cholescintigraphy, 131
Biotinylated iodo-polylysine, for pretargeted radiation delivery, 1147
Blastomycosis, North American
^{67}Ga-citrate and bone scintigraphy, 458
successful ^{67}Ga imaging of, 958
Blood flow
accurate local measurements with dynamic PET, fast determination of input function delay and dispersion by multilinear minimization, 1770
automated analysis program for evaluation of PET studies, 968
cerebral
abnormal regional response to auditory stimulation in childhood autism, 307(ab)
during behavioral challenge in obsessive compulsive disorder, 180(ab)
and benzodiazepine receptor in animal model for Alzheimer's disease, 943(ab)
coupling with glucose metabolism in Alzheimer's disease, 463(ab)
double tracer autoradiography using I-125 Iomazenil and ^{99m}Tc HMPAO in experimental brain ischemia, 935(ab)
dynamic quantitative ^{133}Xe regional SPECT on PRISM 3-headed tomograph, 266(ab)
effect of hypercapnia and hyperventilation in moyamoya disease, 246(ab)
evaluation in acute and subacute closed-head injury by means of ^{99m}Tc HMPAO SPECT, 998(ab)
gender differences with PET, 264(ab)
ictal regional SPECT in temporal lobe epilepsy relative to surgical outcome, 82(ab)
in locked-in syndrome, 291
in major depression *vs.* Alzheimer's disease, 1090, 1101
mild to moderate regional abnormalities, ^{99m}Tc ECD *vs.* ^{133}Xe SPECT in, 747
noninvasive regional measurements using ^{99m}Tc hexamethylpropylene amine oxime, 366(ab)
partition coefficient, graphic plot analysis, ^{123}I IMP and dynamic SPECT validation studies using ^{15}O water and PET, 498

regional effect of amphetamine during cognitive activation, 1067(ab)
regional effect of intravenous persantine in normal subjects, 265(ab)
regional state dependent change during craving for alcohol in alcoholics, by repeat ^{99m}Tc HMPAO SPECT, 996(ab)
sequential quantitative measurements using split dose ^{123}I IMP SPECT method, 986(ab)
single-pass cerebral extraction and capillary permeability-surface area product of several imaging agents, 641
SPECT HMPAO and balloon test occlusion, predicting tolerance prior to permanent cerebral artery occlusion, 1243
SPECT in temporary balloon occlusion of carotid and intracerebral arteries, 1239
decreased coronary reserve in idiopathic dilated cardiomyopathy assessed using PET with ^{15}O water, 134(ab)
effect of changes on distribution volume of ^{11}C raclopride binding, 949(ab)
local renal, mapping with PET and ^{15}O water, 196(ab)
myocardial
assessment of endothelial function with PET cold pressor test in patients with various degrees of atherosclerosis, 137(ab)
biokinetics of ^{99m}Tc tetrofosmin and, 1254
comparison of factors influencing cost-effectiveness of diagnosis and management of coronary disease, 136(ab)
comparison of ^{13}N ammonia measurement techniques, 192(ab)
dynamic and gated PET ^{13}N ammonia imaging confirms inhomogeneous tracer retention but homogeneous perfusion in normal subjects, 132(ab)
identification of viable myocardium in patients with chronic coronary artery disease using ^{15}O water and PET, 88(ab)
is Patlak graphical analysis method applicable to measurement with ^{13}N ammonia?, 1831(le)
measurement by radiolabeled tracers, 1518
parametric images for quantitative measurements in humans, 862
PET measurement permits recognition of viable and non-viable myocardium in chronic myocardial infarction, 87(ab)
quantification using ^{13}N ammonia and dynamic PET, 488
quantification using PET and ^{13}N ammonia in patients with angiographically documented coronary artery disease, 133(ab)
rest and hyperemic, during estradiol therapy in post-menopausal women by ^{13}N ammonia and PET, 802(ab)
resting, maintenance in dysfunctional myocardium with ^{201}Tl redistribution, 171(ab)
simultaneous measurement of oxygen consumption and, ^{11}C acetate, compartmental model for, 4(ab)
^{99m}Tc teboroxime, uptake, *vs.* ^{201}Tl and ^{99m}Tc sestamibi, 255
validation of ^{13}N ammonia tracer kinetic model for quantification using PET, 83
myocardial extraction of ^{99m}Tc MBI in isolated rabbit heart, 927
penile, tumescence, 523(le)
PET functional brain mapping, comparison and optimization of data acquisition strategies, 150(ab)
posterior cerebral artery infarction, and related visual field defects, SPECT and MRI in, 1009
prefrontal, in schizophrenia, 305(ab)
pulmonary systemic, evaluation using ECG gated acquisition, 1441
quantitative ^{15}O water studies, noninvasive arterial monitor for, 1000
quantitative PET, 1006
regional FDG uptake *vs.*, in untreated primary breast cancers, 290(ab)
relationship of functional outcome and, after coronary revascularization, 761(ab)
Tc-94m teboroxime synthesis, dosimetry and initial PET imaging studies, 1058
teboroxime as marker following reperfusion of myocardial infarction, 48(ab)
tissue, simple method for estimation using Cu-PTSM and PET, 1132(ab)

Blood pool imaging
development of synthetic polymer based agent labeled with ^{99m}Tc, 149(ab)
evaluation of ^{111}In polyclonal IgG to quantitate atherosclerosis in Watanabe heritable hyperlipidemic rabbits with scintigraphy, 1316
inhomogeneity of gated and ungated bull's-eyes, ^{99m}Tc sestamibi *vs.* ^{201}Tl, 281
metastatic malignancy masquerading as hepatic hemangioma on labeled RBC scintigraphy, 1172
MIBG evaluation as potential tracer for monitoring doxorubicin cardiomyopathy, 1282
quantitative gated SPECT, enhanced sensitivity for non-invasive assessment of coronary artery disease, 131(ab)
removal of early non-specific activity from antifibrin images, application to rat model of pulmonary embolism, 855(ab)

Blood sampling
high-speed automated discrete, for PET, 1357
^{15}O water and ^{15}O labeled RBC require separate external dispersion corrections, 197(ab)
radioactivity, orbital ^{111}In DTPA octreotide accumulation in Graves' orbitopathy not based on, 158(ab)

Blood-time activity curve, new estimation method accounting for PET accumulated counts in tracer kinetic modeling, 154(ab)

Bone. *See also* Skeleton
absorbed dose calculations in Haversian canals for several beta-emitting radionuclides, 1361
can mineral in hip be predicted from spinal bone mineral density measurements in clinical practice?, 706(ab)
"cold hip" sign *vs.* avascular femoral head, 1827(le)
comparison of ^{111}In IgG, ^{99m}Tc HMPAO WBC, and ^{99m}Tc MDP imaging and conventional x-ray in rabbit model of acute and chronic osteomyelitis, 328(ab)
density, estrogen and, 803(ab)
detection of hypervascular brown tumors on three-phase scan, 2188, 2198
disorders, regional assessment of skeletal fluoride kinetics with ^{18}F PET in, 437(ab)
early detection of avascular necrosis, animal model of, 710(ab)
enthesopathy of patellar tendon insertion, isotretinoin therapy, 455
femoral and lumbar mineral density in ankylosing spondylitis, 704(ab)
fractures, scintimetric evaluation of remodeling after, 1403
functional staging of cancer patients in prediction of therapeutic response and survival, 1087
imaging with energy-weighted acquisition, 997
measurements of mineral in thoracic spine by fan beam dual energy x-ray absorptiometry, 701(ab)
metabolic disease, bone scanning in, 2247
metabolism in cortical and trabecular bone in normal women and women with osteoporosis, 703(ab)
metastasis
in breast cancer, 291(ab)
EXAFS structural characterization of solutions of ^{186}Re HEDP therapeutic agent for, 146(ab)
FDA approves new therapy for, 30N(8)
MRI and SPECT in renal allograft recipients, 381
osteosarcoma presenting as intestinal obstruction, 1990
Paget's disease, in patient with breast cancer, 1214
Pancoast tumor as cause of reflex sympathetic dystrophy, 1992
rib infarction and pulmonary infiltrates, simultaneous occurrence in sickle cell disease with acute chest syndrome, 614
scans
compared with x-ray findings in osteoporotic vertebral fractures, 439(ab)
correlation with serum PSA levels in treatment of prostate cancer, 121(ab)
MRI *vs.*, in detecting spinal metastases, 2191
radiographic correlation of suspicious lesions on, 716(ab)
three-phase, comparative value of MRI in musculoskeletal infection, 329(ab)
scintigraphy
compared with MRI in diagnosis of skeletal metastases in prostate cancer at initial presentation, 120(ab)
difference in intervertebral fusion rate of cervical and lumbar spine assessment by, 712(ab)
disseminated North American blastomycosis, 458
"doughnut sign" due to hemangioendothelioma, 297
effect of clodronate treatment in metastatic breast cancer, 1039
^{67}Ga, in tuberculous and nontuberculous infectious spondylitis, 853
intraosseous meningioma appearance over five years, 961
in metabolic bone disease, 2247
oncology and infection, 2236
orthopedic scanning, 2241
quantitative, for evaluation of lower limb growth plate activity in normal children, 1063(ab)
value in children with unilateral congenital growth disorders, 1064(ab)
yield for identifying occult malignancy in patients with musculoskeletal pain, 122(ab)
^{153}Sm EDTMP biodistribution and dosimetry estimation, 1031

^{153}Sm EDTMP in metastases of hormone refractory prostate carcinoma, 1839
SPECT, diagnosis of partial and total physeal arrest by, 1410
SPECT in recent meniscal tears, 713(ab)
spine and femur mineral density in varying severity spinal osteoporosis, 702(ab)
^{99m}Tc HMDP negative tumors, ^{18}F FDG PET in, 288
^{99m}Tc MDP uptake and biodistribution during rat tibial bone repair, 104
^{99m}Tc nanocolloid scintigraphy in orthopedic infections, comparison with ^{111}In labeled leukocytes, 1646
therapy in nuclear medicine, 1037
tumors, use of early, late and SPECT thallium imaging in evaluating activity of, 123(ab)
upper spine, radiation dose from therapeutic administrations of ^{131}I sodium iodide, 695

Bone marrow
ablation
design of treatment planning strategy for radionuclide therapy, 1026(ab)
estimation of red marrow doses from Ho-166 administered for, 786(ab)
Ho-166 DOTMP for, 125(ab)
antigranulocyte antibody scans in cancer patients with suspected bone superscan, 720(ab)
assessment in Paget's disease, with ^{99m}Tc antigranulocyte antibody BW 250/183, 721(ab)
changes in end plates in association with disc degeneration, SPECT and lumbar MRI in back pain with emphasis on, 711(ab)
changes in ^{99m}Tc nanocoll localization as result of treatment with recombinant human granulocyte colony stimulating factor in canine model, 840(ab)
dosimetry for radioimmunotherapy, 689
theoretical derivation of red marrow to blood activity concentration ratio, 782(ab)
immunoscintigraphy in staging of low, intermediate, and high grade non-Hodgkin's lymphoma, comparison with iliac crest biopsy, 1000(ab)
myelosuppression secondary to ^{131}I Lym-1 therapy for B-cell malignancies, 512(ab)
usefulness of immunoscintigraphy using ^{99m}Tc antigranulocyte monoclonal antibody in patients with suspected bone metastases, 1002(ab)

Bonte, Frederick J., people in nuclear medicine, 20N(6)

Book reviews
Atlas of Nuclear Medicine Imaging 2nd edition, 1837
Cancer Imaging Manual, 1396
Cardiologia Nuclear, 171
Dose and Risk in Diagnostic Radiology: How Big? How Little?, 1838
Fifth International Radiopharmaceutical Dosimetry Symposium May 7-10, 1991, 527
High Resolution CT of the Lung, 1220
Imaging of Sports Injuries: A Multimodality Approach, 870
Imaging Techniques of the CNS of the Neonate, 171
Measurement of Dose Equivalents from External Photon and Electron Radiations, 171
MRI: Cardiovascular System, 1396
New Developments in Myocardial Imaging, 527
Nuclear Medicine Annual 1992, 172
Nuclear Medicine Procedure Manual, 1837
Nuclear Medicine Procedure Manual 1992, 527
Orthopedic Radiology: A Practical Approach, 2nd edition, 1221
Photon, Electron, Proton and Neutron Interaction Data for Body Tissues, 171
Positron Emission Tomography of the Heart, 1220
Practical Nuclear Medicine, 869
Radiological Assessment: Sources and Exposures, 869
Reading the Chest Radiograph: A Physiologic Approach, 1396
Selected Atlases of Bone Scintigraphy, 1220
Update on Nuclear Cardiology: Advances in Thallium Perfusion Imaging, 1221

Brain
acetate metabolism, dual tracer autoradiography of, 936(ab)
activation of lexical decision in psychopaths using SPECT, 306(ab)
affinity labeling of neuroreceptors using gamma rays, 95(ab)
alcohol effects, 798
benzodiazepine receptor distribution in anxiety disorders, study with ^{123}I Iomazenil, 181(ab)
biodistribution and dosimetry of ^{123}I IBF, 1910
blood flow
in locked-in syndrome, 291
and partition coefficient, graphic plot analysis, 498
regional improvement with treatment in chronic cocaine polydrug users, 723
single-pass cerebral extraction and capillary permeability-surface area product of several imaging agents, 641
cerebral artery, SPECT HMPAO and balloon test occlusion, 1243
cerebral cortical activation and spreading cortical depression visualized by mAChR-linked phosphatidyl inositide response with ^{11}C labeled diacylglycerol, 941(ab)
cerebral infarction within 6 hours after onset, 367(ab)
cerebral palsy prediction in high-risk neonates, 1223
cerebral vasodilatory capacity mapping using ^{99m}Tc DTPA-HSA SPECT and acetazolamide in moyamoya disease, 1984
cerebrovascular accident associated with dipyridamole ^{201}Tl myocardial imaging, 128
childhood tumors, ^{201}Tl *vs.* ^{99m}Tc MIBI SPECT in evaluation of, 1045
cholinergic neurons in, in vivo mapping using SPECT and (-)-5-^{123}I IBVM, 93(ab)
circulation in moyamoya disease, effect of hypercapnia and hyperventilation on, 246(ab)
clinical evaluation of interictal ^{18}F FDG PET in partial epilepsy, 1892
clinical evaluation of ^{201}Tl SPECT in supratentorial gliomas, 2085, 2089
collateral perfusion assessment with ^{99m}Tc HMPAO SPECT during temporary internal carotid artery occlusion, 1235
comparability of FDG PET studies in probable Alzheimer's disease, 1460
comparison of phantom and human gray/white matter ratios, 933(ab)
co-registration methods for three-dimensional images, 274(ab)
correction strategy for head movement during imaging, 276(ab)
^{11}C raclopride binding in, reproducibility of repeated measures, 609
death, ^{99m}Tc HMPAO in determination in children, 203(ab)
decreased hippocampal blood flow during episode of transient global amnesia, 981(ab)
distribution of D2 dopamine receptors in healthy men, MRI based analysis of SPECT images acquired with ^{123}I IBF, 940(ab)
dopaminergic D2 receptor SPECT imaging in Rett syndrome, increase of specific binding in striatum, 1717
double tracer autoradiography using I-125 Iomazenil and ^{99m}Tc HMPAO in experimental ischemia, 935(ab)
dual isotope SPECT imaging for monitoring cognitive activation, initial studies in humans, 267(ab)
equilibrium quantification of human benzodiazepine receptors with use of ^{11}C flumazenil and PET, 432(ab)
evaluation of swine glucose metabolism in thioacetamide-induced hepatic encephalopathy using FDG PET, 961(ab)
examination of neural control of eye movements with PET, 932(ab)
first experience with new D2 ligand ^{123}I IBF, comparison with ^{123}I IBZM, 934(ab)
functional imaging in elderly, 1101
functional intercorrelations among multi-focal responses to thermal pain in humans, 220(ab)
functional mapping of flow and back-diffusion rate of ^{123}I IMP, 839
fusion of morphological MRI and CT images with functional SPECT images in studies of, 499(ab)
glucose metabolism response to GABA-A stimulation studied with PET in temporal lobe epilepsy, 78(ab)
high-resolution SPECT, somatostatin receptor imaging in pituitary using, 159(ab)
high-resolution SPECT imager, feasibility of, 99(ab)
histopathologic validation of blood flow SPECT in differential diagnosis of dementias, 461(ab)
hypermetabolic fungal infection with PET FDG studies, 143(ab)
hyperperfusion in late life chronic fatigue syndrome and late life depression, 993(ab)
ictal SPECT using ^{99m}Tc HMPAO, methods for rapid preparation and optimal deployment during spontaneous seizures, 666
I-125 2'-IDZ as potential imaging agent for SPECT investigations of benzodiazepine receptors, 932
I-125 implants, verification with dedicated SPECT camera, 892(ab)
imaging of primary and remote ischemic lesions by in vivo autoradiography, benzodiazepine binding sites and glucose metabolism, 957(ab)
increased cerebral perfusion after detachable balloon embolization of carotid

cavernous fistula on ^{99m}Tc HMPAO SPECT, 1987
infections, PET FDG accuracy in distinguishing lymphoma from, in AIDS, 142(ab)
influence of acute an chronic administration of ethanol on local glucose utilization of rat, 968(ab)
intraoperative assessment of malignancies using ^{201}Tl, 138(ab)
investigation of functional neuroanatomy of syntactic processing and sentence comprehension using PET, 222(ab)
in vivo dopamine transporter sites imaging in human using ^{11}C WIN 35,428 PET, 938(ab)
local glucose utilization, changes in awake rat during acute and chronic ethanol administration, 793
malignant tumor chemotherapy efficacy, utility of ^{201}Tl and ^{99m}Tc sestamibi SPECT for early determination of, 974(ab)
metabolism of 6-[^{18}F]FDOPA is enhanced in patients with Parkinson's disease, 114(ab)
methotrexate-induced neurotoxicity, appearance on ^{111}In WBC, ^{67}Ga-citrate and ^{201}Tl chloride scintigraphy, 1377
mirror movements during recovery from stroke, 225(ab)
modeling approach to eliminate the need to separate arterial plasma in ^{15}O inhalation PET, 1333
neutral TcN-dithiocarbamate complex bearing ester groups as potential imaging agent for cerebral perfusion, 63(ab)
oxygen utilization, individual correction of dispersion did not alter estimates of, 942(ab)
patterns of regional glucose metabolism in unipolar and bipolar depressive disorders, 183(ab)
perfusion imaging with ^{99m}Tc ECD, normal pattern in children, 990(ab)
PET, FDOPA in, quantitation of putamen uptake constant of, 679
PET and autoradiographic method with continuous inhalation of ^{15}O gas, 1672
PET functional mapping, comparison and optimization of data acquisition strategies, 150(ab)
PET studies of working memory in humans, 221(ab)
phantom, accuracy of registration of PET, SPECT and MR images of, 1587
phosphoinositide turnover imaging linked to muscarinic cholinergic receptor in central nervous system by PET, 1543
physical performance of dedicated annular scanner "Ceraspect," 894(ab)
practical procedures and pharmacological applications of quantitative PET, 1006
primate, PET images of phosphoinositide response in, 94(ab)
principal axes and surface fitting methods for three-dimensional image registration, 2019
prognostic and diagnostic usefulness of FDG-PET in primary tumor management, 141(ab)
protein kinase C imaging using ^{11}C-labeled phorbol esters, 431
qualitative analysis of regional cerebral function in healthy volunteers, normal patterns and changes with age, 991(ab)
quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease, atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators, 1681
quantitative SPECT discriminates Alzheimer's disease from normal aging, 982(ab)
quantitative SPECT in Alzheimer's disease and normal aging, 2044
regional cerebral blood flow abnormalities, mild to moderate, ^{99m}Tc ECD *vs.* ^{133}Xe SPECT in, 754
regional distribution and metabolism in guinea pigs of ^{11}C CP-96,345 non-peptide NK-1 antagonist, 1121(ab)
regional glucose metabolism
in Alzheimer's disease, effect of age of onset on, 7(ab)
modeling plasma activity curve for PET measurement of, 152(ab)
regional glucose metabolism in coma, vegetative and persistent vegetative state, 369(ab)
regional glucose utilization with ^{18}F FDG and PET in heterogeneous tissues, 360
regionally differential vascular reactivity to vibrotactile stimulation of right fingers, 223(ab)
response to visual cognitive stimulation assessed by ^{99m}Tc HMPAO in Alzheimer type dementia, 11(ab)
scintigraphic studies of oropharyngo-esophageal function in stroke and other neurologic disorders, 34(ab)
serotonin uptake sites, ^{11}C McN-5652Z as PET radiotracer for study of, 120
SPECT
neural network classifier for, 100(ab)
in patients with cortical visual loss, 1447
^{99m}Tc HMPAO, segmental analysis of, high correlation between temporal defects and memory loss in, 9(ab)
^{201}Tl in childhood brain tumors, 201(ab)
SPECT activation images, propagation of registration errors in, 900(ab)
SPECT and MRI in posterior cerebral artery infarction and related visual field defects, 1009
SPECT and planar imaging in crack abuse, 899
spectrum of regional glucose consumption in choreatic disorders, 118(ab)
stereotactic localization of functional images, automated detection of intercommissural line for, 322
stereotactic transformation of PET scans by deformation of standard atlas, 279(ab)
synthesis and mouse uptake of ^{11}C-labeled inhibitors of prolyl endopeptidase, 23(ab)
synthesis of new class of imaging agents containing TcN multiple bond, 537(ab)
^{99m}Tc HMPAO perfusion SPECT, ^{123}I IBZM dopamine D2 receptor and, Huntington's disease and, 1274
^{99m}Tc HMPAO SPECT, in detection of postural cerebral hypoperfusion in patients with cerebrovascular disease, 1931
^{99m}Tc HMPAO SPECT evaluation of autistic disorder, 308(ab)
^{99m}Tc HMPAO SPECT in diagnosis of chronic fatigue syndrome, 182(ab)
^{99m}Tc HMPAO SPECT perfusion studies, test-retest variability in normal human subjects, 248(ab)
^{99m}Tc HMPAO SPECT scan in schizophrenia, 309(ab)
temporal lobe findings in SPECT studies of patients with mood disorders, may be influenced by biological properties of radioligand, 184(ab)
three-dimensional imaging, stationary hemispherical SPECT, 474
three-dimensional PET-PET image registration and enhancement of signal/noise ratio in functional patterns, motor task and, 151(ab)
3-D registration of SPECT and MRI images, 893(ab)
tissue heterogeneity effects on FDG parameter estimates, 153(ab)
^{201}Tl uptake from CSF compartment, 99
trapezoid rule improves calculation of tissue radioactivity, 869(ab)
tumor characterization using dual-isotope SPECT with thallium, somatostatin analog, anti-EGF antibody, 969(ab)
tumor detection by SPET using ^{201}Tl and ^{99m}Tc labeled BC-2 monoclonal antibody, 459(ab)
tumor growth, IUDR uptake and retention as measure of, 1152
tumor proliferative activity, assessment using ^{131}I IUDR, 139(ab)
tumors, ^{111}In octreotide SPECT in, 140(ab)
unified processing environment for image fusion, 863(ab)
whole body distribution of new selective muscarinic antagonist, radioiodinated IQNP, 937(ab)
whole body distribution of new selective muscarinic antagonist radioiodinated IQNP, 937(ab)

BRC exemptions. *See* "Below regulatory concern" exemptions

Breast
cancer
bone metastases in, 291(ab)
new monoclonal antibody ^{99m}Tc 170H.82 for imaging, 1003(ab)
Paget's disease in patient with, 1214
radioimmunotherapy with ^{90}Y/^{111}N BRE-3, 204(ab)
^{99m}Tc MIBI in evaluation of patients with primary carcinoma of breast, 557(ab)
^{99m}Tc sestamibi prone breast imaging in patients with suspicion of, 559(ab)
^{201}Tl scintigraphy complementary role with mammography in diagnosis of, 2095
untreated, regional FDG uptake *vs.* blood flow in, 290(ab)
mass abnormalities, ^{201}Tl scintigraphy in evaluation of, 18
PET assessment with FDG and FES, 218(ab)
^{99m}Tc sestamibi prone imaging in patients with suspicion of breast cancer, 559(ab)

Bromine-76 FLB 457, high affinity PET ligand for studying dopamine D2 receptors, evaluation in baboon and human, 407(ab)

Bromine-76 MBBG
analog of norepinephrine for PET investigation of heart adrenergic reuptake system, 494(ab)
as PET radiotracer for mapping sympathetic nerves of heart, 1739

C

CAD. *See* Coronary artery disease

Camera
beta, improved detectability in low activity applications, 449(ab)
dedicated annular brain scanner "Ceraspect," physical performance of, 894(ab)

dedicated SPECT, come of age, 1789
gamma, slat collimation for high sensitivity 2D and 3D emission imaging, 28(ab)
multi-detector, detection and correction of patient motion in dynamic and static myocardial SPECT using, 1349
pinhole collimation for ultra-high resolution, small-field-of-view SPECT studies, 29(ab)
scintillation
channel ratio method of scatter correction for radionuclide image quantitation, 330
high resolution pinhole SPECT for small animal imaging, 27(ab)
Cancer. *See also* Carcinoma; Metastasis; Oncology; Tumors
accurate detection of liver metastases in patients with primary malignancies using PET-FDG imaging, 13(ab)
athymic mice bearing colon cancer xenografts, ^{99m}Tc labeling of trisuccin conjugated to monoclonal antibody CC49, 107(ab)
bladder, radioiodinated IUDR in, 493(ab)
blood glucose concentration influence on FDG uptake in, PET study of, 1
bone scintigraphy, 2236
breast, radioimmunotherapy with ^{90}Y/^{111}N BRE-3, 204(ab)
cardiac and whole-body ^{18}F FDG studies in septumless PET scanner, 868(ab)
colon, refractory, phase II trial of CC-49 in, 205(ab)
differentiation of benign and malignant pulmonary opacities with FDG-PET, 73(ab)
dose uptake ratio, 286(ab)
estrogen receptor-positive, I-125 IVME2 *vs.* ^{123}I IBHPE in, 272
evaluation of suspected malignant pulmonary lesions with ^{201}Tl SPECT, 556(ab)
EXAFS structural characterization of solutions of ^{186}Re HEDP therapeutic agent for bone metastasis, 146(ab)
FDG-PET, 6
FDG-PET evaluation of vertebral compression fractures in, 17(ab)
fit-constrained parametric images using FDG, 155(ab)
functional staging of patients in prediction of therapeutic response and survival, 1087
fusion of FDG PET with CT or MRI to localize foci of increased activity, 1190
head and neck, advanced, FDG imaging after chemotherapy, 12
lung, detection with ^{99m}Tc sestamibi, 558(ab)
myeloid leukemias, ^{131}I M195 radioimmunotherapy trials in, 207(ab)
NDA sought for cancer imaging radiolabeled peptide, 24N(1)
occult, yield of bone scintigraphy for identification in patients with musculoskeletal pain, 122(ab)
parathyroid hormone-related protein radioassay for evaluation of humoral hypercalcemia of malignancy, 505(ab)
prostate, correlation of bone scans and serum PSA levels in treatment of, 121(ab)
protein synthesis rate determination with ^{11}C tyrosine, 876(ab)
Re-188 generator readied for clinical treatment, 33N(7)
suspected malignant solitary pulmonary nodules, PET-FDG pre-surgical evaluation of patients with, 72(ab)
thyroid
high-activity ^{123}I for diagnostic evaluation of patients with, 161(ab)
medullary, 1267
versatile imaging peptide nears FDA approval, 33N(7)
Carbon-11
estimation of upper limits on human radiation absorbed doses from compounds labeled with, 2208
novel method for introduction of, 272(ab)
preparation of three novel functional M1 selective muscarinic agonists, 18(ab)
Carbon-11 acetate
cerebral metabolism of, dual tracer autoradiography of, 936(ab)
modeling of myocardial kinetics by simultaneously fitting data from multiple ROIs, 193(ab)
Carbon-11 CGP 20712A, beta 1-selective adrenoceptor ligand for cardiac imaging, synthesis and evaluation of, 188(ab)
Carbon-11 CO, improved catalyst method for production of, 1103(ab)
Carbon-11 DAG
PET, of phosphoinositide response in primate brain, 94(ab)
phosphoinositide turnover imaging linked to muscarinic cholinergic receptor in central nervous system by PET, 1543
rapid incorporation into membrane phospholipids in C6-glioma as probe for tumor proliferating potential, 1054(ab)
Carbon-11 dapoxetine, potential agent for PET studies of serotonin reuptake, 1117(ab)
Carbon-11 diprenorphine, different kinetics in patients with absence epilepsy with and without provocation of seizures, 224(ab)
Carbon-11 EPI
^{11}C HED *vs.*, for evaluation of sympathetic neurons of heart, 42(ab)
evaluation in isolated working rat heart, 174(ab)
Carbon-11 forskolin, ligand for visualization of adenylate cyclase-related second messenger sytem in brain, 1117B(ab)
Carbon-11 HED
^{11}C EPI *vs.*, for evaluation of sympathetic neurons of heart, 42(ab)
myocardial kinetics of, retention mechanisms and effects of norepinephrine, 1287
synthesis of, 1102(ab)
Carbon-11 McN, serotonin uptake site imaging with, 91(ab)
Carbon-11 McN-5652Z, PET radiotracer for studying serotonin uptake sites, 120
Carbon-11 MET
^{18}F FDG *vs.*, in head and neck cancer, 1711
uptake in head and neck cancer, 77(ab)
Carbon-11 methyl hypofluorite, development of, 272(ab)
Carbon-11 methyl triflate, on-line method for production, 268(ab)
Carbon-11 MQNB, quantification of myocardial muscarinic receptors, 981
Carbon-11 N-methylnorfenfluramine, D- and L-, in-vivo behavior as serotonin reuptake ligands in rats and monkeys, 90(ab)
***o*-Carbon-11 palmitic acid**, synthesis and initial evaluation as cardiac imaging agent, 311(ab)
Carbon-11 phorbol esters, protein kinase C imaging, 431
Carbon-11 prolyl endopeptidase inhibitors, synthesis and mouse brain uptake of, 23(ab)
Carbon-11 raclopride
binding in human brain, reproducibility of repeated measures, 609
dopaminergic-cholinergic interaction measured with PET and, in normal human subjects, 263(ab)
sensitivity of PET measurements to changes in endogenous dopamine, 262(ab)
Carbon-11 TBZ, PET and, in vivo human imaging of monoaminergic nerve terminals using, 92(ab)
Carbon-11 triamcinolone acetonide, synthesis for PET, 1111(ab)
Carbon-11 WIN 35,428, PET, in vivo dopamine transporter sites imaging in human using, 938(ab)
Carbon-14 urea, breath test, radiation dose estimates for, 821
Carbon dioxide, enriched O-18, cryogenic solid target for production of ^{18}F from, 269(ab)
Carbon dioxide TCD, cerebrovascular vasodilatory tests, 244(ab)
Carcinoembryonic antigen (CEA)
anti-CEA antibody imaging in colon cancer, 324(ab)
anti-CEA monoclonal antibody in colorectal carcinoma, 1656
phase I radioimmunotherapy with, 206(ab)
anti-CEA monoclonal antibody conjugated to bifunctional transition metal carborane complex, pharmacokinetics in tumor-bearing mice, 1294
high affinity anti-CEA murine monoclonal antibody, successful humanization of, 1020(ab)
^{123}I monoclonal antibody fragments, in colorectal cancer imaging, 61
Carcinoma, bronchial, plasma glucose levels and ^{18}F FDG uptake, 355
Carcinoma, bronchogenic, staging of, FDG-PET in, 74(ab)
Carcinoma, hepatocellular, FDG-PET *vs.* histological findings in assessment of, 12(ab)
Carcinoma, lung, PET follow up studies for evaluation of treatment response in, 75(ab)
Carcinoma, ovarian. *See also* Ovarian neoplasms
quantitation of CA-MOv18 antigen in sections of, 1004(ab)
supra-additive effect of ^{32}P chromic phosphate and CDDP in, 217(ab)
Carcinoma, testicular, refractory, phase I radioimmunotherapy trials with ^{131}I 5F9.3 monoclonal antibody, 208(ab)
Carcinoma, thyroid
circulating ^{131}I thyroxine in, 36(ab)
differentiated tumors, imaging with ^{99m}Tc(V)DMSA, 37(ab)
imaging with PET FDG, 38(ab)
metastatic, bronchogenic carcinoma mimicking, 809
papillary, false-positive scans in, 2280(le)
Cardiology
ASNC formation, 28N(4)
proselytism, retroversion and fiscal nihilism in, 1823
U.S. radiopharmaceutical sales, 28N(4)
Cardiomyopathy
Adriamycin
MIBG evaluation as potential tracer for monitoring, 1282
myocardial substrate utilization and left ventricular function in, 52(ab), 1529
dilated

effects of beta-blockade therapy with ACEI on global and regional left ventricular function in patients with, 128(ab)
idiopathic, decreased coronary reserve assessed using PET with ^{15}O water, 134(ab)
hypertrophic, complicated with ventricular aneurysm and myocardial necrosis, 2227
ischemic and nonischemic, human pathologic correlation with PET in, 39
left ventricular dilatation, significant cause of decreased specificity in myocardial ^{99m}Tc sestamibi tomography, 481(ab)
outcome of, prediction using ^{123}I MIBG myocardial SPECT, 46(ab)
primary hypertrophic, ^{123}I MIBG scintigraphy as index of severity in, 45(ab)
serial course of left ventricular function, perfusion and fatty acid uptake in, in hamster, 1309

Cardiotoxicity, assessment by ^{111}In antimyosin studies
bolus administration *vs.* continuous infusion of doxorubicin, 43(ab)
^{123}I MIBG *vs.*, 44(ab)

Cardiovascular system. *See also* Heart
comparison of factors influencing cost-effectiveness of diagnosis and management of coronary disease, 136(ab)
disease, research fellowships awarded to investigators of PET and SPECT diagnoses, 29N(7)
dynamic and gated PET ^{13}N ammonia imaging confirms inhomogeneous myocardial tracer retention but homogeneous perfusion in normal subjects, 132(ab)
infections, detection with radiolabeled leukocytes, 868(le)
novel approach to quantifying extent and severity of perfusion defects on canine myocardium by PET polar mapping, 756(ab)
relationship of segmental uptake of ^{99m}Tc sestamibi to resting regional wall motion, 728(ab)
user-definable bullseye database analysis, 738(ab)

CCK. *See* Cholecystokinin

CEA. *See* Carcinoembryonic antigen

Center for Devices and Radiological Health (CDRH), FDA seeking advisors for committee, 32N(5)

Central nervous system
nonmalignant lesions, FDG-PET in lymphoma differentiation from, in AIDS, 567
primary lymphoma in non-AIDS patients, comparison of ^{201}Tl SPECT and ^{18}F FDG PET with MRI in evaluation of, 219(ab)

Cerebral blood flow. *See* Blood flow, cerebral

Cerebral palsy, prediction in high-risk neonates, ^{99m}Tc HMPAO SPECT study of, 1223

Cerebrospinal fluid compartment, brain uptake of ^{201}Tl from, 99

Cerebrovascular disease. *See also* Stroke
dipyridamole testing in patients with, 1389(le)
identification of diaschisis using Diamox ^{99m}Tc HMPAO SPECT measures of cerebrovascular reactivity, 249(ab)
quantitative assessment of cerebrovascular reserve using ^{123}I IMP SPECT split dose method, 245(ab)
vasodilatory tests, Diamox SPECT and CO_2 TCD, 244(ab)

Channel ratio method, scatter correction for radionuclide image quantitation, 330

Chemotactic peptides, high affinity, Tc-labeled, 62(ab)

Chemotherapy
enhancement of ^{99m}Tc sestamibi accumulation in multidrug resistant cells by cytotoxic drugs and MDR reversing agents, 560(ab)
FDG imaging of advanced head and neck cancer after, 12
for Hodgkin's disease, ^{201}Tl scintigraphy for assessment of ^{67}Ga avid mediastinal mass following, 1326
regional, efficacy assessment in soft tissue sarcomas by FDG-PET, 1053(ab)
tumor resistance to, use of anti-sense for prediction of, 23N(5)

Chest
acute chest syndrome, simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease with, 614
tumors, residual or recurrent, PET differentiation from posttherapy changes, 162(ab)
x-ray
fallacy as basis for comparing radiogenic risks, 532(ab)
findings in patients with pulmonary embolism, 1074(ab)
V/Q match is less likely to represent pulmonary embolism if Q is "decreased" rather than "absent," 58(ab)

Children. *See* Pediatric patients

Cholecystitis
acute
delayed imaging has unacceptably low positive predictive value when compared to morphine augmentation, 300(ab)
morphine-augmented *vs.* delayed hepatobiliary scintigraphy, 506
morphine-augmented cholescintigraphy in, false-negative, bile leak from gallbladder perforation mimicking bowel activity and, 131

Cholecystokinin (CCK)
interaction with erythromycin in vivo, on gallbladder contraction in prairie dog model, 298(ab)
pre-scintigraphic administration of, efficacy for hepatobiliary scans in patients with systemic illnesses, 299(ab)

Chromium-51, complexes, rapid synthesis at tracer concentrations, 1089(ab)

Clean Air Act, EPA, 24N(4), 34N(7)

Clodronate, effect of treatment on bone scintigraphy in metastatic breast cancer, 1039

Cobalt-55 monoclonal antibodies, for tumor imaging with PET, 1104(ab)

Cocaine
chronic polydrug users, regional cerebral blood flow improvement with treatment in, 723
crack abuse, SPECT and planar brain imaging in, 899

Coded apertures, stationary hemispherical SPECT imager for three-dimensional brain imaging, 474

Colitis, pseudomembranous, unsuspected, in critical care patients, ^{111}In leukocyte scintigraphic detection of, 35(ab)

Collimator
astigmatic (neurofocal), contrast recovery, sensitivity, and resolution compared with standard parallel hole collimators for SPECT brain imaging, 910(ab)
comparison of parallel beam, fan beam, and cone beam for 3D SPECT brain imaging based on mutual information criterion, 930(ab)
cone beam, for magnification SPECT bone imaging of extremities, 708(ab)
cone beam and fan beam and parallel beam in SPECT, evaluation of lesion detectability by continuous ROC analysis, 321(ab)
evaluation of ^{111}In polyclonal IgG to quantitate atherosclerosis in Watanabe heritable hyperlipidemic rabbits with scintigraphy, effect of age and treatment with antioxidants or ethinylestradiol, 1316
and filter selection, simulating ^{99m}Tc cerebral perfusion studies with three-dimensional Hoffman brain phantom, 929(ab)
high resolution slit aperture for imaging small animals with SPECT, 26(ab)
investigation of effects and design of source collimation for transmission imaging in SPECT, 899(ab)
McSPECT II, 24(ab)
phantom study of breast tissue attenuation in myocardial imaging, 992
pinhole collimation for ultra-high resolution, small-field-of-view SPECT studies, 29(ab)
planar activity quantitation using low resolution measured attenuation scans, 858(ab)
post-reconstruction artificial neural network for compensation of, in SPECT, 67(ab)
slat collimation for high sensitivity 2D and 3D emission imaging, 28(ab)

Colorectal neoplasms
bispecific monoclonal antibody-mediated targeting of ^{111}In DTPA dimer to primary colorectal tumors, pharmacokinetics, biodistribution, scintigraphy and immune response, 1662
clinical comparison of radiolocalization of two anti-TAG-72 monoclonal antibodies, 1009(ab)
current imaging strategies, 537(suppl)
^{123}I-labeled CEA monoclonal antibody fragments in imaging, 61
immunoscintigraphy in surgical management, 541(suppl)
phase II trial of CC-49 in refractory colon cancer, 205(ab)
radioimmunoscintigraphy with ^{99m}Tc IgG3 labeled whole human monoclonal antibody 88BV59, 1007(ab)
repeated administration of OncoScint in, interim report of safety, efficacy and HAMA development, 1006(ab)
tumor targeting in vivo and metabolic fate of I-125 IUDR following intratumoral injection in patients with, 1175

Commentary
application of effective dose equivalent to nuclear medicine patients, 714
debate sparked by, 1825(le)
disposal of small quantities of radioactive materials in local landfills, 349
future of nuclear medicine, 27N(9)
Lines from the President, 34N(3), 50N(6), 32N(9)
medical imaging in the nineties, 157
proselytism, retroversion and fiscal nihilism in nuclear cardiology, 1823
scientific highlights of Asia and Oceania Congress in Nuclear Medicine and Biology, 17N(5)
SNM/ACNP government relations, 22N(4), 19N(7)

SNM annual meeting highlights, 13N(8)
tough choices: who is to make the call?, 860
Compline, 2272
Computed tomography (CT)
alignment of data with planar nuclear medicine images, 498(ab)
colorectal cancer imaging, radioimmunodetection complementing, 61
comparative efficacy of PET-FDG in detection of tumor sites in patients with abdominal and pelvic malignancies, 215(ab)
cone beam, orthogonal-view transmission maximum likelihood for, 319(ab)
FDG PET fusion with, to localize foci of increased activity, 1190
Computer-aided transcription, graphic user interface-based nuclear medicine reporting system, 515
Computer and Instrumentation Council, SNM and, co-sponsoring symposium on desktop computing in nuclear medicine, 18N(1)
Computers
artificial intelligence, use in medical diagnosis, 510
desktop, 18N(1)
enhanced MAG3 high resolution renal parenchymal imaging, focal renal parenchymal abnormalities on, 549(ab)
high resolution b/w printers, blue-noise dithering for printing scintigrams on, 860(ab)
massively parallel, application for three-dimensional maximum a posteriori reconstruction in SPECT, 71(ab)
multicenter evaluation of new automated analysis program for PET flow studies, 759(ab)
nuclear medicine network for remote viewing and distributed processing, 859(ab)
open architecture nuclear medicine processing system, 452(ab)
quality control expert system, object oriented approach to, 862(ab)
quantitation of ^{67}Ga lung uptake, 1076(ab)
rapidly converging iterative reconstruction algorithms in SPECT, 1793
simulation study of false myocardial perfusion defects, 109(ab)
software
accuracy of registration of PET, SPECT and MR images of brain phantom, 1587
advantages and disadvantages of SCANWriter report generating program, 1835(le)
automated daily quality control program, 853(ab)
bone imaging with energy-weighted acquisition, 997
correction and characterization of scattered events in three-dimensional PET using scanners with retractable septa, 671
graphic user interface-based nuclear medicine reporting system, 515
iterative reconstruction methods for nonuniform attenuation distribution in SPECT, 1204
methods for improving quantitation of putamen uptake constant of FDOPA in PET studies, 679
public-domain simulation system for emission tomography, 233(ab)
quantitative same-day rest-stress ^{99m}Tc sestamibi SPECT, 1494
results of clinical ROC study comparing filtered backprojection and maximum likelihood estimator images in FDG PET studies, 1198
scanning line source for simultaneous emission and transmission measurements in SPECT, 1752
systolic pressure alteration effects on radionuclide measurements of left ventricular filling dynamics, 747
unified processing environment for image fusion, 863(ab)
versatile library for medical image processing using object-oriented language, 453(ab)
3-D reconstruction of gastric contents and sequential ratios of simultaneous double head recordings demonstrating gastric displacement due to body position, 814(ab)
Conduction defects, right bundle branch block, normal coronary angiogram and, reversible ^{201}Tl perfusion defects in, 1218(le)
Congress
erects ambiguous wall against BRC exemptions, 20N(1)
low-level radioactive waste policy, 34N(7)
NRC inquiries, 20N(7)
subcommittees, radiation protection, 22N(4)
supercollider killed in House, 32N(8)
Copper-62 PTSM, initial evaluation as tumor blood flow agent in man, comparison studies with ^{15}O water, 1052(ab)
Copper-64
high specific activity, production and purification for PET imaging, 1108(ab)
tested as radioimmunotherapy agent, 22N(7)
Copper-64 monoclonal antibody
anticolon-carcinoma, initial clinical study in colorectal cancer, 322(ab)
optimization of preparation of fragments for improved biodistribution, 105(ab)
potential for radioimmunotherapy, 1018(ab)
Copper-67 monoclonal antibody, potential for radioimmunotherapy, 1018(ab)
Coronary artery disease (CAD)
assessment of endothelial function with PET cold pressor test in patients with various degrees of atherosclerosis, 137(ab)
atherosclerosis imaging, 1321
biokinetics of ^{99m}Tc tetrofosmin and, 1254
cardiac PET, 978
characterization of reinjection ^{201}Tl image, 879
chronic, identification of viable myocardium using ^{15}O water and PET, 88(ab)
clinical value in adding first-pass function imaging to perfusion imaging when using coronary vasodilator, 523(ab)
comparison between dipyridamole and dobutamine for detection of, ^{201}Tl perfusion imaging with pharmacologic intervention and, 381(ab)
comparison of factors influencing cost-effectiveness of diagnosis and management of, 136(ab)
comparison of ^{99m}Tc Q3 and ^{201}Tl for detection in man, 478(ab)
deoxyglucose and ^{99m}Tc glucarate distribution in, 1303
diagnosis on ^{201}Tl imaging, ROC comparison of simultaneous transmission emission tomography to routine SPECT for, 281(ab)
dipyridamole SPECT isonitrile perfusion imaging *vs.* dobutamine stress echocardiography for detection of, 376(ab)
enhanced sensitivity for non-invasive assessment of, quantitative gated blood pool SPECT imaging and, 131(ab)
evaluation of ^{111}In polyclonal IgG to quantitate atherosclerosis in Watanabe heritable hyperlipidemic rabbits with scintigraphy, 1316
family history of, evaluation of coronary flow reserve in asymptomatic males with hyperlipidemia and, 760(ab)
glycogen accumulation in chronically hypoperfused myocardium with maintained FDG uptake, 5(ab)
immediate ^{201}Tl reinjection following stress imaging, in myocardial viability detection, 737
impact of antianginal medications, peak heart rate and stress level on prognostic value of normal exercise myocardial perfusion imaging study, 1467
improved detection by Bayesian enhancement of myocardial perfusion scintigraphic images, 739(ab)
initial results in detection and localization, using ^{13}N ammonia, automated analysis program for PET study evaluation, 968
known or suspected, safety and clinical utility of combined intravenous dipyridamole/symptom-limited exercise stress test with ^{201}Tl imaging in, 2053
left ventricular mass and infarct size estimation from ^{13}N ammonia PET, 826
long-term follow up of myocardial perfusion abnormalities in patients with Kawasaki disease, 213(ab)
low likelihood of coronary events in young patients with normal ^{201}Tl SPECT, 210(ab)
lung/heart ratio from dipyridamole thallium images predicts, following cardiac transplantation, 750(ab)
MIBG evaluation as potential tracer for monitoring doxorubicin cardiomyopathy, 1282
multiple vessel, improved identification by addition of exercise wall motion anal to ^{99m}Tc sestamibi myocardial perfusion SPECT, 519(ab)
myocardial perfusion defect size after early and delayed ^{99m}Tc sestamibi SPECT after stress, 187
myocardial perfusion imaging and dynamic analysis with ^{99m}Tc tetrofosmin, 1478
negative ^{201}Tl SPECT and positive Rb-82 PET myocardial perfusion imaging, 400
recovery of myocardial function following coronary revascularization, 84(ab)
relationship between acute coronary flow reduction and teboroxime scan defects in patients undergoing PTCA, 521(ab)
relationship of blood flow and functional outcome after coronary revascularization, role of PET, 761(ab)
reverse redistribution on resting ^{201}Tl cardiac imaging in, relation to coronary anatomy and ventricular function, 725(ab)
reversible ^{201}Tl perfusion defects in right bundle branch block and normal coronary angiogram, 1218(le)
risk stratification in elderly patient after coronary artery bypass grafting, prognostic value of radionuclide cineangiography in, 126(ab)
teboroxime, sestamibi and ^{201}Tl as markers of myocardial hypoperfusion, comparison

by quantitative dual-isotope autoradiography in rabbits, 1510
three-vessel, radionuclide cineangiography during exercise and therapeutic implications in stable patients with, 129(ab)
^{201}Tl myocardial perfusion tomography one to five years after successful coronary angioplasty, 296(ab)
^{201}Tl reinjection and improvement of left ventricular function following revascularization, 172(ab)
transient occlusion, simultaneous assessment of myocardial perfusion and left ventricular function during, 1(ab)
validation of ^{13}N ammonia tracer kinetic model for quantification of myocardial blood flow using PET, 83
value of dobutamine ^{99m}Tc sestamibi SPECT and echocardiography in detection, *vs.* coronary angiography, 889, 895
CT. *See* Computed tomography
Cuello, Jorge L., Du Pont Award, 29N(7)
Cyclotron, PET, regulation, 25N(4)
Cysteine, can challenge assay predict in vivo stability and biodistribution of ^{99m}Tc labeled to antibodies?, 231(ab)

D

Daley, Luke, Du Pont Award, 29N(7)
Davison, Alan, Paul C. Aebersold Award, 26N(5)
Dementia, diagnostic accuracy of FDG-PET in, 6(ab)
2-Deoxy-D-glucose, intra-tumoral distribution in xenografts of human ovarian adenocarcinoma, autoradiographic evaluation of, 75
12-Deoxyphorbol 13-isobutyrate-20-[1^{11}C] butyrate, potential ligand for PET, 431
Department of Energy (DOE)
funding of neutron capture therapy research, 29N(4)
isotope supply, 34N(7)
labs bill would enhance technology transfer, 52N(6)
"molecular nuclear medicine" grants, funding for medical applications programs, 15N(2)
^{99}Mo plan, 20N(4)
new research director, 34N(7)
proposes two isotope initiatives, 47N(6)
report hints at restructuring of isotope program, 49N(6)
stop-gap isotope plan, 13N(4), 24N(4)
Depression
Alzheimer's disease *vs.*, regional cerebral blood flow in, 1090, 1101
unipolar and bipolar, patterns of regional cerebral glucose metabolism in, 183(ab)
Diabetes
gastric antral motility disturbances in, characterization using scintigraphic technique, 576
long-term efficacy of cisapride use in treatment of gastropathy in, 819(ab)
non-insulin-dependent, detection of glomerular hyperfiltration using two plasma sample method of ^{51}Cr EDTA in Koreans with, without overt proteinuria, 518(ab)
type 2, heart and skeletal muscle glucose disposal by PET in, 2064
Digoxin, and myocardial uptake of ^{123}I MIBG in left ventricular hypertrophy secondary to valvular aortic stenosis, 57
15-(p-Iodophenyl)-3,3-Dimethylpentadecanoic acid (DMIPPA), uptake, oxidation, and lipid distribution, *vs.* IHDA and pIPPA in normal myocardium, 649
Dipyridamole
high dose *vs.* standard dose, comparison of side effects and hemodynamic changes with, 748(ab)
high incidence of nonresponders to, in pre-liver transplant patients, 751(ab)
myocardial perfusion defect size after early and delayed ^{99m}Tc sestamibi SPECT, 187
perfusion scintigraphy, relationship of diagnostic accuracy to hemodynamic response on, 380(ab)
prognostic importance of transient ventricular dilation by, 735(ab)
testing in cerebrovascular patients, 1389(le)
thallium scan variables, gender differences for long term cardiac event-free survival in vascular surgery patients, 736(ab)
^{201}Tl myocardial imaging
additive value of radionuclide ventriculography for risk stratification prior to vascular surgery, 292(ab)
cerebrovascular accident associated with, 128
transient left ventricular cavity dilatation induced by, significance as assessed by ^{99m}Tc sestamibi SPECT, 297(ab)
Disintegrins, labeled, preliminary evaluation for thrombus imaging, 258(ab)
Diuresis, renography, 1029(le)
false-positive, method for minimization, normalized clearance-to-uptake slope ratio, 762
validation of renal output efficiency as objective quantitative parameter in evaluation of upper urinary tract obstruction, 845
DMIPPA. *See* 15-(p-Iodophenyl)-3,3-Dimethylpentadecanoic acid
DNA flow cytometry, proliferative activity of human cancer cells, FDG uptake *vs.*, 414
Dobutamine
increases detection of viability by ^{99m}Tc sestamibi in canine ischemia model, 384(ab)
^{99m}Tc sestamibi imaging, beta blocker therapy does not affect, 747(ab)
^{99m}Tc sestamibi SPECT and echocardiography in coronary artery disease detection, *vs.* coronary angiography, 889
DOE. *See* Department of Energy
Dopamine
dopaminergic-cholinergic interaction measured with PET and ^{11}C raclopride in normal human subjects, 263(ab)
D1 receptor, ^{123}I TISCH SPECT, dosimetry, 208
D2 receptors
effect of nitrous oxide and methohexital anesthesia on binding of ^{3}H NMSP, 939(ab)
estimation of binding potential in striatum with ^{123}I IBZM SPECT, 2076
first experience with new ligand ^{123}I IBF compared with ^{123}I IBZM, 934(ab)
imaging with ^{123}I IBZM SPECT in patients with parkinsonian syndrome, 980(ab)
multiple radiotracer studies of in vivo in control and dopamine-depleted mice, 190(ab)
occupancy as function of intravenous rising dose of RWJ-37796 in normal living human brain, 434(ab)
quantification of binding potential in striatum with ^{123}I IBZM SPECT, 987(ab)
radiohalogeno derivatives of tropapride for PET and SPECT investigations of, 995(ab)
striatal and extrastriatal, quantification using NFPE, 528(ab)
striatal imaging by IBZM-scintigraphy in schizophrenic patients treated with typical or atypical neuroleptics, 304(ab)
effects of intravenous ethanol on intrasynaptic measures in human basal ganglia, 527(ab)
endogenous, sensitivity of PET measurement with ^{11}C raclopride to changes in, 262(ab)
6-^{18}F, comparison with 6-^{18}F FNE, 619
in vivo release of, displacement of ^{123}I IBF equilibrium binding by D-amphetamine to measure in, 186(ab)
in vivo transporter sites, imaging in human using ^{11}C WIN 35,428 PET, 938(ab)
5-iodo-3-tyramine as potential metabolic tracer for, 1096(ab)
PET imaging of reuptake sites in Parkinson's disease by ^{11}C WIN 35,428 and PET, 115(ab)
receptor density, in vivo assessment in pituitary macroadenoma and correlation with in vitro assay, 530(ab)
reproducibility of repeated measures of ^{11}C raclopride binding in human brain, 609
transporters
MIBG uptake by, 1140
selective labeling in vitro and in vivo in rat brain using I-125 RTI-55 combined with clomipramine, 952(ab)
striatal, SPECT imaging demonstrates loss in Parkinson's disease, 116(ab)
Doxorubicin. *See also* Adriamycin
antimyosin positivity in cardiotoxicity, earlier than conventional evidence, 1507
bolus administration *vs.* continuous infusion, cardiotoxicity assessment by ^{111}In antimyosin studies, 43(ab)
cardiomyopathy, MIBG evaluation as potential tracer for monitoring, 1282
cardiotoxicity during administration of, ^{123}I MIBG *vs.* ^{111}In antimyosin studies for assessment of, 44(ab)
detection of cardiotoxicity in patients with sarcomas by ^{111}In antimyosin monoclonal antibody studies, 1503
Dual-energy x-ray absorptiometry, of forearm, 441(ab)
Duodenum
chronic ulcer, gastric emptying after laparoscopic anterior seromyotomy and posterior truncal vagotomy in, 30(ab)
ileal duplication, ^{99m}Tc pertechnetate scintigraphy in, 294
Du Pont Award, Jorge L. Cuello and Luke Daley, 29N(7)
Dyspepsia, idiopathic, characterization of gastric emptying pathophysiology in, using scintigraphy, 31(ab)

E

Edge detection, varying threshold SPECT technique for spleen volume, *vs.* CT volumes, 963
Editorials
alcohol and its effects on brain, 798
antimyosin positivity in doxorubicin cardiotoxicity, earlier than conventional evidence, 1507

atherosclerosis imaging, 1321
clinical PET, 1132
dedicated SPECT cameras come of age, 1789
exercise-dipyridamole myocardial perfusion imaging, 2061
FDG accumulation in tumor tissue, 419
FDG-PET in oncology, 6
functional brain imaging in elderly, 1101
functional staging of cancer patients in prediction of therapeutic response and survival, 1087
hepatic handling of radiopharmaceuticals, usefulness of in vitro model, 2030
high technology squared, 889
immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
is nuclear medicine viable and can it measure viability?, 924
is the whole really the sum of the parts?, 2198
measurement of myocardial blood flow by radiolabeled tracers, 1518
optimization of radioiodine therapy of thyrotoxicosis, 1638
PET in patient evaluation before and after heart transplantation, 834
pheochromocytoma localization, 180
practical procedures and pharmacological applications of quantitative PET, 1006
second generation hypoxia imaging agents, 411
simultaneous ^{201}Tl/^{99m}Tc dual-isotope cardiac SPECT, 2006
SPECT HMPAO and balloon test occlusion, 1243
thallium reinjection imaging, search for optimal protocol, 743
therapy in nuclear medicine, 1037
^{201}Tl SPECT in evaluation of gliomas, 2089
what should we expect from cardiac PET?, 978

Effective dose equivalent, application to nuclear medicine patients, 714

Ejection fraction
estimation using filtered first pass studies, 386(ab)
left ventricular
assessed from gated ^{99m}Tc sestamibi SPECT, 1871
development of ambulatory recorder for measurement with miniature CsI photodiode detector, 842(ab)
first-pass radionuclide angiography with ^{99m}Tc, 394
MIBG evaluation as potential tracer for monitoring doxorubicin cardiomyopathy, 1282
validation of peak diastolic filling rates and, determined from gated ^{99m}Tc sestamibi myocardial perfusion image inversion, 520(ab)

Elderly. *See also* Aging
functional brain imaging in, 1101
risk stratification after coronary artery bypass grafting, prognostic value of radionuclide cineangiography in, 126(ab)

Embolism, pulmonary. *See* Pulmonary embolism

Encephalopathy
hepatic, situs inversus diagnosed by per rectal portal scintigraphy, surgical results for portacaval shunt in, 301
HIV, SPECT, 185(ab)

Environmental Protection Agency (EPA)
Clean Air Act, 24N(4), 34N(7)
emission standards, 29N(10)

Epilepsy. *See also* Seizures
absence, different kinetics of ^{11}C diprenorphine with and without provocation of seizures, 224(ab)
complex partial, PET-FDG and post-surgical seizure outcome in, 79(ab)
focal, medically intractable, ^{123}I Iomazenil SPECT in presurgical work-up of patients with, 80(ab)
ictal SPECT using ^{99m}Tc HMPAO, methods for rapid preparation and optimal deployment during spontaneous seizures, 666
partial, clinical evaluation of interictal ^{18}F FDG PET in, 1892
temporal lobe
glucose metabolism response to GABA-A stimulation studied with PET in, 78(ab)
localizing power of ictal regional cerebral blood flow relative to surgical outcome, 82(ab)
refractory, regional alteration of benzodiazepine receptor distribution in, 81(ab)

Erythromycin
effects on gastric emptying, alcohol absorption, and small intestinal transit, 582
interaction with CCK in vivo, on gallbladder contraction in prairie dog model, 298(ab)
intravenous, effects on gastric emptying following esophagogastrectomy, 32(ab)

E-selectin, labeled monoclonal antibody against, imaging inflammation and vascular activation with, 243(ab)

Esophagus
intravenous erythromycin effects on gastric emptying following esophagogastrectomy, 32(ab)
is a semi-solid swallow a better test of transit than multiple liquid swallows?, 818(ab)
role of esophageal functional scintigraphy and barium studies in management of endoscopic variceal sclerotherapy, 817(ab)
scintigraphic studies of oropharyngo-esophageal function in stroke and other neurologic disorders, 34(ab)
scintigraphy *vs.* pH probe for quantification of pediatric gastroesophageal reflux, 1228
sequential ten-second acquisitions for detection of gastroesophageal reflux, 658

Estrogen
bone density and, comparison of tamoxifen and hypoestrogenemia, 803(ab)
I-125 IVME2 *vs.* ^{123}I IBHPE, distribution in immature female rat, 272
receptor-binding radiopharmaceuticals for imaging of estrogen receptor-positive human breast tumors, 1056(ab)

Europe, perspective on future of nuclear medicine, 169

European Association of Nuclear Medicine, scientific highlights of EANM Congress 1992, 17N(2)

Exercise
captopril scintirenography, 1158(ab)
diagnostic value of myocardial SPECT using ^{99m}Tc tetrofosmin in study of coronary artery disease, 480(ab)
ECG, comparison of factors influencing cost-effectiveness of diagnosis and management of coronary disease, 136(ab)
effect on equivalence between adenosine and exercise ^{201}Tl myocardial tomography in coronary artery disease, 379(ab)
myocardial perfusion defect size after early and delayed ^{99m}Tc sestamibi SPECT, 187
radionuclide cineangiography during, and therapeutic implications in stable patients with three-vessel coronary disease, 129(ab)
radionuclide ventriculography, prognostic efficacy in patients with and without prior myocardial infarction, 127(ab)
renography, reproducibility of results, 554(ab)
in renovascular hypertension, 48
^{99m}Tc MIBI myocardial tomography, comparison between adenosine and, 752(ab)
treadmill score in medically treated patients with coronary artery disease, comparison of prognostic value of SPECT ^{201}Tl imaging in, 294(ab)

Extracorporeal immunoadsorption, tumor-to-normal tissue ratio, 448

Eye, movements, examination of neural control with PET, 932(ab), 963(ab)

F

Fab fragments, CEA monoclonal antibody F(ab')$_2$ and Fab', ^{123}I labeled, in colorectal cancer imaging, 61

Fatty acids
^{18}F labeled, for quantitative PET studies of myocardial metabolism, 425(ab)
^{123}I, uptake, oxidation, and lipid distribution in normal canine myocardium, 649
metabolism, myocardial uptake of ^{123}I branched fatty acid analogue as marker of, 726(ab)
uptake, and left ventricular function and perfusion, serial course in cardiomyopathic hamster, 1309

FDA. *See* Food and Drug Administration

Fertility
radionuclide hysterosalpingography, appropriate for new assisted reproduction techniques, 797(ab)
sperm cell dynamics in female rabbit genital tract after insemination monitored by radiolabeled spermatozoa, 1134

Fever, of unknown origin, scintigraphy with ^{111}In polyclonal IgG in, 242(ab)

Fibroblasts, Chinese hamster ovary, hypoxia effect on accumulation of ^{99m}Tc glucarate and ^{99m}Tc gluconate, 242

Fluorine-18
cardiac PET, 978
cryogenic solid target for production from enriched O-18 CO_2, 269(ab)
electrophilic, new method for production starting from aqueous ^{18}F, 270(ab)
human striatal signal, recovery, slice oriented PET, 481
identification of metallic silver crystals in water target used for routine production, 273(ab)
no carrier added ^{18}F 4-fluorophenylsulfonyl compounds, one-step labeling of antiepileptic drug fluoresone and interleukin enhancer CL 259,763, 271(ab)

Fluorine-18 aromatics, synthesis via polymer bound tin reagents, 1105(ab)

Fluorine-18 BMY 14802, synthesis and PET studies of, 246

Fluorine-18-BPA, uptake depending on DNA synthesis and melanin incorporation in B16 melanomas in vivo studied by double-tracer microautoradiography, 1118(ab)

Fluorine-18-fallypride, as improved PET radiotracer for dopamine D2 receptors, 1129(ab)
Fluorine-18-FBT, molecular decomposition-reconstitution approach to novel vesamicol receptor radioligands, 21(ab)
6-Fluorine-18-FDA, heart uptake, metabolism, and effect of desipramine, 619
Fluorine-18-FDG
accumulation in inflammation tissue, 412(ab)
assessment of myocardial viability early during post-ischemic reperfusion in pigs with, 179(ab)
bacterial endotoxin test, PET, 469
^{11}C methionine *vs.*, in head and neck cancer, 1711
effects of hypoxia on cultured human tumor cell uptake of, 288(ab)
improving purity of preparations, 1114(ab)
influence of plasma glucose levels on uptake in bronchial carcinoma, 355
initial estimation of unidirectional clearance of, 954(ab)
maintained uptake, glycogen accumulation in chronically hypoperfused myocardium, 5(ab)
for monitoring early response of human adenocarcinoma cell line to radiotherapy, 773
in myocardial viability assessment, 89(ab)
PET
accuracy in distinguishing cerebral infections from lymphoma in patients with AIDS, 142(ab)
attenuation scans, cardiac, three-dimensional registration of, 311
comparability in probable Alzheimer's disease, 1460
in differentiation of recurrent or residual musculoskeletal sarcomas from posttherapy changes, 124(ab)
dynamic studies for assessment of ovarian cancer, 14(ab)
effects of tissue heterogeneity on parameter estimates, 153(ab)
fusion with CT or MRI to localize foci of increased activity, 1190
hypermetabolic cerebral fungal infection with, 143(ab)
initial assessment in imaging of malignant melanoma, 1420
interictal, clinical evaluation in partial epilepsy, 1892
lung tumor metastasis to breast detected by, 1571
in lymphoma differentiation from nonmalignant CNS lesions, in AIDS, 567
pediatric tumor studies, 199(ab)
pheochromocytoma studies, 41(ab)
prognostic and diagnostic usefulness in primary brain tumor management, 141(ab)
quantitative analysis of glucose utilization by, in detecting myocardial viability, 3(ab)
residual/recurrent ovarian cancer detection using, 16(ab)
in ^{99m}Tc HMDP negative bone tumors, 288
thyroid cancer imaging with, 38(ab)
planar imaging, influence of high and low insulin levels during eugylcemic clamping, 757(ab)
planar scintigraphy, early treatment response in malignant lymphoma as determined by, 1706
regional cerebral glucose utilization in heterogeneous tissues, 360
regional uptake *vs.* blood flow in untreated primary breast cancers, 290(ab)
rotating PET scanner using BGO block detectors, 1367
SPECT, in detection of viable myocardium during hyperinsulinemic glucose clamping, 727(ab)
standardized uptake values corrected for body surface area, less dependent on body size than values corrected for body weight, 287(ab)
uptake and cancer cell proliferative activity, 414
uptake in head and neck cancer, 77(ab)
Fluorine-18-FDGal, high accumulation by well-differentiated hepatomas of mice and rats, 780
6-Fluorine-18-FDOPA
frame-to-frame registration for movement correction of dynamic studies, 275(ab)
metabolism is enhanced in patients with Parkinson's disease, 114(ab)
putamen uptake constant in PET studies, methods for improving quantitation of, 679
Fluorine-18-FDOPA
and analogs, efficiency removal of tin contaminants from preparations of, 1110(ab)
NCA asymmetric, preparation from ^{18}F florid ion, 1106(ab)
Fluorine-18-FEOBV, vesicular tracer for mapping central cholinergic neurons in vivo, preclinical studies of, 490(ab)
Fluorine-18-FES, radiotoxicity in cell culture, 783(ab)
Fluorine-18-2-F-L-FMPT, synthesis of potential PET tracer for tyrosine hydroxylase activity, 22(ab)
Fluorine-18-fluoxetine, as potential marker for serotonin uptake sites, 1112(ab)
Fluorine-18-FMFMT, specific central dopamine probe, 959(ab)
Fluorine-18-FMISO, imaging of hypoxia and reoxygenation in human tumors with, 76(ab)
6-Fluorine-18-FNE, heart uptake, metabolism, and effect of desipramine, 619
Fluorine-18-5-F-6-NQP, PET radioligand for serotonin uptake sites, synthesis and biological evaluation of, 19(ab)
Fluorine-18-MDL11939, synthesis and in vivo evaluation of, 20(ab)
Fluorine-18-MIBG, novel synthesis for PET studies, 1107(ab)
Fluorine-18-N-allyl-S-fluoropropylepidepride, very potent and specific dopamine D2 PET radioligand, 958(ab)
Fluorine-18-PFBG, potential tracer for imaging heart and tumor using PET, 312(ab)
6-Fluorine-18-TP-3 monoclonal antibody, fragment, imaging osteosarcoma in dogs using PET and, 1017(ab)
Fluorine-18-uracil, PET studies after systemic administration of, in patients with liver metastases from colorectal carcinoma, 1075
Fluorodeoxyglucose
blood glucose concentration influence on uptake in cancer, PET study of, 1
fit-constrained parametric images of cancer using, 155(ab)
in head and neck cancer, advanced, imaging after chemotherapy, 12
lymphoma *vs.* nonmalignant CNS lesions in AIDS and, 567
myocardial perfusion and myocardial cell death, 866(le)
PET
in assessment of hepatocellular carcinoma, comparison with histological findings, 12(ab)
in dementia, diagnostic accuracy, 6(ab)
in differentiation of benign and malignant pulmonary opacities, 73(ab)
evaluation of vertebral compression fractures in cancer, 17(ab)
initial evaluation of imaging of metastatic testicular neoplasms, 15(ab)
in oncology, 6
in patients with malignant lymphoma, 1022(ab)
predictive importance in patients with temporal lobe seizures, 83(ab)
residual/recurrent ovarian cancer detection using, 16(ab)
results of clinical ROC study comparing filtered backprojection and maximum likelihood estimator images in, 1198
uptake, in vitro assessment of, 2278(le)
uptake and proliferative activity of human cancer cells, 414
uptake into normal bone marrow is markedly increased by recombinant G-CSF and GM-CSF, 1137(ab)
Food and Drug Administration (FDA)
approves new bone metastasis therapy, 30N(8)
NDA sought for cancer imaging radiolabeled peptide, 24N(1)
NRC regulations on departures from manufacturer's instructions, 523(le)
overhauls adverse event reporting system, 30N(10)
PET plan panned by physicians, 26N(4)
radiopharmaceuticals, 24N(4)
seeking advisors for medical devices committee, 32N(5)
versatile cancer imaging peptide nears approval, 32N(7)
Fracture
scintimetric evaluation of remodeling after, 1403
vertebral compression, in cancer patients, FDG PET evaluation of, 17(ab)

G

Gallbladder. *See also* Hepatobiliary tract
contraction, interaction in vivo between CCK and erythromycin in prairie dog model, 298(ab)
ejection fraction, nondiagnostic for sphincter of Oddi dysfunction in patients with intact gallbladder, 815(ab)
emptying, fatty meal superior to continuous sincalide infusion in normal healthy volunteers, 301(ab)
perforation, bile leak mimicking bowel activity and false-negative result in morphine-augmented cholescintigraphy, 131
with rim sign, prompt visualization of, 1169
Gallium-67
avid mediastinal mass following therapy for Hodgkin's disease, ^{201}Tl scintigraphy for assessment of, 1326
benign mediastinal and parahilar uptake of, in treated lymphoma, 1330

distribution in normal and hypotransferrinemic tumor-bearing mice, 2135
elevated uptake in rheumatoid lung patient, cellular basis for, 351(le)
gonadal uptake and localization in rodent model, 770(ab)
lung uptake, computer quantitation of, 1076(ab)
scintigraphy
early detection of lymphoma recurrence with, 2101
in tuberculous and nontuberculous infectious spondylitis, 853
skeletal scintigraphy in determining prognosis for children with stage IV neuroblastoma, 1082, 1087
successful imaging of North American pulmonary blastomycosis, 958
transferrin-dependent and independent uptake of, in transformed and untransformed cells, 1032(ab)
unsuspected complications of bacterial endocarditis imaged by, 955
Gallium-67-citrate
disseminated North American blastomycosis, 458
in liquid gastric emptying scintigraphy, 1619(le)
postradiotherapy, unilateral sialadenitis on, 953
^{99m}Tc citrate *vs.*, for imaging inflammatory lesions, 332(ab)
usefulness in patients with acute disseminated tuberculosis, and comparison with chest x-rays, 1918
Gallium-68
clinical PET, 1132
potential tracers for imaging heart with PET, 228
Gamma camera
dual detector, measurement of glomerular filtration rate using, 351(ab)
energy spectrum analysis for each section of image using radionuclide spectroscopy sytem for multi-isotope study, 865(ab)
^{131}I images, scatter correction in, 236(ab)
miniature, clinical, 448(ab)
planar Ho-166 imaging, 864(ab)
slat collimation for high sensitivity 2D and 3D emission imaging, 28(ab)
Gastric emptying
antral motility disturbance characterization, in diabetes, using scintigraphic technique, 576
characterization of pathophysiology in idiopathic dyspepsia using scintigraphy, 31(ab)
delayed, postprandial gastric motility in infants with gastroesophageal reflux and, 2120
erythromycin effects on, 582
^{67}Ga in liquid scintigraphy, 1619(le)
intravenous erythromycin effects on, following esophagogastrectomy, 32(ab)
after laparoscopic anterior seromyotomy and posterior truncal vagotomy in chronic duodenal ulcer, 30(ab)
liquids in prediction of abnormal solid phase, 33(ab)
rates established with dual isotope scintigraphy, corrected for tissue attenuation, scatter, and patient movement, 822(ab)
and small bowel transit, in portal hypertension, 443(ab)
solid
effect of soup on, 821(ab)
lag phase in, 1701
Gastroesophageal reflux
pediatric, scintigraphy *vs.* pH probe for quantification of, 1228
sequential ten-second acquisitions for detection, 658
Gastrointestinal tract
can liquids be used to predict abnormal solid phase gastric emptying?, 33(ab)
characterization of gastric emptying pathophysiology in idiopathic dyspepsia using scintigraphy, 31(ab)
effect of misoprostol on postprandial intestinal transit and motility in patients with intestinal dysmotility, 813(ab)
ileal duplication of stomach and duodenum, ^{99m}Tc pertechnetate scintigraphy in, 294
localization of gastroenteropancreatic tumors with ^{111}In somatostatin analogue, 156(ab)
scintigraphy *vs.* pH probe for quantification of pediatric gastroesophageal reflux, 1228
sequential ten-second acquisitions for detection of gastroesophageal reflux, 658
Gated blood pool imaging. *See also* Blood pool imaging
application and interpretation of principal component analysis of, 843(ab)
load independence of early diastolic filling parameters in anesthetized canine model, 1520
SPECT
first harmonic analysis provides refined assessment of site of initial activation of accessory pathways in patients with Wolff-Parkinson-White syndrome, 744(ab)
fully automatic identification of cardiac blood pool in, 891(ab)
quantitative, enhanced sensitivity for non-invasive assessment of coronary artery disease, 131(ab)
^{99m}Tc sestamibi *vs.* ^{201}Tl, inhomogeneity of bull's-eyes, 281
Gaucher's disease, ^{111}In leukocyte imaging, 818
Generators, isotope
clinical PET, 1132
eluate effects on labeling efficiency of ^{99m}Tc sestamibi kits, 730(ab)
^{68}Ga radiopharmaceutical that is retained in myocardium, 1127
improved W-188/Re-188 and ^{99}Mo/^{99m}Tc gel chemistry, 144(ab)
in vivo Dy-166/Ho-166, development for radionuclide radiotherapy, 1080(ab)
Genital tract, female rabbit, sperm cell dynamics after insemination monitored by radiolabeled spermatozoa, 1134
Glomerular filtration rate (GFR). *See also* Kidney
ambulatory renal monitor, 199
easy procedure for determination in children using ^{99m}Tc DTPA, one plasma sample and external counting with thyroid probe, 470(ab)
measurement in terms of extracellular fluid volume, 471(ab)
measurement using dual detector gamma camera and geometric mean and comparison with reference in vitro method, 351(ab)
Glucose
blood, influence of concentration on FDG uptake in cancer, PET study of, 1
cerebral metabolism response to GABA-A stimulation studied with PET in temporal lobe epilepsy, 78(ab)
changes in local utilization in awake rat during acute and chronic ethanol administration, 793
changes of metabolism and cell proliferation in treated osteosarcoma cells, 1035(ab)
concordantly increased GLUT 1 gene expression and FDG-uptake in human pancreatic carcinoma, 1044(ab)
consumption of intracranial meningioma in relation to histological grading, proliferation rate and cellular density, 1043(ab)
decreased left frontal metabolism is noted in young normal males, 874(ab)
heart and skeletal muscle disposal in type 2 diabetic patients as determined by PET, 2064
insulin and non-insulin mediated myocardial utilization during hyperglycemic clamp in type-1 diabetes evaluated with PET and FDG, 758(ab)
mapping of utilization in brain, improved method with fixed vascular volume, 950(ab)
myocardial metabolism, resting, maintenance in dysfunctional myocardium with ^{201}Tl redistribution, 171(ab)
paradoxical increase of human brain metabolism induced by GABA-A agonist, demonstrated by PET, 411(ab)
patterns of regional cerebral metabolism in unipolar and bipolar depressive disorders, 183(ab)
quantitative analysis of utilization by ^{18}F FDG PET in detecting myocardial viability, 3(ab)
regional cerebral metabolic rate for, modeling plasma activity curve for PET measurement of, 152(ab)
regional cerebral metabolism in Alzheimer's disease, effect of age of onset on, 7(ab)
regional cerebral metabolism in coma, vegetative and persistent vegetative state, 369(ab)
regional cerebral utilization with ^{18}F FDG and PET in heterogeneous tissues, 360
regional metabolic activity in Alzheimer's disease, quantitation of, after correction for effects of atrophy, 8(ab)
spectrum of regional cerebral consumption in choreatic disorders, 118(ab)
value of quantitative analysis of utilization in detection of myocardial viability by PET, 2068
Glycogen, accumulation in chronically hypoperfused myocardium with maintained FDG uptake, 5(ab)
Granulocytes
^{111}In
^{99m}Tc WBCs *vs.*, for examination of patients with inflammatory bowel disease, 1052
using Ficoll-Hypaque technique in diagnosis of synthetic vascular graft infection, 238(ab)
pulmonary, kinetics, 165(ab)
Graves' orbitopathy, orbital ^{111}In DTPA octreotide accumulation in, not based on blood-pool radioactivity, 158(ab)

H

Harris, C. Craig, Hevesy Nuclear Medicine Pioneer Award, 24N(5)

Head and neck cancer
advanced, FDG imaging after chemotherapy, 12
comparison of ^{18}F FDG and ^{11}C MET in, 1711
labeling of monoclonal antibodies with ^{186}Re using MAG3 chelate for radioimmunotherapy of, 1953
squamous, detection of lymph node metastases with MRI and FDG-PET in, 216(ab)
uptake of ^{18}F FDG and ^{11}C MET in, 77(ab)
Health care access
reimbursement, 19N(7), 28N(10)
U.S. efforts failing to improve, 30N(5)
Health care policy, 19N(7), 28N(10), 32N(11)
Heart. *See also* Cardiovascular system; Myocardium
absence of nonneuronal uptake of MIBG in denervated rabbit hearts, 176(ab)
application and interpretation of principal component analysis of gated images, 843(ab)
assessment of cardiotoxicity by ^{111}In antimyosin studies, bolus administration *vs.* continuous infusion of doxorubicin, 43(ab)
assessment of endothelial function with PET cold pressor test in patients with various degrees of atherosclerosis, 137(ab)
atherosclerosis imaging, 1321
^{99m}Tc labeled peptides for, 259(ab), 260(ab)
automated analysis program for evaluation of PET studies, 968
bacterial endocarditis, unsuspected complications imaged by ^{67}Ga scanning, 955
biodistribution and imaging of ^{99m}Tc native LDL and oxidized LDL, 261(ab)
biokinetics of ^{99m}Tc tetrofosmin, 1254
blood pool, fully automatic identification in gated SPECT images, 891(ab)
^{76}Br MBBG, PET radiotracer for mapping sympathetic nerves of, 1739
cardiac events within 12 months after non-ischemic non-invasive imaging test in patients with prior myocardial infarction, 295(ab)
^{11}C forskolin as ligand for visualization of adenylate cyclase-related second messenger system, 1944
characterization of reinjection ^{201}Tl image, 879
clinical decisions, 860
comparison of 6-^{18}F FNE and 6-^{18}F FDA and, 619
comparison of true and false neurotransmitters in, 491(ab)
comparison of uptake, oxidation, and lipid distribution of IHDA, pIPPA, and DMIPPA, 649
concordance of nutritive myocardial perfusion reserve and flow velocity reserve in conductance vessels, 717
detection of patient motion during tomographic myocardial perfusion imaging, 1341
detection of ventricular dysfunction and carditis in children with Kawasaki disease using equilibrium multigated blood pooling ventriculography and ^{99m}Tc HMPAO WBC heart scan, 1066(ab)
distribution of deoxyglucose and ^{99m}Tc glucarate in acutely ischemic myocardium, 1303
dobutamine ^{99m}Tc sestamibi SPECT and echocardiography, coronary angiography *vs.*, in coronary artery disease detection, 895
double labeled 6-FDA to assess factors responsible for kinetics of 6-[^{18}F]FDA in baboon, 310(ab)
early assessment of perfusion, function, viability and prognosis after first myocardial infarction, 335(ab)
early myocardial clearance kinetics of ^{99m}Tc teboroxime in differentiation of normal and flow-restricted canine myocardium at rest, 630
effect of cardiopulmonary bypass surgery on pulmonary vascular permeability, assessment by transvascular transport of ^{67}Ga, 1077(ab)
effect of motion on SPECT imaging, 1355
evaluation of ^{11}C EPI in isolated working rat heart, 174(ab)
evaluation of pulmonary systemic blood flow using ECG gated acquisition, 1441
failure, effects of drug therapy on oxygen consumption and cardiac efficiency determined using ^{11}C acetate PET, 427(ab)
^{18}F PFBG as potential tracer, 312(ab)
gender differences for long term event-free survival in vascular surgery patients, analysis of clinical and dipyridamole thallium scan variables, 736(ab)
glycogen accumulation in chronically hypoperfused myocardium with maintained FDG uptake, 5(ab)
human pathologic correlation with PET in ischemic and nonischemic cardiomyopathy, 39
hypertrophic myocardium, approaches to identify and characterize, 1013
^{131}I IVM as marker for myocardial hypoxia, 918
immediate ^{201}Tl reinjection following stress imaging, in myocardial viability detection, 737
impact of antianginal medications
peak heart rate, and level of stress on prognostic value of normal exercise ^{201}Tl studies, 337(ab)
peak heart rate and stress level on prognostic value of normal exercise myocardial perfusion imaging study, 1467
infections, detection with radiolabeled leukocytes, 868(le)
left ventricular mass and infarct size estimation from ^{13}N ammonia PET based on pathological examination of explanted hearts, 826
left ventricular peak power during exercise, noninvasive approach for assessment of contractile reserve, 1877
left ventricular systolic and diastolic function measurements using ambulatory radionuclide monitor, effects of different time averaging on accuracy of, 1602
load independence of early diastolic filling parameters in anesthetized canine model, 1520
mechanical overload hypertrophy and failure, dynamic analysis of ^{123}I MIBG scintigrams in, 589
MIBG potential as tracer for monitoring doxorubicin cardiomyopathy, 1282
MIBG uptake by norepinephrine, dopamine and serotonin transporters, 1140
MIBG uptake in patients with aortic stenosis, 1392(le)
motion detection and correction in SPECT, new methodological approach to, 358(ab)
myocardial extraction of ^{99m}Tc MBI in isolated rabbit heart, 927
myocardial kinetics of ^{11}C HED, retention mechanisms and effects of norepinephrine, 1287
myocardial perfusion and necrosis estimates with ^{38}K and PET in experimental myocardial infarction, 49(ab)
myocardial substrate utilization and left ventricular function in Adriamycin cardiomyopathy, 1529
negative ^{201}Tl SPECT and positive Rb-82 PET myocardial perfusion imaging, 400
noninvasive diagnosis of transplant arteriopathy with dipyridamole thallium scintigraphy, 2049
parametric images for quantitative measurements of regional myocardial blood flow in humans, 862
PET
^{13}N ammonia, automated region definition for, 336
potential ^{68}Ga tracers, 228
procedure for patient repositioning and compensation for misalignment between transmission and emission data in, 137
SNM Cardiovascular Council position paper on clinical use of, 1385
SNM position paper, 25N(4)
Tc-94m teboroxime, 1058
PET attenuation scans, three-dimensional registration of, 311
phantom evaluation of simultaneously acquired dual-isotope rest ^{201}Tl/stress ^{99m}Tc SPECT images, 1998
phantom study of breast tissue attenuation in myocardial imaging, 992
prognostic importance of transient ventricular dilation by dipyridamole, 735(ab)
prognostic value of normal ^{99m}Tc sestamibi myocardial perfusion imaging, 211(ab)
proselytism, retroversion and fiscal nihilism in nuclear cardiology, 1823
quantitative perfusion imaging assessing acquired discrete peripheral pulmonary artery stenosis, 1995
rapid back to back adenosine stress/rest ^{99m}Tc teboroxime myocardial perfusion SPECT using triple-detector camera, 1485
reverse redistribution on resting ^{201}Tl imaging in coronary artery disease, relation to coronary anatomy and ventricular function, 725(ab)
reversible ^{201}Tl perfusion defects in right bundle branch block and normal coronary angiogram, 1218(le)
ribose infusion reduces MIBI but not ^{201}Tl extraction in isolated rabbit heart, 177(ab)
risk stratification prior to vascular surgery, 293(ab)
serial course of left ventricular function, perfusion and fatty acid uptake in cardiomyopathic hamster, 1309
simultaneous ^{201}Tl/^{99m}Tc SPECT, experimental verification of energy weighted dual isotope technique for, 108(ab)
simultaneous transmission-emission ^{201}Tl imaging, 280(ab)
SPECT
correction for attenuation and geometric point response distortions in, 111(ab)
importance of attenuation compensation and its implementation in, 110(ab)

^{99m}Tc, non-uniform compensation using acquired transmission data, 112(ab)
sympathetic neurons, ^{11}C EPI *vs.* ^{11}C HED for evaluation of, 42(ab)
synthesis and evaluation of ^{11}C CGP 20712A, a beta 1-selective adrenoceptor ligand for imaging of, 188(ab)
synthesis and initial evaluation of *o*-^{11}C palmitic acid as imaging agent, 311(ab)
synthetic peptide immunogens for development of cardiac myosin light chain-1 specific radioimmunoassay, 2144
systolic pressure alteration effects on radionuclide measurements of left ventricular filling dynamics, 747
^{99m}Tc in first-pass angiographic studies of left ventricular function, 394
thallium reverse redistribution in perspective, 1692
^{201}Tl reinjection and improvement of left ventricular function following revascularization, 172(ab)
transplantation
evaluation of allograft vasculopathy by ^{99m}Tc teboroxime washout, 734(ab)
PET in patient evaluation before and after, 834
uptake mechanism of neutral myocardial imaging agent ^{99m}Tc N-NOET, 65(ab)
what should we expect from cardiac PET?, 978
Helicobacter pylori, radiation dose estimates for C-14 urea breath test, 821
Hemangioendothelioma, bone, scintigraphic "doughnut sign" on skeletal imaging, 297
Hemangioma, hepatic
cavernous, 2278(le)
metastatic malignancy masquerading as, on labeled RBC scintigraphy, 1172
^{99m}Tc RBC SPECT, 375
Hemoglobin, liposome encapsulated, use of ^{99m}Tc liposome labeling procedure to monitor circulation properties in rat shock model, 542(ab)
Hepatobiliary tract. *See also* Gallbladder; Liver
cholescintigraphy in diagnosis of acute cholecystitis, morphine augmentation is superior to delayed imaging, 1866
efficacy of quantitative cholescintigraphy in diagnosis of sphincter of Oddi dysfunction, 302(ab)
factors altering excretion of ^{99m}Tc MAG3, 515(ab)
hot spot scan in focal nodular hyperplasia, 2105
imaging pattern in patients suspected of biliary leak, 303(ab)
prompt visualization of gallbladder with rim sign, 1169
scintigraphy
cavernous hepatic hemangioma, 849
CCK administration before, efficacy in patients with systemic illnesses, 299(ab)
in evaluation of solitary solid liver masses, 697
morphine-augmented
delayed imaging *vs.*, in suspected acute cholecystitis, 506
false-negative, bile leak from gallbladder perforation mimicking bowel activity and, 131
pediatric, hepatic extraction fraction determination by deconvolution analysis, 214
quantitative, in children with cystic fibrosis and liver disease, 1060(ab)
Hevesy Nuclear Medicine Pioneer Award, C. Craig Harris, 24N(5)
Hip, MRI and SPECT bone scans in renal allograft recipients, 381
Hippuric acid, transport disturbance, renovascular hypertension, 48
HIV. *See* Human immunodeficiency virus
Hodgkin's disease, therapy for, ^{201}Tl scintigraphy for assessment of ^{67}Ga avid mediastinal mass following, 1326
Holmium-166 DOTMP, new agent for bone marrow ablation, 125(ab)
Human immunodeficiency virus (HIV). *See also* Acquired immunodeficiency syndrome (AIDS)
encephalopathy and depression, SPECT in, 185(ab)
focal infection in, ^{111}In polyclonal human IgG in identification of, 1621
radioimmunodetection of Pneumocystis carinii pneumonia in, 239(ab)
Hydrogen-3 acetate, cerebral metabolism of, dual tracer autoradiography of, 936(ab)
Hydrogen-3 AF-DX 116, selective M2 muscarinic receptor antagonist, rat in vivo binding and pharmacokinetic profile of, 1130(ab)
Hydroxyapatite, ocular implants
determination of vascularization and vascular ingrowth rate by ^{99m}Tc MDP bone scan, 709(ab)
^{99m}Tc MDP evaluation, 467
Hyperlipidemia, family history of coronary artery disease and, evaluation of coronary flow reserve in asymptomatic males with, 760(ab)
Hypertension
pulmonary
emphysema *vs.*, pulmonary perfusion distribution following single lung transplantation in, 167(ab)
perfusion lung scintigraphic patterns of histologic subtypes, 1071(ab)
role of ventilation-perfusion lung scanning in diagnostic evaluation of patients with, 1075(ab)
renovascular
diagnosis with captopril renal scintigraphy in patient with solitary kidney, 1166
dynamic renal imaging with ^{99m}Tc sestamibi in assessment of, 552(ab)
MAG3/enalaprilat protocol for diagnosis in single visit, 1154(ab)
perfusion abnormality in, 48
Hyperthermia
effect on uptake of monoclonal antibody in small cell lung cancer xenografts, 1012(ab)
transurethral treatment of benign prostate hypertrophy, Xe-prostate clearance study after, 553(ab)
Hyperthyroidism, quick diagnosis with semiquantitative 30-minute ^{99m}Tc MIBI thyroid uptake, 71
Hyperventilation, effect on cerebral circulation in moyamoya disease, 246(ab)
Hypoxia
effect on accumulation of ^{99m}Tc glucarate and ^{99m}Tc gluconate by Chinese hamster ovary cells, 242
effects on cultured human tumor cell uptake of thymidine, L-methionine and FDG, 288(ab)
in heart, novel ^{99m}Tc labeled nitroheterocycle capable of identification of, 722(ab)
imaging in human tumors with ^{18}F FMISO, 76(ab)
myocardial
characterization of ^{131}I IVM as marker for, 918
^{131}I HDA metabolism in, 51(ab)
myocardial kinetics of putative hypoxic tissue marker after regional ischemia and reperfusion, 53(ab)
PDT-induced, in Dunning prostate tumors, ^{123}I IAZA, 405
synthesis of 4-substituted misonidazole derivatives for imaging, 314(ab)
^{99m}Tc nitroimidazole complexes localizing, separation of isomers of, 64(ab)
tumor, and tumor perfusion, 885

I

ICP. *See* Institute for Clinical PET
IHDA. *See* 17-Iodoheptadecanoic acid
Immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
Immunoconjugates
linker-, ^{111}I and ^{90}Y labeled, 938
radiolabeled, synthesis, metal chelate stability studies, and enzyme digestion of peptide-linked DOTA derivative and its corresponding, 104(ab)
Immunoscintigraphy
antibodies in, 2264
with anti-PMN monoclonal antibody for diagnosis of septic loosening of hip prosthesis, 333(ab)
of bone marrow
in staging of low, intermediate, and high grade non-Hodgkin's lymphoma, 1000(ab)
usefulness using ^{99m}Tc antigranulocyte monoclonal antibody in patients with suspected bone metastases, 1002(ab)
of colorectal cancer, with ^{99m}Tc IgG3 labeled whole human monoclonal antibody 88BV59, 1007(ab)
of infection, ^{99m}Tc antigranulocyte antibody *fragment*, 240(ab)
in management of ovarian cancer, clinical utility of, 545(suppl)
in prostate cancer, current applications of, 549(suppl)
in surgical management of colorectal cancer, 541(suppl)
^{99m}Tc anti-AFP Fab1, in evaluation of treated germ cell tumors, 1001(ab)
Impotence, penile blood flow, tumescence, 523(le)
Indium-111
biotin derivatives labeled with, influence of endogenous biotin on biodistribution in mice, 1091(ab)
chelated derivatives of ANP for in vivo imaging of receptors, 226(ab)
gonadal uptake and localization in rodent model, 770(ab)
immunoscintigraphy
clinical utility in ovarian cancer management, 545(suppl)
current applications in prostate cancer, 549(suppl)
in surgical management of colorectal cancer, 541(suppl)
Indium-111-antimyosin, cardiotoxicity assessment by
bolus administration *vs.* continuous infusion of doxorubicin, 43(ab)
^{123}I MIBG *vs.*, 44(ab)

Indium-111-antimyosin Fab, identification and characterization of hypertrophic myocardium, 1013
Indium-111-antisense probes, noninvasive imaging of c-myc oncogene mRNA with, in mammary tumor in mouse, 1039(ab)
Indium-111-CYT-103, repeated administration in colorectal carcinoma patients, interim report of safety, efficacy and HAMA development, 1006(ab)
Indium-111-DTPA
bispecific monoclonal antibody-mediated targeting dimer to primary colorectal tumors, pharmacokinetics, biodistribution, scintigraphy and immune response, 1662
effect of degree of conjugation per MoAB on metabolism and clearance of its ^{111}In chelate in mice, 228(ab)
receptor targeted proteins, intracellular metabolism of, 1728
Indium-111-DTPAAHON, labeling neutrophils by hybridization with, 841(ab)
Indium-111-DTPA IgG
lung imaging in patients with pulmonary infections, 1078(ab)
phase III safety and efficacy study in patients with suspected inflammation or infection, 831(ab)
Indium-111-DTPA octreotide
orbital accumulation in Graves' orbitopathy not based on blood-pool radioactivity, 158(ab)
somatostatin receptor imaging in pituitary using, 159(ab)
Indium-111-granulocytes
compared with ^{99m}Tc WBCs for examination of patients with inflammatory bowel disease, 1052
using Ficoll-Hypaque technique in diagnosis of synthetic vascular graft infection, 238(ab)
Indium-111-leukocytes
cardiovascular infection detection with, 868(le)
in Gaucher's disease, 818
scintigraphy
in cutaneous sarcoidosis, 812
in detection of unsuspected pseudomembranous colitis in critical care patients, 35(ab)
Indium-111-linker-immunoconjugates, evaluation in nude mice and dogs, 938
Indium-111-lymphocytes, scintigraphy, direct assessment of efficacy of anti-rejection therapy using, 755(ab)
Indium-111-monoclonal antibody
A7, novel chemical linker with hydrocarbon spacer for, 102(ab)
BrE-3, radioimmunolocalization of metastatic breast carcinoma using, 1067
C110, radioimmunoscintigraphy in colorectal carcinoma, 1656
can length of hydrocarbon bond in chemical spacer alter pharmacokinetics of, 103(ab)
effect of transferrin serum levels on deposition in liver and axial skeleton, 1143(ab)
to eosinophil peroxidase, radioimmunodetection of Hodgkin's disease and non-Hodgkin's lymphomas with, 1246
spatial localization of metastatic processes using, CT and SPECT image registration and fusion for, 562(suppl)
Indium-111-octreotide
scintigraphy
for detection of paragangliomas, 873
in patients with paraganglioma or medullary thyroid carcinoma, 555(ab)
SPECT, in patients with brain and pituitary tumors, 140(ab)
Indium-111-oxine, biodistribution of labeled platelets in dog injected with anti-thrombocytic monoclonal antibody, 476(ab)
Indium-111-pentetreotide, biodistribution in patients with carcinoid tumors, 157(ab)
Indium-111-platelets
autologous, sequestration, correlation with splenectomy in idiopathic thrombocytopenic purpura, 182
combined with B-mode ultrasonography, in functional and anatomical evaluation of carotid atherothrombosis, 828(ab)
correlation of splenic sequestration studies and clinical outcomes in cancer patients, 477(ab)
Indium-111-polyclonal IgG
evaluation of accuracy for detecting infection, 241(ab)
identifying focal infection in HIV, 1621
to quantitate atherosclerosis in Watanabe heritable hyperlipidemic rabbits with scintigraphy, effect of age and treatment with antioxidants or ethinylestradiol, 1316
scintigraphy, in fever of unknown origin, 242(ab)
Indium-111-somatostatin analogue, localization of gastroenteropancreatic tumors with, 156(ab)
Indium-111-transferrin, in imaging and quantitation of intestinal protein loss in patients with stomach cancer, 392(ab)
Indium-114m
effect of protein and pH on exchange from IgG and HSA to lactoferrin, 1138(ab)
mutagenic effects in rat, 531(ab)
Infants. *See* Pediatric patients
Infarct
myocardial. *See* Myocardial infarction
posterior cerebral artery, and related visual field defects, 1009
pulmonary, ventilation-perfusion/chest x-ray match less likely to represent pulmonary embolism if Q is "decreased" rather than "absent," 58(ab)
rib, pulmonary infiltrates and, simultaneous occurrence in sickle cell disease with acute chest syndrome, 614
Infection
bacterial
localization of ^{111}In IgG, ^{99m}Tc IgG and ^{111}In WBC at sites of, 1975
^{99m}Tc HYNIC derivatized chemotactic peptide analogs for imaging focal sites, 836(ab), 196
bone scintigraphy, 2236
cardiovascular, detection with radiolabeled leukocytes, 868(le)
dissociation of indium from IgG in foci of, 417(ab)
early detection of avascular necrosis, animal model of, 710(ab)
evaluation of accuracy of ^{111}In polyclonal IgG for detection of, 241(ab)
focal
biodistribution and imaging studies of ^{99m}Tc labeled liposomes in rats with, 2160
comparison of ^{99m}Tc SHNH labeled IgG, ^{99m}Tc HIG Technescan, and ^{111}In Macroscint DTPA-IgG in rat model of, 839(ab)
fungal, hypermetabolic cerebral, with PET FDG studies, 143(ab)
imaging inflammation and vascular activation with labeled monoclonal antibody against E-selectin, 243(ab)
imaging of focal sites of inflammation in non-human primates with ^{99m}Tc labeled human polyclonal IgG, 832(ab)
imaging of inflammation/abscess with IMMU-MN3, 827(ab)
of joint replacements, radionuclide diagnosis of, 331(ab)
labeling neutrophils by hybridization with ^{111}In DTPAAHON, 841(ab)
new class of radiopharmaceutical for imaging, ^{99m}Tc "infection," 474(ab)
nuclear imaging of acute inflammatory lesions with recombinant human interleukin-8, 416(ab)
pulmonary, ^{111}In DTPA IgG lung imaging in, 1078(ab)
soft tissue, and osteomyelitis, new antigranulocyte Fab' fragment for diagnosis of, 830(ab)
suspected inflammation or, phase III safety and efficacy study of ^{111}In DTPA IgG in patients with, 831(ab)
synthetic vascular graft, ^{111}In labeled granulocytes using Ficoll-Hypaque technique in diagnosis of, 238(ab)
^{99m}Tc labeled chemotactic peptides for imaging, 833(ab)
tuberculous and nontuberculous spondylitis, ^{67}Ga scintigraphy in, 853
viral encephalitis, detection in children by ^{99m}Tc HMPAI brain SPECT, 984(ab)
Infertility. *See* Fertility
Inflammatory bowel disease, prospective comparative study of ^{99m}Tc WBCs and ^{111}In granulocytes for examination of patients with, 1052
In memoriam, William H. Oldendorf, 871
Insemination, sperm cell dynamics in female rabbit genital tract after, monitored by radiolabeled spermatozoa, 1134
Institute for Clinical PET (ICP), management merger, 32N(7)
Insulin
effect on FDG-PET imaging in patients with lymphoma, 1049(ab)
influence of high and low levels on planar ^{18}F FDG imaging during euglycemic clamping, 757(ab)
and non-insulin mediated myocardial glucose utilization during hyperglycemic clamp in type-1 diabetes evaluated with PET and FDG, 758(ab)
Intestine, small, transit, erythromycin effects on, 582
Iodine-123, high-activity, for diagnostic evaluation of patients with thyroid cancer, 161(ab)
Iodine-123-BMIPP, identification and characterization of hypertrophic myocardium, 1013
Iodine-123-BZA, phase II scintigraphic clinical trial of malignant melanoma and metastases with, 1260
Iodine-123 CEA monoclonal antibody fragments, colorectal cancer imaging, 61
Iodine-123-doxycycline, detection of metalloproteinases in arthritic rat tissues by imaging with, 1087(ab)

Iodine-123 fatty acids
myocardial uptake of branched analogue as marker of fatty acid metabolism, comparison with kinetics of ^{11}C palmitate, 726(ab)
uptake, oxidation, and lipid distribution in normal canine myocardium, 649
Iodine-123-HDA, assessment of myocardial viability early during post-ischemic reperfusion in pigs with, 179(ab)
Iodine-123-IAZA
PDT-induced hypoxia in Dunning prostate tumors, 405
tumor hypoxia and tumor perfusion, 885
Iodine-123-IBF
biodistribution and dosimetry of, potent radioligand for imaging D2 dopamine receptor, 1910
displacement of equilibrium binding by D-amphetamine to measure in vivo dopamine release, 186(ab)
first experience with, comparison with ^{123}I IBZM, 934(ab)
Iodine-123-IBHPE, I-125 IVME2 *vs.*, distribution in immature female rat, 272
Iodine-123-IBZM
in metastatic melanoma, 1028(ab)
new D2 ligand ^{123}I IBF compared with, 934(ab)
Iodine-123-IBZM dopamine D2 receptor
estimation of binding potential in striatum with SPECT, 2076
striatal imaging in schizophrenic patients treated with typical or atypical neuroleptics, 304(ab)
and ^{99m}Tc HMPAO brain perfusion SPECT in evaluation of patients with and at risk for Huntington's disease, 1274
Iodine-123-ILIS, dopaminergic D2 receptor SPECT imaging in Rett syndrome, increase of specific binding in striatum, 1717
Iodine-123-IMP
cerebral blood flow and partition coefficient, graphic plot analysis, 498
functional mapping of flow and back-diffusion rate in human brain, 839
in lobar primary pulmonary lymphoma, 1980
SPECT, new graphic method for estimation of distribution volume in differential diagnosis of PSP and Parkinson's disease, 119(ab)
SPECT split dose method, quantitative assessment of cerebrovascular reserve using, 245(ab)
transrectally administered, temporal changes of biodistribution in chronic liver disease, 442(ab)
uptake and localization, SPECT and planar brain imaging in crack abuse, 899
Iodine-123-Iomazenil
formation of ^{123}I 1-iodobutane in labeling by iododestannylation, 356(ab)
SPECT, in presurgical work-up of patients with medically intractable focal epilepsy, 80(ab)
SPECT brain imaging demonstrates significant benzodiazepine receptor reserve in human and non-human primate brain, 408(ab)
Iodine-123-IUDR, uptake and retention as measure of tumor growth, 1152
Iodine-123-IVM, nuclear medicine viability, 924
Iodine-123-MIBG
absence of nonneuronal uptake in denervated rabbit hearts, 176(ab)
cardiac uptake in patients with aortic stenosis, 1392(le)
dynamic analysis of scintigrams in cardiac mechanical overload hypertrophy and failure, 589
factors limiting precision and accuracy, 793(ab)
identification and characterization of hypertrophic myocardium, 1013
^{111}In antimyosin *vs.*, to assess cardiotoxicity during doxorubicin administration, 44(ab)
mild to moderate degree of uptake in adrenals must be carefully interpreted for diagnosis of pheochromocytoma, 39(ab)
myocardial SPECT, cardiomyopathy outcome prediction using, 46(ab)
myocardial uptake in left ventricular hypertrophy secondary to valvular aortic stenosis, 57
pheochromocytoma evaluation with, improved by SPECT imaging, 40(ab)
scintigraphy, as index of severity in primary hypertrophic cardiomyopathy, 45(ab)
SPECT, in children, 1062(ab)
Iodine-123-TISCH, dosimetry, 208
Iodine-123-Tyr-3-octreotide, scintigraphy, role in staging of small-cell lung cancer, 1397
Iodine-125
brain implants, verification with dedicated SPECT camera, 892(ab)
extracorporeal immunoadsorption, tumor-to-normal tissue ratio, 448
Iodine-125-D(L) norfenfluramine, 1100(ab)
Iodine-125-ICAR, M1 selective muscarinic antagonist, 1101(ab)
Iodine-125-2'-IDZ, as potential imaging agent for SPECT investigations of benzodiazepine receptors, 932
Iodine-125-IgG, mouse, modification of charge following radioiodination with various oxidants, 1145(ab)
Iodine-125-Iomazenil, ^{99m}Tc HMPAO and, in double tracer autoradiography in experimental brain ischemia, 935(ab)
Iodine-125-IQNP, new selective muscarinic antagonist, whole body distribution of, 937(ab)
Iodine-125-IUDR
diagnostic and therapeutic implications of uptake in exfoliated cells obtained from patients with bladder cancer, 1038(ab)
in radiotherapy of solid brain tumors in rats, 1123(ab)
tumor targeting in vivo and metabolic fate of, following intratumoral injection in patients with colorectal cancer, 1175
Iodine-125-IVME2, ^{123}I IBHPE *vs.*, distribution in immature female rat, 272
Iodine-125-MIBG
potential as tracer for monitoring doxorubicin cardiomyopathy, 1282
uptake, by norepinephrine, dopamine and serotonin transporters, 1140
Iodine-125-PAB, malignant melanoma imaging agent, 2169
Iodine-125-SAP, scintigraphy, amyloidosis regression demonstrated by, 473(ab)
Iodine-131
absorbed dose calculations in Haversian canals, 1361
bronchogenic carcinoma mimicking metastatic thyroid carcinoma, 809
characteristics, 1219(le)
dose selection and absorbed dose profiles in treatment of diffuse toxic goiters, 387
efficacy for thyroid ablation, 1927
gamma camera images, scatter correction in, 236(ab)
immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
long-term results from two schedules of treatment for toxic multinodular goiter, 795(ab)
no harm to infants from mothers' therapy, 32N(7)
optimization of therapy of thyrotoxicosis, 1638
radiation absorbed doses, correlation to nodal metastases, 524(le)
scintigraphy, paradoxical changes in findings in advanced follicular thyroid cancer, 1574
therapy, in differentiated thyroid carcinoma in childhood, 1061(ab)
therapy for thyroid cancer, detection of chromosomal aberration induced by, 784(ab)
vitamin C as radioprotector against, 637
Iodine-131-CC-49, phase II trial in refractory colon cancer, 205(ab)
Iodine-131-HDA, metabolism in normal, ischemic, and hypoxic canine myocardium, 51(ab)
Iodine-131-hippurate, renovascular hypertension, 48
Iodine-131-IPPA, potential for clinical evaluation of pancreatic insufficiency by urine analysis, 946
Iodine-131-IQNP, new selective muscarinic antagonist, whole body distribution of, 937(ab)
Iodine-131-IUDR
assessment of brain tumor proliferative activity using, 139(ab)
uptake and retention as measure of tumor growth, 1152
Iodine-131-IVM, characterization as marker for myocardial hypoxia, 918
Iodine-131-MIBG
imaging of pheochromocytomas, correlation with CT, MR and surgery, 791(ab)
lesion detection in neuroblastoma, 865(le)
pheochromocytoma localization, 180
scintigraphy, preoperative and postoperative evaluation of paragangliomas, 173
trace element enhancement of therapy exchange yields, 148(ab)
Iodine-131-monoclonal antibodies, anti-small cell lung cancer, radiotherapy in mice with, 1013(ab)
Iodine-131-monoclonal antibody
M195, radioimmunotherapy trials in patients with myeloid leukemias, 207(ab)
MN-14F9(ab)$_2$, phase I radioimmunotherapy with, 206(ab)
Iodine-131- Na, low *vs.* high dose therapy in thyrotoxicosis, 796(ab)
Iodine-131-sodium iodide, therapeutic administrations of, radiation dose to upper spine from, 695
Iodine-131-thyroxine, circulating, in thyroid cancers, 36(ab)
17-Iodoheptadecanoic acid (IHDA), uptake, oxidation, and lipid distribution *vs.* pIPPA and DMIPPA in normal canine myocardium, 649
Iodo-polylysine, biotinylated, for pretargeted radiation delivery, 1147
Iron-59, transferrin-dependent and independent uptake of, in transformed and untransformed cells, 1032(ab)
Isoflurane, changes in ^{99m}Tc RBC distribution in ferret induced by, 829(ab)

Isotretinoin, enthesopathy of patellar tendon insertion, 455

J

Jay, Michael, Berson-Yalow Award, 30N(7)
Joint
bone SPECT in recent meniscal tears, 713(ab)
rheumatic diseases, imaging with ^{99m}Tc labeled OKT3, 714(ab)
uptake of Tc-99 anti-rat-CD4 monoclonal antibody, in rat adjuvant arthritis, 92
Jones, Alan, Paul C. Aebersold Award, 26N(5)
Journal of Nuclear Medicine (JNM)
appraisal of primacy claim policy, 1616(le)
new editor, 25N(4), 29N(4)
34th year of publishing, 38N(6)

K

Kawasaki disease, long-term follow up of myocardial perfusion abnormalities in, 213(ab)
Kidney
acute tubular necrosis, radiolabeled lysozyme as potential imaging agent in, 187(ab)
ambulatory renal monitor, 2276(le)
captopril administration effects on scintigraphic parameters, 517(ab)
clinical evaluation of new renal tracer ^{99m}Tc LLEC, in transplanted patients, 514(ab)
clinical value of triple head SPECT imaging with ^{99m}Tc DMSA as initial diagnostic tool in adult women with recurrent acute pyelonephritis, 551(ab)
cortical blood flow, comparison of ^{13}N ammonia and ^{15}O water for quantification with PET, 195(ab)
determination of plasma flow using ^{99m}Tc MAG3, 1167(ab)
diuretic renography, 1029(le)
dynamic imaging with ^{99m}Tc sestamibi in hypertension patients, potential for assessment of renovascular disorders, 552(ab)
estimation of quantitative images using planar scintigraphy, 852(ab)
focal renal parenchymal abnormalities on MAG3 high resolution computer enhanced imaging and their significance, 549(ab)
improved formulas for estimation of renal depth in adults, 1766
mapping of local blood flow with PET and ^{15}O water, 196(ab)
measurement of GFR using dual detector gamma camera and geometric mean and comparison with reference in vitro method, 351(ab)
normalized clearance-to-uptake slope ratio, method to minimize false-positive diuretic renograms, 762
optimum sample times for single-injection, multisample renal clearance methods, 1761
perfusion abnormality in renovascular hypertension, 48
quantitation of parenchymal retention of ^{99m}Tc MAG3 in renal transplants, 1156(ab)
quantitative evaluation of blood flow in renovascular hypertension by ^{13}N ammonia and dynamic PET, 1166(ab)
quantitative measurement of blood flow and oxidative metabolism with ^{11}C acetate PET, 347(ab)
rapid measurement of total and regional blood flow with PET and ^{15}O water in patients with different degrees of renal failure, 349(ab)
real-time monitoring, ambulatory, 199
reduced uptake of ^{99m}Tc labeled Fab' fragments in animal model using cleavable chelator, 1147(ab)
renal output efficiency, validation as objective quantitative parameter in evaluation of upper urinary tract obstruction, 845
reproducibility of exercise renography results, 554(ab)
scars, ^{99m}Tc DMSA SPET in looking for, 550(ab)
scintigraphy, in acute scleroderma, 1163
solitary, diagnosis of renovascular hypertension with captopril renal scintigraphy in patient with, 1166
SPECT imaging with ^{99m}Tc DMSA for detection of scars in children with vesicoureteric reflux, 198(ab)
^{99m}Tc DTPA renal uptake-plasma volume product, as quantitative estimation of glomerular filtration rate, 1390(le)
transplantation
avascular necrosis in MRI and SPECT bone scans, 381
carcinoma in transplanted kidney detected with MAG3 scintigraphy, 2185
tubulointerstitial disease, poor ^{99m}Tc DMSA renal uptake and, 354(le)
uptake of TC-99m DTPA, quantification using planar scintigraphy, 1184
uptake of ^{99m}Tc DTPA, ^{99m}Tc DMSA *vs.*, 1217(le)
validation of blood flow quantification by ^{13}N ammonia and dynamic PET in hypertensive patients, 1164(ab)
Kinetic analysis
in canine myocardium, surface barrier β detector for measurement, 882(ab)
of ^{11}C diprenorphine in patients with absence epilepsy with and without provocation of seizures, 224(ab)
cellular, of FDG uptake by tumor tissue components in vivo studied by microautoradiography, 1136(ab)
clinical evaluation of model for quantification of liver function with ^{99m}Tc PMT and dynamic scintigraphy, 810(ab)
comparison with equilibrium SPECT measurements of benzodiazepine receptor binding potential in human subjects, 994(ab)
of ^{11}C PYRIL metabolites in plasma and brain, 947(ab)
of intracellular hybridization of c-myc mRNA oncogene with ^{111}In ASDON probes in leukemic cells, 1051(ab)
myocardial ^{11}C acetate, by simultaneously fitting data from multiple ROIs, 193(ab)
^{13}N ammonia, for quantification of myocardial blood flow, using PET, validation of, 83
new approach to estimate radiation dosimetry of flow-based radiotracers, 762(ab)
new estimation method accounting for PET accumulated counts of blood-time activity curves, 154(ab)
of pulmonary granulocytes, 165(ab)
putative hypoxic tissue marker after regional ischemia and reperfusion, 53(ab)
quantification by, unified approach to, 706
of relationship between cerebral metabolism and lactate concentration, 956(ab)
Krypton-81m
controlled delivery of boli in normal subjects, results and implications of, 1859
inhaled in lung imaging, radiation absorbed dose estimates from, 1382
underestimation of segmental defect size in lung scanning, 370
Kuranz, John, people in nuclear medicine, 29N(6)

L

LAMPF. *See* Los Alamos Meson Physics Facility
Laparoscopy, anterior seromyotomy and posterior truncal vagotomy, in chronic duodenal ulcer, gastric emptying after, 30(ab)
Leukocytes. *See also* White blood cells
^{111}In
cardiovascular infection detection with, 868(le)
in Gaucher's disease, 818
scintigraphy, in cutaneous sarcoidosis, 812
^{99m}Tc, ^{111}In granulocytes *vs.*, for examination of patients with inflammatory bowel disease, 1052
^{99m}Tc HMPAO, clinical experience in detection of inflammatory and infectious diseases, 837(ab)
Ligands
biological properties of, temporal lobe findings in SPECT studies of patients with mood disorders may be influenced by, 184(ab)
^{11}C CGP 20712A, synthesis and evaluation of, 188(ab)
^{11}C-labeled phorbol esters, protein kinase C imaging, 431
^{11}C MQNB, quantification of myocardial muscarinic receptors, 981
D2, ^{123}I IBF, comparison with ^{123}I IBZM, 934(ab)
D3, for SPECT imaging, 529
factors underlying D-amphetamine induced displacement of dopamine D2 radioligands in rhesus monkeys, 526(ab)
5-HT2 receptor specific, ^{18}F MDL11939, 20(ab)
iodinated tetralins as potential sigma ligands for SPECT imaging, 353(ab)
novel, for mapping central cholinergic innervation, 357(ab)
novel nitrogen heterocycle based N3S, preparation and unexpected labelling properties of, 539(ab)
N2S2 and N2SO, novel ^{99m}Tc complexes based on, 538(ab)
PET, for serotonin uptake sites, synthesis and biological evaluation of, 19(ab)
potential, for mapping dopamine reuptake sites by SPECT, 1094(ab)
potential for SPECT study of brain MAO, 1098(ab)
potential 5-HT$_{1a}$, 354(ab)
potentially useful M3-selective cholinoceptor for PET imaging, 1120(ab)
serotonin reuptake, 90(ab)
tripodal *tris*(salicylaldimine), functionalized, Ga complexes, 228
vesamicol receptor, novel, molecular decomposition-reconstitution approach to, 21(ab)
Linear accelerator, "Star Wars," put to medical use, 30N(8)
Lipoproteins, biodistribution and imaging of ^{99m}Tc native LDL and oxidized LDL, 261(ab)

Liver. *See also* Hepatobiliary tract
alcoholic cirrhosis, prognostic value of aminopyrine breath test *vs.* Child-Turcotte-Pugh score, 809(ab)
cavernous hepatic hemangioma, 849, 2278(le)
comparison of hepatic metabolism of 16α-[^{18}F]FES and 16β-[^{18}F] FMOX utilizing isolated hepatocytes from different species, 189(ab)
comparison of methods for identifying early methotrexate-induced hepatotoxicity in patients with rheumatoid arthritis, 1905
effective portal venous flow evaluation using echo-Doppler flowmetry combined with per jejunal portal scintigraphy in chronic disease of, 1103
evaluation of experimental tumors using ^{18}F FDG PET, 2124
handling of radiopharmaceuticals, usefulness of in vitro model, 2030
hemangioma
metastatic malignancy masquerading as, on labeled RBC scintigraphy, 1172
^{99m}Tc RBC SPECT, 375
hepatic arterial flow study and SPECT using ^{99m}Tc MAA in embolized and nonembolized hepatocellular carcinoma, 811(ab)
hepatic extraction fraction, determination by deconvolution analysis, in pediatric population, 214
hepatocellular carcinoma, FDG-PET *vs.* histological findings in assessment of, 12(ab)
high accumulation of ^{18}F FDGal by well-differentiated hepatomas of mice and rats, 780
histological and functional evaluation in chronic disease by ^{99m}Tc GSA scintigraphy, 824(ab)
intracellular metabolism of ^{111}In DTPA labeled receptor targeted proteins, 1728
investigation of lobar distribution of inferior mesenteric blood flow by ^{123}I IMP, 825(ab)
isolated perfused rat, hepatobiliary handling of I-125 Tyr3 octreotide and ^{111}In DTPA D-Phe1-octreotide by, 2025
metastases
accurate detection using PET-FDG, 13(ab)
clinical utility of tagged RBC liver blood pool imaging study in distinguishing hemangiomas from, 816(ab)
from colorectal carcinoma, radioimmunoscintigraphy using ^{131}I monoclonal antibody F19, 327(ab)
misleading figure of focal activity in, 2276(le)
new technique to evaluate transplant patients, 447(ab)
orthotopic transplantation, quantification of liver function using C-14 aminopyrine breath test, 446(ab)
perfused, handling of somatostatin analogues by, 801(ab)
physiopathological significance of ^{201}Tl per rectum scintigraphy in cirrhosis, 1642
portacaval shunt, surgical results in situs inversus diagnosed by per rectal portal scintigraphy, 301
pretargeted radiation delivery to, BIP for, 1147
quantitative evaluation of severity of disease by ^{99m}Tc DTPA GSA, 823(ab)
solitary solid masses, hepatic scintigraphy in evaluation of, 697
subtraction for tumor imaging using ^{201}Tl, ^{99m}Tc colloid and three head SPECT, 390(ab)
uptake creates artifactual defects in ^{99m}Tc myocardial SPECT images, quantitative phantom analysis, 902(ab)
Los Alamos Meson Physics Facility (LAMPF), early closing of accelerator, effect on nuclear medicine research, 51N(6)
Lung
bronchogenic carcinoma mimicking metastatic thyroid carcinoma, 809
carcinoma, PET follow up studies for evaluation of treatment response in, 75(ab)
clinical evaluation of mucociliary transport system in diffuse panbronchiolitis using aerosol inhalation cinescintigraphy, 1070(ab)
controlled delivery of Kr-81m boli in normal subjects, results and implications of, 1859
detailed analysis of patients with matched ventilation-perfusion defects and chest radiographic opacities, 1851
detection of primary cancer with ^{99m}Tc sestamibi, 558(ab)
different features of pulmonary metastases in differentiated thyroid cancer, natural history and multivariate statistical analysis of prognostic variables, 1626
differentiation of benign and malignant opacities with FDG-PET, 73(ab)
does detoxification reverse acute alveolitis of crack smokers?, 164(ab)
effect of cardiopulmonary bypass surgery on pulmonary vascular permeability, assessment by transvascular transport of ^{67}Ga, 1077(ab)
evaluation of suspected malignant pulmonary lesions with ^{201}Tl SPECT, 556(ab)
evaluation of systemic blood flow using ECG gated acquisition, 1441
^{67}Ga uptake, computer quantitation of, 1076(ab)
hypertrophic pulmonary osteoarthropathy in nasopharyngeal carcinoma, as early sign of pulmonary metastasis, 719(ab)
^{111}In DTPA IgG imaging, in patients with pulmonary infections, 1078(ab)
^{111}In polyclonal human IgG, identifying focal infection in HIV, 1621
interobserver variability in scintigraphy interpretation, 1834(le)
lobar primary lymphoma, 1980
localization of ^{111}In labeled IgG, PMN and anti-ICAM1 in rat model for ARDS, 1135(ab)
North American blastomycosis
disseminated, ^{67}Ga-citrate and bone scintigraphy, 458
successful ^{67}Ga imaging of, 958
observation of fullerenes in Technegas ventilation unit, 1082(ab)
open bronchial stump post-pneumonectomy, ^{133}Xe ventilation imaging, 462
PET imaging of non-small-cell carcinoma with ^{11}C MET, relationship between radioactivity uptake and flow-cytometric parameters, 1886
pretargeted radiation delivery to, BIP for, 1147
primary pulmonary hypertension, perfusion lung scintigraphic patterns of histologic subtypes, 1071(ab)
pulmonary granulocyte kinetics, 165(ab)
pulmonary segmental projection charts for use in identification of segmental anatomy on lung scan images, 486(ab)
radioaerosol ventilation imaging, complete nose closure and, 1835(le)
radioimmunodetection of Pneumocystis carinii pneumonia in HIV patients, 239(ab)
revised scintigraphic criteria for interpretation of ventilation-perfusion scans for pulmonary embolism, 59(ab)
rheumatoid disease, cellular basis for elevated ^{67}Ga uptake in, 351(le)
role of ^{123}I Tyr-3-octreotide scintigraphy in staging of small-cell cancer, 1397
scans, intermediate probability, prevalence of thromboembolic disease in patients with, 55(ab)
scintigraphy, in acute chest syndrome in children with sickle cell disease, 1059(ab)
single transplants
pulmonary perfusion distribution following, difference between emphysema group and primary pulmonary hypertension group, 167(ab)
quantitative ventilation-perfusion scintigraphy in, 166(ab)
suspected malignant solitary nodules of, pre-surgical evaluation using PET-FDG imaging, 72(ab)
^{99m}Tc aerosol colloid formulation with improved delivery efficiency for ventilation imaging, 268
^{99m}Tc DTPA aerosol clearance, inhaled furosemide effect on, 163(ab)
^{99m}Tc in first-pass angiographic studies of left ventricular function, 394
two-step targeting of experimental metastases with biotinylated antibody and radiolabeled streptavidin, 1011(ab)
underestimation of segmental defect size, 370
uniformity of scan interpretation, diagnostic algorithms and, 661
uptake of ^{99m}Tc laminin peptide PA22-2 is decreased in emphysema and increased in tumored lung, 1133(ab)
ventilation-perfusion/chest x-ray match less likely to represent pulmonary embolism if Q is "decreased" rather than "absent," 58(ab)
ventilation-perfusion scans, 353(le)
abnormalities induced by bronchoalveolar lavage, 1854
in PIOPED study, 1109, 1119
probability category distribution in university and community hospitals, 57(ab)
role in diagnostic evaluation of patients with pulmonary hypertension, 1075(ab)
Lymph nodes
false-positive, by radioimmunoguided surgery, 804
^{111}In leukocyte imaging in Gaucher's disease, 818
metastases, detection in squamous head-neck cancer with MRI and FDG-PET, 216(ab)
reactive, comparison of FDG, L-methionine and thymidine accumulation into experimental infections and, 413(ab)
sentinal, location in high-risk melanoma of trunk, 1435
small metastases, gamma probe assisted ex vivo detection following administration of ^{111}In monoclonal antibodies to colorectal cancers, 1818
Lymphoma
assessment of brain tumor proliferative activity using ^{131}I IUDR, 139(ab)
B-cell

^{131}I QSPECT dosimetry of patients treated with monoclonal antibodies, 509(ab)
new antibody for, 30N(10)
early detection of recurrence with ^{67}Ga scintigraphy, 2101
FDG-PET in differentiation from nonmalignant CNS lesions, in AIDS, 567
malignant, FDG-PET in, 1022(ab)
pilot therapy with fractionated Cu-67 BAT LYM-1, 370(ab)
primary CNS, in non-AIDS patients, comparison of ^{201}Tl SPECT and ^{18}F FDG PET with MRI in evaluation of, 219(ab)
treated, benign mediastinal and parahilar uptake of ^{67}Ga in, 1330
Lymphoscintigraphy, in high-risk melanoma of trunk, predicting draining node groups, defining lymphatic channels and locating sentinal node, 1435

M

Magnetic resonance imaging (MRI)
bone scans in renal allograft recipients, 381
compared with bone scintigraphy in diagnosis of skeletal metastases in prostate cancer at initial presentation, 120(ab)
comparison to scintigraphy, in volume estimation of large multinodular goiters, 794(ab)
comparison with ^{201}Tl SPECT and ^{18}F FDG PET in evaluation of primary CNS lymphoma in non-AIDS patients, 219(ab)
detection of lymph node metastases in squamous head-neck cancer with FDG-PET and, 216(ab)
evidence for coupling of carboxyl group coordination to amine deprotonation, ReO(EC) complexes derived from cysteine, 147(ab)
FDG PET fusion with, to localize foci of increased activity, 1190
high-resolution, of brain, error bounds for five registration techniques based on, 948(ab)
integrated display, manipulation and analysis of images, 497(ab)
lumbar, in back pain with emphasis on marrow changes in end plates in association with disc degeneration, 711(ab)
multislice cerebral blood volume mapping of brain tumors, comparison with PET studies using FDG and CO, 985(ab)
and PET with ^{18}F FDG for detection of pancreatic cancer, 877(ab)
in posterior cerebral artery infarction and related visual field defects, 1009
quantitative analysis of data in normal aging and Alzheimer's disease, 1681
radionuclide bone scans *vs.*, in detecting spinal metastases, 2191, 2198
three-dimensional coordinate matching between PET and, using maximum gradient method, 278(ab)
305-member stereotactic atlas for activation studies, 277(ab)
used for anatomic information, registration and relative quantitation of SPECT and PET data in neuroimaging with, 496(ab)
Magnetic resonance spectroscopy (MRS)
fluorinated macromolecular probes as biosensors for non-invasive pH assessment with, 495(ab)
P-31, estimation of concentrations of phosphorous metabolites using, 861(ab)
Malignant melanoma. *See* Melanoma
Mansfield, Robert K., Berson-Yalow Award, 30N(7)
Mathematical modeling
compartmental model for simultaneous measurement of myocardial blood flow and oxygen consumption, ^{11}C acetate, 4(ab)
quantification of myocardial muscarinic receptors with PET in humans, 981
radiolabeled antibodies as cancer therapeutics, 1028(le)
Medical Internal Radiation Dose (MIRD) Committee
application of effective dose equivalent to nuclear medicine patients, 714
report on radiation absorbed dose estimates from inhaled Kr-81m gas in lung imaging, 1382
Medicare, fee schedule, 22N(4)
Medi-Physics Award, Carolyn J. Anderson, 22N(7)
Melanoma
high-risk of trunk, lymphoscintigraphy in, 1435
imaging agent, I-125 PAB, 2169
initial assessment of PET using FDG in imaging of, 1420
phase II scintigraphic clinical trial with ^{123}I BZA, 1260
Meningioma
intraosseous, appearance on bone scintigraphy over five years, 961
^{201}Tl SPECT for predicting histological types of, 2091
Metastasis. *See also* Cancer
axillary lymph node, comparison of detection on attenuation corrected and uncorrected whole body PET images in patients with breast cancer, 547(ab)
bone
in breast cancer, 291(ab)
EXAFS structural characterization of solutions of ^{186}Re HEDP therapeutic agent for, 146(ab)
FDA approves new therapy for, 30N(8)
circulating ^{131}I thyroxine in thyroid cancers, 36(ab)
intraoperative assessment of brain malignancies using ^{201}Tl, 138(ab)
liver
accurate detection using PET-FDG, 13(ab)
masquerading as hepatic hemangioma on labeled RBC scintigraphy, 1172
lung
different features in differentiated thyroid cancer, 1626
experimental, two-step targeting with biotinylated antibody and radiolabeled streptavidin, 1011(ab)
nodal, correlation of radiation absorbed doses to, 524(le)
prostate, ^{153}Sm EDTMP biodistribution and dosimetry estimation, 1031
spatial localization of metastatic processes, CT and SPECT image registration and fusion using radiolabeled monoclonals, 562(suppl)
testicular, initial evaluation of FDG PET imaging of, 15(ab)
thyroid carcinoma, bronchogenic carcinoma mimicking, 809
Methionine
effects of hypoxia on cultured human tumor cell uptake of, 288(ab)
in vitro assessment of uptake, 2278(le)
for monitoring early response of human adenocarcinoma cell line to radiotherapy, ^{18}F FDG and thymidine *vs.*, 773
PET
in differentiation of recurrent or residual musculoskeletal sarcomas from posttherapy changes, 124(ab)
in differentiation of recurrent or residual tumor from posttreatment changes, 214(ab)
Methotrexate, neurotoxicity induced by, appearance on ^{111}In WBC, ^{67}Ga-citrate and ^{201}Tl chloride scintigraphy, 1377
Micrometastases
circulating ^{131}I thyroxine in thyroid cancers, 36(ab)
radiolabeled antibodies as cancer therapeutics, 1028(le)
MIRD Committee. *See* Medical Internal Radiation Dose Committee
Molecular medicine, new, 165
Molecular recognition units, monoclonal antibodies and, 533(suppl)
Molybdenum-99
DOE plan, 20N(4)
high purity fission, production in South Africa, 1828(le)
Monitoring response, benign mediastinal and parahilar uptake of ^{67}Ga in treated lymphoma, 1330
Monoamine transporters, MIBG uptake by, 1140
Monoclonal antibodies
anti-CEA
conjugated to bifunctional transition metal carborate complex, pharmacokinetics in tumor-bearing mice, 1294
successful humanization of high affinity murine monoclonal antibody MN-14, 1020(ab)
anti-EGFR, comparison of phase I trials of, 1005(ab)
antiferritin, evaluation of ^{111}In and ^{90}Y labeled linker-immunoconjugates in nude mice and dogs, 938
anti-ICAM-1, myocardial uptake in detecting acute myocardial infarction of rat, 257(ab)
anti-TAG-72, clinical comparison of radiolocalization of two, 1009(ab)
CC49, ^{99m}Tc labeling of trisuccin conjugated to, 107(ab)
CEA fragments, ^{123}I, in colorectal cancer imaging, 61
chemical modification to afford discriminated release of hippurate-like chelate in non-target for target-selective radioactivity delivery, 106(ab)
colorectal cancer, current imaging strategies, 537(suppl)
direct labeling with ^{99m}Tc by novel photoactivation process, 397(ab)
directly and indirectly ^{99m}Tc labeled, 109
effect of degree of DTPA conjugation per, on metabolism and clearance of its ^{111}In chelate in mice, 228(ab)
enhanced quantitative radioimmunotherapy imaging with MIRDOSE dosimetry software, 510(ab)
against E-selectin, imaging inflammation and vascular activation with, 243(ab)
hyperthermia effect on uptake of, in small cell lung cancer xenografts, 1012(ab)

imaging agents in nuclear medicine, 531(suppl)
IMMU-MN3, imaging of inflammation/abscess with, 827(ab)
^{111}In, spatial localization of metastatic processes using, CT and SPECT image registration and fusion for, 562(suppl)
intact and F(ab')2 fragments of MX-35, comparative study in xenograft model, 1015(ab)
intra-tumoral distribution in xenografts of human ovarian adenocarcinoma, autoradiographic evaluation of, 75
^{131}I-YBI-450-2106, radioimmunopharmacokinetics of, 1139(ab)
kit-formulated conjugation of NHS-BAT ester to, ^{99m}Tc labeling and radioimmunoscintigraphy, 1019(ab)
labeling with ^{211}At using SAPC, 396(ab)
lack of HAMA response in patients imaged with ImmuRAID-CEA and ImmuRAID-MN3, 1008(ab)
M195, in acute myelogenous leukemia, 422
Mu-9, clinical evaluation for targeting gastrointestinal carcinoma, 375(ab)
murine, Re-188, 209(ab)
new strategy for labeling with ^{111}In, 394(ab)
peptides and molecular recognition units and, 533(suppl)
planar imaging, attenuation correction of geometric mean images, 237(ab)
in radioimmunoscintigraphy, 2264
radiolabeled
acceptance by medical insurers, 32N(3)
integrated approach to estimating biodistribution and radiation absorbed dose from, 511(ab)
radiolabeled stabilized F(ab')$_2$ fragments of antiferritin in nude mouse model, 2152
^{186}Re
dosimetry, 908
radioimmunotherapy, preparation and evaluation, 260
synthesis, metal chelate stability studies, and enzyme digestion of peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates, 104(ab)
synthesis and characterization of new tripeptide bifunctional chelating agent for radiolabeling of, 398(ab)
^{99m}Tc 170H.82, for imaging breast cancer, 1003(ab)
^{99m}Tc-labeled anti-rat CD4, joint uptake and body distribution of, in rat adjuvant arthritis, 92
^{99m}Tc-labeled OKT3, imaging rheumatic joint diseases with, 714(ab)
vascular thrombus detection, scintigraphic methods for, 554(suppl)

Morphine-augmented cholescintigraphy
delayed imaging has unacceptably low positive predictive value for acute cholecystitis when compared to, 300(ab)
delayed imaging *vs.*, in suspected acute cholecystitis, 506
false-negative, bile leak from gallbladder perforation mimicking bowel activity and, 131

Motion. *See* Patient motion

Motor function, mirror movements during recovery from stroke, 225(ab)

Movement disorders
choreatic, spectrum of regional cerebral glucose consumption in, 118(ab)
Parkinson's disease. *See* Parkinson's disease

MRI. *See* Magnetic resonance imaging

MRS. *See* Magnetic resonance spectroscopy

Multidrug resistance, enhancement of ^{99m}Tc sestamibi accumulation in MDR cells by cytotoxic drugs and MDR reversing agents, 560(ab)

Muscarinic receptors
IQNP high affinity antagonist, in vitro and in vivo evaluation of, 1128(ab)
myocardial, quantification with PET in humans, 981
new selective antagonist, whole body distribution of, 937(ab)
PET images of phosphoinositide response in primate brain, 94(ab)
preparation of three ^{11}C-labeled novel functional M1 selective agonists, 18(ab)
quantification in vivo with ^{11}C NMPB and PET, distinction of ligand delivery and binding, 430(ab)

Musculoskeletal system, recurrent or residual sarcomas, FDG and methionine PET in differentiation from posttherapy changes, 124(ab)

Myocardial infarction
acute
does myocardial denervation contribute to silent ischemia early after, 47(ab)
models for predicting long-term outcome by quantitative adenosine tomography, 212(ab)
myocardial uptake of radiolabeled anti-ICAM-1 monoclonal antibody in detection in rat, 257(ab)
myocardial viability assessment by sequential PET scan following, 89(ab)
rest-redistribution on SPECT ^{201}Tl scintigraphy after, predicts normal wall motion on low dose dobutamine echocardiography, 170(ab)
totally occluded infarct-related artery and, role of quantitative planar ^{201}Tl imaging for viability determination, 728
deoxyglucose and ^{99m}Tc glucarate distribution in, 1303
experimental
myocardial perfusion and necrosis estimates with ^{38}K and PET in, 49(ab)
SPECT and planar imaging with instant ^{99m}Tc antimyosin kit, 191(ab)
left ventricular mass and infarct size estimation from ^{13}N ammonia PET, based on pathological examination of explanted hearts, 826
prior
cardiac events within 12 months after non-ischemic non-invasive imaging test in patients with, 295(ab)
prognostic efficacy of exercise radionuclide ventriculography and coronary angiography in patients with and without, 127(ab)
rapid imaging with ^{99m}Tc-labeled antimyosin recombinant single-chain Fv, 234
teboroxime is marker of blood flow following reperfusion of, 48(ab)

Myocardial ischemia
acute, deoxyglucose and ^{99m}Tc glucarate distribution in, 1303
assessment of myocardial viability early during reperfusion after, in pigs with ^{18}F FDG and ^{123}I HDA, 179(ab)
assessment of perfusion defect size after SPECT imaging with ^{99m}Tc sestamibi after stress, 187
diagnosis by using exercise and rest myocardial scintigraphy using ^{99m}Tc tetrofosmin, 479(ab)
early myocardial clearance kinetics of ^{99m}Tc teboroxime, 630
human pathologic correlation with PET in ischemic and nonischemic cardiomyopathy, 39
hypertrophic cardiomyopathy complicated with ventricular aneurysm and myocardial necrosis, 2227
^{131}I HDA metabolism in, 51(ab)
^{131}I IVM as marker for myocardial hypoxia, 918
left ventricular mass and infarct size estimation from ^{13}N ammonia PET, based on pathological examination of explanted hearts, 826
nitrates improve detection of ischemic by viable myocardium by ^{201}Tl reinjection SPECT, 1472
planar and SPECT imaging using novel ^{99m}Tc nitroimidazole, 50(ab)
right ventricular ^{201}Tl kinetics in pulmonary hypertension, relation to right ventricular size and function, 1695
silent
does myocardial denervation contribute, early after acute myocardial infarction, 47(ab)
spontaneous, assessed by ^{99m}Tc sestamibi imaging, 134
Tc-94m teboroxime synthesis, dosimetry and initial PET imaging studies, 1058
thallium reverse redistribution in perspective, 1692
uptake mechanism of neutral myocardial imaging agent ^{99m}Tc N-NOET, 65(ab)

Myocardium. *See also* Myocardial infarction; Myocardial ischemia
accuracy of ^{201}Tl SPECT at rest for evaluation of viability, in comparison to ^{18}F FDG PET, 729(ab)
assessment of cardiotoxicity by ^{111}In antimyosin studies, bolus administration *vs.* continuous infusion of doxorubicin, 43(ab)
assessment of coronary reserve in man, comparison of PET with ^{15}O water and intracoronary Doppler technique, 1899
assessment of residual viability with ^{99m}Tc MIBI, 749(ab)
assessment of viability early during post-ischemic reperfusion in pigs with ^{18}F FDG and ^{123}I HDA, 179(ab)
automated analysis program for evaluation of PET studies, 968
blood flow
assessment of endothelial function with PET cold pressor test in patients with various degrees of atherosclerosis, 137(ab)
quantification using PET, validation of ^{13}N ammonia tracer kinetic model for, 83
quantification using PET and ^{13}N ammonia in patients with angiographically documented coronary artery disease, 133(ab)
resting, maintenance in dysfunctional myocardium with ^{201}Tl redistribution, 171(ab)
simultaneous measurement of oxygen consumption and, ^{11}C acetate, compartmental model for, 4(ab)
blood flow measurement by radiolabeled tracers, 1518

- catheter ablation induced necrosis, antimyosin antibody imaging for identification of, 256(ab)
- cell death, FDG and, myocardial perfusion and, 866(le)
- characteristics of glucose metabolism in hypertrophic cardiomyopathy, PET study using ^{18}F FDG, 426(ab)
- comparison of different techniques for calculating blood flow, 343(ab)
- comparison of factors influencing cost-effectiveness of diagnosis and management of coronary disease, 136(ab)
- comparison of ^{13}N ammonia blood flow measurement techniques, 192(ab)
- comparison of uptake, oxidation, and lipid distribution of IHDA, pIPPA, and DMIPPA, 649
- compartment model for measurement of regional blood flow with ^{11}C MTP and PET, 342(ab)
- decreased coronary reserve in idiopathic dilated cardiomyopathy assessed using PET with ^{15}O water, 134(ab)
- detection and correction of patient motion in dynamic and static SPECT using multi-detector camera, 1349
- differentiation of perfusion abnormalities from attenuation effects on combined ^{201}Tl/^{99m}Tc sestamibi studies using relative regional activity profiles, 255(ab)
- dipyridamole stress ^{99m}Tc sestamibi tomography, independent predictor of adverse outcome following acute ischemic events, 338(ab)
- dipyridamole ^{201}Tl imaging, cerebrovascular accident associated with, 128
- dobutamine ^{99m}Tc sestamibi SPECT and echocardiography, coronary angiography *vs.*, in coronary artery disease detection, 889
- does denervation contribute to silent ischemia early after acute myocardial infarction?, 47(ab)
- does perfusible tissue index reflect tissue that can exchange water or flow heterogeneity?, 344(ab)
- dynamic and gated PET ^{13}N ammonia imaging confirms inhomogeneous tracer retention but homogeneous perfusion in normal subjects, 132(ab)
- dynamic PET studies using image-derived input functions, 440
- dysfunctional, resting myocardial blood flow and glucose metabolism maintenance with ^{201}Tl redistribution in, 171(ab)
- effect of motion on ^{201}Tl SPECT studies, 1845
- effect of TTC staining on distribution of radiolabeled pharmaceuticals, 178(ab), 1722
- effects of changes in wall thickening on ECG gated SPECT ^{99m}Tc sestamibi images, 382(ab)
- exercise-dipyridamole perfusion imaging, 2061
- false perfusion defects, computer simulation study of, 109(ab)
- ^{18}F FDG in viability assessment, 89(ab)
- function after coronary revascularization, perfusable tissue index parallels oxidative metabolism in predicting recovery of, 135(ab)
- ^{68}Ga radiopharmaceutical that is retained in, 1127
- glucose metabolism, simple method to quantitate from MB ratio in myocardial ^{18}F FDG study, 875(ab)
- glucose utilization during hyperglycemic clamp in type-1 diabetes evaluated with PET and FDG, insulin and non-insulin mediated, 758(ab)
- glucose utilization enhancement by Acipimox, 429(ab)
- hibernating, detection by gated blood pool scintigraphy under low dose dobutamine and isosorbide dinitrate infusion, 378(ab)
- hypertrophic, approaches to identification and characterization, 1013
- ^{123}I-MIBG SPECT, cardiomyopathy outcome prediction using, 46(ab)
- ^{123}I-MIBG uptake in left ventricular hypertrophy secondary to valvular aortic stenosis, 57
- influence of patient height/weight and type of stress on count rates with ^{201}Tl and ^{99m}Tc sestamibi, 731(ab)
- kinetics of putative hypoxic tissue marker after regional ischemia and reperfusion, 53(ab)
- long-term follow up of perfusion abnormalities in patients with Kawasaki disease, 213(ab)
- modeling of ^{11}C acetate kinetics by simultaneously fitting data from multiple ROIs, 193(ab)
- multicenter evaluation of new automated analysis program for PET flow studies, 759(ab)
- necrosis, hypertrophic cardiomyopathy complicated with ventricular aneurysm and, 2227
- normal, ischemic, and hypoxic, ^{131}I HDA metabolism in, 51(ab)
- normal *vs.* flow restricted, early myocardial clearance kinetics of ^{99m}Tc teboroxime in differentiation, 630
- novel approach to quantifying extent and severity of canine perfusion defects by PET polar mapping, 756(ab)
- optimal identification of viability with SPECT, 85(ab)
- oxygen consumption, refined method for quantification using mean transit time with ^{11}C acetate and dynamic PET, 878(ab), 2038
- oxygen consumption rate, effect of plasma time activity curve shape on estimates with ^{11}C acetate studies, 194(ab)
- oxygen metabolism in untreated Graves' disease assessed by PET with ^{11}C acetate, 428(ab)
- parametric images for quantitative measurements of regional blood flow in humans, 862
- perfusion
  - absolute, quantification with ^{38}K and PET, 341(ab)
  - assessment of defect size after SPECT imaging with ^{99m}Tc sestamibi after stress, 187
  - biokinetics of ^{99m}Tc tetrofosmin and, 1254
  - detection of patient motion during tomographic imaging, 1341
  - dobutamine ^{99m}Tc sestamibi SPECT and echocardiography, coronary angiography *vs.*, 895
  - dynamic SPECT using ^{99m}Tc teboroxime for quantification of, 733(ab)
  - estimation with PET and ^{15}O water administered by constant intravenous infusion, 340(ab)
  - FDG and, myocardial cell death and, 866(le)
  - glycogen accumulation in chronically hypoperfused myocardium with maintained FDG uptake, 5(ab)
  - human pathologic correlation with PET in ischemic and nonischemic cardiomyopathy, 39
  - imaging with ^{99m}Tc tetrofosmin, 222
  - inhomogeneity of gated and ungated SPECT ^{99m}Tc sestamibi bull's-eyes, comparison with ^{201}Tl, 281
  - nutritive reserve, flow velocity reserve and, in conductance vessels, 717
  - prognostic implications of dipyridamole ^{99m}Tc sestamibi SPECT imaging, 336(ab)
  - scintigraphy, personnel radiation dosimetry from ^{99m}Tc sestamibi *vs.* ^{201}Tl, 1210
  - simultaneous assessment of left ventricular function and, during transient coronary occlusion, 1(ab)
  - SPECT images, patient motion effects on, 303
  - ^{99m}Tc tetrofosmin, human biodistribution, dosimetry, and safety of use in imaging, 30
  - ^{201}Tl SPECT, left ventricular cavity-to-myocardial count ratio, resting left ventricular dysfunction, 193
- perfusion abnormalities, gated SPECT with ^{99m}Tc sestamibi for assessment of, 601
- perfusion and necrosis estimates with ^{38}K and PET in experimental myocardial infarction, 49(ab)
- perfusion defect reversibility, independence of regional asynergy and, 86(ab)
- perfusion imaging and dynamic analysis with ^{99m}Tc tetrofosmin, 1478
- PET measurement of regional blood flow permits recognition of viable and non-viable myocardium in chronic myocardial infarction, 87(ab)
- prognostic relevance of ^{111}In antimyosin Fab accumulation in patients with dilated cardiomyopathy, 753(ab)
- prognostic value of normal ^{99m}Tc sestamibi perfusion imaging, 211(ab)
- quantification of muscarinic receptors with PET in humans, 981
- quantitative SPECT, feasibility of multicenter trial assessed by means of cardiac phantom, 723(ab)
- recovery of function following coronary revascularization, 84(ab)
- regional glucose utilization rate and flow metabolism ratio under fasting, oral glucose loading and hyperinsulinemic euglycemic clamping and comparison with flow in normal subjects, 870(ab)
- rest and hyperemic blood flow during estradiol therapy in post-menopausal women by ^{13}N ammonia and PET, 802(ab)
- reverse redistribution in resting ^{201}Tl scintigraphy in patients with coronary artery disease, relation to coronary anatomy and ventricular function, 1688
- reversible ^{201}Tl perfusion defects in right bundle branch block and normal coronary angiogram, 1218(le)
- right ventricular ^{201}Tl kinetics in pulmonary hypertension, relation to right ventricular size and function, 1695
- role of quantitative planar ^{201}Tl for determining viability, in acute myocardial infarction

and totally occluded infarct-related artery, 728
sensitivity of dual isotope perfusion imaging for detection of specific atherosclerotic lesions, comparison to angiography, 254(ab)
simultaneous rest ^{201}Tl/stress ^{99m}Tc perfusion SPECT, spill correction technique for, 903(ab)
structure-activity relationships for cationic Ga radiopharmaceuticals, 313(ab)
substrate utilization and left ventricular function in Adriamycin cardiomyopathy, 52(ab), 1529
^{99m}Tc teboroxime uptake in cultured cells, *vs.* ^{201}Tl and ^{99m}Tc sestamibi, 255
thickness by gated PET and SPECT, variability and bias, 856(ab)
^{201}Tl perfusion tomography one to five years after successful coronary angioplasty, 296(ab)
^{201}Tl SPECT in Bland-White-Garland syndrome, 2182
up-regulation of beta-adrenergic receptors early after sympathetic chemical denervation in dogs assessed with PET and ^{11}C CGP12177, 175(ab)
uptake mechanism of neutral imaging agent ^{99m}Tc N-NOET, 65(ab)
uptake of ^{123}I branched fatty acid analogue as marker of fatty acid metabolism, comparison with kinetics of ^{11}C palmitate, 726(ab)
uptake of radiolabeled anti-ICAM-1 monoclonal antibody in detecting acute myocardial infarction of rat, 257(ab)
vectorized Monte Carlo code for modeling photon transport in non-uniform media for SPECT, 895(ab)
viability detection by PET, value of quantitative analysis of glucose utilization in, 2068
viable
  detection by FDG SECT during hyperinsulinemic glucose clamping, 727(ab)
  identification in patients with chronic coronary artery disease using ^{15}O water and PET, 88(ab)
  nitroglycerin enhanced ^{201}Tl reinjection for detection of, 173(ab)

N

National Biomedical Tracer Facility, DOE's stop-gap isotope plan and, 13N(4), 24N(4)
Nelp, Wil B., people in nuclear medicine, 32N(6)
Neuroblastoma
comparison of biodistribution data with TLD absorbed dose measurements using monoclonal antibody 3F8 ^{131}I conjugates in xenografted athymic nude mice, 423(ab)
determination of GD2 antigen concentration in, using monoclonal antibody 3F8 by quantitative autoradiography, 457(ab)
lesion detection with ^{131}I MIBG, 865(le)
optimized diagnostic strategy for, in opsoclonus-myoclonus, 1922
SIMS microscopy imaging of intratumor biodistribution of MIBG in human SK-N-SH cell line xenografted into nude mice, 1565
stage IV, ^{67}Ga and ^{99m}Tc MDP skeletal scintigraphy in determining prognosis for children with, 1082, 1087
Neurons
absence of nonneuronal uptake of MIBG in denervated rabbit hearts, 176(ab)
brain uptake of ^{201}Tl from CSF compartment, 99
cholinergic
  in vivo mapping in human brain using SPECT and (-)-5-^{123}I IBVM, 93(ab)
  synthesis and in vivo evaluation of ^{99m}Tc DADT-BVM as potential marker for, 541(ab)
sympathetic, MIBG uptake by, 1140
Neurotoxicity
of acute mercury poisoning, PET FDG brain studies in 10 patients, 988(ab)
methotrexate-induced, appearance on ^{111}In WBC, ^{67}Ga-citrate and ^{201}Tl chloride scintigraphy, 1377
Neutron capture therapy, DOE funding of research, 29N(4)
Newsline, Commentary
Asia and Oceania Congress in Nuclear Medicine and Biology, 17N(5)
future of nuclear medicine, 27N(9)
Lines from the President, 34N(3), 50N(6), 32N(9)
SNM/ACNP government relations, 22N(4), 19N(7)
SNM annual meeting highlights, 13N(8)
Nitric oxide synthase, probe for, in vivo rat biodistribution of no-carrier-added I-125 DPI, 355(ab)
Nitrogen-13, parametric images for quantitative measurements of regional myocardial blood flow in humans, 862
Nitrogen-13-ammonia
bacterial endotoxin test, PET, 469
cardiac PET, 978
  automated region definition for, 336
comparison of myocardial blood flow measurement techniques, 192(ab)
comparison with ^{15}O water for quantification of renal cortical blood flow with PET, 195(ab)
coronary artery disease detection and localization using, initial results with automated analysis program for PET study evaluation, 968
dynamic and gated PET imaging confirms inhomogeneous myocardial tracer retention but homogeneous perfusion in normal subjects, 132(ab)
in situ production, post irradiation ^{13}C and ^{2}H NMR analysis of aqueous ethanol and acetic acid solutions for, 1115(ab)
in-target preparation of, 1113(ab)
kinetic model for quantification of myocardial blood flow using PET, validation of, 83
myocardial blood flow quantification, 488
PET, left ventricular mass and infarct size estimation from, based on pathological examination of explanted hearts, 826
Nitroimidazoles, viability, 924
Nontumor-promoting activity, ^{11}C labeled phorbol esters, protein kinase C imaging, 431
Norepinephrine
6-^{18}F, comparison with 6-^{18}F FDA, 619
transporters, MIBG uptake by, 1140
North American blastomycosis
^{67}Ga-citrate and bone scintigraphy, 458
successful ^{67}Ga imaging of, 958
NRC. *See* Nuclear Regulatory Commission
Nuclear blast test veterans, U.S funds study, 24N(1)
Nuclear medicine
cultivating subspecialists for, 1826(le)
desktop computing, 18N(1)
digital, highly integrated department, 854(ab)
early closing of accelerator could impede research, 51N(6)
future of, autonomy or integration?, 27N(9)
graphic user interface-based reporting system, 515
and health care reform, 32N(11)
human element integral to future of, 1825(le)
in Israel, 1826(le)
"molecular nuclear medicine" grants, 15N(2)
more than just medical imaging, 1617(le)
network for remote viewing and distributed processing, 859(ab)
new directions for medical imaging in the nineties, 157
new molecular medicine, 167
no more Edsel mechanics needed in, 1826(le)
payment schedule threatens future of specialty, 1827(le)
people in nuclear medicine, 20N(6)
perspective from Europe on future of, 169
practical algorithm for assessing flood field uniformity in, 847(ab)
prognosis by, 1087
quantification by kinetic analysis in, unified approach to, 706
research opportunities, 52N(6)
training for future, 167
validity of voxel based Monte Carlo simulations in, energy spectrum analysis, 232(ab)
Nuclear Regulatory Commission (NRC)
ACMUI, 20N(7)
agreement states, 20N(7)
budget appropriations, 29N(10)
budget security, 20N(7)
changing rules on radioactive waste storage, 28N(5)
confusion about radiation safety in medicine, 34N(3)
congressional hearings, 29N(10)
congressional inquiries, 20N(7)
Curtiss leaves, 30N(8)
enforcement actions, 20N(7)
fees threaten research reactors, 30N(10)
licensing fees, 22N(4)
new boss touts self-regulation, 23N(10)
patient "follow-up," chairman's mandate, 30N(3)
patient release criteria, 20N(7)
pregnancy rule, 20N(7)
proposed amendments, 25N(9)
radiation protection, 22N(4)
radiopharmacy regulations, 22N(4), 20N(7), 29N(10)
regulations on departures from manufacturer's instructions, 523(le)
toward a balanced perspective, 17N(10)
user fees, 29N(10)

O

Ocular implants, hydroxyapatite, ^{99m}Tc MDP evaluation, 467
Office of Health Care Policy (OHCP), availability of bulletin, 29N(4)
Oldendorf, William H., *In Memoriam*, 871
Oncology. *See also* Cancer
new engine for PET/SPECT, 13N(8)

Orbit, ^{111}In DTPA octreotide accumulation in Graves' orbitopathy not based on blood-pool radioactivity, 158(ab)
Oropharynx, scintigraphic studies of oropharyngo-esophageal function in stroke and other neurologic disorders, 34(ab)
Osteonecrosis, dysbaric, animal model of, 710(ab)
Ovarian neoplasms
adenocarcinoma, xenografts of, intra-tumoral distribution of 2-DG and monoclonal antibodies in, autoradiographic evaluation of, 75
clinical immunoscintigraphy of ovarian carcinoma using ^{131}I 145-9 monoclonal antibody, 1651
dynamic ^{18}F FDG PET studies for assessment of, 14(ab)
FDG uptake and proliferative activity, 414
immunoscintigraphy in management of, clinical utility of, 545(suppl)
influence of anti-idiotypic HAMA on three different tumor marker assays in ovarian cancer patients, 503(ab)
quantitation of CA-MOv18 antigen in sections of ovarian carcinoma, 1004(ab)
residual/recurrent cancer, detection using FDG PET, 16(ab)
supra-additive effect of ^{32}P chromic phosphate and CDDP in, 217(ab)
targeting with MOv-18 monoclonal antibody labeled with ^{99m}Tc, 323(ab)
tissue distribution of radiolabeled cMOV18 IgG, F(ab')2, and Fab' in, 326(ab)
Ovary, cells, Chinese hamster, hypoxia effect on accumulation of ^{99m}Tc glucarate and ^{99m}Tc gluconate, 242
Oxygen
consumption, simultaneous measurement of myocardial blood flow and, ^{11}C acetate, compartmental model for, 4(ab)
metabolic rate of, modeling approach to eliminate need to separate arterial plasma in ^{15}O inhalation PET, 1333
myocardial consumption rate, effect of plasma time activity curve shape on estimates with ^{11}C acetate studies, 194(ab)
Oxygen-15, PET, study of regional cerebral blood flow measured during behavioral challenge in obsessive compulsive disorder, 180(ab)
Oxygen-15 gas, PET and autoradiographic method with continuous inhalation of, 1672
Oxygen-15 RBC, and ^{15}O water require separate external dispersion corrections, 197(ab)
Oxygen-15 water
comparison with ^{13}N ammonia for quantification of renal cortical blood flow with PET, 195(ab)
concordance of nutritive myocardial perfusion reserve and flow velocity reserve in conductance vessels, 717
decreased coronary reserve in idiopathic dilated cardiomyopathy assessed using PET with, 134(ab)
in identification of viable myocardium in patients with chronic coronary artery disease, 88(ab)
^{13}N ammonia *vs.*, for quantification of myocardial blood flow using PET, 83
and ^{15}O labeled red blood cells require separate external dispersion corrections, 197(ab)
PET, suggests that regional brain activation during performance of specific memory tasks is abnormal in patients with schizophrenia, 1068(ab)
PET compared with, in assessment of coronary reserve in man, 1899
practical procedures and pharmacological applications of quantitative PET, 1006
quantitative blood flow studies, noninvasive arterial monitor for, 1000
Oxygen-18, new supplier breaks isotope monopoly, 52N(6)
Oxygen-18 CO_2, enriched, cryogenic solid target for production of ^{18}F from, 269(ab)

P

Paget's disease, in patient with breast cancer, 1214
Palladium-109, complex, synthesis and characterization of phosphorous-hydrazide steroid conjugate and, 145(ab)
Pancreas
agent for potential clinical evaluation of pancreatic insufficiency by urine analysis, 946
cancer
diagnosis with PET and FDG, 1055(ab)
experimental radioimmunotherapy employing ^{131}I monoclonal antibody PAM4, 1010(ab)
localization of gastroenteropancreatic tumors with ^{111}In somatostatin analogue, 156(ab)
Pancreatic lipase, site specific/stable radioiodination, ^{131}I 1,2-Pal-3-IPPA, urine analysis, 946
Parathyroid
adenoma
comparative study of ^{99m}Tc sestamibi/^{201}Tl with ^{99m}Tc pertechnetate subtraction scintigraphy and ultrasonography in localization of, 804(ab)
relative ^{201}Tl and ^{99m}Tc MIBI uptake in, 807(ab)
hyperfunctioning tissue, intraoperative validation of ^{99m}Tc sestamibi and ^{123}I subtraction technique for preoperative localization of, 805(ab)
scintigraphy, ^{99m}Tc pertechnetate, ^{201}Tl, and ^{99m}Tc sestamibi, 808(ab)
subtraction scintigraphy, ^{201}Tl/^{99m}Tc, ultrastructural histology correlation with, 24
^{99m}Tc sestamibi as imaging agent, 806(ab)
Parkinson's disease
dysphagia in parkinsonism, assessment by solid phase radionuclide scintigraphy, 812(ab)
functional receptor testing in patients with idiopathic Parkinson's syndrome *vs.* Parkinson plus syndrome, 117(ab)
metabolism of 6-[^{18}F]FDOPA is enhanced in patients with, 114(ab)
new graphic method for estimation of distribution volume on ^{123}I IMP SPECT in differential diagnosis of PSP and, 119(ab)
PET imaging of dopamine reuptake sites by ^{11}C WIN 35,428 and PET, 115(ab)
SPECT imaging demonstrates loss of striatal dopamine transporters in, 116(ab)
Patient motion
automatic correction for artifacts in dynamic radionuclide studies using cross-correlation method, 501(ab)
correction algorithm for studies acquired from multiple head cameras, 500(ab)
correction system for tomographic imaging based on CCD video cameras, 359(ab)
detection and correction in cardiac PET imaging, using automated registration algorithm, 883(ab)
detection and correction in dynamic and static myocardial SPECT using multi-detector camera, 1349
detection during tomographic myocardial perfusion imaging, 1341
effect on cardiac SPECT imaging, 1355
effect on ^{201}Tl SPECT, 1845
head
correction strategy during brain imaging, 276(ab)
SPECT and PET reconstruction methods accounting for, 360(ab)
during tomographic myocardial perfusion imaging, effectiveness of detection methods, 740(ab)
Paul C. Aebersold Award, Alan Jones and Alan Davison, 26N(5)
Pediatric patients
autism in, abnormal regional cerebral blood flow response to auditory stimulation in, 307(ab)
hepatobiliary scintigraphy, determination of hepatic extraction fraction by deconvolution analysis, 214
high-resolution SPECT imaging of spine in, 202(ab)
normalized clearance-to-uptake slope ratio for minimization of false-positive diuretic renograms, 762
PET FDG studies of tumors in, 199(ab)
postprandial gastric motility in infants with gastroesophageal reflux and delayed gastric emptying, 2120
^{99m}Tc HMPAO in brain death determination, 203(ab)
^{201}Tl scintigraphy, in solid tumors, 200(ab)
^{201}Tl scintigraphy for assessment of ^{67}Ga avid mediastinal mass following therapy for Hodgkin's disease, 1326
Penis
blood flow, tumescence, 523(le)
hemodynamics, design and implementation of circumferential non-imaging probe with superior temporal resolution for measurement of, 1160(ab)
15-(p-Iodophenyl)pentadecanoic acid (pIPPA), uptake, oxidation, and lipid distribution *vs.* IHDA and DMIPPA in normal canine myocardium, 649
Peptides
ANP, ^{111}In chelated derivatives for in vivo imaging of receptors, 226(ab)
ApoB synthetic, ^{99m}Tc labeled, for atherosclerosis imaging in hyperlipidemic rabbits, 260(ab)
cancer imaging, 32N(7)
chemotactic
high affinity Tc-labeled, 62(ab)
in vivo bioactivity and biodistribution of analogs in nonhuman primates, 2130
^{99m}Tc labeled, for infection imaging, 833(ab)
^{99m}Tc labeled for localizing acute bacterial infection in rabbit, 2176
^{99m}Tc labeled HYNIC derivatized analogs for imaging focal sites of bacterial infection, 836(ab), 1964
cyclic, ^{99m}Tc labeled, for thrombus imaging, 60(ab)
monoclonal antibodies and, 533(suppl)
radiolabeled, cancer imaging, NDA sought for, 24N(1)

radiopharmaceuticals, 2253
receptor targeted radiolabeled polypeptides, intracellular metabolism, 229(ab)
snake venom, preliminary evaluation for thrombus imaging, 258(ab)
synthesis, metal chelate stability studies, and enzyme digestion of peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates, 104(ab)
synthetic, 15N(11)
synthetic immunogens for development of cardiac myosin light chain-1 specific radioimmunoassay, 2144
^{99m}Tc labeled
evaluation for imaging atherosclerotic lesions in vivo, 259(ab)
evaluation for imaging infection in rabbit model, 414(ab)
imaging of focal sites of inflammation in non-human primates with, 415(ab)
Pericarditis, unsuspected complications of bacterial endocarditis imaged by G-67 scanning, 955
Peripheral vascular disease, functional imaging, 865(le)
PET. *See* Positron emission tomography
Phantom
Alderson, quantitative SPECT imaging with ^{67}Cu in, 901(ab)
comparison with human gray/white matter ratios, 933(ab)
pinhole collimation for ultra-high resolution, small-field-of-view SPECT studies, 29(ab)
quantitative analysis of hepatic uptake creating artifactual defects in ^{99m}Tc myocardial SPECT images, 902(ab)
spill correction technique for simultaneous rest ^{201}Tl/stress ^{99m}Tc myocardial perfusion SPECT, 903(ab)
Pheochromocytoma
evaluation with ^{123}I MIBG improvement by SPECT imaging, 40(ab)
histopathologically proven, 24-hr urinary catecholamines are normal in some patients with positive MIBG scans and, 792(ab)
^{131}I MIBG imaging of, correlation with CT, MR and surgery, 791(ab)
^{123}I MIBG in, factors limiting precision and accuracy, 793(ab)
localization, 180
mild to moderate degree of ^{123}I MIBG uptake in adrenals must be carefully interpreted for diagnosis of, 39(ab)
PET FDG studies of, 41(ab)
Phorbol esters, ^{11}C-labeled, protein kinase C imaging, 431
Phosphoinositide, PET images of response in primate brain, 94(ab)
Phospholipid ethers, radioiodinated analog, selective localization in human tumor xenografts, 787
Phosphorus-31
MRS, estimation of concentrations of phosphorous metabolites using, 861(ab)
MRS changes in tumor Pi/NTP ratios in response to radioimmunotherapy, 421(ab)
Phosphorus-32 chromic phosphate
radiosynovectomy for treatment of hemarthrosis and synovitis associated with hemophilia, 715(ab)
supra-additive effect with CDDP in ovarian carcinoma, 217(ab)
pH probe, scintigraphy *vs.*, for quantification of pediatric gastroesophageal reflux, 1228
PKC. *See* Protein kinase C
Planar imaging
activity quantitation using low resolution measured attenuation scans, 858(ab)
attenuation correction of geometric mean images, accuracy of quantitation, 237(ab)
brain, in crack abuse, 899
correlation of sestamibi defect size with flow in chronic infarct model, 385(ab)
early and late, and SPECT thallium imaging in evaluating activity of soft tissue and bone tumors, 123(ab)
estimation of quantitative renal images using, 852(ab)
^{18}F FDG, influence of high and low insulin levels during eugylcemic clamping, 757(ab)
gamma camera, Ho-166, 864(ab)
pheochromocytoma evaluation with ^{123}I MIBG is improved by use of SPECT imaging, 40(ab)
quantification of renal uptake of ^{99m}Tc DTPA using, 1184
SPECT and, of ischemic canine myocardium using novel ^{99m}Tc nitroimidazole, 50(ab)
and SPECT of experimental myocardial infarction with instant ^{99m}Tc antimyosin kit, 191(ab)
^{99m}Tc DMSA SPET *vs.*, in looking for renal scars, 550(ab)
^{201}Tl
quantitative, for determining viability in acute myocardial infarction and totally occluded infarct-related artery, 728
stress, quantitative reproducibility of, 168(ab)
Plasma
activity curve for PET measurement of regional cerebral metabolic rate for glucose, 152(ab)
arterial, modeling approach to eliminate need to separate, in ^{15}O inhalation PET, 1333
D-dimer in evaluation of suspected pulmonary embolus, 896
protein binding of renal agents, 1162(ab)
^{99m}Tc DTPA renal uptake-plasma volume product, as quantitative estimation of glomerular filtration rate, 1390(le)
time activity curve
construction from contaminated left ventricular measurements in dynamic cardiac PET FDG studies and improving estimation of MMRGlc, 885(ab)
effect of shape on estimates of myocardial oxygen consumption rate with ^{11}C acetate studies, 194(ab)
Platelets
effect of SC-47643 and heparin on deposition, and fibrin accretion in canine arteriovenous shunt model, 838(ab)
immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
^{111}In, autologous, sequestration, correlation with splenectomy in idiopathic thrombocytopenic purpura, 182
vascular thrombus, scintigraphic methods for detection of, 554(suppl)
Positron emission tomography (PET)
alcohol and its effects on brain, 798
assessment of agents to monitor early response of human adenocarcinoma cell line to radiotherapy, 773
attenuation correction using count-limited transmission data in, 143
attenuation scans, cardiac, three-dimensional registration of, 311
automated iterative three-dimensional registration of images, 2009
and autoradiographic method with continuous inhalation of ^{15}O gas, 1672
bacterial endotoxin test, 469
block detectors, effect of index of refraction on detector element identification in, 866(ab)
blood glucose concentration influence on FDG uptake in cancer, 1
^{76}Br MBBG as radiotracer for mapping sympathetic nerves of heart, 1739
can zooming be used in EM reconstruction of images?, 887(ab)
cardiac, SNM Cardiovascular Council position paper on clinical use of, 1385
cerebral glucose metabolism response to GABA-A stimulation studied with, in temporal lobe epilepsy, 78(ab)
^{11}C-labeled phorbol esters as potential ligands, protein kinase C imaging, 431
clinical, 1132, 2269
practical iterative reconstruction technique for, 873(ab)
^{11}C-McN-5652Z radiotracer for studying serotonin uptake sites, 120
compared with ^{15}O water and intracoronary Doppler technique, in assessment of coronary reserve in man, 1899
comparison of apparent vascular volume images for water, oxygen and CO in, 944(ab)
comparison of high specific activity 6-^{18}F FNE and 6-^{18}F FDA, heart uptake, metabolism, and effect of desipramine, 619
concordance of nutritive myocardial perfusion reserve and flow velocity reserve in conductance vessels, 717
of ^{11}C PK 11195 binding to peripheral benzodiazepine receptors in Alzheimer's disease, 465(ab)
^{11}C raclopride, sensitivity of measurements to changes in endogenous dopamine, 262(ab)
^{11}C TBZ and, in vivo human imaging of monoaminergic nerve terminals using, 92(ab)
^{64}Cu tested as radioimmunotherapy agent, 22N(7)
^{11}C WIN 35,428, in vivo dopamine transporter sites imaging in human using, 938(ab)
cyclotrons, regulation, 25N(4)
determination of skeletal muscle viability with, 436(ab)
differentiation of residual or recurrent chest tumors from posttherapy changes, 162(ab)
dopaminergic-cholinergic interaction measured with ^{11}C raclopride and, in normal human subjects, 263(ab)
dynamic
myocardial blood flow quantification, 488
total graphical analysis of data with identification of up to four parameters, 886(ab)
dynamic and gated ^{13}N ammonia imaging confirms inhomogeneous myocardial tracer retention but homogeneous perfusion in normal subjects, 132(ab)
dynamic cardiac studies using image-derived input functions, 440
empirical observation of resolution degradation utilizing block detectors, 404(ab)
endothelial function assessment with cold pressor test in patients with various

degrees of coronary atherosclerosis, 137(ab)
to estimate FU therapy outcome in patients with liver metastases, 1023(ab)
evaluation of ^{11}C MDL72,978A as MAO-B inhibitor for, 1116(ab)
evaluation of coronary flow reserve in asymptomatic males with hyperlipidemia and family history of coronary artery disease, 760(ab)
evaluation of emission-transmission misregistration in thorax, 872(ab)
evidence of viability identifies high risk patients with reverse redistribution on planar thallium imaging, 334(ab)
examination of neural control of eye movements with, 932(ab), 963(ab)
^{18}F BMY 14802, potential antipsychotic drug, 246
^{18}F FDG
dynamic studies for assessment of ovarian cancer, 14(ab)
recovery of myocardial function following coronary revascularization, 84(ab)
in ^{99m}Tc HMDP negative bone tumors, 288
FDA plan panned by physicians, 26N(4)
FDG
accuracy in distinguishing cerebral infections from lymphoma in patients with AIDS, 142(ab)
advanced head and neck cancer after chemotherapy, 12
assessment of breast lesions with, 218(ab)
in assessment of hepatocellular carcinoma, comparison with histological findings, 12(ab)
in bronchogenic carcinoma staging, 74(ab)
comparability in probable Alzheimer's disease, 1460
comparative efficacy of CT in detection of tumor sites in patients with abdominal and pelvic malignancies, 215(ab)
comparison with MRI in evaluation of primary CNS lymphoma in non-AIDS patients, 219(ab)
in dementia, diagnostic accuracy, 6(ab)
for detection of pancreatic cancer, 391(ab)
in differentiation of benign and malignant pulmonary opacities, 73(ab)
in differentiation of recurrent or residual musculoskeletal sarcomas from posttherapy changes, 124(ab)
in early delayed radiation necrosis following cerebral stereotactic radiosurgery, 976(ab)
effects of tissue heterogeneity on parameter estimates, 153(ab)
effects on quantitation of comparison of anatomically defined *vs.* physiologically based regional localization, 2201
evaluation of experimental liver tumors using, 2124
evaluation of vertebral compression fractures in cancer, 17(ab)
fusion with CT or MRI to localize foci of increased activity, 1190
hypermetabolic cerebral fungal infection with, 143(ab)
imaging in abdomen and pelvis, 1027(ab)
initial assessment in imaging of malignant melanoma, 1420
initial assessment of detection of skeletal metastatic prostate carcinoma, 1045(ab)
initial evaluation of imaging of metastatic testicular neoplasms, 15(ab)
lung tumor metastasis to breast detected by, 1571
in lymphoma differentiation from nonmalignant CNS lesions, in AIDS, 567
in oncology, 6
in patients with malignant lymphoma, 1022(ab)
pediatric tumor studies, 199(ab)
pheochromocytoma studies, 41(ab)
and post-surgical seizure outcome in complex partial epilepsy, 79(ab)
predictive importance in patients with temporal lobe seizures, 83(ab)
in pre-surgical evaluation of patients with suspected malignant solitary pulmonary nodules, 72(ab)
prognostic and diagnostic usefulness in primary brain tumor management, 141(ab)
in prostatic cancer, 1021(ab)
quantitative analysis of glucose utilization by, in detecting myocardial viability, 3(ab)
residual/recurrent ovarian cancer detection using, 16(ab)
results of clinical ROC study comparing filtered backprojection and maximum likelihood estimator images in, 1198
thyroid cancer imaging with, 38(ab)
FDG uptake and cancer cell proliferative activity, 414
FDOPA in
performance evaluation of different optimization methods for intra-subject registration of images, 879(ab)
quantitation of putamen uptake constant of, 679
simplified quantitative studies using estimated input function derived from population blood curve, 867(ab)
FES, assessment of breast lesions with, 218(ab)
^{18}F 2FDMF as potential imaging agent for brain glycosidases, biodistribution and tissue assays, 1124(ab)
^{18}F fluoroacylated octreotide for quantitative somatostatin receptor imaging with, 315(ab)
follow up studies for evaluation of treatment response in patients with lung carcinoma, 75(ab)
^{18}F PFBG as potential tracer, 312(ab)
functional brain mapping, comparison and optimization of data acquisition strategies, 150(ab)
^{68}Ga radiopharmaceutical that is retained in myocardium, 1127
gated, myocardial thickness by, 856(ab)
gender differences in cerebral blood flow with, 264(ab)
heart, 978
cardiovascular research fellowships awarded to investigators of diagnosis, 29N(7)
potential ^{68}Ga tracers, 228
procedure for patient repositioning and compensation for misalignment between transmission and emission data, 137
SNM position paper, 25N(4)
heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by, 2064
high accumulation of ^{18}F FDGal by well-differentiated hepatomas of mice and rats, 780
high resolution, with solid state scintillation detectors, 403(ab)
high-speed automated discrete blood sampling for, 1357
identification and characterization of hypertrophic myocardium, 1013
in identification of viable myocardium in patients with chronic coronary artery disease, 88(ab)
images of phosphoinositide response in primate brain by, 94(ab)
imaging of dopamine reuptake sites in Parkinson's disease by ^{11}C WIN 35,428 and, 115(ab)
imaging of non-small-cell lung carcinoma with ^{11}C MET, relationship between radioactivity uptake and flow-cytometric parameters, 1886
integrated display, manipulation and analysis of images, 497(ab)
investigation of functional neuroanatomy of syntactic processing and sentence comprehension using, 222(ab)
in ischemic and nonischemic cardiomyopathy, human pathologic correlation with, 39
IUDR uptake and retention as measure of tumor growth, 1152
^{38}K and, myocardial perfusion estimates with, in experimental myocardial infarction, 49(ab)
mapping of local renal blood flow with ^{15}O water and, 196(ab)
measurement of cerebral metabolism following noradrenergic challenge in patients with posttraumatic stress disorder and in healthy subjects, 972(ab)
measurement of regional cerebral metabolic rate for glucose, modeling plasma activity curve for, 152(ab)
measurement of regional myocardial blood flow permits recognition of viable and non-viable myocardium in chronic myocardial infarction, 87(ab)
methionine
in differentiation of recurrent or residual musculoskeletal sarcomas from posttherapy changes, 124(ab)
in differentiation of recurrent or residual tumor from posttreatment changes, 214(ab)
and MRI with ^{18}F FDG for detection of pancreatic cancer, 877(ab)
multicenter evaluation of new automated analysis program for flow studies, 759(ab)
myocardial kinetics of ^{11}C HED, retention mechanisms and effects of norepinephrine, 1287
myocardial muscarinic receptor quantification with, 981
^{13}N ammonia
cardiac, automated region definition for, 336
left ventricular mass and infarct size estimation from, 826
tracer kinetic model for quantification of myocardial blood flow using, validation of, 83
new estimation method accounting for accumulated counts of blood-time activity curves in tracer kinetic modeling, 154(ab)
noise reduction in attenuation correction by maximum likelihood histogram sharpening of attenuation images, 101(ab)
^{15}O, study of regional cerebral blood flow measured during behavioral challenge in obsessive compulsive disorder, 180(ab)

^{15}O inhalation, modeling approach to eliminate need to separate arterial plasma in, 1333
in oncology, 13N(8)
^{15}O water, decreased coronary reserve in idiopathic dilated cardiomyopathy assessed using, 134(ab)
in patient evaluation before and after heart transplantation, 834
performance characteristics of new generation scanner, 401(ab)
performance evaluation of high resolution scanner ECAT EXACT HR, 402(ab)
phosphoinositide turnover imaging linked to muscarinic cholinergic receptor in central nervous system by, 1543
plasma glucose levels and ^{18}F FDG uptake in bronchial carcinomas, 355
polar mapping, novel approach to quantifying extent and severity of perfusion defects on canine myocardium by, 756(ab)
potential tracer for tyrosine hydroxylase activity, 22(ab)
power spectra estimation for adaptive Wiener filter reconstruction, 881(ab)
private center opens in New York, 53N(6)
quantification of myocardial flow and coronary flow reserve using ^{13}N ammonia in patients with angiographically documented coronary artery disease, 133(ab)
quantitative, practical procedures and pharmacological applications of, 1006
quantitative analysis of data in normal aging and Alzheimer's disease, 1681
quantitative ^{15}O water blood flow studies, noninvasive arterial monitor for, 1000
radiation dose to technologists during quantitative *vs.* qualitative studies, 769
radioligand for serotonin uptake sites, synthesis and biological evaluation of, 19(ab)
Rb-82
  essential or not?, 1834(le)
  myocardial perfusion imaging, 400
recovery of resolution by finite elements method, 97(ab)
re-evaluation of amino acid studies, 1936
regional cerebral glucose utilization with ^{18}F FDG in heterogeneous tissues, 360
relationship of blood flow and functional outcome after coronary revascularization, 761(ab)
reproducibility of repeated measures of ^{11}C raclopride binding in human brain, 609
rotating scanner using BGO block detectors, 1367
semi-quantitative assessment of recurrent brain tumors using ^{11}C methionine and ^{18}F FDG, 973(ab)
sequential myocardial scan following myocardial infarction, 89(ab)
serial measurements of renal cortical blood flow in kidney transplants in swine model, 348(ab)
simultaneous emission CT and x-ray transmission CT using composite x- and gamma-ray detectors, 400(ab)
skeletal fluoride kinetics and bone mineral density with DXA in beagles with nutritional osteoporosis, 700(ab)
slice oriented, recovery of human striatal signal, 481
spatial dependence of scatter energy spectrum, 851(ab)
spectral analysis of scatter distributions in dual energy acquisition mode on, 889(ab)
stereotactic transformation of scans by deformation of standard brain atlas, 279(ab)
studies of function of dopamine transporter in cocaine abusers, 406(ab)
studies of neuroblastoma with ^{11}C HED, 1034(ab)
studies of reversible and irreversible MAO B inhibitors, 525(ab)
studies of working memory in humans, 221(ab)
study of remote effects of stroke on 5HT2 serotonergic specific binding, clinical correlations, 971(ab)
superiority over MRI for early diagnosis of dementia of Alzheimer's type, 464(ab)
after systemic administration of ^{18}F uracil in patients with liver metastases from colorectal carcinoma, 1075
Tc-94m teboroxime, 1058
tests fees *vs.* quality of care for SPECT *vs.*, and cost-effectiveness of diagnosis and management of coronary disease, 136(ab)
theoretical decoding resolution limits of detector design using quadrant sharing photomultipliers and cross-coupled BGO, 405(ab)
for therapy management in treated malignant lymphomas, 1033(ab)
three-dimensional
  correction and characterization of scattered events in, using scanners with retractable septa, 671
  for improved patient throughput, 880(ab)
  integration display of emission and transmission images, 888(ab)
three-dimensional brain image registration and enhancement of signal/noise ratio in functional patterns, motor task and, 151(ab)
three-dimensional coordinate matching between MRI and, using maximum gradient method, 278(ab)
as tool in insanity defense, 13N(1)
total body imaging of recurrent recto-sigmoid cancer with ^{18}F FDG, 1041(ab)
tumor localization and systemic distribution of effector cells monitored by, 289(ab)
validation of tissue density measurements from transmission images, 548(ab)
value of quantitative analysis of glucose utilization in detection of myocardial viability by, 2068
Potassium-38, and PET, myocardial perfusion and necrosis estimates with, in experimental myocardial infarction, 49(ab)
Pregnancy
  and birth histories, after ^{131}I therapy in differentiated thyroid cancer, 787(ab)
  NRC rule, 20N(7)
  placental transfer and fetal biodistribution of radioiodine in guinea pig, 767(ab)
  placental transfer of technetium labeled radiopharmaceuticals in guinea pig, 778(ab)
Progestin, technetium and, improved complex as potential imaging agent for steroid receptors, 61(ab)
Progressive supranuclear palsy, new graphic method for estimation of distribution volume on ^{123}I IMP SPECT in differential diagnosis of Parkinson's disease and, 119(ab)
Prolyl endopeptidase, inhibitors, ^{11}C-labeled, synthesis and mouse brain uptake of, 23(ab)
Prostate, benign hypertrophy, prostatic hemodynamic change after transurethral hyperthermic treatment of, 553(ab)
Prostatic neoplasms
  correlation of bone scans and serum PSA levels in treatment of prostate cancer, 121(ab)
  immunoscintigraphy in, current applications of, 549(suppl)
  ^{111}In 7-E11-C5.3 anti prostate antibody, utility in preoperative workup of patients with carcinoma of prostate, 458(ab)
  metastatic cancer, ^{153}Sm EDTMP biodistribution and dosimetry estimation, 1031
  PET with ^{18}F FDG in cancer, 1021(ab)
  PSA levels in patients with newly diagnosed cancer, association with occurrence and pattern of metastases on staging bone scintigraphy, 1025(ab)
  rate of change in serum PSA *vs.* PSA level as screening test for prostate cancer, 504(ab)
Protein kinase C (PKC), ^{11}C-labeled phorbol esters as potential ligands for PET, 431
Pulmonary embolism
  application of neural networks to ventilation-perfusion imaging for diagnosis of, 850(ab)
  chest radiograph findings in, 1074(ab)
  comparison of clinical presentation and outcome in younger *vs.* older patients, 1073(ab)
  detailed analysis of patients with matched ventilation-perfusion defects and chest radiographic opacities, 1851
  diagnostic algorithms and lung scan interpretation, uniformity of, 661
  less likely represented by ventilation-perfusion/chest x-ray match if Q is "decreased" rather than "absent," 58(ab)
  prevalence of thromboembolic disease in patients with intermediate probability lung scans, 55(ab)
  rat model of, removal of early non-specific blood pool activity from antifibrin images applied to, 855(ab)
  regional distribution, observation from PIOPED study, 56(ab)
  revised scintigraphic criteria for interpretation of ventilation-perfusion scans for, 59(ab)
  simple model of, in rat, 1072(ab)
  suspected
    plasma D-dimer in evaluation of, 896
    ventilation imaging with "Pertechnegas" in, 488(ab)
  underestimation of segmental defect size, 370
  ventilation-perfusion scintigraphy in PIOPED study, 54(ab), 1109, 1119

Q

Quality assurance, WBC labeling with test based on adherence, 345
Quality control
  automated daily QC program, 853(ab)
  expert system, object oriented approach to, 862(ab)
Quality management, Pennsylvania medical center fined for alleged violations, 32N(8)

R

Radiation dosimetry
  absorbed dose calculations in Haversian canals for several beta-emitting radionuclides, 1361

automating large-scale processing of data, 780(ab)
bone marrow, for radioimmunotherapy, 689
correlation of radiation absorbed doses to nodal metastases, 524(le)
effective dose equivalent application to nuclear medicine patients, 714
estimates for C-14 urea breath test, 821
estimates for ^{18}F 4-FDG, 779(ab)
estimates for ^{99m}Tc P215, peptide for imaging of atherosclerotic plaques, 764(ab)
estimation of maximum possible organ radiation doses from ^{11}C labeled compounds, 763(ab)
estimation of upper limits on human radiation absorbed doses from ^{11}C labeled compounds, 2208
exposure to surgical personnel during intraoperative immunoscintimetry after application of ^{111}In or ^{99m}Tc labeled monoclonal antibodies, 773(ab)
Hanford Environmental Dose Reconstruction Project, 25N(1)
heterogeneity of microscopic dose distribution in radioimmunotherapy, theoretical analysis of, 1016(ab)
human studies of ^{111}In labeled polyclonal IgG, 769(ab)
of ^{123}I Epidepride, 772(ab)
of ^{123}I IBF, 1910
  imaging ligand of D2 dopamine receptor, 774(ab)
immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
internal, using data derived from autoradiographs, 1811
^{123}I TISCH, 208
^{131}I treatment of diffuse toxic goiters, 387
IUDR uptake and retention as measure of tumor growth, 1152
monoclonal antibody M195 in acute myelogenous leukemia, 422
optimized dose planning of radioiodine therapy of benign thyroidal diseases, 1632
personnel
  comparison for quantitative *vs.* qualitative PET studies, 775(ab)
  from ^{99m}Tc sestamibi *vs.* ^{201}Tl myocardial perfusion scintigraphy, 1210
quantitative *vs.* qualitative PET, radiation dose to technologists during, 769
radiation absorbed dose estimates from inhaled Kr-81m gas in lung imaging, 1382
radiolabeled antibodies as cancer therapeutics, 1028(le)
rates from patients undergoing ^{201}Tl study, 776(ab)
^{186}Re monoclonal antibodies, 908
revised, for FDOPA with carbidopa pretreatment, 768(ab)
structural changes in dosimeter matrix and parameters affecting accuracy for mini-TLDs, 781(ab)
of ^{99m}Tc ATC in visualization of internal mammary lymph nodes, 766(ab)
^{99m}Tc tetrofosmin, 30
therapeutic administrations of ^{131}I sodium iodide, radiation dose to upper spine from, 695
three-dimensional, for radioimmunotherapy treatment planning, 790(ab), 1595
time-dose fractionation in radioimmunotherapy, implications for selecting radionuclides, 1801

Radioactive waste
BRC exemptions, 20N(1)
danger in too many waste sites, 52N(6)
disposal of small quantities in local landfills, 349
low-level, 24N(4), 34N(7), 17N(9), 32N(10)
public opinion poll, 30N(5)
storage, NRC changing rules, 28N(5)
unregulated, waste handlers and hospitals at odds, 25N(2)

Radioimmunoassay
cardiac myosin light chain-1 specific, synthetic peptide immunogens for development of, 2144
immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
one-step, porous polymeric membranes for, 502(ab)
synthetic membranes used to simplify, 30N(7)

Radioimmunodetection
colorectal cancer, with ^{123}I labeled CEA monoclonal antibody fragments, 61
medullary thyroid cancer, using bispecific anti-CEA/anti-In-DTPA antibody and ^{111}In DTPA dimer, 1267
of Pneumocystis carinii pneumonia, in HIV patients, 239(ab)
preoperative, with ^{99m}Tc monoclonal antibodies in colorectal and gynecological surgery, 325(ab)
of small tumors, Monte Carlo Study of, 857(ab)
of thrombi, in presence of circulating antigen D-dimer, 754(ab)

Radioimmunoguided surgery, false-positive lymph nodes by, 804

Radioimmunotherapy. *See also* Radiotherapy
breast cancer, with ^{90}Y/^{111}N BRE-3, 204(ab)
of cancer, labeling of monoclonal antibodies with ^{186}Re using MAG3 chelate for, 1953
ChL-6, biologic enhancement shown by correlation of effector cell, complement and lymphokine activation with therapeutic effects, 372(ab)
clinical implementation of combined 3-D and MIRD-based dosimetry with ^{131}I CC49 monoclonal antibody, 508(ab)
clinical implementation of modeling-based treatment planning, ^{131}I M195 antibody against chronic myelogenous leukemia, 418(ab)
^{64}Cu tested as agent, 22N(7)
design of SPECT based 3-D treatment planning program for, 507(ab)
enhancement strategy for, immunoadsorption, 1020
experimental, of pancreatic cancer employing ^{131}I monoclonal antibody PAM4, 1010(ab)
heterogeneity of microscopic radiation dose distribution in, theoretical analysis of, 1016(ab)
^{131}I M195 trials in patients with myeloid leukemias, 207(ab)
isotope selection calculations based on antibody uptake from 3-D reconstructions of serial autoradiographs, 420(ab)
monoclonal antibody M195 in acute myelogenous leukemia, 422
parallel and cone beam, study of resolution and sensitivity for, 316(ab)
phase I
  with ^{131}I MN-14F(ab)$_2$, 206(ab)
  using Re-188 labeled murine monoclonal antibody, 209(ab)
phase I trials of refractory testicular carcinoma with ^{131}I 5F9.3 monoclonal antibody, 208(ab)
preclinical comparison of toxicity and, for Mu-9 anti-CSAp IgG labeled with ^{131}I, ^{90}Y or Re-188, 1014(ab)
radiolabeled antibodies as cancer therapeutics, 1028(le)
radon dosimetry and, implications of RBE-LET relationship for alpha-emitters in vivo for, 536(ab)
^{186}Re monoclonal antibodies
  dosimetry, 908
  preparation and evaluation, 260
time-dose fractionation in, implications for selecting radionuclides, 1801
time-dose-fractionation in, implications to selection of radionuclides, 419(ab)

Radioiodination, estrogens, comparative distribution, 272

Radioisotopes. *See also specific radioisotopes*
Brookhaven Linac isotope producer, 16N(2), 1828(ie)
DOE isotope program, report hints at restructuring, 49N(6)
DOE proposes two initiatives, 47N(6)
dual, brain SPECT imaging for monitoring cognitive activation, 267(ab)

Radioligands. *See* Ligands; *specific ligands*

Radionuclides. *See also specific radiotracer*
ambulatory monitor, left ventricular systolic and diastolic function measurements using, 1602
comparison of bone scans and magnetic resonance imaging in detecting spinal metastases, 2191, 2198
dual
  comparison of diagnostic accuracy with same day ^{99m}Tc isonitrile stress/^{201}Tl rest perfusion scintigraphy, 251(ab)
  diagnostic accuracy of stress perfusion scintigraphy using ^{201}Tl at rest and ^{99m}Tc isonitrile with stress, 253(ab)
experimental validation of magnetically enhanced therapy, 371(ab)
high resolution slit aperture for imaging small animals with SPECT, 26(ab)
hysterosalpingography, appropriate for new assisted reproduction techniques, 797(ab)
image quantitation, channel ratio method of scatter correction for, 330
inexpensive conversion of dual Gantry multidetector body scanner to determine distribution for dosimetry, 785(ab)
metallic, novel biological method to evaluate chelating agents for labeling antibodies with, 230(ab)
nonlinear estimation of scattered photons using neural networks, 848(ab)
parameter evaluation of dynamic studies compressed by principal component analysis and JPEG technique, 849(ab)
rare earth, chemistry of novel macrocyclic aminophosphonic acids chelates and their in vivo biodistribution, 1134(ab)
^{186}Re, monoclonal antibodies for immunotherapy, 260
spectroscopy system for multi-isotope study, gamma-ray energy spectrum analysis for each section of image using, 865(ab)
utility of Ommayograms in patients with leptomeningeal carcinomatosis, 966(ab)
whole body cylindrical detector for small animal imaging, 25(ab)

Radiopharmaceuticals
cardiology dominating U.S. sales, 28N(4)
effect of TTC staining on distribution of, 178(ab), 1722
effects of ban on enriched uranium exports, 19N(3)
EXAFS structural characterization of solutions of Rh-186 HEDP, therapeutic agent for metastatic bone cancer, 146(ab)
^{18}F BMY 14802, potential antipsychotic drug, 246
^{18}F FBT, molecular decomposition-reconstitution approach to novel vesamicol receptor radioligands, 21(ab)
FDA regulation, 24N(4)
high resolution slit aperture for imaging small animals with SPECT, 26(ab)
manufacturer's instructions, NRC regulations on departures, 523(le)
peptide, 2253
preparation of three ^{11}C labeled novel functional M1 selective muscarinic agonists, 18(ab)
ReO(EC) complexes derived from cysteine, 147(ab)
studies of cyclosporin-A toxicity in rats, and correlation with histological findings, 1086(ab)
synthesis and characterization of phosphorous-hydrazide steroid conjugate and its Pd-109 complex, 145(ab)
^{99m}Tc tetrofosmin, myocardial perfusion imaging, 222
tough choices and comfort level, 1829(le)
Radiopharmacy, NRC regulations, 22N(4), 20N(7)
Radioprotection
against ^{131}I, vitamin C in, 637
NRC, 22N(4)
Radiotherapy. *See also* Radioimmunotherapy
BIP for pretargeted delivery of, 1147
comparison of ^{67}Cu and ^{64}Cu as potential radionuclides for, 535(ab)
early response of human adenocarcinoma cell line to, assessment of agents for monitoring, 773
for metastatic bone cancer, EXAFS structural characterization of solutions of Rh-186 HEDP, 146(ab)
in mice, with ^{131}I labeled anti-small cell lung cancer monoclonal antibody, 1013(ab)
unilateral sialadenitis after, ^{67}Ga-citrate imaging, 953
Radiotracers. *See also specific radiotracer*
antisense oligonucleotides as, for diagnostic nuclear medicine, 1084(ab)
dual, autoradiography of cerebral acetate metabolism, 936(ab)
high resolution slit aperture for imaging small animals with SPECT, 26(ab)
kinetic modeling, new estimation method accounting for PET accumulated counts of blood-time activity curves, 154(ab)
Monte Carlo simulations of cross-talk component in dual isotope imaging, 234(ab)
multiple, studies of dopamine D2 receptors in vivo in control and dopamine-depleted mice, 190(ab)
potential, for mapping PEP in CNS, 1099(ab)
Receiver operating characteristic (ROC) analysis
comparability of FDG PET studies in probable Alzheimer's disease, 1460
comparison of simultaneous transmission emission tomography to routine SPECT for diagnosis of coronary artery disease on ^{201}Tl imaging, 281(ab)
continuous, evaluation of lesion detectability with cone beam, fan beam and parallel beam collimation in SPECT by, 321(ab)
diagnostic algorithms and lung scan interpretation, uniformity of, 661
results of study comparing filtered backprojection and maximum likelihood estimator images in FDG PET studies, 1198
Receptors
affinity labeling of neuroreceptors using gamma rays, 95(ab)
benzodiazepine
cerebral distribution in anxiety disorders, 181(ab)
regional alteration of distribution in refractory temporal lobe epilepsy revealed by group averaging techniques, 81(ab)
beta-adrenergic, myocardial, up-regulation early after sympathetic chemical denervation in dogs assessed with PET and ^{11}C CGP12177, 175(ab)
dopamine D2, multiple radiotracer studies of in vivo in control and dopamine-depleted mice, 190(ab)
EGF
and blockage on human tumor tissue by MAb 425 and its fragments, 1029(ab)
monoclonal antibodies against, 1005(ab)
functional testing in patients with idiopathic Parkinson's syndrome *vs.* Parkinson plus syndrome, 117(ab)
5-HT2, ^{18}F MDL11939 as potent specific ligand, 20(ab)
^{111}In chelated derivatives of ANP for in vivo imaging of, 226(ab)
mu-opioid, ethanol increases binding in man measured by ^{11}C carfentanil and PET, 1069(ab)
muscarinic
myocardial, quantification with PET in humans, 981
PET images of phosphoinositide response in primate brain, 94(ab)
nicotine, radioiodinated (S)-5-iodonicotine as new radiopharmaceutical for SPECT studies in brain, 1093(ab)
nicotinic cholinergic, in vivo labeling in brain using ^{3}H CYT, 946(ab)
octreotide scintigraphy for detection of paragangliomas, 873
opioid, delta, imaging in man, 410(ab)
P-glycoprotein, quantitation of expression in vivo with I-125 MRK-16 monoclonal antibody, 454(ab)
somatostatin
imaging in endocrine ophthalmopathy with ^{111}In DTPA-PHE-octreotide and high resolution SPECT, 798(ab)
imaging in pituitary using ^{111}In DTPA octreotide and high resolution brain SPECT, 159(ab)
scintigraphy in malignant lymphoma, 800(ab)
scintigraphy of endocrine tumors, 799(ab)
steroid, improved progestin-technetium complex as potential imaging agent for, 61(ab)
targeted radiolabeled polypeptides, intracellular metabolism, 229(ab)
vesamicol, novel radioligands, molecular decomposition-reconstitution approach to, 21(ab)
Rectum
colorectal cancer
current imaging strategies, 537(suppl)
^{123}I labeled CEA monoclonal antibody fragments in imaging, 61
immunoscintigraphy in surgical management, 541(suppl)
per rectal portal scintigraphy, situs inversus diagnosed by, surgical results for portacaval shunt in, 301
Reflux, gastroesophageal, sequential ten-second acquisitions for detection, 658
Regional wall motion
first-pass radionuclide angiographic studies of left ventricular function with ^{99m}Tc, 394
MIBG evaluation as potential tracer for monitoring doxorubicin cardiomyopathy, 1282
resting, relationship of segmental uptake of ^{99m}Tc sestamibi to, 728(ab)
^{201}Tl reinjection and improvement of left ventricular function following revascularization, 172(ab)
Renal function. *See also* Kidney
non-invasive real-time measurement of, 1616(le)
in acute care of patients at risk of acute renal failure, 1161(ab)
prognostic value of assessment in children with primary vesicoureteral reflux, 468(ab)
quantification of renal uptake of ^{99m}Tc DTPA using planar scintigraphy, 1184
relative, effect of different ROIs for background correction in patients with unilateral nephrectomy, 346(ab)
ReO(EC) complexes derived from cysteine, NMR and structural evidence for coupling of carboxyl group coordination to amine deprotonation, 147(ab)
Renography
captopril, with ^{99m}Tc MAG3, 1157(ab)
diuretic, 1029(le)
false-positive, method for minimization, normalized clearance-to-uptake slope ratio, 762
validation of renal output efficiency as objective quantitative parameter in evaluation of upper urinary tract obstruction, 845
exercise, reproducibility of results, 554(ab)
MAG3, artificial neural network classifier for analysis, 844(ab)
^{99m}Tc MAG3, automated detection of parenchymal pixels in, 845(ab)
Renovascular hypertension. *See* Hypertension, renovascular
Reperfusion, of myocardial infarction, teboroxime is marker of blood flow following, 48(ab)
Report generation, graphic user interface-based system, 515
Rhenium-186-HEDP
chemistry and biological behavior of particles, potential radiopharmaceutical for radiation synovectomy, 1536
multiple injections of, biodistribution effects in rats of, 1085(ab)
therapeutic agent for metastatic bone cancer, EXAFS structural characterization of solutions of, 146(ab)
Rhenium-186 monoclonal antibodies
chimeric NR-Lu-13, 2111
dosimetry, 908
radioimmunotherapy, preparation and evaluation, 260
using MAG3 chelate for radioimmunotherapy of cancer, 1953
Rhenium-188, generator readied for clinical cancer treatment, 33N(7)

Rhenium-188 monoclonal antibody, phase I radioimmunotherapy using, 209(ab)
Rheumatoid disease
joint, imaging with ^{99m}Tc labeled OKT3, 714(ab)
lung, cellular basis for elevated ^{67}Ga uptake in, 351(le)
Ribose, infusion reduces MIBI but not ^{201}Tl extraction in isolated rabbit heart, 177(ab)
ROC analysis. *See* Receiver operating characteristic analysis
Rotating scanner, PET, using BGO block detectors, 1367
Rubidium-82, PET
assessment of regional skeletal muscle perfusion with, 345(ab)
cardiac, 978
essential or not?, 1834(le)
myocardial perfusion imaging, 400

S

Salivary glands, postradiotherapy unilateral sialadenitis, ^{67}Ga-citrate imaging, 953
Samarium-153-EDTMP
administered for bone pain, pharmacokinetics and toxicity of, 534(ab)
biodistribution and dosimetry estimation, 1031, 2280(le)
in bone metastases of hormone refractory prostate carcinoma, 1839
comparisons of chelate structures on lesion to normal bone uptake ratios by QARG, in rat lesion model, 1083(ab)
multidose, for painful bone metastasis, 1047(ab)
Samarium-153 HEDP, chemistry and biological behavior of particles, potential radiopharmaceutical for radiation synovectomy, 1536
Sarcoidosis, cutaneous, ^{111}In leukocyte scintigraphy in, 812
Sarcoma
hemangioendothelial, scintigraphic "doughnut sign" on skeletal imaging, 297
musculoskeletal, recurrent or residual, FDG and methionine PET in differentiation from posttherapy changes, 124(ab)
osteosarcoma, imaging in dogs using ^{18}F TP-3 monoclonal antibody fragment and PET, 1017(ab)
Scatter, correction
assessment of scatter components in very high resolution PET scanner, 545(ab)
channel ratio method for radionuclide image quantitation, 330
Compton
compensation using triple-energy window method for single- and dual-isotope SPECT, 2216
by curve fitting photopeak region of energy spectra acquired at every image point, 235(ab)
dual photopeak window, investigation using extended windows, 284(ab)
in ^{131}I gamma camera images, subtraction-windows *vs.* spectral-fitting in, 236(ab)
iterative estimation of patient outer contour from emission tomographic projection images, 904(ab)
limitations of dual energy technique, results in 2D and 3D acquisitions from two commercial PET systems, 544(ab)
new method for quantitative SPECT, modified convolution subtraction with dual energy window for ^{131}I, 909(ab)
nonlinear estimation of scattered photons in radionuclide imaging using neural networks, 848(ab)
post-reconstruction artificial neural network for, in SPECT, 67(ab)
quantitative comparison of extended dual photon window and iterative reconstruction based, 285(ab)
simple, non-uniform, for SPECT, 896(ab)
spatial dependence of scatter energy spectrum, 851(ab)
three-dimensional PET
with plane integrals, 890(ab)
using scanners with retractable septa, 671
validation of spectral-image acquisition system, 451(ab)
Scintigraphy
appearance of pathophysiologic loci in central type tinnitus, ^{99m}Tc HMPAO study of, 992(ab)
blue-noise dithering for printing scintigrams on high resolution b/w printers, 860(ab)
bone
compared with MRI in diagnosis of skeletal metastases in prostate cancer at initial presentation, 120(ab)
difference in intervertebral fusion rate of cervical and lumbar spine assessment by, 712(ab)
disseminated North American blastomycosis, 458
"doughnut sign" due to hemangioendothelioma, 297
intraosseous meningioma appearance over five years, 961
in metabolic bone disease, 2247
oncology and infection, 2236
orthopedic scanning, 2241
SPECT in recent meniscal tears, 713(ab)
yield for identifying occult malignancy in patients with musculoskeletal pain, 122(ab)
CCK administration before, efficacy for hepatobiliary scans in patients with systemic illnesses, 299(ab)
in characterization of gastric antral motility disturbances, in diabetes, 576
characterization of gastric emptying pathophysiology in idiopathic dyspepsia using, 31(ab)
dynamic MAG3, role in diagnosis of acute pyelonephritis, 469(ab)
evaluation of bile dynamics following endoscopic sphincterotomy, 820(ab)
exercise, in renovascular hypertension, 48
^{67}Ga, early detection of lymphoma recurrence with, 2101
heart and skeletal muscle, in dermato/polymyositis, 707(ab)
hepatobiliary
morphine-augmented, false-negative, bile leak from gallbladder perforation mimicking bowel activity and, 131
morphine-augmented *vs.* delayed imaging, suspected acute cholecystitis, 506
pediatric, hepatic extraction fraction determination by deconvolution analysis, 214
^{123}I MIBG
dynamic analysis of, in cardiac mechanical overload hypertrophy and failure, 589
as index of severity in primary hypertrophic cardiomyopathy, 45(ab)
^{131}I MIBG, preoperative and postoperative evaluation of paragangliomas, 173
^{111}In leukocyte
in cutaneous sarcoidosis, 812
in detection of unsuspected pseudomembranous colitis in critical care patients, 35(ab)
^{111}In octreotide, in patients with paraganglioma or medullary thyroid carcinoma, 555(ab)
^{111}In polyclonal IgG, in fever of unknown origin, 242(ab)
myocardial perfusion, personnel radiation dosimetry from ^{99m}Tc sestamibi *vs.* ^{201}Tl in, 1210
oropharyngo-esophageal function in stroke and other neurologic disorders, 34(ab)
of pancreatic transplants, comparison of radionuclide angiogram and blood pool imaging with ^{201}Tl, 826(ab)
parathyroid, ^{99m}Tc pertechnetate, ^{201}Tl, and ^{99m}Tc sestamibi, 808(ab)
per jejunal portal, evaluation of effective portal venous flow in chronic liver diseases using echo-Doppler flowmetry combined with, 1103
pH probe *vs.*, for quantification of pediatric gastroesophageal reflux, 1228
portal, per rectal, surgical results for portacaval shunt in situs inversus diagnosed by, 301
revised criteria for interpretation of ventilation-perfusion scans for pulmonary embolism, 59(ab)
subtraction, parathyroid, ^{201}Tl/^{99m}Tc, ultrastructural histology correlation with, 24
^{99m}Tc pertechnetate, in ileal duplication of stomach and duodenum, 294
thyroid, unusual findings in adenoma, 465
^{201}Tl
for assessment of ^{67}Ga avid mediastinal mass following therapy for Hodgkin's disease, 1326
complementary role with mammography in diagnosis of breast cancer, 2095
left ventricular cavity-to-myocardial count ratio, resting left ventricular dysfunction, 193
in mass abnormalities of breast, 18
in pediatric solid tumors, 200(ab)
ventilation-perfusion
in PIOPED study, 54(ab)
quantitative, in single lung transplants, 166(ab)
vesicoureteral, direct, 466(ab)
WBC, routine application of fractionated HMPAO stored at −70°C for, 151
Scintillation camera
channel ratio method of scatter correction for radionuclide image quantitation, 330
high resolution pinhole SPECT for small animal imaging, 27(ab)
Scintillator, small fiberoptically coupled plastic positron probe, 450(ab)
Scleroderma, acute, renal scintigraphy in, 1163
Seizures. *See also* Epilepsy
frontal lobe, focus localization with ictal ^{99m}Tc HMPAO SPECT, 978(ab)
localizing focus with FDG-PET imaging in temporal lobe epilepsy, using modified lateralization criteria, 979(ab)
post-surgical outcome and PET-FDG imaging, in complex partial epilepsy, 79(ab)

spontaneous, rapid preparation and optimal deployment of ^{99m}Tc HMPAO during, 666
temporal lobe, predictive importance of FDG-PET in, 83(ab)
Self-referral, bans on, 22N(4)
Serotonin
potent receptor specific ligand, ^{18}F MDL11939, 20(ab)
reuptake ligands, 90(ab)
transporters, MIBG uptake by, 1140
uptake sites
highly potent indanamine 5-HT uptake blockers as radiotracers for imaging of, 1092(ab)
imaging with ^{11}C McN, 91(ab)
PET radiotracer for studying, 120
synthesis and biological evaluation of PET radioligand for, 19(ab)
Shunt
arteriovenous, effect of SC-47643 and heparin on platelet deposition and fibrin accretion in canine model, 838(ab)
portacaval, surgical results in situs inversus diagnosed by per rectal portal scintigraphy, 301
right-to-left, scintigraphic sign for detection of, 1607
Sialadenitis, unilateral, postradiotherapy, ^{67}Ga-citrate imaging, 953
Sickle cell disease, with acute chest syndrome, simultaneous occurrence of rib infarction and pulmonary infiltrates in, 614
Siegel, Barry A., people in nuclear medicine, 42N(6)
Single photon emission computed tomography (SPECT)
adenosine, quantitative, models for predicting long-term outcome after acute myocardial infarction by, 212(ab)
adenosine ^{201}Tl, comparison of results using four- *vs.* six-minute infusion protocol, 737(ab)
application of massively parallel computer for three-dimensional maximum a posteriori reconstruction in SPECT, 71(ab)
in back pain, with emphasis on marrow changes in end plates in association with disc degeneration, 711(ab)
and biodistribution studies with ^{99m}Tc CBPAO, new brain perfusion imaging agent, 970(ab)
biplane gated, and gated equilibrium and first-pass radionuclide angiographic quantitative measures of left ventricular systolic and diastolic performance, 130(ab)
bone
diagnosis of partial and total physeal arrest by, 1410
in recent meniscal tears, 713(ab)
bone scans in renal allograft recipients, 381
bone scintigraphy of spine in patients with malignant tumors, utility of, 717(ab)
brain, neural network classifier for, 100(ab)
brain activation images, propagation of registration errors in, 900(ab)
brain blood flow, in temporary balloon occlusion of carotid and intracerebral arteries, 1239
brain dopamine D2 receptor imaging in humans with ^{123}I IBZM administered as constant infusion, 435(ab)
cardiac
correction for attenuation and geometric point response distortions in, 111(ab)
importance of attenuation compensation and its implementation in, 110(ab)
cardiac imaging, effect of motion on, 1355
cerebral activation of lexical decision in psychopaths using, 306(ab)
clinical evaluation of high spatial resolution reconstruction technique using fan-beam collimator, 921(ab)
clinical validation of CT/MRI registration and, in radiolabeled monoclonal antibody studies of colorectal carcinoma, 374(ab)
comparison of manual and automated coregistration of brain images without use of external fiducial markers, 919(ab)
comparison of 3-D surface and transparency renderings to tomographic slice images for detection of coronary artery disease, 931(ab)
converging-beam, method for modeling photon scatter in, 917(ab)
correction, iterative reconstruction methods for nonuniform attenuation distribution, 1204
in crack abuse, 899
demonstrates loss of striatal dopamine transporters in Parkinson's disease, 116(ab)
determination of attenuation map from projection data alone, 918(ab)
Diamox, cerebrovascular vasodilatory tests, 244(ab)
dopaminergic D2 receptor imaging in Rett syndrome, increase of specific binding in striatum, 1717
dual isotope brain imaging for monitoring cognitive activation, initial studies in humans, 267(ab)
dual isotope myocardial perfusion imaging, sensitivity for detection of specific atherosclerotic lesions, 254(ab)
dynamic, using ^{99m}Tc teboroxime for quantification of myocardial perfusion, 733(ab)
dynamic quantitative ^{133}Xe regional cerebral blood flow on PRISM 3-headed tomograph, 266(ab)
dynamic validation studies, graphic plot analysis for cerebral blood flow and partition coefficient, 498
EEG-lead attenuation in, 923(ab)
evaluation of lesion detectability with cone beam, fan beam and parallel beam collimation in, by continuous ROC analysis, 321(ab)
evaluation of quantification using in vivo dog studies and ^{99m}Tc MAA, 96(ab)
fast and stable weighted least squares-conjugate gradient algorithm for, 98(ab)
fast transmission CT for determining attenuation maps using collimated line source, rotatable air-copper-lead attenuators and fan-beam collimation, 1577
FDG, in detection of viable myocardium during hyperinsulinemic glucose clamping, 727(ab)
^{67}Ga, unsuspected complications of bacterial endocarditis imaged by, 955
^{67}Ga-citrate, disseminated North American blastomycosis, 458
gated, myocardial thickness by, 856(ab)
gated ^{99m}Tc sestamibi, left ventricular ejection fraction assessed from, 1871
generalized dual energy window scatter compensation for, 283(ab)
heart, cardiovascular research fellowships awarded to investigators of diagnosis, 29N(7)
high-resolution brain imager
feasibility of, 99(ab)
somatostatin receptor imaging in pituitary using, 159(ab)
high-resolution imaging of spine, in children and adolescents, 202(ab)
high resolution slit aperture for imaging small animals with, 26(ab)
high resolution triple head, in infectious spondylitis, 330(ab)
in HIV encephalopathy and depression, 185(ab)
^{123}I IMP, functional mapping of flow and back-diffusion rate in human brain, 839
^{123}I TISCH, dosimetry, 208
ictal, ^{99m}Tc HMPAO, rapid preparation and optimal deployment during spontaneous seizures, 666
identification and characterization of hypertrophic myocardium, 1013
^{123}I IMP
new graphic method for estimation of distribution volume in differential diagnosis of PSP and Parkinson's disease, 119(ab)
quantitative assessment of cerebrovascular reserve using split dose method, 245(ab)
^{123}I Iomazenil, in presurgical work-up of patients with medically intractable focal epilepsy, 80(ab)
^{131}I IUDR, assessment of brain tumor proliferative activity using, 139(ab)
image registration and fusion for spatial localization of metastases using radiolabeled monoclonals, 562(suppl)
imaging of hypoxic brain, 365(ab)
imaging of sigma receptors in vivo in primates, 1097(ab)
^{123}I MIBG, myocardial, cardiomyopathy outcome prediction using, 46(ab)
in improvement of pheochromocytoma evaluation with ^{123}I MIBG, 40(ab)
inactive enantiomer of β-CIT, tracer of nonspecific brain uptake, 1131(ab)
independence of regional asynergy and myocardial perfusion defect reversibility, 86(ab)
^{111}In octreotide, in patients with brain and pituitary tumors, 140(ab)
investigation of effects and design of source collimation for transmission imaging in, 899(ab)
in vivo mapping of cholinergic neurons in human brain using (-)-5-^{123}I IBVM and, 93(ab)
iterative estimation of patient outer contour from emission tomographic projection images, 904(ab)
iterative reconstruction algorithm with natural pixel basis, 66(ab)
IUDR uptake and retention as measure of tumor growth, 1152
less than 2mm high resolution, with pinhole collimator for small animals, 925(ab)
localizing power of ictal regional cerebral blood flow in temporal lobe epilepsy relative to surgical outcome, 82(ab)
McSPECT II, design and construction of, 24(ab)
measurement of benzodiazepine receptor number and affinity in primate brain, comparison with in vitro values, 431(ab)

metastatic malignancy masquerading as hepatic hemangioma on labeled RBC scintigraphy, 1172
method for estimating parameters of a fan-beam and cone-beam system, using five point sources, 912(ab)
modeling effects of composition and inhomogeneity of scattering media on scatter response function in, 282(ab)
multi-radionuclide, elimination of scattered photons in simultaneous data acquisition for, 914(ab)
myocardial
  detection and correction of patient motion using multi-detector camera, 1349
  emission based technique for obtaining attenuation correction data for, 898(ab)
myocardial perfusion images, patient motion effects on, 303
myocardial perfusion imaging, detection of patient motion during, 1341
noise and spatial resolution properties of ML-EM reconstructed images, 69(ab)
in oncology, 13N(8)
optimal identification of myocardial viability with, 85(ab)
phantom study of breast tissue attenuation in myocardial imaging, 992
physical performance evaluation of Toshiba GCA-9300A triple-headed system, 1778
pinhole, high resolution, for small animal imaging, 27(ab)
pinhole collimation for ultra-high resolution, small-field-of-view studies, 29(ab)
planar imaging and, of ischemic canine myocardium using novel ^{99m}Tc nitroimidazole, 50(ab)
and planar imaging of experimental myocardial infarction with instant ^{99m}Tc antimyosin kit, 191(ab)
post-reconstruction artificial neural network for compensation of collimator, attenuation and scatter effects in, 67(ab)
proselytism, retroversion and fiscal nihilism in nuclear cardiology, 1823
quantitative effects of count rate dependent Wiener filter on image quality, basal ganglia phantom study simulating ^{123}I dynamic SPECT imaging, 905(ab)
quantitative gated blood pool imaging, enhanced sensitivity for non-invasive assessment of coronary artery disease, 131(ab)
quantitative imaging with ^{67}Cu in Alderson phantom, 901(ab)
quantitative same-day rest-stress ^{99m}Tc sestamibi, definition and validation of stress normal limits and criteria for abnormality, 1494
rapid back to back adenosine stress/rest ^{99m}Tc teboroxime myocardial perfusion, using triple-detector camera, 1485
rapidly converging iterative reconstruction algorithms in, 1793
regularized iterative reconstruction method which preserves sharp edges, 924(ab)
reversible ^{201}Tl perfusion defects in right bundle branch block and normal coronary angiogram, 1218(le)
routine, ROC comparison to simultaneous transmission emission tomography for diagnosis of coronary artery disease on ^{201}Tl imaging, 281(ab)
scanning line source for simultaneous emission and transmission measurements in, 1752
segmentation of body, lungs, and patient table from scatter and primary window images in, 928(ab)
simple non-uniform scatter correction for, 896(ab)
simultaneous imaging of ^{201}Tl and ^{99m}Tc using four energy windows, 897(ab)
simultaneous ^{201}Tl/^{99m}Tc cardiac imaging, experimental verification of energy weighted dual isotope technique for, 108(ab)
single- and dual-isotope, Compton scatter compensation using triple-energy window method for, 2216
slat collimation for high sensitivity 2D and 3D imaging, 28(ab)
stationary hemispherical imager for three-dimensional brain imaging, 474
study of abnormal regional cerebral blood flow response to auditory stimulation in childhood autism, 307(ab)
symmetry computed analysis of perfusion reconstructed slices, 922(ab)
system with two opposing detectors, cone-beam tomography using orbits satisfying data sufficiency condition for, 318(ab)
Tanaka's filtered iterative reconstruction method can make EM algorithm practical for clinical use in, 68(ab)
^{99m}Tc DMSA
  clinical value of triple head imaging as initial diagnostic tool in adult women with recurrent acute pyelonephritis, 551(ab)
  for detection of renal scars in children with vesicoureteric reflux, 198(ab)
  renal scans, 1065(ab)
^{99m}Tc ECD *vs.* ^{133}Xe, in mild to moderate regional cerebral blood flow abnormalities, 754
^{99m}Tc HMPAO
  in assessment of collateral cerebral perfusion during temporary internal carotid artery occlusion, 1235
  brain perfusion, ^{123}I IBZM dopamine D2 receptor and, Huntington's disease and, 1274
  brain scan in schizophrenia, 309(ab)
  brain scans, segmental analysis of, 9(ab)
  in detection of postural cerebral hypoperfusion in patients with cerebrovascular disease, 1931
  in diagnosis of chronic fatigue syndrome, 182(ab)
  Diamox, in identification of diaschisis in stroke, 249(ab)
  evaluation of brain in autistic disorder, 308(ab)
  high resolution, in probable Alzheimer's disease, *vs.* FDG PET, 10(ab)
  methodological features for neurostimulation studies with, 1217(le)
  in patients with cortical visual loss, 1447
  pre-, intra-, and postoperative monitoring in patients with severe carotid stenosis, 247(ab)
  in prediction of cerebral palsy in high-risk neonates, 1223
  regional cerebral blood flow improvement with treatment in cocaine users, 723
  regional cerebral blood flow in chronic alcoholism, relation to neuropsychological testing, 1452
  resting and activation patterns of prefrontal blood flow in schizophrenia, 305(ab)
  test-retest variability of brain perfusion studies in normal human subjects, 248(ab)
^{99m}Tc RBC, liver hemangioma, 375
^{99m}Tc sestamibi
  gated, for assessment of myocardial perfusion abnormalities, 601
  gated and ungated bull's-eyes, inhomogeneity, comparison with ^{201}Tl, 281
  myocardial perfusion defect size after stress, 187
  quantitative program for assessment of perfusion defect severity in stress imaging with, 732(ab)
  significance of transient dipyridamole-induced left ventricular cavity dilatation as assessed by, 297(ab)
^{99m}Tc sestamibi perfusion images, abnormal segmental contraction creates defects despite normal myocardial blood flow, 724(ab)
temporal lobe findings in mood disorders may be influenced by biological properties of radioligand, 184(ab)
tests fees *vs.* quality of care for PET *vs.*, and cost-effectiveness of diagnosis and management of coronary disease, 136(ab)
thallium imaging in evaluating activity of soft tissue and bone tumors, 123(ab)
three-dimensional Bayesian reconstruction for, 70(ab)
3-D registration of brain images, 893(ab)
^{201}Tl
  accuracy at rest for evaluation of myocardial viability in comparison to ^{18}F FDG PET, 729(ab)
  in childhood brain tumors, 201(ab)
  clinical evaluation in supratentorial gliomas, 2085, 2089
  comparison of prognostic value in treadmill exercise score in medically treated patients with coronary artery disease, 294(ab)
  comparison with MRI in evaluation of primary CNS lymphoma in non-AIDS patients, 219(ab)
  effect of motion on, 1845
  left ventricular cavity-to-myocardial count ratio, resting left ventricular dysfunction, 193
  low likelihood of coronary events in young patients with normal results, 210(ab)
  myocardial imaging in Bland-White-Garland syndrome, 2182
  myocardial perfusion imaging, 400
  for predicting histological types of meningiomas, 2091
^{201}Tl scintigraphy, rest-redistribution after acute myocardial infarction predicts normal wall motion on low dose dobutamine echocardiography, 170(ab)
two- and three-dimensional, fast reconstruction method for, 915(ab)
vectorized Monte Carlo code for modeling photon transport in non-uniform media for, 895(ab)
verification of varying threshold edge detection technique for spleen volume, *vs.* CT volumes, 963
view from the top, 907(ab)
whole body cylindrical detector for small animal imaging, 25(ab)

Skeleton. *See also* Bone
^{67}Ga and ^{99m}Tc MDP scintigraphy in determining prognosis for children with stage IV neuroblastoma, 1082
metastases, MRI *vs.* bone scintigraphy in diagnosis in prostate cancer at initial presentation, 120(ab)
scintigraphic "doughnut sign" due to hemangioendothelioma of bone, 297
Skin, ^{111}In leukocyte scintigraphy in cutaneous sarcoidosis, 812
Small intestine, transit, erythromycin effects on, 582
Snake venom, Russian, radioactive, 28N(5)
Society of Nuclear Medicine (SNM)
actions of Board of Trustees, 25N(4)
annual meeting highlights, 13N(8)
annual meeting preview, 22N(5)
Cardiovascular Council position paper, on clinical use of cardiac PET, 1385
coordinator to staff new office, 24N(1)
election results, 32N(7)
government relations update, 22N(4), 19N(7), 28N(10)
medical imaging in the nineties, 157
Mid-Winter Meeting, desktop computing, 18N(1)
nominees for offices, 25N(4)
relocation to Washington, 25N(4)
restructuring, 25N(4)
plan passes Board of Trustees, 26N(10)
Soft tissue
infections, new antigranulocyte Fab' fragment for diagnosis of, 830(ab)
localization of bone seeking radiopharmaceuticals, 1612
sarcomas, detection and grading with PET and FDG, 1030(ab)
tumors, use of early, late and SPECT thallium imaging in evaluating activity of, 123(ab)
Software. *See* Computers, software
Somatostatin
handling of analogues by perfused rat liver, 801(ab)
localization of gastroenteropancreatic tumors with ^{111}In somatostatin analogue, 156(ab)
receptor imaging in endocrine ophthalmopathy, with ^{111}In DTPA-PHE-octreotide and high resolution SPECT, 798(ab)
receptor imaging in pituitary using ^{111}In DTPA octreotide and high resolution brain SPECT, 159(ab)
receptor positive tumors, human in vivo detection by ^{111}In octreotide, 1031(ab)
receptor scintigraphy in malignant lymphoma, 800(ab)
receptor scintigraphy of endocrine tumors, 799(ab)
receptor scintigraphy with ^{111}In octreotide, in localization of gastrinomas and metastases in Zollinger-Ellison syndrome, 389(ab)
scintigraphy, in granulomatous diseases, Sjögren's syndrome and rheumatoid arthritis, 472(ab)
SPECT. *See* Single photon emission computed tomography
Sperm cell labeling, in monitoring sperm cell dynamics in female rabbit genital tract after insemination, 1134
Spine
continuing loss of vertebral mineral density in renal transplants, 440(ab)
difference in intervertebral fusion rate of cervical and lumbar spine, assessment by bone scintigraphy, 712(ab)
high-resolution SPECT imaging, in children and adolescents, 202(ab)
lumbar, bone mineral density heterogeneity, 705(ab)
SPECT and lumbar MRI in back pain, with emphasis on marrow changes in end plates in association with disc degeneration, 711(ab)
tuberculous and nontuberculous spondylitis, ^{67}Ga scintigraphy in, 853
vertebral compression fractures in cancer patients, FDG PET evaluation of, 17(ab)
Spleen
idiopathic thrombocytopenic purpura, splenectomy correlation with sequestration of autologous ^{111}In labeled platelets, 182
pretargeted radiation delivery to, BIP for, 1147
volume, verification of varying threshold edge detection SPECT technique for, *vs.* CT volumes, 963
Stenosis
aortic, cardiac uptake of MIBG in patients with, 1392(le)
valvular aortic, left ventricular hypertrophy secondary to, myocardial uptake of ^{123}I MIBG in, 57
Stereotaxy
automated, detection of intercommissural line for localization of functional brain images, 322
305-member MRI-based atlas for activation studies, 277(ab)
transformation of PET scans by deformation of standard brain atlas, 279(ab)
Sternberg Fellowship, establishment, 33N(7)
Stomach
antral motility disturbance characterization, in diabetes, using scintigraphic technique, 576
erythromycin effects on, 582
ileal duplication, ^{99m}Tc pertechnetate scintigraphy in, 294
lag phase in solid gastric emptying, comparison of quantification by physiological and mathematical definitions, 1701
postprandial gastric motility in infants with gastroesophageal reflux and delayed gastric emptying, 2120
regional motility in healthy volunteers, cisapride effect on, 393(ab)
Streptavidin
conjugated C110 IgG antibody, evaluation for tumor detection, 1119(ab)
conjugated monoclonal antibodies and radiolabeled biotin, distributed pharmacokinetic model of two-step imaging and treatment protocols, 1552
preparation of immunoconjugates of monoclonal antibody CC49 for 2-step targeting of colon cancer with ^{111}In and ^{99m}Tc biotin, 395(ab)
pretargeted, BIP for localization to, 1147
Stress imaging
immediate ^{201}Tl reinjection following, in myocardial viability detection, 737
^{99m}Tc sestamibi, rest ^{201}Tl and, quantitative assessment of reversibility for separate acquisition dual isotope myocardial perfusion SPECT, 250(ab)
^{99m}Tc sestamibi SPECT myocardial perfusion defect size, 187
quantitative program for assessment of perfusion defect severity in, 732(ab)
^{201}Tl
cost-effective selection of patients for reinjection prior to redistribution imaging using criteria based on quantitative analysis of, 169(ab)
quantitative reproducibility of, 168(ab)
resting myocardial blood flow and glucose metabolism maintenance in dysfunctional myocardium with redistribution, 171(ab)
Striatum
^{11}C raclopride binding, reproducibility of repeated measures, 609
does FDOPA uptake decrease with age?, 989(ab)
estimation of dopamine D2 receptor binding potential with ^{123}I IBZM SPECT, 2076
in vivo visualization of transplants in primate model of Huntington's disease, 960(ab)
recovery of signal in slice oriented PET, 481
SPECT imaging demonstrates loss of dopamine transporters in Parkinson's disease, 116(ab)
Stroke
associated with dipyridamole ^{201}Tl myocardial imaging, 128
characterizing penumbra with NMR spectroscopy and SPECT, 364(ab)
dementia and, intrasubject comparison of Neurolite to Ceretec in, 945(ab)
diaschisis in, identification using Diamox ^{99m}Tc HMPAO SPECT measures of cerebrovascular reactivity, 249(ab)
dipyridamole testing in, 1389(le)
mirror movements during recovery from, 225(ab)
scintigraphic studies of oropharyngo-esophageal function in, 34(ab)
Strontium-89 chloride, therapy in nuclear medicine, 1037
Substance abuse
does detoxification reverse acute alveolitis of crack smokers?, 164(ab)
evaluation of chronic toluene abuse patients using cerebral perfusion SPECT, 997(ab)
mapping ^{11}C methamphetamine and ^{11}C Ecstasy binding sites in monkey brain with PET, 1109(ab)
regional cerebral blood flow improvement with treatment in chronic cocaine polydrug users, 723
Subtraction scintigraphy, parathyroid, ^{201}Tl/^{99m}Tc, ultrastructural histology correlation with, 24
Surgery
coronary artery bypass grafting, prognostic value of radionuclide cineangiography for risk stratification in elderly after, 126(ab)
effect of cardiopulmonary bypass surgery on pulmonary vascular permeability, assessment by transvascular transport of ^{67}Ga, 1077(ab)
intraoperative assessment of brain malignancies using ^{201}Tl, 138(ab)
monitoring with ^{99m}Tc HMPAO SPECT in patients with severe carotid stenosis, 247(ab)
PET differentiation of residual or recurrent chest tumors from changes after, 162(ab)
PET-FDG evaluation before, in patients with suspected malignant solitary pulmonary nodules, 72(ab)
radioimmunoguided, false-positive lymph nodes by, 804

results, for portacaval shunt in situs inversus, 301
value of ^{123}I Iomazenil SPECT in presurgical work-up of patients with medically intractable focal epilepsy, 80(ab)
vascular
cardiac risk stratification prior to, 293(ab)
gender differences for long term cardiac event-free survival in, 736(ab)

Sympathetic nervous system
left ventricular innervation in arrhythmogenic right ventricular disease, 2(ab)
MIBG uptake by norepinephrine, dopamine and serotonin transporters, 1140
up-regulation of myocardial beta-adrenergic receptors early after sympathetic chemical denervation in dogs assessed with PET and ^{11}C CGP12177, 175(ab)

T

TCT. *See* Transmission computed tomography (TCT)

Teboroxime
kinetics as indicator of myocardial blood flow, 363(ab)
marker of blood flow following reperfusion of myocardial infarction, 48(ab)

Technetium-94m, production from isotopically enriched Mo-94 MoO_3, 1151(ab)

Technetium-94m teboroxime, synthesis, dosimetry and initial PET imaging studies, 1058

Technetium-99m
alternate synthesis of thiolactone for labeling biopeptides with, 1152(ab)
analysis of DNA single strand breaks in patients and in vitro caused by, 788(ab)
bone imaging with energy-weighted acquisition, 997
cardiac SPECT, non-uniform compensation using acquired transmission data, 112(ab)
compared with Am-241 as transmission source for attenuation correction of ^{201}Tl cardiac SPECT, 113(ab)
development of synthetic polymer based blood pool imaging agent labeled with, 149(ab)
directly and indirectly labeled antibodies, 109
dual labeling of human Ig with ^{90}Y and, using EDTB, 1140(ab)
evidence for coupling of carboxyl group coordination to amine deprotonation relevance to, ReO(EC) complexes derived from cysteine, 147(ab)
first-pass angiographic studies of left ventricular function, 394
high affinity chemotactic peptides labeled with, 62(ab)
high resolution slit aperture for imaging small animals with SPECT, 26(ab)
independence of regional asynergy and myocardial perfusion defect reversibility, 86(ab)
labeling of antibodies with, 1617(le)
load independence of early diastolic filling parameters in anesthetized canine model, 1520
lung scan, uniformity of interpretation, diagnostic algorithms and, 661
metastatic malignancy masquerading as hepatic hemangioma on labeled RBC scintigraphy, 1172
novel bifunctional chelating system for, 540(ab)
novel complexes based on new N2S2 and N2SO ligands, 538(ab)
peptides labeled with
atherosclerosis imaging in hyperlipidemic rabbits, 260(ab)
evaluation for imaging atherosclerotic lesions in vivo, 259(ab)
preparation and unexpected labelling properties of novel nitrogen heterocycle based N3S ligands, 539(ab)
progestin and, improved complex as potential imaging agent for steroid receptors, 61(ab)
prompt visualization of gallbladder with rim sign, 1169
renal scintigraphy in acute scleroderma, 1163
scintigraphic evaluation of liver masses, cavernous hepatic hemangioma, 849
scintigraphy *vs.* pH probe for quantification of pediatric gastroesophageal reflux, 1228
single-pass cerebral extraction and capillary permeability-surface area product, 641
SPECT
and MRI, in posterior cerebral artery infarction and related visual field defects, 1009
simultaneous imaging of ^{201}Tl and, 897(ab)
systolic pressure alteration effects on radionuclide measurements of left ventricular filling dynamics, 747
^{201}Tl and
experimental verification of energy weighted dual isotope technique for simultaneous SPECT cardiac imaging with, 108(ab)
parathyroid subtraction scintigraphy, ultrastructural histology correlation with results of, 24
uptake mechanism of neutral myocardial imaging agent ^{99m}Tc N-NOET, 65(ab)
uptake of cationic complexes in cultured human colon carcinoma cells, 1127(ab)
use of polylysine as linker for chelate and biotin, 1088(ab)

Technetium-99m anti-AFP Fab1, radioimmunoscintigraphy, in evaluation of treated germ cell tumors, 1001(ab)

Technetium-99m antibodies, can cysteine-challenge assay predict in vivo stability and biodistribution of?, 231(ab)

Technetium-99m antigranulocyte antibody *fragment*, immunoscintigraphy of infection, 240(ab)

Technetium-99m antimyosin, recombinant single-chain Fv, rapid infarct imaging, 234

Technetium-99m anti-rat-CDR monoclonal antibody, joint uptake and body distribution of, in rat adjuvant arthritis, 92

Technetium-99m-citrate, ^{67}Ga-citrate *vs.*, for imaging inflammatory lesions, 332(ab)

Technetium-99m colloid, aerosol, formulation with improved delivery efficiency for lung ventilation imaging, 268

Technetium-99m cyclic peptides, for thrombus imaging, 60(ab)

Technetium-99m-DADT-BVM, potential marker for cholinergic neurons, synthesis and in vivo evaluation of, 541(ab)

Technetium-99m-diphosphonate, diagnosis of partial and total physeal arrest by bone SPECT, 1410

Technetium-99m-DMSA
renal uptake
poor, and tubulointerstitial disease of kidney, 354(le)
^{99m}Tc-DTPA *vs.*, 1217(le)
scintigraphy
in urinary tract infection in children, 467(ab)
use in detection of renal scarring in children with repeated urinary tract infections, 1165(ab)
SPECT, for detection of renal scars in children with vesicoureteric reflux, 198(ab)
SPET, looking for renal scars with, 550(ab)
triple head SPECT imaging as initial diagnostic tool in adult women with recurrent acute pyelonephritis, 551(ab)

Technetium-99m-DTPA
aerosol deposition and clearance in experimental acute pulmonary embolism, 489(ab)
aerosol lung clearance, inhaled furosemide effect on, 163(ab)
captopril renogram, quantitative analysis of, 1416
diagnosis of renovascular hypertension with captopril renal scintigraphy in patient with solitary kidney, 1166
false-positive diuretic renograms, method for minimization, normalized clearance-to-uptake slope ratio, 762
improved post-perfusion aerosol inhalation imaging for rapid diagnosis of pulmonary embolism, 487(ab)
quantification of renal uptake using planar scintigraphy, 1184
real-time monitoring of renal function, ambulatory, 199
renal uptake-plasma volume product, as quantitative estimation of glomerular filtration rate, 1390(le)
^{99m}Tc DMSA and, differential renal uptake of, 1217(le)

Technetium-99m-ECD, SPECT
brain, in stroke, 967(ab)
usefulness in diseases of central nervous system, special reference to comparison to ^{123}I IMP and ^{99m}Tc HMPAO SPECT, 983(ab)
^{133}Xe *vs.*, in mild to moderate regional cerebral blood flow abnormalities, 747

Technetium-99m glucarate
accumulation by Chinese hamster ovary cells, hypoxia effect on, 242
distribution in acutely ischemic myocardium, 1303

Technetium-99m gluconate, accumulation by Chinese hamster ovary cells, hypoxia effect on, 242

Technetium-99m-HMDP
negative bone tumors, ^{18}F FDG PET in, 288
scintimetric evaluation of remodeling after bone fractures in man, 1403

Technetium-99m-HMPAO
brain SPECT
in detection of postural cerebral hypoperfusion in patients with cerebrovascular disease, 1931
increased cerebral perfusion after detachable balloon embolization of carotid cavernous fistula on, 1987
in Rett's syndrome, 1058(ab)
brain SPECT with memory activation in Alzheimer's disease, 462(ab)
in determination of brain death in children, uncoupling of flow and function, 203(ab)
fractionated, stored at −70°C, routine application for WBC scintigraphy, 151
gonadal uptake and localization in rodent model, 770(ab)
high resolution SPECT in probable Alzheimer's disease, *vs.* FDG PET, 10(ab)

ictal SPECT using, methods for rapid preparation and optimal deployment during spontaneous seizures, 666
I-125-Iomazenil and, in double tracer autoradiography in experimental brain ischemia, 935(ab)
regional cerebral blood flow improvement with treatment in chronic cocaine polydrug users, 723
response to visual cognitive stimulation assessed by, in Alzheimer type dementia, 11(ab)
SPECT
in assessment of collateral cerebral perfusion during temporary internal carotid artery occlusion, 1235
and balloon test occlusion, predicting tolerance prior to permanent cerebral artery occlusion, 1243
brain scan in schizophrenia, 309(ab)
and CT and MRI in evaluation of patients with chronic brain injury, 965(ab)
in diagnosis of chronic fatigue syndrome, 182(ab)
Diamox, in identification of diaschisis in stroke, 249(ab)
evaluation of brain in autistic disorder, 308(ab)
indicates that some posterior cerebral perfusion abnormalities may resolve in selected patients with extrinsic vertebral artery compression after surgery, 368(ab)
methodological features for neurostimulation studies with, 1217(le)
in patients with cortical visual loss, 1447
pre-, intra-, and postoperative monitoring in patients with severe carotid stenosis, 247(ab)
in prediction of cerebral palsy in high-risk neonates, 1223
regional cerebral blood flow in chronic alcoholism, relation to neuropsychological testing, 1452
resting and activation patterns of prefrontal blood flow in schizophrenia, 305(ab)
test-retest variability of brain perfusion studies in normal human subjects, 248(ab)
value for prediction of cerebral palsy in high-risk neonates, 1057(ab)
SPECT brain scans, segmental analysis of, high correlation between temporal defects and memory loss in, 9(ab)
spermatozoa radiolabeled with, in monitoring sperm cell dynamics in female rabbit genital tract after insemination, 1134
Technetium-99m-HMPAO leukocytes
clinical experience in detection of inflammatory and infectious diseases, 837(ab)
in diagnosis of focal purulent disease, 1428
Technetium-99m-HMPAO WBC
cardiovascular infection detection with, 868(le)
in patients presenting with abdominal pain, 444(ab)
Technetium-99m-HSA, new methods for labeling, 387(ab)
Technetium-99m-IgG
comparison with ^{99m}Tc HIG Technescan and ^{111}In Macroscint DTPA-IgG in rat model of focal infection, 839(ab)
and MIBG evaluation as potential tracer for monitoring doxorubicin cardiomyopathy, 1282
polyclonal, human
in diagnosis of focal purulent disease, 1428
imaging of focal sites of inflammation in non-human primates with, 832(ab)
Technetium-99m-IL2, labeling and purification for in vivo detection of chronic lymphocytic infiltration, 1141(ab)
Technetium-99m-LDL, biodistribution and imaging of oxidized LDL and, 261(ab)
Technetium-99m leukocytes, compared with ^{111}In granulocytes for examination of patients with inflammatory bowel disease, 1052
Technetium-99m liposome
biodistribution and imaging studies in rats with focal infection, 2160
evaluation as tumor imaging and drug delivery agent, 1148(ab)
labeling with long-chain alkyl monohydroxamamides, 1149(ab)
use of labeling procedure to monitor circulation properties of liposome encapsulated hemoglobin in rat shock model, 542(ab)
Technetium-99m LLEC, clearance, estimation by simplified method, 516(ab)
Technetium-99m lymphocytes, new approach to labeling in vitro, evaluation of radiolabeled cell immune functions, 1126(ab)
Technetium-99m-MAA
evaluation of SPECT quantification using in vivo dog studies and, 96(ab)
prevalence of thromboembolic disease in patients with intermediate probability lung scans, 55(ab)
scintigraphic sign for detection of right-to-left shunts, 1607
ventilation-perfusion scintigraphy in PIOPED study, 1109, 1119
Technetium-99m MAG3
clearance of, preliminary results of multicenter trial to determine by single sample and camera based techniques, 1163(ab)
diuretic renography, 1029(le)
high resolution computer enhanced renal parenchymal imaging, clinical significance of renal parenchymal abnormalities on, 549(ab)
identification of factors optimizing radiochemical purity of, 1159(ab)
renography, automated detection of parenchymal pixels in, 845(ab)
scintigraphy, carcinoma in transplanted kidney detected with, 2185
validation of renal output efficiency as objective quantitative parameter in evaluation of upper urinary tract obstruction, 845
validity of determination of clearance from cardiac time-activity curve obtained during routine renal imaging, 350(ab)
Technetium-99m-MBI, myocardial extraction, in isolated rabbit heart, 927
Technetium-99m-MDP
biomatrix hydroxyapatite ocular implants, 467
bone scintigraphy
in determining prognosis for children with stage IV neuroblastoma, 1082, 1087
effect of clodronate treatment in metastatic breast cancer, 1039
enthesopathy of patellar tendon insertion, isotretinoin therapy, 455
intraosseous meningioma appearance on bone scintigraphy over five years, 961
MRI and SPECT bone scans in renal allograft recipients, 381
Paget's disease in patient with breast cancer, 1214
uptake and biodistribution during rat tibial bone repair, 104
uptake in primary amyloidosis, with review of mechanisms of soft tissue localization of bone seeking radiopharmaceuticals, 1612
utility with SPECT in hydroxyapatite ocular implants, 438(ab)
Technetium-99m-MIBI
in evaluation of patients with primary carcinoma of breast, comparison with ^{201}Tl, 557(ab)
separate-day SPECT, fast stress and rest acquisitions for, 524(ab)
SPECT
discrepancies in perfusion defect estimates between ^{13}N ammonia PET and, not explained by differences in tracer behavior, 483(ab)
vs. ^{201}Tl in evaluation of childhood brain tumors, 1045
thyroid uptake, semiquantitative 30-minute, quick diagnosis of hyperthyroidism with, 71
Technetium-99m monoclonal antibodies
determination of specific and nonspecific binding and its significance on tissue distribution, 1144(ab)
directly and indirectly labeled, 109
kit-formulated conjugation of NHS-BAT ester to, 1019(ab)
lack of HAMA response in patients imaged with ImmuRAID-CEA and ImmuRAID-MN3, 1008(ab)
OKT3, imaging rheumatic joint diseases with, 714(ab)
in prediction of dosimetry of ^{186}Re monoclonal antibodies, 908
Technetium-99m N
multiple bond, synthesis of new class of brain imaging agents containing, 537(ab)
synthesis of neutral dithiocarbamate complex with, bearing ester groups, 63(ab)
Technetium-99m nanocolloid
changes in marrow localization as result of treatment with recombinant human granulocyte colony stimulating factor in canine model, 840(ab)
scintigraphy in orthopedic infections, comparison with ^{111}In labeled leukocytes, 1646
Technetium-99m nitroimidazole
complexes, separation of isomers of, 64(ab)
novel, planar and SPECT imaging of ischemic canine myocardium using, 50(ab)
Technetium-99m-pertechnetate
postradiotherapy unilateral sialadenitis, 953
scintigraphy, in ileal duplication of stomach and duodenum, 294
Technetium-99m Q3, new myocardial imaging agent
organ uptake and biodistribution studies of, 765(ab)
preparation for clinical studies, 1153(ab)
Technetium-99m RBC, distribution in ferret, isoflurane induced changes in, 829(ab)
Technetium-99m-sestamibi
clinical decisions, 860
combined with ^{201}Tl studies, differentiation of myocardial perfusion abnormalities from attenuation effects using relative regional activity profiles, 255(ab)
detection of primary lung cancer with, 558(ab)
dynamic renal imaging with, in hypertensive patients, 552(ab)

enhancement of accumulation in multidrug resistant cells by cytotoxic drugs and MDR reversing agents, 560(ab)
gated SPECT, left ventricular ejection fraction assessed from, 1871
generator eluate effects on labeling efficiency of kits, 730(ab)
increased lung uptake in diagnosis of coronary artery disease, 482(ab)
influence of patient height/weight and type of stress on count rates in myocardium with, 731(ab)
intraoperative validation of subtraction technique for preoperative localization of hyperfunctioning parathyroid tissue, 805(ab)
as marker of myocardial hypoperfusion, 1510
miniaturized and rapid paper chromatographic technique for radiochemical quality control of, 1090(ab)
myocardial multiple-gated SPECT simulation for determining accuracy of count-based systolic wall-thickening measurement, 383(ab)
normal myocardial perfusion imaging, prognostic value of, 211(ab)
as parathyroid imaging agent, 806(ab)
personnel radiation dosimetry from myocardial perfusion scintigraphy, ^{201}Tl compared with, 1210
prone breast imaging in patients with suspicion of breast cancer, 559(ab)
relationship of segmental uptake to resting regional wall motion, 728(ab)
SPECT
gated, for assessment of myocardial perfusion abnormalities, 601
gated and ungated bull's-eyes, inhomogeneity, comparison with ^{201}Tl, 281
myocardial perfusion defect size after stress, 187
quantitative same-day rest-stress, 1494
significance of transient dipyridamole-induced left ventricular cavity dilatation as assessed by, 297(ab)
SPECT and echocardiography, dobutamine, value in coronary artery disease detection, *vs.* coronary angiography, 889, 895
spontaneous silent myocardial ischemia assessed by, 134
stress, rest ^{201}Tl and, quantitative assessment of reversibility for separate acquisition dual isotope myocardial perfusion SPECT, 250(ab)
stress SPECT, quantitative program for assessment of perfusion defect severity in, 732(ab)
uptake in cultured myocardial cells, *vs.* ^{99m}Tc teboroxime, 255

Technetium-99m sulphur colloid, erythromycin effects on gastric emptying, alcohol absorption, and small intestinal transit, 582

Technetium-99m-teboroxime
dynamic SPECT using, for quantification of myocardial perfusion, 733(ab)
early myocardial clearance kinetics in differentiation of normal and flow-restricted canine myocardium at rest, 630
in vitro uptake in carcinoma cell lines and normal cells, 1949
rapid back to back adenosine stress/rest myocardial perfusion SPECT using triple-detector camera, 1485
tomographic imaging, comparison with ^{201}Tl imaging following intravenous dipyridamole infusion, 522(ab)
uptake in cultured myocardial cells, *vs.* ^{201}Tl and ^{99m}Tc sestamibi, 255

Technetium-99m-tetrofosmin
biokinetics of, 1254
human biodistribution, dosimetry, and safety of, 30
myocardial perfusion imaging, 222
myocardial perfusion imaging and dynamic analysis with, 1478

Technetium-99m-TMPAO, evaluation of isomers of, evidence that GSH is not significantly involved in cerebral retention, 1150(ab)

Technetium-99m-trisuccin, conjugated to monoclonal antibody CC49, biodistribution in athymic mice bearing colon cancer xenografts, 107(ab)

Technetium-99m(V)-DMSA
imaging of differentiated thyroid tumors with, 37(ab)
pituitary adenoma imaging using, 160(ab)
scintigraphic evaluation of tenosynovial giant-cell tumor using, 1745
uptake in intra-abdominal massive deposit of amyloid protein, 815

Technologists, PET, radiation dose during quantitative *vs.* qualitative studies, 769

Technology, transfer, DOE labs bill would enhance, 52N(6)

Temporal lobe epilepsy
predictive importance of FDG-PET in, 83(ab)
refractory, regional alteration of benzodiazepine receptor distribution in, 81(ab)

Temporal sampling, dynamic cardiac PET studies using image-derived input functions, 440

Ten-second acquisitions, sequential, for detection of gastroesophageal reflux, 658

Testes
metastatic neoplasms, initial evaluation of FDG/PET imaging of, 15(ab)
mouse, vitamin C as radioprotector against ^{131}I, 637
refractory carcinoma of, phase I radioimmunotherapy trials with ^{131}I 5F9.3 monoclonal antibody, 208(ab)
uptake of ^{111}In in patients from ^{111}In labeled platelets, 777(ab)

Thallium-201
adenosine SPECT, comparison of results using four- *vs.* six-minute infusion protocol, 737(ab)
brain SPECT, in childhood brain tumors, 201(ab)
brain uptake from CSF compartment, 99
cardiac SPECT, comparison of Am-241 and ^{99m}Tc as transmission sources for attenuation correction of, 113(ab)
characterization of reinjection image, 879
clinical decisions, 860
clinical evaluation of SPECT in supratentorial gliomas, 2085, 2089
combined with ^{99m}Tc sestamibi studies, differentiation of myocardial perfusion abnormalities from attenuation effects using relative regional activity profiles, 255(ab)
cost-effective selection of patients for reinjection prior to redistribution imaging using criteria based on quantitative analysis of stress image, 169(ab)
dipyridamole scintigraphy, noninvasive diagnosis of cardiac transplant arteriopathy with, 2049
identification and characterization of hypertrophic myocardium, 1013
immediate reinjection following stress imaging, in myocardial viability detection, 737
influence of patient height/weight and type of stress on count rates in myocardium with, 731(ab)
intraoperative assessment of brain malignancies using, 138(ab)
as marker of myocardial hypoperfusion, 1510
myocardial imaging, dipyridamole and additive value of radionuclide ventriculography for risk stratification prior to vascular surgery, 292(ab)
cerebrovascular accident associated with, 128
myocardial perfusion tomography, one to five years after successful coronary angioplasty, 296(ab)
myocardial SPECT in Bland-White-Garland syndrome, 2182
normal exercise myocardial perfusion imaging study, impact of antianginal medications, peak heart rate and stress level on prognostic value of, 1467
perfusion imaging with pharmacologic intervention, comparison between dipyridamole and dobutamine for detection of coronary artery disease, 381(ab)
per rectum scintigraphy, physiopathological significance in liver cirrhosis, 1642
personnel radiation dosimetry from myocardial perfusion scintigraphy, ^{99m}Tc sestamibi compared with, 1210
planar, quantitative, role for determining viability in acute myocardial infarction and totally occluded infarct-related artery, 728
redistribution, resting myocardial blood flow and glucose metabolism maintenance in dysfunctional myocardium with, 171(ab)
reinjection
and improvement of left ventricular function following revascularization, 172(ab)
nitroglycerin enhanced, for detection of viable myocardium, 173(ab)
repeated planar stress imaging, quantitative reproducibility of, 168(ab)
rest, and stress ^{99m}Tc sestamibi, quantitative assessment of reversibility for separate acquisition dual isotope myocardial perfusion SPECT, 250(ab)
rest/delayed SPECT, adjunctive value to demonstrate reversibility of fixed ^{99m}Tc sestamibi perfusion defects, 252(ab)
resting cardiac imaging, reverse redistribution in coronary artery disease, 725(ab)
resting myocardial scintigraphy, reverse redistribution in patients with coronary artery disease, 1688
reverse redistribution in perspective, 1692
reversible perfusion defects in right bundle branch block and normal coronary angiogram, 1218(le)
ribose infusion reduces MIBI but not ^{201}Tl extraction in isolated rabbit heart, 177(ab)
right ventricular kinetics in pulmonary hypertension, relation to right ventricular size and function, 1695
scintigraphy

for assessment of ^{67}Ga avid mediastinal mass following therapy for Hodgkin's disease, 1326
complementary role with mammography in diagnosis of breast cancer, 2095
improves life expectancy in heart attack survivors, 35N(10)
mass abnormalities of breast, 18
paradoxical changes in findings in advanced follicular thyroid cancer, 1574
in pediatric solid tumors, 200(ab)
search for optimal protocol for reinjection imaging, 743
simultaneous transmission-emission cardiac imaging, 280(ab)
SPECT
accuracy at rest for evaluation of myocardial viability in comparison to ^{18}F FDG PET, 729(ab)
adenosine, quantitative, models for predicting long-term outcome after acute myocardial infarction by, 212(ab)
comparison of prognostic value in treadmill exercise score in medically treated patients with coronary artery disease, 294(ab)
comparison with MRI in evaluation of primary CNS lymphoma in non-AIDS patients, 219(ab)
detection of thymic abnormality in myasthenia gravis with, 1048(ab)
in evaluation of lung and mediastinal disease, 1037(ab)
evaluation of suspected malignant pulmonary lesions with, 556(ab)
in follow-up of patients with lung cancer during radiotherapy, 1042(ab)
gated and ungated bull's-eyes, inhomogeneity, comparison with ^{99m}Tc sestamibi, 281
left ventricular cavity-to-myocardial count ratio, resting left ventricular dysfunction, 193
low likelihood of coronary events in young patients with normal results, 210(ab)
myocardial perfusion imaging, 400
for predicting histological types of meningiomas, 2091
vs. ^{99m}Tc MIBI in evaluation of childhood brain tumors, 1045
SPECT scintigraphy, rest-redistribution after acute myocardial infarction predicts normal wall motion on low dose dobutamine echocardiography, 170(ab)
^{99m}Tc and
experimental verification of energy weighted dual isotope technique for simultaneous SPECT cardiac imaging with, 108(ab)
parathyroid subtraction scintigraphy, ultrastructural histology correlation with results of, 24
^{99m}Tc MIBI *vs.*, in evaluation of patients with primary carcinoma of breast, 557(ab)
thyroid adenoma, 465
24-hour redistribution scintigraphy, superior to rest sestamibi imaging in identification of myocardial viability with SPECT, 85(ab)
uptake in cultured myocardial cells, *vs.* ^{99m}Tc teboroxime, 255
Thallium-201-chloride
in lobar primary pulmonary lymphoma, 1980
reversible perfusion defects in right bundle branch block and normal coronary angiogram, 1218(le)
sequential, ^{67}Ga-citrate and, in AIDS, 834(ab)
Therapeutic nuclear medicine, 1037
bone marrow dosimetry for radioimmunotherapy, 689
bronchogenic carcinoma mimicking metastatic thyroid carcinoma, 809
correlation of radiation absorbed doses to nodal metastases, 524(le)
dosimetry of ^{186}Re monoclonal antibodies, 908
immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
monoclonal antibody M195 in acute myelogenous leukemia, 422
optimization of radioiodine therapy of thyrotoxicosis, 1638
^{153}Sm-EDTMP biodistribution and dosimetry estimation, 1031
time-dose fractionation in radioimmunotherapy, implications for selecting radionuclides, 1801
trace element enhancement of ^{131}I MIBG therapy exchange yields, 148(ab)
Thermoluminescent dosimeters, radiation dose to PET technologists during quantitative *vs.* qualitative studies, 769
Thrombocytopenia
^{111}In labeled platelet sequestration, 182
prediction in patients treated with ^{186}Re HEDP, 1046(ab)
Thrombosis
functional and anatomical evaluation of carotid atherothrombosis, 828(ab)
^{111}In FBD as new imaging agent, 475(ab)
novel monoclonal antibody Fab' kit with dual ^{99m}Tc labeling sites for thrombus imaging, 399(ab)
preliminary evaluation of labeled disintegrins for thrombus imaging, 258(ab)
scintigraphic methods for detection of, 554(suppl)
^{99m}Tc labeled cyclic peptides for thrombus imaging, 60(ab)
Thymidine
effects of hypoxia on cultured human tumor cell uptake of, 288(ab)
for monitoring early response of human adenocarcinoma cell line to radiotherapy, ^{18}F-FDG and methionine *vs.*, 773
uptake, in vitro assessment of, 2278(le)
uptake and proliferative activity of human cancer cells, FDG uptake *vs.*, 414
Thymidine kinase, HSV-specified, NCA IVaraU probes for detection of, 1095(ab)
Thyroglobulin, circulating ^{131}I thyroxine in thyroid cancers, 36(ab)
Thyroid
ablation, assessment of ^{131}I efficacy for, 1927
adenoma, unusual scintigraphic findings, 465
benign diseases of, optimized dose planning of radioiodine therapy of, 1632
cancer
advanced follicular, paradoxical changes in ^{131}I scintigraphic findings in, 1574
differentiated, different features of pulmonary metastases in, 1626
high-activity ^{123}I for diagnostic evaluation of patients with, 161(ab)
correlation of radiation absorbed doses to nodal metastases, 524(le)
differentiated carcinoma, chromatographic identification in serum of endogenously radioiodinated thyroid hormones after ^{131}I whole-body scintigraphy in follow-up of patients with, 2032
dose selection and absorbed dose profiles in radioiodine treatment of diffuse toxic goiters, 387
Graves' orbitopathy, orbital ^{111}In DTPA octreotide accumulation not based on blood-pool radioactivity in, 158(ab)
long-term results of two schedules of radioiodine treatment for toxic multinodular goiter, 795(ab)
low occurrence of clinically significance ophthalmopathy after ablative treatment with radioactive iodine for Graves' hyperthyroidism, 1829(le)
medullary cancer
^{111}In octreotide scintigraphy in patients with, 555(ab)
radioimmunodetection using bispecific anti-CEA/anti-In-DTPA antibody and ^{111}In DTPA dimer, 1267
metastatic carcinoma, bronchogenic carcinoma mimicking, 809
optimization of radioiodine therapy of thyrotoxicosis, 1638
papillary carcinoma, false-positive scans in, 2280(le)
radioiodine therapy in thyrotoxicosis, low *vs.* high dose ^{131}I Na therapy, 796(ab)
semiquantitative 30-minute ^{99m}Tc MIBI uptake, in quick diagnosis of hyperthyroidism, 71
volume estimation of large multinodular goiters, comparison of MRI and scintigraphy, 794(ab)
Thyroid neoplasms
circulating ^{131}I thyroxine in, 36(ab)
differentiated, imaging with ^{99m}Tc(V)DMSA, 37(ab)
imaging with PET FDG, 38(ab)
nodal metastases, correlation with radiation absorbed doses, 524(le)
unusual scintigraphic findings in adenoma, 465
Thyroxine, ^{131}I, circulating, in thyroid cancers, 36(ab)
Tracers
^{68}Ga, potential for imaging heart with PET, 228
PET, potential, for tyrosine hydroxylase activity, 22(ab)
Transmission computed tomography (TCT), fast, for determining attenuation maps using collimated line source, rotatable air-copper-lead attenuators and fan-beam collimation, 1577
Transplantation
cardiac
evaluation of allograft vasculopathy by ^{99m}Tc teboroxime washout, 734(ab)
PET in patient evaluation before and after, 834
liver, new technique to evaluate patients, 447(ab)
renal
avascular necrosis in MRI and SPECT bone scans, 381
carcinoma in transplanted kidney detected with MAG3 scintigraphy, 2185
single lung
pulmonary perfusion distribution following, difference between emphysema group and primary pulmonary hypertension group, 167(ab)
quantitative ventilation-perfusion scintigraphy in, 166(ab)
Transporters
dopamine, in vivo sites imaging in human using ^{11}C WIN 35,428 PET, 938(ab)
norepinephrine, dopamine and serotonin, MIBG uptake by, 1140
Treatment planning, monoclonal antibody M195 in acute myelogenous leukemia, 422

Triphenyl tetrazolium chloride (TTC), effect of staining on distribution of radiolabeled pharmaceuticals, 178(ab), 1722
TTC. *See* Triphenyl tetrazolium chloride
Tubulointerstitial disease, poor ^{99m}Tc DMSA renal uptake in, 354(le)
Tumescence, evaluation of penile blood flow, 523(le)
Tumors. *See also* Cancer; *specific location; specific type*
adenocarcinoma, early response of cell line to radiotherapy, agents for monitoring, 773
"anatometabolic" imaging, 1190
assessment of efficacy of ^{131}I for thyroid ablation, 1927
benign mediastinal and parahilar uptake of ^{67}Ga in treated lymphoma, 1330
bispecific monoclonal antibody-mediated targeting of ^{111}In DTPA dimer to primary colorectal tumors, 1662
blood glucose concentration influence on FDG uptake in cancer, PET study of, 1
bone
hemangioendothelioma, scintigraphic "doughnut sign" on skeletal imaging, 297
^{99m}Tc HMDP negative, ^{18}F FDG PET in, 288
brain
assessment of proliferative activity using ^{131}I IUDR, 139(ab)
intraoperative assessment using ^{201}Tl, 138(ab)
prognostic and diagnostic usefulness of FDG-PET in management, 141(ab)
^{201}Tl *vs.* ^{99m}Tc MIBI SPECT in evaluation of children with, 1045
breast
effect of clodronate treatment on bone scintigraphy in, 1039
radioimmunolocalization of metastatic carcinoma using ^{111}In methyl benzyl DTPA BrE-3 monoclonal antibody, 1067
bronchogenic carcinoma mimicking metastatic thyroid carcinoma, 809
carcinoid, ^{111}In pentetreotide biodistribution in patients with, 157(ab)
chemotherapy resistance of, use of anti-sense for prediction of, 23N(5)
chest, residual or recurrent, PET differentiation from posttherapy changes, 162(ab)
clinical immunoscintigraphy of ovarian carcinoma using ^{131}I 145-9 monoclonal antibody, 1651
colorectal cancer
current imaging strategies, 537(suppl)
PET studies after systemic administration of ^{18}F uracil in patients with liver metastases from, 1075
comparative efficacy of PET-FDG and CT in detection of tumor sites in patients with abdominal and pelvic malignancies, 215(ab)
correlation of radiation absorbed doses to nodal metastases, 524(le)
early treatment response in malignant lymphoma as determined by planar ^{18}F FDG scintigraphy, 1706
effects of hypoxia on cultured human tumor cell uptake of thymidine, L-methinoine and FDG, 288(ab)
evaluation of Cu(PTSM) as tracer of perfusion, comparison with labeled microspheres in spontaneous canine neoplasms, 492(ab)
evaluation of recurrence in irradiated tumor bed with PET-FDG, 1050(ab)
FDG and methionine PET in differentiation of recurrent or residual musculoskeletal sarcomas from posttherapy changes, 124(ab)
FDG uptake and proliferative activity of human cancer cells, 414
fit-constrained parametric images using FDG, 155(ab)
^{18}F PFBG as potential tracer, 312(ab)
functional staging of cancer patients in prediction of therapeutic response and survival, 1087
^{67}Ga distribution in normal and hypotransferrinemic tumor-bearing mice, 2135
gastroenteropancreatic, localization with ^{111}In somatostatin analogue, 156(ab)
glioma, functional imaging correlates of prognosis, 975(ab)
growth of, IUDR uptake and retention as measure of, 1152
hepatomas, well-differentiated, high accumulation of ^{18}F FDGal by, 780
Ho-166 DOTMP for bone marrow ablation, 125(ab)
hypervascular brown, detection on three-phase bone scan, 2188
hypoxia and perfusion, 885
hypoxia and reoxygenation in, imaging with ^{18}F FMISO, 76(ab)
^{123}I IAZA, PDT-induced hypoxia in Dunning prostate tumors, 405
I-125-IVME2 *vs.* ^{123}I IBHPE in estrogen receptor-positive cancers, 272
immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
immunoscintigraphy in surgical management of colorectal cancer, 541(suppl)
improved localization and radioimaging with chemically modified monoclonal antibodies, 455(ab)
initial assessment of PET using FDG in imaging of malignant melanoma, 1420
in vitro cytotoxicity of MABG, 1024(ab)
in vitro uptake of ^{99m}Tc teboroxime in carcinoma cell lines and normal cells, 1949
liver, evaluation using ^{18}F FDG PET, 2124
localization and systemic distribution of effect cells monitored by PET, 289(ab)
lung, metastasis to breast detected by ^{18}F FDG PET, 1571
malignant, ^{111}In laminin peptide fragments for detection of, 1081(ab)
metastatic malignancy masquerading as hepatic hemangioma on labeled RBC scintigraphy, 1172
metastatic processes, spatial localization of, CT and SPECT image registration and fusion using radiolabeled monoclonals, 562(suppl)
mice with, pharmacokinetics of anti-CEA monoclonal antibody conjugated to bifunctional transition metal carborane complex in, 1294
neuroendocrine, of gastrointestinal tract, detection by somatostatin receptor scintigraphy, 388(ab)
non-small-cell lung carcinoma, PET imaging with ^{11}C MET, 1886
paragangliomas
^{131}I MIBG scintigraphy in preoperative and postoperative evaluation, 173
octreotide scintigraphy for detection of, 873
PET follow-up studies for evaluation of treatment response in patients with lung carcinoma, 75(ab)
plasma glucose levels and ^{18}F FDG uptake in bronchial carcinomas, 355
preclinical comparison of therapy and toxicity for Mu-9 anti-CSAp IgG labeled with ^{131}I, ^{90}Y or Re-188, 1014(ab)
prostate, current applications of immunoscintigraphy in, 549(suppl)
quantitative evaluation of uptake in laboratory animals using in vivo and ex vivo imaging, 1040(ab)
radioimmunodetection of Hodgkin's disease and non-Hodgkin's lymphomas with monoclonal antibody to eosinophil peroxidase, 1246
radiolabeled antibodies as cancer therapeutics, 1028(le)
recurrent carcinoid and occult distant metastasis, visualization by ^{99m}Tc sestamibi, 1748
residual or recurrent, methionine PET in differentiation from posttreatment changes, 214(ab)
role of ^{123}I Tyr-3-octreotide scintigraphy in staging of small-cell lung cancer, 1397
role of P-glycoprotein in accumulation of ^{201}Tl and ^{99m}Tc sestamibi in cells, 1125(ab)
scintigraphic evaluation of tenosynovial giant-cell tumor using ^{99m}Tc(V)-DMSA, 1745
small
detectability in Monte Carlo study of radioimmunodiagnosis, 857(ab)
treatment with magnetically enhanced radionuclide therapy, 422(ab)
soft tissue and bone, use of early, late and SPECT thallium imaging in evaluating activity of, 123(ab)
solid, solitary, liver, hepatic scintigraphy in evaluation of, 697
targeting in vivo and metabolic fate of I-125 IUDR following intratumoral injection in patients with colorectal cancer, 1175
thyroid, high-activity ^{123}I for diagnostic evaluation of patients with, 161(ab)
tissue heterogeneity effects on FDG parameter estimates, 153(ab)
^{201}Tl scintigraphy for assessment of ^{67}Ga avid mediastinal mass following therapy for Hodgkin's disease, 1326
urinoma, study of frequency of rejection mimicking on ^{99m}Tc DTPA imaging of renal transplants, 1155(ab)
xenografts, human, selective localization of radioiodinated phospholipid ether analog in, 787
Tumor-seeking agents
autoradiographic evaluation of intra-tumoral distribution of 2-DG and monoclonal antibodies in ovarian adenocarcinoma xenografts, 75
clinical immunoscintigraphy of ovarian carcinoma using ^{131}I 145-9 monoclonal antibody, 1651
clinical utility of immunoscintigraphy in ovarian cancer management, 545(suppl)
early response of human adenocarcinoma cell line to radiotherapy, 773
extracorporeal immunoadsorption to increase tumor-to-normal tissue ratio, 448
FDG uptake and proliferative activity of human cancer cells, 414
functional staging of cancer patients in prediction of therapeutic response and survival, 1087

immunoadsorption, enhancement strategy for radioimmunotherapy, 1020
immunoscintigraphy in surgical management of colorectal cancer, 541(suppl)
initial assessment of PET using FDG in imaging of malignant melanoma, 1420
monoclonal antibody M195 in acute myelogenous leukemia, 422
octreotide scintigraphy for detection of paragangliomas, 873
phase II scintigraphic clinical trial of malignant melanoma and metastases with ^{123}I BZA, 1260
radioimmunodetection of Hodgkin's disease and non-Hodgkin's lymphomas with monoclonal antibody to eosinophil peroxidase, 1246
radioimmunolocalization of metastatic breast carcinoma using ^{111}In methyl benzyl DTPA BrE-3 monoclonal antibody, 1067
radiolabeled antibodies as cancer therapeutics, 1028(le)
scintigraphic evaluation of tenosynovial giant-cell tumor using ^{99m}Tc(V)-DMSA, 1745
selective localization of radioiodinated phospholipid ether analog in human tumor xenografts, 787
^{99m}Tc(V)DMSA uptake in intra-abdominal massive deposit of amyloid protein, 815
tumor targeting in vivo and metabolic fate of I-125 IUDR following intratumoral injection in patients with colorectal cancer, 1175

Tyrosine hydroxylase, activity, potential PET tracer for, 22(ab)

U

Ulcer, duodenal, chronic, gastric emptying after laparoscopic anterior seromyotomy and posterior truncal vagotomy in, 30(ab)
Urea, C-14, breath test, radiation dose estimates for, 821
Urinary tract
24-hr urinary catecholamines are normal in some patients with positive MIBG scans and histopathologically proven pheochromocytomas, 792(ab)
upper, obstruction, validation of renal output efficiency as objective quantitative parameter in evaluation of, 845

V

Vagotomy, truncal, posterior, laparoscopic anterior seromyotomy and, in chronic duodenal ulcer, gastric emptying after, 30(ab)
Vanadium-48, as transmission source for attenuation correction of PET images, 871(ab)
Vascular disease, peripheral, functional imaging, 865(le)
Ventilation
controlled delivery of Kr-81m boli in normal subjects, results and implications of, 1859
diagnostic algorithms and lung scan interpretation, uniformity of, 661
plasma D-dimer in evaluation of suspected pulmonary embolus, 896
radiation absorbed dose estimates from inhaled Kr-81m gas in lung imaging, 1382
^{99m}Tc aerosol colloid formulation for imaging, 268
X-133 imaging, open bronchial stump post-pneumonectomy, 462
Ventilation-perfusion
application of neural networks to imaging for diagnosing pulmonary embolism, 850(ab)
detailed analysis of patients with matched ventilation-perfusion defects and chest radiographic opacities, 1851
lung scanning, 353(le)
and high resolution MRI techniques in patients with pulmonary embolism, 484(ab)
influence of results on pulmonary angiography procedure, 485(ab)
probability category distribution in university and community hospitals, 57(ab)
role in diagnostic evaluation of patients with pulmonary hypertension, 1075(ab)
match with chest x-ray less likely to represent pulmonary embolism if Q is "decreased" rather than "absent," 58(ab)
revised scintigraphic criteria for interpretation of scans for pulmonary embolism, 59(ab)
scintigraphy
in PIOPED study, 54(ab), 1109, 1119
quantitative, in single lung transplants, 166(ab)
Ventricular function
left
in Adriamycin cardiomyopathy, 52(ab)
biplane gated SPECT, gated equilibrium, and first-pass radionuclide angiographic quantitative measures of systolic and diastolic performance, 130(ab)
development of ambulatory recorder for measuring ejection fracture with miniature CsI photodiode detector, 842(ab)
diagnostic reliability of evaluating dilatation and hypertrophy with radionuclide ventriculography, echocardiography and ECG correlation with autopsy, 743(ab)
effects of beta-blockade therapy with ACEI in patients with dilated cardiomyopathy, 128(ab)
first-pass radionuclide angiography with ^{99m}Tc, 394
global and regional measurement by cardiac PET, 424(ab)
measurements using ambulatory radionuclide monitor, 1602
non-deterministic knowledge-based boundary detector, 745(ab)
and perfusion and fatty acid uptake, serial course in cardiomyopathic hamster, 1309
perfusion defect size after early and late ^{99m}Tc sestamibi SPECT after stress, 187
prognostic importance of transient dilation by dipyridamole, 735(ab)
rest-redistribution SPECT thallium imaging to assess viability in left ventricular dysfunction, 339(ab)
simultaneous assessment of myocardial perfusion and, during transient coronary occlusion, 1(ab)
sympathetic innervation in arrhythmogenic right ventricular disease, 2(ab)
systolic and diastolic, effects of adenosine on perfusion and, 377(ab)
^{201}Tl reinjection and improvement following revascularization, 172(ab)
^{201}Tl SPECT, left ventricular cavity-to-myocardial count ratio, 193
right, arrhythmogenic right ventricular disease, sympathetic left ventricular innervation in, 2(ab)
Ventriculography, radionuclide
additive value to dipyridamole ^{201}Tl imaging for risk stratification prior to vascular surgery, 292(ab)
dobutamine, in assessment of myocardial viability after thrombolytic therapy for acute myocardial infarction, 746(ab)
exercise, prognostic efficacy in patients with and without prior myocardial infarction, 127(ab)
first pass, comparing five second half-life Ir-191m and ^{99m}Tc DTPA using high count rate "multicrystal" camera, 742(ab)
Vesamicol receptors, radioligands, molecular decomposition-reconstitution approach to, 21(ab)
Vitamin A, radioprotection against incorporated radionuclides in vivo, 533(ab)
Vitamin B12, malabsorption, new radiofarmacon in diagnosis of, 445(ab)
Vitamin C, as radioprotector against ^{131}I, 637

W

Weis, Arthur M., people in nuclear medicine, 30N(6)
Welch, Michael J., people in nuclear medicine, 40N(6)
White blood cells. *See also* Leukocytes
quality assurance of labeling with test based on adherence, 345
scintigraphy, fractionated HMPAO stored at −70°C, routine application, 151

X

Xenografts
comparative study of intact and F(ab')2 fragments of monoclonal antibody MX-35 in, 1015(ab)
human ovarian adenocarcinoma, intra-tumoral distribution of 2-DG and monoclonal antibodies in, autoradiographic evaluation of, 75
human tumor, selective localization of radioiodinated phospholipid ether analog in, 787
Xenon-133
dynamic quantitative regional cerebral blood flow SPECT on PRISM 3-headed tomograph, simulation and phantom studies of, 362(ab)
prostate clearance study, and prostatic hemodynamic change after transurethral hyperthermic treatment of benign prostate hypertrophy, 553(ab)
regional cerebral blood flow imaging with CERASPECT stationary ring camera, 361(ab)
regional cerebral blood flow system using triple-headed SPECT camera, development of and initial results from, 906(ab)
SPECT
dynamic quantitative regional cerebral blood

flow on PRISM 3-headed tomograph, 266(ab)
^{99m}Tc ECD *vs.*, in mild to moderate regional cerebral blood flow abnormalities, 754
ventilation imaging
open bronchial stump post-pneumonectomy, 462
prevalence of thromboembolic disease in patients with intermediate probability lung scans, 55(ab)
Xenon-133m, ^{131}I decay and, 1219(le)

Y

Yttrium-90
analogous radiotherapeutics, measurement of ^{86}Y pharmacokinetics with PET and radiation dose calculation of, 2222
dual labeling of human Ig with ^{99m}Tc and, using EDTB, 1140(ab)
new bifunctional chelates for labeling of monoclonal antibodies, comparative biodistribution in non-tumor bearing nude mice, 1122(ab)
Yttrium-90 colloid, synovectomy of knee, therapeutic value of, 718(ab)
Yttrium-90 linker-immunoconjugates, evaluation in nude mice and dogs, 938